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The discipline of natural product synthesis serves to provide a platform for reaction discovery, the 
development of unique methodology, elucidation of biochemical pathways and structure 
conformation. This thesis will explore some bio-inspired cascade reactions towards the synthesis 
of the busseihydroquinone (chapter two), rhodonoid (chapter three), rubiginosin (chapter four) 
and nyingchinoid (chapter five) families of natural products, through the synthesis and 
derivatization of chromenes (Scheme 1).1 Efforts towards the total synthesis of the indole alkaloid 
(±)-hinckdentine A will also be explored (chapter Six). 
 
Scheme 1 – Bio-inspired Approaches Towards the Total Synthesis of the Busseihydroquinone, 
Rhodonoid, Rubiginosin, and Nyingchinoid Families of Natural Products 
 
It is hoped that these results will highlight the power of biomimetic cascade reactions in total 
synthesis and will offer insight into the challenges associated with these natural products.  
 
1 For more work featuring the derivatization of chromenes see: M. A. Coleman, L. Burchill, C. J. Sumby, J. 
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Chapter One – Introduction to Natural Product Synthesis 
1.1 Natural Products 
At the beginning of the eighteenth century the word ‘organic’ referred to a substance obtained 
directly or indirectly from a living entity.1 It was not until the 1770s that French chemist Antione 
Lavoisier established the composition of these natural products. Showing through combustion 
that all vegetable derived substances were composed of carbon, hydrogen and oxygen; while 
animal derived substances also contained nitrogen, phosphorus and sulfur.2  
  
At the time, the idea that all of life’s complexities could be explained so succinctly by a 
composition of only six elements seemed inconceivable. Yet, the simple act of mixing these 
elements did not spontaneously produce life.3 In an attempt to explain this, scientists began 
championing a new belief system “vitalism”, the idea that all organic substances were produced 
under the influence of a ‘vital force’ and regulated by principles different from those of inorganic 
substances.4 Consequently, it was thought impossible to prepare any organic substance artificially 
or synthetically in a laboratory.  
 
This belief went unquestioned until 1828, when German chemist Friedrich Wöhler famously 
produced urea (1.1) from inorganic silver isocyanate 1.2 and inorganic ammonium chloride 1.3 
through an ammonium isocyanate intermediate 1.4 (Scheme 1.1).5 Wöhler’s synthesis marked a 
pioneering advancement towards this new field of chemistry, organic chemistry. 
 
 
Scheme 1.1 – Wöhler’s Synthesis of Urea5 
 
Despite the structural simplicity of urea (1.1) containing only one carbon atom and no carbon-
carbon or carbon-hydrogen bonds, this reaction (later named the Wöhler reaction) is the first 
reported example of natural product synthesis, the art of constructing molecules of nature in the 
laboratory.6 At the time, Wöhler’s synthesis served to correct the notion of “vitalism” showing 
that the synthesis of organic molecules was not exclusive to nature, and that organic compounds 
could in fact be synthesized from inorganic substances. 
 
AgNCO + NH4Cl NH4NCO H2N NH2
O
1.2 1.3 1.4 1.1: urea
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It should be acknowledged that the dissolution of “vitalism”, a theory that had been championed 
for many years by many luminaries was destined to be a slow process. Indeed, it would take over 
50 years to refute these alchemic ideas within scientific circles.7 Biologist Louis Pasteur was 
famous for his scepticism, creating debate in 1857 with rival chemist Justus Von Liebig, arguing 
that only living organisms were responsible for the process of fermentation.8 In non-scientific 
circles today these belief systems are still common, particularly in alternative medicines.7 
 
The next significant milestone for the early pioneers of organic chemistry was overcome some 20 
years after the Wöhler synthesis in 1845 by another German chemist A. W. Hermann Kolbe, 
uniting two carbon atoms to synthesize acetic acid (1.5).9 This was done through reaction of water 
(1.6), hydrogen 1.7 and elemental carbon 1.8 in the presence of chlorine and iron disulphide 
(Scheme 1.2). At the time this synthesis was unprecedented, involving the construction of an 
organic molecule from the simplest of units, the elements themselves. 
 
 
Scheme 1.2 – Kolbe’s Synthesis of Acetic Acid9 
 
Naturally, the synthesis of both urea (1.1) and acetic acid (1.5) were not isolated discoveries but 
occurred in the midst of a chemical revolution of modern organic chemistry.10 These days, natural 
product synthesis is considered the flagship of organic synthesis. In pursuit of synthesizing natural 
products chemists hope to develop efficient and elegant synthetic routes, pushing chemical 
boundaries towards targets with higher molecular complexity and showcasing the scope and 
limitations of chemical synthesis at any given time. However, whether successful or not, greater 
value often lies in the endeavour of natural product synthesis which provides a platform for 
reaction discovery and the testing of novel methodology.11 Additionally, natural product synthesis 
provides structure confirmation (and often structural revision), develops reactions with controlled 
stereochemistry, and serves to synthesize compounds without the exhaustive mining of natural 
supplies.12 This last point is of particular importance when quantities accessible in nature are 
infeasible from a pharmaceutical perspective. Moreover, the inherent biological activity of these 
compounds often makes them good lead targets towards more effective and potent drugs. This 






1.5: acetic acid1.6: water
FeS2, Cl2
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“Natural products are the result of three billion years of development of the living world, and 
they have survived the natural selection process over a long period of evolution. I am convinced 
they always carry a message, which is our job to decipher”  
−	Vladimir Prelog, 1975 
 
In fact, studies show that more than one third of all US FDA approved drugs over the past 20 years 
are derived from or inspired by natural products, and that more than 65% of the developed small-
molecule cancer drugs from 1981 – 2019 originated from natural products.14  
 
1.2 The Biosynthesis of Natural Products 
In the broad sense, natural products can be classified according to two distinct classes; primary 
metabolites and secondary metabolites.15 Primary metabolites are chemicals necessary for 
physiological functions required for the normal growth, development and reproduction of cells. 
This includes nucleic acids, amino acids (i.e. 1.9, 1.10 and 1.11), proteins, carbohydrates (i.e. 1.12), 
and lipids, as well as urea (1.1) and acetic acid (1.5) (vide supra) (Figure 1.1).16 As primary 
metabolites are crucial for all living organisms there is often very little structural diversity in these 
metabolites, even between different genus and kingdoms.  
 
Conversely, secondary metabolites are chemicals not directly involved in these critical processes. 
Instead, they often possess cytotoxic properties which have been optimized through evolution as 
agents against competing organisms. As a result, secondary metabolites tend to be more 
structurally diverse, possessing unique and complex molecular architectures with interesting 
pharmacological properties.17 It is for this reason that secondary metabolites such as alkaloids (i.e. 
1.13), terpenoids (i.e. 1.14), flavonoids, glycosides and polyketides (i.e. 1.15) remain at the 




Figure 1.1 – Examples of Primary (a) and Secondary Metabolites (b)15 - 17 
 
Evidently it follows that the same compounds responsible for primary metabolism, are also 
responsible for the production of secondary metabolites. One example of this includes pyruvate 
(1.19), which is not only a fundamental molecule in primary metabolism (within the citric acid 
cycle) but is also a direct precursor towards various secondary metabolites.18, 19 This includes 
polyketides 1.20 formed from repeat condensation/ decarboxylation reactions of acetyl CoA 
(1.21) and malonyl CoA (1.22) in the presence of a polyketide synthase enzyme (Scheme 1.3). 
Fatty acids 1.23, synthesized through an acyl CoA carboxylase enzyme, and terpenes derived from 
isopentenyl pyrophosphate (IPP) (1.24) and dimethylallyl pyrophosphate (DMAPP) units (1.25). 
Interestingly, terpene biosynthesis occurs via two distinct pathways: the mevalonate pathway and 
the MEP (2-C-methylerythritol 4-phosphate) pathway.20, 21 The mevalonate pathway is generally 
used by most eukaryotes (including archaea and humans), while the MEP pathway is more 
common in eubacteria. Naturally there are clear exemptions to this rule, for example both 
pathways are found to occur in plants with the MEP pathway occurring in plastids and the 
































































































a. primary metabolites b. secondary metabolites
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Scheme 1.3 – The Biosynthesis of Various Secondary Metabolites from Pyruvate20, 21 
 
Polyketide units act as powerful compounds towards the divergent biosynthesis of a range of 
natural products through cyclization to give phenolic natural products (i.e. 1.34 – 1.37), as well as 
through reduction and elimination reactions giving rise to a wide range of functional groups such 
























































































































Figure 1.2 – Examples of Polyketide Derived Natural Products22 
 
Additionally, terpenes derived from IPP (1.24) and DMAPP (1.25) are formed via nucleophilic 
attack of the IPP terminal alkene toward the allylic carbon of DMAPP.23 Formation of an alkene 
from the resulting carbocation occurs to give geranyl pyrophosphate (GPP) (1.40) (Scheme 1.4). 
This compound can undergo hydrolysis to give geraniol or can undergo further electrophilic 
reactions to give farnesyl pyrophosphate (FPP) (1.41), geranylgeranyl pyrophosphate (GGP) (1.42), 
and squalene (1.43).24 As the carbon skeleton is derived from both regularly and irregularly linked 
isoprene units, the resulting terpenes are only ever a factor of 5 carbon units. This is known as the 
biogenetic isoprene C5 rule and was first described by Leopold Ružička in 1953.25  
 
 














































































1.41: farnesyl pyrophosphate (FPP)
15 carbons
































Terpenes are not only responsible for many of the fragrances abundant in plants, but they also 
play a crucial role in the biosynthesis of more complex natural products such as steroids.26 This 
occurs via oxidation of squalene (1.43) to squalene epoxide (1.44), followed by a polyene 
cyclization and a series of Wagner-Meerwein 1,2-shifts to afford lanosterol (1.45) (Scheme 1.5).27 
Lanosterol itself is the direct biosynthetic precursor to all animal and fungal steroids. 
 
 
Scheme 1.5 – The Biosynthesis of Lanosterol from Squalene27 
 
Steroids have crucial roles in cell metabolism as hormone signalling molecules within the 
endocrine system, and as important components of the plasma membrane responsible for the 
control of membrane fluidity.28 Investigations into the biological activity of these compounds first 
began in the early 1930s when it was found that extracts of adrenocortical tissue could counteract 
acute adrenal failure.29 Since then, steroids have been widely used in the pharmaceutical industry 
to treat a range of diseases such as anaemia,30 asthma, 31 brain tumours, 32 breast cancer, 33 
osteoporosis34 and psoriasis to name a few.35 Indeed, the history behind steroid biosynthesis is 
quite intriguing and will be revisited later in this chapter (vide infra). 
 












































Linear terpenes can also undergo electrophilic cyclization reactions to give compounds such as     
(–)-limonene (1.47). These cyclic terpenes can then undergo oxidation in the presence of various 
cytochrome P450 enzymes to give terpenoid natural products such as (–)-menthol (1.48) and (–)-
carvone (1.49) (Scheme 1.6).36, 37 Terpenoids are derived from terpenes typically through addition 
of oxygen and often through cyclization reactions. Not only are they a major contributor to the 
chiral pool,38 they are also a diverse class of natural products in their own right. In fact, it is 




Scheme 1.6 – The Biosynthesis of (–)-Menthol and (–)-Carvone36, 37 
 
Terpenoids can be further derivatized to give natural products with mixed biosynthetic origins 
known as meroterpenoids. One notable example includes the biosynthesis of chromenes 1.53 
derived from prenylation, oxidation and electrocyclization reactions of polyketide derived phenols 
1.54 (Scheme 1.7).40 Chromenes can then undergo further reactions such as allylic oxidations, 
cycloadditions and epoxidations to give more complex natural products (i.e. 1.55 – 1.62).41 - 47 This 
field was pioneered by British chemist Leslie Crombie, whose work will be the basis of much of 
this thesis (vide infra).48 Although transformations involving chromenes in nature occur through 
enzyme facilitated pathways, these reactions are often predisposed and can be mimicked 
synthetically in the laboratory through the use of the appropriate reaction conditions. This 









































Scheme 1.7 – Natural Products Synthesized from Chromenes41 - 47 
 
1.3 The History of Biomimetic Synthesis 
The concept of biomimetic synthesis was first proposed by British Nobel laureate Sir Robert 
Robinson in 1917 referring to the execution of a series of reactions designed to parallel or mimic 
a proposed biosynthesis.51 However the term was not coined until some 56 years later in 1973 by 
Ronald Breslow.49 Robinson is also credited with achieving the earliest reported biomimetic total 
synthesis involving the alkaloid tropinone (1.64), a synthetic precursor to the drug atropine (1.65) 
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Curiously, atropine itself is a compound with a rich history. It is one of the key bioactive 
compounds found in the Solanaceae family of plants including Atropa belladonna (deadly 
nightshade) and Mandragora officinarum (mandrake), plants famous for their medicinal and 
hallucinogenic effects.52 It was first isolated in 1831 by pharmacist Heinrich F. G. Mein,53 and later 
synthesized by chemist and Nobel laureate Richard Willstätter in 1903.54 It is important to 
recognize that although Willstätter synthesis was pivotal in providing structure confirmation at 
the time, it was a convoluted synthesis requiring 19-steps for the conversion of cycloheptanone 
1.66 to tropinone (1.64) and had an overall yield of 0.8% (Scheme 1.8). Reduction of tropinone 
with zinc amalgam to the alcohol tropine (1.67), followed by esterification with tropic acid (1.68) 
then afforded atropine (1.65).  
 
 
Scheme 1.8 – Willstätter’s Total Synthesis of Atropine54 
 
In 1914 at the start of World War I there was a great need for large quantities of atropine due to 
its use as an antidote to counter the effects of G-Series nerve agent being used in Germany at the 
time.7 It was then that Robinson developed a one-pot synthesis of tropinone synthesized through 
a double Mannich reaction of succinaldehyde (1.76), methylamine (1.77), and acetonedicarboxylic 






































































Scheme 1.9 – Robinson’s Biomimetic Synthesis of Tropinone51 
Robinson’s total synthesis of tropinone represents a remarkable achievement in organic synthesis, 
being ahead of its time in terms of retrosynthetic logic and being many years before the 
biosynthesis was elucidated.56 What is unique about this synthesis is that it not only serves as a 
reminder of the importance of biomimetic chemistry in the development of complex molecule 
synthesis, but it also highlights the direct application of total synthesis to serve the needs of the 
general public.  
Later that year, Robinson went on to propose that squalene (1.43) could be a possible precursor 
to cholesterol (1.80), and in 1934 proposed a concept for this transformation (Scheme 1.10).57, 58 
Although Robinson’s initial assignment was incorrect, work in this area was continued in 1945 by 
Robert B. Woodward and Konrad E. Bloch using isotopic labelling experiments to outline the 
pathway from squalene to cholesterol, this time featuring a revised orientation of squalene.59  
 
 
Scheme 1.10 – Robinson and Woodward’s Proposal for Cholesterol Biosynthesis57 – 59 
 
Further work in the 1950s by pioneers Sir Derek H. R. Barton, Gilbert Stork and Albert Eschenmoser 
then led to a new field of chemistry, polyene cyclization and the development of the Stork-
Eschenmoser hypothesis.60 This hypothesis proposed that the biosynthesis of cholesterol was 
occurring through a cationic cyclization pathway from the linear polyene squalene to the 
tetracyclic product lanosterol (1.45).  
CHO
CHO





























































It was not until 1962 that Eugene Tamelen was the first to identify squalene epoxide (1.44) as the 
precursor in the biosynthesis of cholesterol (vide supra).27 Extensive studies by William S. Johnson 
later investigated the requirements and constraints of these polyene cyclizations. Specifically, 
how different chemical reagents such as Lewis acids and Brønsted acids could be used to aid the 
stabilization of these proposed cationic carbenium intermediates, that would ordinarily be 
stabilized under enzymatic control. One example includes the total synthesis of progesterone 
(1.81) synthesized through a bio-inspired cationic polyene cyclization of 1.82 (Scheme 1.11).61 This 
polyene cyclization occurs through an acid promoted elimination of water and a tandem 1,5-diene 
and alkyne cyclization to give 1.83. Ozonolysis then affords the triketone 1.84, and aldol 
condensation gives progesterone (1.81) in 45% over 2-steps.  
 
Scheme 1.11 – Johnson’s Bio-inspired Synthesis of progesterone 
Of course, biomimetic synthesis is somewhat limited favouring reactions in nature that are not 
under enzymatic control. This subject was explored by Clayton Heathcock: 62 
“The basic assumption of this approach is that nature is the quintessential process development 

















































favourable chemical pathways – favourable enough that the skeleton could have arisen by a non-
enzymatic reaction in the primitive organism. If a molecule produced in this purely chemical 
manner was beneficial to the organism, enzymes would have evolved to facilitate the production 
of this useful material” 
− Clayton Heathcock, 1996 
Heathcock highlights the obvious bias for biomimetic chemistry to favour reactions under non-
enzymatic control and suggests that the production of spontaneously arising compounds which 
confer a benefit to an organism may evolve to be synthesized under enzymatic control. Implying 
that most biological reaction pathways have a degree of predisposed reactivity. Provided that the 
suitable reagents and conditions are identified it is possible that reactions occurring in nature 
under enzymatic control can be mimicked synthetically in a laboratory without the need for 
enzymes.  
 
1.4 Reaction Cascades in Biomimetic Synthesis 
A cascade reaction, also known as a tandem or domino reaction, comprises of two or more 
consecutive reactions that occur spontaneously with each sequence being reliant on the previous 
step.63 Not only does this allow for a large number of transformations to occur in a single step, 
increasing efficiency and decreasing the purifications required, but it also affords the ability to 
install molecular complexity in a selective manner.  
One example includes Heathcock’s total synthesis of (±)-protodaphniphylline (1.85) from the 
squalene derived acyclic dialdehyde 1.86 (Scheme 1.12).64 This cascade is proposed to occur 
through condensation of ammonia with 1.86 to afford the 𝛼-hydroxy imine 1.87. Further 
dehydration then gives the corresponding 2,3-dihydropyridine 1.88 intermediate, which 
undergoes an acid catalyzed [4+2] cycloaddition to give imine 1.89. Finally, a concomitant aza-ene 




Scheme 1.12 – Heathcock’s Biomimetic Total Synthesis of (±)-Protodaphniphylline64  
 
This impressive reaction cascade results in the formation of 7 new bonds and 5 new rings in a 
single step! Later work on this sequence, through substitution of ammonia with methyl amine 
gave an improved yield of 65% and efforts towards a “diversity orientated synthesis” have led to 
the synthesis of a wide range of daphniphyllum alkaloid natural products.65 
 
Another more recent example of the use of cascade reactions in biomimetic synthesis includes 
the total synthesis of (+)-brevianamide A and B (1.90 and 1.91) through the biosynthetic precursor 
(+)-dehdydroxy-brevanamide E (1.92).66 In this sequence (+)-dehdydroxy-brevanamide E is 
oxidized in the presence of m-CPBA to give intermediates 1.93 and 1.94 (Scheme 1.13). Further 
reaction in the presence of LiOH then mediates the key one-pot reaction cascade, involving a 5-
exo-trig ring opening, [1,2]-shift and a [4+2] cycloaddition of to afford (+)-brevianamide A (as the 
major product) alongside (+)-brevianamide B (minor product, not shown) in a combined yield of 
63%. This work by the Lawrence group, highlights how cascade reactions in biomimetic synthesis 
can be used to clarify biosynthetic pathways. 
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Scheme 1.13 – Biomimetic Synthesis of (+)-Brevianamide A and B66  
 
1.5 Dearomatization Approaches to Biomimetic Chemistry 
One approach towards initiating cascade reactions is through dearomatization. Dearomatization 
reactions are organic reactions involving the loss of aromaticity in arenes. Due to the high stability 
of aromatic structures and their prevalence in nature, once dearomatized the formation of 
reactive transient intermediates such ortho- and para- quinone methides (o-QMs and p-QMs) are 
then primed to undergo further reaction cascades.67  
Furthermore, o- and p-QMs have been shown to play important roles in the biosynthesis of many 
complex natural products.68 Recent work by Alison R. H. Narayan’s group in this area has extended 
to the use of biocatalysts in the dearomatization of resorcinol type phenols.69 In simple terms, this 
involves the use of enzymes to perform chemical transformations that are not native to the 
original substrate.   
A variety of other methods to induce dearomatization also exist. This includes thermal 
dearomatization,70 reduction (through formal addition of one or more molecules of H2 e.g. Birch 
reduction),71 oxidation (via organic oxidants such as hypervalent iodine, electrochemical oxidation 
















































































dearomatization (such as Büchner ring expansions),74 Brønsted catalyzed dearomatization and 
alkylative dearomatization (Scheme 1.14).75 
After dearomatization has occurred, the corresponding o- and p-QMs (i.e. 1.98) are then able to 
provide direct access to a range of unique transformations. Most commonly this includes 
conjugate additions (i.e. 1.99), [4+2] cycloadditions (i.e. 1.100) and oxa-6𝜋-electrocyclizations 
which result in the formation of (2H)-chromenes (i.e. 1.101). More recently, spiroepoxidations 
(i.e. 1.102) have become an increasingly popular strategy in biomimetic chemistry, and will be 
explored later in this thesis (chapter Five, vide infra).76 
 
 
Scheme 1.14 – Methods for the Generation and Derivatization of o-QMs76 
 
Arguably one of the most notable examples of biomimetic total synthesis through an o-QM 
includes Chapman’s biomimetic synthesis of (±)-carpanone (1.18) (Scheme 1.15).77 First published 
in 1971, this sequence involves phenolic coupling of sesamol derived desmethylcarpacin 1.107 to 
afford the corresponding o-QM 1.108. A subsequent [4+2] cycloaddition then reveals (±)-
















































Scheme 1.15 – Chapman’s Biomimetic Synthesis of (±)-Carpanone77 
 
Additionally, p-QMs have also been used extensively in biomimetic dimerization reactions. This 
includes the first reported total synthesis of (±)-griffipavixanthone (1.109) by John Porco’s group 
(Scheme 1.16).78 In this example, a readily accessible vinyl p-QM xanthone based monomer 1.110 
underwent a ZnI2 mediated [4+2] cycloaddition between an in situ generated diene 1.111. Further 
arylation of the resulting p-QM 1.112 and finally demethylation then gave (±)-griffipavixanthone. 
 
 
Scheme 1.16 – Reichl’s Biomimetic Synthesis of (±)-Griffipavixanthone78 
 
Despite this reaction being initially poor yielding (only 5% over 2-steps), further modification 
towards an asymmetric synthesis using a chiral phosphoric acid led to an improved yield of 25%, 



































MeMe 1.  ZnI2, DCE
2. p-MeC6H4SH
























































Of course, o- and p-QMs aren’t only restricted to [4+2] cycloadditions but can undergo a variety 
of transformations. Perhaps one of the most common is the reaction of o-QMs to undergo oxa-
6𝜋-electrocyclizations resulting in the formation of chromenes 1.101 (vide supra). This approach 
was emphasised in Malerich and Trauner’s total synthesis of (±)-pinnatal (1.113) and (±)-
sterekunthal A (1.114) (Scheme 1.17).80 In this sequence Knoevenagel condensation of aldehyde 
1.115 with the hydroxynapthoquinone 1.116 afforded the 1,2-dicarbonyl 1.117. The 
corresponding oxa-6𝜋-electrocyclization reaction then provided the THP protected chromene 
1.118. Acidic cleavage and oxidation gave aldehyde 1.119. Interestingly, but perhaps not 
unsurprisingly 1.119 reacted spontaneously at room temperature to afford (±)-pinnatal (1.113) in 
91%.  Heating 1.113 in benzene then gave the co-isolated natural product (±)-sterekunthal A 
(1.114) via a retro Diels-Alder. In this sequence it is the synthesis of the functionalized aldehyde 
1.119 that allows quick access to 1.113 and 1.114. This concept of using functionalized aldehydes 






































1.  p-TsOH, MeOH
2. (COCl)2, DMSO





























These syntheses not only showcase how the reactivity of dearomatized structures through o- and 
p-QMs can enable unique transformations, but also highlight the importance of biosynthetic 
speculation. Through the consideration of biosynthetic routes with the help of co-isolated natural 
products, it becomes easier to facilitate the divergent synthesis of whole families of natural 
products. Furthermore, biosynthetic speculation can also assist in the case of natural product 
misassignment. 
 
1.6 Bio-Inspired Structural Revisions of Natural Products 
By the end of the 19th century, structural determination of compounds was considered a laborious 
task often requiring years of work. Efforts to identify molecular structures were focused 
exclusively through chemical synthesis by means of degradation and derivatization studies, with 
specific focus on the identification of functional groups.81  
 
Notable examples include some of the work of Richard Willstätter who determined the structure 
of a variety of tropane alkaloids including atropine (1.65), hyoscyamine, scopolamine, calystegine 
and cocaine (vide supra).54 He also went on to research the chemical composition of chlorophyll, 
identifying two major types of chlorophyll (known today as chlorophyll A and chlorophyll B).82 
Willstätter determined their formulae correctly as C55H72O5N4Mg and C55H70O6N4Mg respectively 
and demonstrated that both molecules contained four pyrrole rings, plus a carboxyl group 
esterified with a long chain alcohol phytol. While the complete structures of chlorophyll still 
eluded him, Willstätter was awarded the Nobel Prize in 1915 for his work.83 In fact, it was not until 
40 years later that R. B. Woodward reported the first total synthesis of these chlorophylls.84 
 
In the 1930s X-ray crystallography was developed, and quickly became considered the cutting-
edge standard for structural elucidation.81 Of course, X-ray crystallography is somewhat limited 
requiring the correct properties and sufficient material for crystallization. However, in the late 
1950s NMR spectroscopy established itself as an indispensable tool for structural elucidation.81 
With all these advancements in analytical characterisation techniques, these days structural 
elucidation is considered standard. This was best sumized by Koji Nakanishi: 85 
 
“Until the mid-1960s, structure determination was an art that could be likened to solving a 
detective case, but with the spectacular advancement in spectroscopy it has become less 
inspiring, and since the mid-1980s, in most cases, structure determination has become routine” 
−	Koji Nakanishi, 1991 
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It is important to realise that although structural determination benefits from the vast array of 
analytical techniques now available, there are still inherent challenges towards the elucidation of 
complex natural products. Indeed, even today a surprisingly large number of structural 
misassignments are still reported in the literature and the value of using biosynthetic rational for 
structural determination remains.86 
 
 
One example includes the total synthesis of (±)-incargranine B (1.120) reported by the Lawrence 
group. Incargranine B was first isolated in 2010 by Shen and co-workers,87 and was initially 
assigned to have the novel indolo[1,7]napthyridine alkaloid structure 1.121 (Scheme 1.18). 
Despite the structurally sound NMR assignment of compound 1.121, biosynthetic speculation 
suggested that the proposed structure was incorrect. Specifically, this natural product was 
believed to be ornithine derived, in which case the breakage and formation of a strangely high 
number of bonds would have had to occur. Instead, it was proposed that a more biosynthetically 
plausible structure involving a dipyrroloquinoline would be more plausible.  
 
 
To test this proposal, a structural revision through total synthesis was reported.88 This involved 
conversion of an acetal protected precursor 1.122 to aldehyde 1.123 in the presence of HCl(aq) 
followed by a condensation/ Mannich/ SEAr cascade sequence to afford diol 1.124 in a 50% yield. 
Subsequent glycosylation and global deprotection then gave the desired target 1.120, which 
gratifyingly matched the original analytical data of (±)-incargranine B.87 
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Another more recent example of structural revision is the total synthesis of (±)-
furoerioaustralasine (1.128) reported in our group in 2019 (Scheme 1.19).44 The structure of (±)-
furoerioaustralasine was initially missassigned with a reported cis relationship between the oxy 
and hydroxyl substituents (1.129).89 In this case it was the co-isolated natural product cis-
erioaustralasine (1.130) that led to a proposed misassignment. It was envisaged that cis-
erioaustralasine could in fact be a direct precursor to (±)-furoerioaustralasine. This could occur 
through an intramolecular SN2 ring opening of the epoxide (1.131) to afford (±)-
furoerioaustralasine with a trans relationship, rather than the reported cis configuration.  
 
Thermal rearrangement of chromene 1.132 involving a retro-6𝜋-electrocyclization, alkene 
isomerisation and an intramolecular hetero-Diels-Alder reaction then afforded the intermediate 
enone 1.133 in 32%. Next, epoxidation with m-CPBA gave the desired exo epoxide 1.131 in 47% 
and finally treatment with TFA afforded (±)-furoerioaustralasine (1.128) in 77%. Pleasingly, the 
obtained NMR data was shown to match that of the reported isolation data.89  
 
 
Scheme 1.19 –Total Synthesis of (±)-furoerioaustralasine (1.128)44 
 
These examples covered in this chapter, not only highlight the enduring value of biomimetic 
chemistry, but showcase the importance of biosynthetic speculation in the structural revision of 
natural products. Herein, this thesis will attempt to explore the biomimetic chemistry of a few 
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Chapter Two – Investigations Towards the Busseihydroquinone and 
Parvinaphthol Families of Natural Products 
*This work was completed with assistance from postdoctoral fellow Dr. Henry P. Pepper, who did 
preliminary work on this project, synthesizing the key orcinol model study enol ether and cyclobutane* 
 
2.1 Introduction 
2.1.1 Busseihydroquinone and Parvinaphthol Families of Natural Products 
Rubiaceae is a diverse family of flowering plants native to tropical and sub-tropical regions. This 
family contains plants of the genus Pentas which have been used extensively in traditional 
medicines for the treatment of malaria, ascariasis, lymphadenitis, snake bites and a variety of 
other conditions.1 These plants are an abundant source of polycyclic meroterpenoid natural 
products such as busseihydroquinones A – E (2.1 – 2.5), first isolated from Pentas bussei in 2012 
and parvinaphthols A – C (2.6 – 2.8) isolated from Pentas parvifola in 2016. There is also an 
unnamed but structurally relevant natural product 2.9, which was isolated from Pentas bussei by 
Bukuru and co-workers (Figure 2.1).2, 3, 4 
 
 










































































2.1.2 Total Synthesis of Parvinaphthol B by Ahn and Han 
To date, the only reported total synthesis of members of the parvinaphthol and 
busseihydroquinone family is the synthesis of parvinaphthol B (2.7) reported by Ahn and Han in 
2017.5 This sequence commenced with the preparation of the known amide 2.10 via synthesis of 
an acid chloride and subsequent amidation of piperonylic acid (2.11) (Scheme 2.1).6 Aldehyde 2.12 
was obtained in excellent yield by ortho- lithiation of amide 2.10 using t-BuLi and formylation with 
DMF.7 Ortho- formyl benzamide 2.12 was then cyclized according to a literature procedure to give 
cyano-isobenzofuranone 2.13.8 A Hauser-Kraus annulation of isobenzofuranone 2.13 with methyl 
acrylate using LiHMDS was then performed to afford dihydroxynapthoate 2.14 in quantitative 
yield. Unfortunately, direct O-methylation of 1,4-dihydroxynapthoate 2.14 did not proceed 
selectively. Alternatively, a 2-step dimethylation and deprotection was used to introduce the 
methyl group into the correct position in 42% over 2-steps. Presumably, the selective deprotection 
occurred due to the hydrogen bond stability between the C4 and C5 of 2.15, affording a concise 
synthesis of 2.7 in 6 linear steps and an overall yield of 27%. 
 
 
Scheme 2.1 – Han and Ahn’s Total Synthesis of Parvinaphthol B5  
 
2.1.3 The Diels-Alder Reaction 
Arguably one of the most important reactions that has influenced total synthesis over the last 
century is the Diels-Alder reaction. This reaction involves a pericyclic [4+2] addition between a Z-
conjugated diene (i.e. 2.16) and at least one 𝜋 bond (typically a substituted alkene i.e. 2.17) 












































































Scheme 2.2 – The Diels-Alder Reaction 
 
This reaction occurs via a single cyclic transition state and proceeds through thermally permitted 
suprafacial/ suprafacial interactions of the diene’s 4𝜋 electron system with the 2𝜋 electron system 
of the dienophile,9 and is best depicted through consideration of frontier molecular orbital (FMO) 
theory (Figure 2.2).  
 
In “normal” electron demand Diels-Alder reactions, it is the highest occupied molecular orbital 
(HOMO) of the electron rich diene which interacts with the lowest unoccupied molecular orbital 
(LUMO) of the electron poor dienophile and leads to the formation of a second bonding molecular 
orbital which is of lower overall energy making the Diels-Alder reaction highly favourable.  
 
Interestingly, this [4+2] cycloaddition can also occur between an electron poor diene and an 
electron rich dienophile when the HOMO-LUMO energy gap is close enough in energy. In this case, 
the diene is acting as the LUMO and the dienophile as the HOMO. This is known as an inverse 
electron demand Diels-Alder reaction and often requires the use of hetero-atoms for this polarity 
reversal to occur. Because of this, the inverse Diels-Alder reaction is often used in natural product 






Figure 2.2 – FMO Diagram of Inverse and Normal Diels-Alder Reactions 
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Unlike the normal demand Diels-Alder reaction, the mechanism for the inverse demand reaction 
is not fully understood.10 The accepted view is that most inverse Diels-Alder reactions occur via 
an asynchronous mechanism where not all bonds are formed and broken at the same time. What 
is certain, is that this mechanism occurs through a boat-like transition state.11 For example, the 
oxa-Diels-Alder reaction between acrolein (2.19) and methyl vinyl ether (2.20) proceeds through 




Scheme 2.3 – The Inverse Demand Diels-Alder Reaction 
 
As normal demand Diels-Alder reactions are concerted these cycloadditions are stereospecific, 
resulting in syn-addition with respect to the diene and dienophile components (Scheme 2.4). This 
can be observed by looking at the Z-dienophile dimethyl maleate (Z-2.23), which gives rise to a 
syn-cyclohexene syn-2.24 when reacted with butadiene (2.16). While E-dimethyl maleate (E-2.23) 
affords the anti-cyclohexene product anti-2.24. Additionally it follows that both the Z,Z and E,E-
dienes (i.e. E,E-2.25) when reacted with dimethyl acetylenedicarboxylate (2.26) give syn-
cyclohexene products (i.e. syn-2.27), while Z,E-distributed diene gives the anti-cyclohexene 
















































In contrast, Diels-Alder reactions in which neighbouring stereocentres are formed next to the new 
bond are under stereoselective control. There are two different possible stereochemical 
outcomes based on the orientation of the dienophile with respect to the diene; either endo (with 
the dienophile molecular orbitals underneath the diene i.e 2.28) or exo (with the dienophile 
molecular orbitals away from the diene i.e. 2.29) (Scheme 2.5). For normal demand Diels-Alder 
reactions the stereochemical outcomes can often be predicted. Despite being more 
stereochemically hindered, the endo transition state is typically preferred due to favourable 
interactions between the 𝜋 systems of the diene and the dienophile. This is known as the 
secondary orbital effect and was first proposed by Woodward and Hoffmann.12  
 
 
Scheme 2.5 – Stereoselective Diels-Alder Reactions 
 
2.1.4 History of the Normal Demand Diels-Alder Reaction 
In 1928 the Diels-Alder reaction was first disclosed by Otto Diels and Kurt Alder, who reacted 
benzoquinone (2.32) and cyclopentadiene (2.33) to afford 2.34 through the mono adduct 2.35 
(Scheme 2.6).13 Over the next 10 years Diels went on to further publish a total of 28 articles in this 




































































It seems for the most part the synthetic community were slow to apply the Diels-Alder reaction in 
the context of total synthesis. It wasn’t until 1951 when Gilbert Stork and co-workers reported 
the total synthesis of cantharidin (2.36).15 This was achieved in 15 linear steps, starting from a 
Diels-Alder reaction of furan (2.37) and dimethyl acetylenedicarboxylate (2.26) to afford 2.38, 
followed by a hydrogenation and a second Diels-Alder reaction with butadiene (2.16) to afford 
2.39 (Scheme 2.7). Next, reduction with LiAlH4 gave the diol 2.40, which was mesylated and 
formation of the thiolate 2.41 occurred through reaction with ethanethiol. Dihydroxylation of the 
ethylenic bond from reaction of 2.41 with OsO4 and thioether reduction using H2 and Raney Ni 
afforded 2.42. A Malaprade reaction16 with periodic acid then gave glycol cleavage of the vicinal 
diol to afford the corresponding dial which was primed to undergo an aldol reaction affording 
aldehyde 2.43. Addition of PhLi and an anionotropic rearrangement then gave 2.44. Finally, 
dehydration, ozonolysis and treatment with hydrogen peroxide then gave cantharidin (2.36).  
 
 








































































One year later in 1952, Woodward and co-workers reported the use of the Diels-Alder reaction in 
a 35 linear step synthesis of (−)-cortisone (2.45) and 40-step synthesis of (−)-cholesterol (2.46) 
(Scheme 2.8).17 This was achieved through reaction of butadiene (2.16) with 4-
methoxytoluquinone (2.47) to afford the Diels-Alder product 2.48 in 86% and furnishing the C ring 
system. Epimerization through reaction with NaOH then gave the desired anti-stereochemistry 
across the ring junction of epi-2.48, followed by a 16-step synthesis of the ketone 2.49. Aldol 
condensation then afforded the enone 2.50 resulting in cyclization of the A ring system. Next a 
one-pot acetal deprotection and Malaprade reaction gave the dialdehyde 2.51, followed by a 
second aldol reaction to give the D ring system of the 𝛼, 𝛽-unsaturated aldehyde 2.52 in 66% over 
2-steps. Finally (−)-cortisone (2.45) was then synthesized in 13-steps which could be further 































































































These two examples highlight the importance of the Diels-Alder reaction in complex molecule 
synthesis. They also demonstrate the importance of approaching complex molecules through 
rational synthetic design, a strategy that first emerged in the 1950s and was further expanded by 
the development of the Woodward-Hoffman rules in 1965.18 This allowed for the prediction of 
stereochemistry and rationalization of activation energies in pericyclic reactions (including the 
Diels-Alder reaction) and helped make the Diels-Alder reaction more accessible to modern 
synthetic chemistry problems.  
 
2.1.5 History of the Inverse Demand Diels-Alder Reaction 
In contrast to the normal demand Diels-Alder reaction, less is known about the inception of the 
reverse demand Diels-Alder reaction. This is most likely due to challenges associated with the 
identification of normal and inverse electron demand reactions before the development of 
current computational methods and initial lack of understanding surrounding FMO theory.19 In a 
general sense, one of the earliest examples of inverse Diels-Alder reactions is often attributed to 
work by Carboni and Lindsey (Scheme 2.9).20 In 1959 they reported the first example of a Diels-
Alder reaction between the electron deficient perfluroalkyl tetrazine 2.53 and phenyl acetylene 
(2.54). This reaction (which is often referred to as the Carboni-Lindsey reaction) resulted in the 
formation of the intermediate 2.55, which underwent a retro-Diels-Alder reaction through loss of 
N2 to afford the pyridazine 2.56.  
 
 
Scheme 2.9 – Carboni and Lindsey’s 1959 Synthesis of pyridazine 2.5620 
 
Another example includes work by Barry Snider and John Duncia in 1980 who reported the 
synthesis of various inverse Diels-Alder reactions of 2,6-dimethyl-2,7-octadienal (2.57) (Scheme 
2.10).21 In an attempted total synthesis of the insecticide iridomyrmecin (2.58), 2.57 was heated 
to 405 °C in a vapour phase pyrolysis flow system to afford the dihydropyran 2.59 in 5%. 
Unfortunately, even after attempting this reaction at a range of different temperatures this 



























found that treatment of 2.57 with the Lewis acid BF3∙OEt2 gave another inverse Diels-Alder product 
2.60 in 49%. Presumably this was forming through isomerization of the 𝛼, 𝛽-unsaturated aldehyde 
to give 2.61, which allowed for an intramolecular Diels-Alder reaction through 2.62.  
 
Scheme 2.10 – Snider and Duncia’s Inverse Diels-Alder Reactions21 
 
One of the most well-known uses of an inverse Diels-Alder reaction includes the formal total 
synthesis of strychnine (2.63) and isostrychnine (2.64) reported by Bodwell in 2002 (Scheme 
2.11).22 This synthesis commenced through reaction of tryptamine (2.65) with 3,6-diisopyridazine 
(2.66) to afford 2.67. N-allylation of the indole moiety then gave 2.68 in 91%, which was subjected 
to hydroboration and an intramolecular Suzuki-Miyaura coupling to afford the cyclophane 2.69 in 
65%. Protection of the secondary amine as a methyl carbamate then gave 2.70, which was heated 
at reflux in DMA to induce the inverse Diels-Alder reaction furnishing the key framework of 2.71. 
Finally, a series of functional group interconversions including reduction, oxidation and 
deprotection gave 2.72 in 28% over 3-steps. This compound had been previously synthesized by 
Rawal and co-workers in 1994 and could be taken on to afford the formal total synthesis of 












































Scheme 2.11 – Li’s Formal Synthesis of Strychnine and Isostrychnine22 
 
Intrigued by the simplicity of these inverse demand Diels-Alder reactions, we considered that a 
similar approach may be applied to the total synthesis of busseihydroquinones C – E (2.3 – 2.5) 
and parvinaphthol C (2.8).  
 
2.1.6 Proposed Biosynthesis of Busseihydroquinones C − E and Parvinaphthol C 
In line with our groups current research into the biosynthesis of polyhydroxynaphthalene 
meroterpenoids24 we became intrigued by the biosynthetic relationship between 
busseihydroquinones C − E (2.3 – 2.5) and parvinaphthol C (2.8). We were particularly facinated 
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Our proposal linking the biosynthesis of busseihydroquinones C (2.3) and D (2.4) is outlined 
(Scheme 2.12). First, we envisaged that allylic oxidation of busseihydroquinone C (2.3) could 
afford the enal 2.75, which would be primed to undergo an intramolecular inverse demand 
hetero-Diels−Alder reaction between the chromene alkene and the tethered 𝛼, 𝛽-unsaturated 
dienophile. This would give the cyclic enol ether 2.76 (most likely an undiscovered natural 
product) via an endo transition state. Next, epoxidation of the enol ether alkene 2.76 could occur 
to give 2.77. Ring opening of the resultant epoxide would then afford 𝛼-hydroxyaldehyde 2.78 




Scheme 2.12 – Proposed Biomimetic Synthesis of busseihydroquinone D 
 
We anticipated that a biosynthetic pathway linking busseihydroquinone C (2.3) to 
busseihydroquinone E (2.5) and parvinaphthol C (2.8) could also be occurring from the same cyclic 
enol ether 2.76 (Scheme 2.13). Herein, we propose that 2.5 and 2.8 are likely isolation artifacts 
formed by the addition of MeOH or EtOH to the “undiscovered” natural product 2.76. Both Pentas 
bussei and Pentas parvifola plants were extracted and purified with MeOH, EtOAc and oxalic-acid 










































































the oxonium ion 2.77 and that the nucleophilic addition of EtOH or MeOH would give 2.5 and 2.8. 
Ethoxy groups are relatively rare in secondary metabolites, and it is not uncommon for natural 
product artifacts to arise from the interaction of MeOH or EtOH employed as solvents in the 




Scheme 2.13 – Proposed Biomimetic Synthesis of busseihydroquinone E and parvinaphthol C 
 
2.2 Results and Discussion 
2.2.1 Orcinol Model Study Featuring ortho-Quinone Methide Cyclizations 
Investigations into the biogenic relationship between the parvinaphthol and busseihydroquinone 
families began by targeting the synthesis of the known chromene 2.78 as a simplified model study 
of busseihydroquinone C (2.3) (Scheme 2.14). Condensation of orcinol (2.79) with citral according 
to a literature procedure by Lou et al. gave access to chromene 2.78 in 82%.26 Riley oxidation of 
2.78 using t-BuO2H and catalytic SeO2 afforded the allylic alcohol 2.80, which was directly oxidized 
using Swern reaction conditions to give enal 2.81. It was found that heating 2.81 at reflux in xylene 
afforded the Diels-Alder product 2.82 in 39% yield and the diastereoisomer 2.83 in 4% yield which 
was presumably forming via the less favorable exo transition state. The structure and relative 
configuration of 2.82 was supported using 2D NMR studies (see 2.4.4), while the structure of 2.83 
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2.5: busseihydroquinone E (R = Et)




Scheme 2.14 – Synthesis of the Key Enol Ether 2.82  
 
Alternatively, exposure of 2.81 to NaH in THF at −78 °C formed 2.82 and 2.83 in a slightly higher 
yield and improved selectivity (Scheme 2.15). Presumably this occurred in a stepwise manner, 
through an intramolecular Michael reaction to afford the o-QM 2.84, followed by an 
intramolecular oxa-Michael reaction. 
 
 
Scheme 2.15 – Stepwise Base Catalyzed [4+2] Cycloaddition of 2.81 
 
With 2.82 in hand, we envisaged that exposure to acid and MeOH would result in protonation and 
a stereoselective addition of MeOH to the enol ether to afford the parvinaphthol C analogue 2.85. 
Instead, 2.82 underwent a ring contraction to give the cyclobutane 2.86 in 54% (Scheme 2.16). 
Presumably this reaction was proceeding via an acid catalyzed ring-opening of 2.82 through a 








































































































Michael reaction with attack of the enol at C8’ to give aldehyde 2.88. An acid catalyzed addition 
of MeOH to 2.88 then formed the dimethoxy acetal 2.86. Interestingly this ring contraction of 2.82 
represents a unique approach towards the synthesis of more functionalized cyclobutane 
meroterpenoids, which are more ordinarily synthesized by intramolecular [2+2] cycloadditions of 




Scheme 2.16 – Ring Contraction of the Enol Ether 2.82  
 
Unfortunately, any attempts to further functionalize the enol ether alkene of 2.82 through 
hydroboration (BH3, THF then; H2O2, NaOH), oxymercuration (Hg(OAc)2, THF then; NaBH4), 
addition of oxalic acid (in MeOH), treatment with KOH (in MeOH/ H2O) and refluxing in MeOH/ 
EtOH gave either no reaction or decomposition. Additionally, we also considered reduction of the 
enol ether alkene and a CH oxidation. However, exposure of 2.82 to hydrogenation conditions 
only gave undesired cleavage of the benzylic C-C bond.  
 
Next, we investigated conversion of the cyclic enol ether 2.82 to the busseihydroquinone D 
analogue 2.89 via an epoxidation, fragmentation and ring-opening cascade (Scheme 2.17). 
Epoxidation of 2.82 with m-CPBA occurred on the less hindered, convex face to give epoxide 2.90, 




























































treatment of a solution of 2.82 with m-CPBA, followed by the addition of p-TsOH after 1 h 
facilitated a ring-opening fragmentation to give the o-QM 2.91. Disappointingly rather than the 
desired elimination reaction of 2.91, we observed an intramolecular oxa-Michael reaction to give 
the tetracyclic aldehyde 2.92 in 81%. The relative configuration of 2.92 was determined by 2D 
NOESY studies. Serendipitously, aldehyde 2.92 contained the same ring system as the 
meroterpenoid rhodonoid D (2.93), and indeed 2.92 could be converted into 2.93 via reduction 




Scheme 2.17 – Ring Contraction of the Enol Ether 2.82 and Synthesis of Rhodonoid D 
 
Attempts to dehydrate 2.92 to give 2.89 were unsuccessful (Table 2.1). Treatment of 2.92 with 4Å 
molecular sieves gave no reaction (entry 1). Acidic conditions also gave no reaction (entries 2 – 
3), while NaH gave decomposition (entry 4). In an attempt to trap the possible o-QM intermediate 
2.91 and preclude the intramolecular oxa-Michael reaction, treatment of 2.92 with Ac2O and 
pyridine at room temperature was undertaken (entry 5). However, this only afforded acetate 





















































2.93: rhodonoid D 2.92
m-CPBA, CH2Cl2













     BF3.OEt2, 0 °C
     CH2Cl2
2. Raney®-Ni, H2









Table 2.1 – Attempted Ring Opening and Dehydration of 2.92 to 2.89 
 
Entry Reagent Conditions Result 
1 -- THF, 4Å sieves, rt, 4 h NR 
2 H2SO4 MeOH, rt, 6 h NR 
3 H3PO4 THF, rt, 6 h NR 
4 NaH PhMe, 4Å sieves, rt, 3 h decomp. 
5 Ac2O pyridine, rt, 3 h 2.94 33% 
 
It was clear from our results that the key epoxidation and fragmentation were occurring, but that 
elimination proving challenging. This led us to consider that a similar fragmentation and 
elimination mediated reaction may be possible through a bromonium intermediate (analogous to 
the epoxide 2.91), and that elimination may be favoured, due to the improved leaving group 
ability of the bromide.  Unfortunately, reaction of the enol ether 2.82 with NBS (1.0 equiv.) in 
CHCl3 at −10 °C gave only bromination to the aromatic ring, affording 2.95 in 68% (Scheme 2.18). 




Scheme 2.18 – Bromination of enol ether 2.82 
 
Intrigued by the role of o-QMs in these cascade reactions, we wanted to investigate how 
protecting the free phenol would effect these transformations. To this end we synthesized the 






















































sulfate and K2CO3 (Scheme 2.19). Riley oxidation with t-BuO2H and catalytic SeO2 gave direct 
access to the methoxy protected enal 2.97 in 94% when the reaction was left for 14 h. 
Unsurprisingly, treatment of enal 2.97 with NaH, THF conditions at −78 °C gave no reaction, 
presumably as the key intramolecular Michael and oxa-Michael cascade was being suppressed. 
While thermal conditions through reflux in xylene gave the endo Diels–Alder product 2.98 
exclusively in a poor yield of 17%. Further reaction of 2.98 when subjected to m-CPBA and p-TsOH 
gave the tetracycle 2.99 in 85%, analogous to results observed in the synthesis of 2.92.  
   
 
 
Scheme 2.19 – Investigation into o-QM Cascades of the Methoxy Protected Chromene 2.96 
 
2.2.2 Naphthalene Model Study Featuring ortho-Quinone Methide Cyclizations 
The undesired transformations of 2.82 into 2.86 (under acidic conditions) and 2.92 (under 
oxidative conditions) led us to attempt these reactions with a closer analogue of the proposed 
biosynthetic intermediate 2.100 (Scheme 2.20). The chromene 2.101 was synthesized from 
commercially available 2,7-dihydroxynaphthalene (2.102) through Knoevenagel condensation 
and oxa-6𝜋-electrocyclization with citral and catalytic EDDA (10 mol%) in 73%. A 2-step allylic 
oxidation of chromene 2.101 then gave the 𝛼, 𝛽-unsaturated aldehyde 2.100, which underwent a 
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Scheme 2.20 – Synthesis of the Enol Ether 2.103 
 
We hoped that 2.103 would undergo addition of MeOH or EtOH to give analogues of 2.5 and 2.9, 
and an oxidative ring-opening to give an analogue of 2.4. However, in a similar vein to our previous 
results treatment of 2.103 with acidic MeOH gave the cyclobutane 2.105, while epoxidation and 





























































































Similar to the orcinol model study, these rearrangements could be replicated with the methoxy 
protected naphthalene 2.107 (Scheme 2.22). Riley oxidation of 2.107 with t-BuO2H and catalytic 
SeO2 afforded enal 2.108 in 48%. Reflux of 2.108 for 3 h gave the intramolecular hetero-Diels-Alder 
endo product 2.109 in 33% and the minor diastereoisomer 2.110 synthesized through the exo 
transition state in 1%. Again, we observed a lower yield of 2.109 when compared to the free 




Scheme 2.22 – Investigation into o-QM Cascades of the Methoxy Protected Chromene 2.107 
 
2.2.3 Normal Electron Demand Diels-Alder Reaction Cascades  
Inspired by our success in the synthesis of model study enol ethers through inverse demand 
intramolecular hetero-Diels-Alder reactions, we considered the possibility of incorporating a 
Wittig reaction, normal demand intramolecular Diels-Alder reaction, and lactonization to afford 
2.111a (Scheme 2.23). This transformation intrigued us due to the formation of 5 stereocentres 
and 3 rings in a single step! Gratifyingly treatment of 2.81 with ethyl (triphenylphosphoranylidene) 
acetate at room temperature afforded the diene 2.112 in 66%. 2.112 was then heated to reflux in 
PhMe with the presence of catalytic BHT to afford 2.111a in 25%.   
 





















































Scheme 2.23 – 2-Step Reaction of Enal 2.81 to Lactone 2.111a 
 
 
Although the obtained 1H NMR spectrum of 2.111a had overlapping H8 and H12 signals, we were 
able to observe key NOE correlations between H7 and H15 and between H7 and H8 (see 2.4.4), 
suggesting that the reaction was proceeding through the endo transition state rather than the exo 




Scheme 2.24 – Proposed Endo and Exo Transition States of 2.112 
 
 
Due to the simplicity of the intramolecular Diels-Alder reaction to only require thermal conditions 
and due to the highly robust nature of most Wittig reactions, a one-pot reaction cascade from 
enal 2.81 to lactone 2.111a was attempted (Scheme 2.25). It was found that refluxing 2.81, ethyl 
(triphenylphosphoranylidene)acetate and BHT for 24 h gave the desired Wittig, intramolecular 




























































































Scheme 2.25 – One-Pot Reaction Cascade from Enal 2.81 to Lactone 2.111a 
 
 
2.2.4 Initial Attempts Towards Busseihydroquinones C − E and Parvinaphthol C 
With some interesting ortho-QM reaction cascades in hand and some promising results in the 
synthesis of the key enol ethers 2.82, 2.98, 2.103 and 2.109, our efforts turned towards synthesis 
of the real parvinaphthol and busseihydroquinone system. We began our approach with an 8-step 
synthesis of 2.113 following literature conditions from Jeong and co-workers (Scheme 2.26).28 This 
began with a reductive dimethylation of 1,4-napthoquinone (2.114) to give 1,4-
dimethoxynapthelene (2.115) in 94%. An iridium catalyzed C-H activation at C6 then afforded a 
borane ester which was oxidized directly to give phenol 2.116 in 60% (over 2-steps). Next, 
bromination at C2 with NBS gave 2.117 in 65%, followed by isopropyl protection to afford 2.118. 
A lithium halogen exchange of 2.118 through reaction with t-BuLi followed by addition of ethyl 
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We investigated conditions for synthesis of chromene 2.120, which upon hydrolysis of the ethyl 
ester would provide busseihydroquinone C (2.3). Unfortunately, all attempts of Knoevenagel 
condensation and oxa-6𝜋-electrocyclization cascades failed (Table 2.2). Reaction conditions using 
EDDA at 3 mol% and 10 mol% gave no reaction, even when left for 48 h (entries 1−2). While 
reaction conditions developed by Chauder and co-workers (PhB(OH)2 and AcOH) gave no reaction 
(entry 3).29 Treatment of 2.113 with pyridine (entries 4−5) and piperidine (entry 6) gave 
decomposition. Finally, we attempted chromenylation with Ti(Oi-Pr)4  at −78 °C → rt, however 




Table 2.2 – Conditions Screened for the Synthesis of Chromene 2.120 
 
Entry Conditions Temperature Time Result 
1 citral, EDDA  
(3 mol%) PhMe 
120 °C 48 h NR 
2 citral, EDDA  
(10 mol%), PhMe 
120 °C 8 h NR 
3 citral, PhB(OH)2 
AcOH, PhMe 
120 °C 24 h NR 
4 citral, pyridine 
PhMe 
120 °C 24 h decomp. 
5 citral, pyridine 120 °C 24 h decomp. 
6 citral, piperidene 
Ac2O, EtOAc 
0 °C → 90 °C 18 h decomp. 
7 citral, Ti(Oi-Pr)4 
PhMe 
−78 °C → rt 16 h NR 
 
 
2.2.5 Further Efforts Towards the Busseihydroquinone and Parvinaphthol Families 
A revised approach featuring an earlier chromenylation was attempted, we hoped that the more 
electron rich naphthol 2.116 would give better yields as well as allowing us access to larger 
quantities of starting material. Unfortunately, treatment with citral using the standard 
chromenylation reaction conditions as previously described (i.e. Table 2.2) gave identical results. 




















2.27). Treatment of 2.116 with geranyl bromide gave the desired product 2.121, however reaction 




Scheme 2.27 – Attempted 2-Step Chromenylation of 2.116 
 
Interestingly, literature from as early as 1962 by Iwai et al. report the similar challenges in the 
synthesis of naphthalene chromenes.30 To overcome these issues the authors report a unique 
approach through intermediate propargyl ethers. Following a modified procedure from Godfrey 
and co-workers we performed a Cu mediated coupling between 2.116 and the literature 
compound 2.123 affording 2.124 in 30% (Scheme 2.28).31 A thermally induced Claisen 
rearrangement, 1,5-hydrogen shift and aromatization then provided the desired chromene 2.122 








































































Our attention then turned towards activation of the C2 position to install the carboxylic acid motif 
of busseihydroquinone C (2.3). Frustratingly, Vilsmeier-Haack formylation conditions only resulted 
in decomposition of 2.122. Interestingly, an attempted bromination of 2.122 at C2 through 
reaction with NBS in CH2Cl2 at 0 °C gave 2.126 in 38% (Scheme 2.29). This reaction is presumably 
proceeding through the bromonium intermediate 2.127 followed by a 6-endo-tet cyclization. 
Serendipitously, the scaffold for 2.127 is analogous to another class of natural products 
rasumatranins A−C and nyingchinoids E and H (i.e. 2.128 −	2.132). We propose that these 
compounds are formed via an analogous route, through a selective epoxidation rather than 
bromination of the chromene motif. Investigation into similar epoxidations and brominations of 
2H-chromenes have been previously reported in our group,32 however the total synthesis of 2.128 
– 2.132 is yet to be realized. 
 
 
Scheme 2.29 – Synthesis of 2.126 Through Bromination of 2.112 
 
Bromination and 6-endo-tet cyclization of 2.122 to afford 2.126 resulted in the formation of 4 new 
stereocentres, careful analysis of the 1H NMR spectrum of 2.126 allowed us to assign the relative 
stereochemistry (Figure 2.3). We observed key NOE correlations between the methoxy at H4’ and 
the methyl group at H15 which would be only possible with the H15 terminal alkene in the axial 




























2.132: rasumatranin C 
(R = bibenzyl)
2.129: rasumatranin B (R = bibenzyl)
2.130: nyingchinoid E (R = Me)





























Figure 2.3 – Relative Configuration of 2.126 
 
Having succeeded in the synthesis of the chromene 2.122 but unable to functionalize at the C2 
carbon, we attempted the 2-step chromenylation of 2.117 through an analogous propargyl ether 
2.133 (Scheme 2.30). We observed higher yields of 2.133 when using the methoxy carbonate 
2.134 rather than the in-situ acetate protected 2.123, affording access to 2.133 in 64%. Analogous 
to the synthesis of 2.122, treatment of 2.133 afforded 2.135 this time in 41% yield. 
 
 
Scheme 2.30 – Synthesis of Chromene 2.135 
 
With access to 2.135, a direct carboxylation through lithium halogen exchange and reaction with 
anhydrous CO2 gave 2.136 in 42% (Scheme 2.31). Unfortunately, all attempts to selectively 
remove the methoxy protecting group at C1 failed. Reaction with BBr3, HBr and AlCl3 conditions 
all afforded decomposition of 2.136 rather than formation of busseihydroquinone C (2.3).  
Instead, we decided to continue this synthesis forward performing a Riley oxidation of 2.136 to 
give enal 2.137 in 30% yield through reaction with catalytic SeO2 and t-BuO2H. Disappointingly, 
heating 2.137 at reflux in xylene did not give the desired intramolecular hetero-Diels-Alder 
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Scheme 2.31 – Attempted Intramolecular Hetero-Diels-Alder Reaction of enal 2.137 
 
Surprisingly, it was found that when quenching the lithium halogen exchange/ carboxylation 
reaction with sat. brine(aq) and leaving the solution to stir for 2 h we obtained what we assigned 
to be 2.139 directly (Scheme 2.32). Frustratingly, we observed the 1H NMR of 2.139 had all the 
expected key diagnostic NOE correlations (i.e. between C3 and C4-OMe, and between C4-OMe 
and C1’), however the obtained spectra did not match that of the natural product 2.3 (Table 2.3). 
We continued with this synthesis affording enal 2.140 from reaction of 2.139, however the 
attempted intramolecular hetero-Diels-Alder reaction failed giving only decomposition of 2.140.  
 
 




























    –78 ºC, 10 min
2. CO2, –78 ºC 
































































    –78 ºC, 10 min
2. CO2, –78 ºC → rt










































Table 2.3 – Comparison of the Reported and Obtained NMR Spectra of 2.3 and 2.139 
 
Assignment 1H NMR (d6-DMSO) 13C NMR 
Sample 2.139 
 (600 MHz)  
Natural Sample 
(800 MHz) 





(800 MHz)  
d6-DMSO 
 Endale et al.2 
1 -- -- 179.3 155.0 
2 -- -- 128.0 102.9 
3 6.66 (s) 7.06 (s) 105.7 104.3 
4 -- -- 155.1 148.5 
4a -- -- 124.5 125.9 
5 -- -- 114.9 114.3 
6 -- -- 151.7 154.4 
7 7.09 (d, J = 9.5 Hz) 7.10 (d, J = 8.7 Hz) 117.4 118.2 
8 8.27 (d, J = 9.6 Hz) 8.11 (d, J = 8.7 Hz) 129.6 124.8 
8a -- -- 130.3 120.8 
1’ 7.64 (d, J = 10.3 Hz) 7.70 (d, J = 10.4 Hz) 124.2 122.5 
2’ 5.64 (d, J = 10.3 Hz) 5.68 (d, J = 10.4 Hz) 125.9 127.3 
3’ -- -- 77.1 77.4 
4’ 1.38 (s) 1.37 (s) 25.6 25.4 
5’ 1.72 – 1.69 (m) 1.67 (m) 40.5 39.9 
6’ 2.09 – 2.06 (m) 2.05 (m) 22.9 22.2 
7’ 5.10 (t, J = 7.4 Hz) 5.05 (t, J = 6.8 Hz) 124.4 123.9 
8’ -- -- 131.8 130.9 
9’ 1.52 (s) 1.49 (s) 25.8 17.4 
10’ 1.61(s) 1.59 (s) 17.7 25.3 
11’ -- -- 185.7 172.6 
1’OH 13.05 (br s) 12.20 (br s) -- -- 
4’OMe 3.89 (s) 3.85 (s) 55.7 55.7 
 
2.3 Conclusion and Future Work 
In summary, we have reported some short model studies featuring the synthesis of the polycyclic 
scaffold of busseihydroquinone E (2.3) and parvinaphthol C (2.8), achieved via diastereoselective 
intramolecular hetero-Diels-Alder reactions of chromene intermediates under basic or thermal 




























synthesis of ring contracted cyclobutane and furan products was developed. This led to a new and 
high yielding approach towards the total synthesis of rhodonoid D (2.93).  
 
We also believe efforts towards busseihydroquinone C (2.3) should be revisited and that a possible 
reassignment should be strongly considered. Finally, the synthesis of bromide 2.126 via a 
bromination and 6-endo-tet cyclization cascade has inspired us to develop a biosynthetic proposal 
towards rasumatranins A−C and nyingchinoids E and H (i.e. 2.128 −	2.132). We hope to explore 







































2.4.1 General Methods 
All chemicals used were purchased from commercial suppliers and used as received. All reactions 
were performed under an inert atmosphere of N2 unless otherwise stated. Thin layer 
chromatography was performed using aluminium sheets coated with silica gel. Visualization was 
aided by viewing under a UV lamp and staining with the appropriate stain followed by heating. All 
Rf values were measured to the nearest 0.05. Flash chromatography was performed using 40-63 
micron grade silica gel. Melting points were recorded on a digital melting point apparatus and are 
uncorrected. Infrared spectra were recorded using an FT-IR spectrometer as the neat compounds. 
High field NMR was recorded using a 600 MHz spectrometer (1H at 600 MHz, 13C at 150 MHz) or a 
500 MHz spectrometer (1H at 500 MHz, 13C at 125 MHz). The solvent used for NMR spectra was 
CDCl3 unless otherwise specified. 1H chemical shifts are reported in ppm on the δ-scale relative to 
TMS (δ 0.0) and 13C{1H} NMR are reported in ppm relative to chloroform (δ 77.16). Multiplicities 
are reported as (br) broad, (s) singlet, (d) doublet, (t) triplet, (q) quartet and (m) multiplet. All J-
values were rounded to the nearest 0.1 Hz. ESI high resolution mass spectra were recorded on a 
Q-TOF mass spectrometer. Photochemistry with UVA light was performed using a generic brand 
commercial LED UV light globe; wavelength: 365 nm. Photochemistry with UVC light was 
performed using a generic brand commercial LED UV light globe; wavelength: 254 nm. 
Photochemical reactions with visible light were performed with a conventional commercial LED 
desk lamp at 240 V with a 4 W 5000 K 32 mÅ globe. Reactions conducted under 470 nm blue LED 
























To a solution of orcinol (2.79) (10.0 g, 81.0 mmol, 1.0 equiv.) in PhMe (250 mL) at room 
temperature was added citral (12.3 mL, 81.0 mmol, 1.0 equiv.) and EDDA (500 mg, 2.43 mmol, 3 
mol%). The reaction was stirred at 110 °C for 5 h. The mixture was cooled to room temperature, 
then concentrated in vacuo. The residue was purified by flash column chromatography on SiO2 
(8:1 hexanes/ EtOAc) to give chromene 2.78 (17.2 g, 82%) as an orange oil. Data for 2.78 matched 
that previously reported in the literature.26 
 
Data for 2.78: 
Rf: 0.40 (5:1 hexanes/ EtOAc).  
FTIR (neat): 3387, 2970, 2924, 1625, 1578, 1509, 1450, 1377, 1330, 1250 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.61 (d, J = 10.0 Hz, 1H), 6.24 (s, 1H), 6.11 (s, 1H), 5.49 (d, J = 10.0 Hz, 
1H), 5.10 (t, J = 7.2 Hz, 1H), 4.73 (br s, 1H), 2.20 (s, 3H), 2.13 – 2.07 (m, 2H), 1.75 – 1.70 (m, 1H), 
1.66 (s, 3H), 1.65 – 1.61 (m, 1H), 1.58 (s, 3H), 1.37 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 154.3, 151.2, 139.7, 131.8, 127.4, 124.4, 116.9, 110.0, 108.5, 106.9, 
78.4, 41.3, 26.4, 25.8, 22.9, 21.7, 17.8 ppm. 



























Chromene 2.78 (1.20 g, 4.83 mmol, 1.0 equiv.) was dissolved in CH2Cl2 (70 mL) and SeO2 (108 mg, 
0.970 mmol, 20 mol%) was added, followed by t-BuO2H (3.20 mL, 5.50 M, 17.4 mmol, 3.6 equiv.). 
The reaction was left to stir at room temperature for 3 h, quenched with sat. Na2SO3 (aq) (70 mL) 
and the product was extracted with CH2Cl2 (70 mL). The organic phase was further washed with 
sat. brine (70 mL), dried with MgSO4, filtered, concentrated and the residue was purified via flash 
chromatography on SiO2 (2:1 hexanes/ EtOAc) to give allylic alcohol 2.80 (560 mg, 42%) as an 
orange oil and aldehyde 2.81 (90 mg, 7%) as a red oil. 
 
Data for 2.80: 
Rf: 0.30 (3:1 hexanes/ EtOAc). 
FTIR (neat): 3361, 2970, 2922, 1665, 1623, 1578, 1449, 1420, 1328, 1271, 1196, 1138, 1096, 1060, 
991, 823 cm-1. 
1H NMR (500 MHz, CDCl3): δ 9.35 (s, 1H), 6.69 (d, J = 10.0 Hz, 1H), 6.51 (t, J = 7.5 Hz, 1H), 6.20 (s, 
1H), 6.14 (s, 1H), 5.45 (d, J = 10.0 Hz, 1H), 5.36 (br s, 1H), 2.57 – 2.43 (m, 2H), 2.20 (s, 3H), 1.92 – 
1.80 (m, 2H), 1.71 (s, 3H), 1.41 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 195.8, 155.4, 153.9, 151.6, 140.1, 139.4, 126.1, 117.9, 109.7, 108.8, 
106.6, 78.1, 39.7, 26.7, 24.3, 21.7, 9.3 ppm. 
HRMS (ESI) m/z: [M+H]+ Calcd for C17H23O3 275.1640; found 275.1642. 
 
Data for 2.81: 
Rf: 0.10 (2:1 hexanes/ EtOAc). 
FTIR (neat): 3310, 2971, 2921, 2861, 1623, 1578, 1509, 1449, 1328, 1285, 1197, 1140, 1078, 1060, 
990, 907, 823, 774, 731 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.63 (d, J = 10.0 Hz, 1H), 6.21 (s, 1H), 6.10 (s, 1H), 5.53 (br s, 1H), 5.45 
(d, J = 10.0 Hz), 5.40 (t, J = 7.1 Hz, 1H), 3.97 (s, 2H), 2.19 – 2.17 (m, 2H), 1.79 – 1.67 (m, 2H), 1.62 
(s, 3H), 1.5 (br s, 1H), 1.38 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 154.1, 151.5, 139.7, 134.7, 126.8, 126.6, 117.2, 109.6, 108.5, 106.8, 
78.3, 69.2, 40.9, 26.7, 22.6, 21.6, 13.7 ppm. 

























A solution of (COCl)2 (0.20 mL, 2.34 mmol, 1.2 equiv.) in CH2Cl2 (20 mL) was cooled to –78 °C. 
DMSO (0.33 mL, 4.67 mmol, 2.4 equiv.) was added and the reaction mixture was stirred for 20 
min. The reaction mixture was then added to a second solution of allylic alcohol 2.80 (534 mg, 
1.95 mmol, 1.0 equiv.) in CH2Cl2 (20 mL) at –78 °C. The reaction was stirred for 10 min, followed 
by addition of Et3N (1.62 mL, 11.7 mmol, 6.0 equiv.) after which time the solution was left to warm 
to room temperature over 1 h. Distilled H2O (20 mL) was added to quench the reaction, the 
product was extracted with CH2Cl2 (40 mL) and the organic solution was washed with sat. brine 
(40 mL), dried with MgSO4, filtered and concentrated. Purification via flash chromatography on 



































Aldehyde 2.81 (2.12 g, 7.40 mmol, 1.0 equiv.) was dissolved in xylene (70 mL) and heated to 140 
°C and stirred for 5 h. After this time the solution was concentrated and purified via flash 
chromatography on SiO2 (6:1 hexanes/ EtOAc) to give enol ether 2.82 (825 mg, 39%) as an orange 
solid and 2.83 (83 mg, 4%) as a white solid.  
 
Data for 2.82:  
Rf: 0.40 (3:1 hexanes/ EtOAc).  
MP: 129 – 133 °C.  
FTIR (neat): 3409, 2955, 2870, 1651, 1634, 1576, 1499, 1446, 1380, 1358, 1334, 1200, 1178, 1142, 
1121, 1081, 1063, 996, 1018, 996, 889, 823, 708, 676 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.22 (br s, 1H), 6.27 (s, 1H), 6.20 (s, 1H), 6.16 (s, 1H), 5.32 (d, J = 8.3 
Hz, 1H), 2.70 (m, 1H), 2.58 (t, J = 9.4 Hz, 1H), 2.21 (s, 3H), 2.04 (m, 1H), 1.93 – 1.87 (m, 1H), 1.73 – 
1.58 (m, 1H), 1.54 (s, 3H), 1.53 – 1.48 (m, 1H), 1.43 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 155.9, 155.8, 140.3, 134.7, 118.0, 109.6, 109.4, 105.1, 85.9, 66.4, 
44.7, 40.1, 37.4, 29.5, 25.8, 21.5, 16.2 ppm. 
HRMS (ESI) m/z: [M+H]+ Calcd for C17H21O3 273.1485; found 273.1486. 
 
Data for 2.83: 
Rf: 0.60 (3:1 hexanes/ EtOAc).  
FTIR (neat): 3392, 2960, 2881, 1675, 1628, 1595, 1510, 1415, 1357, 1302, 1182, 1122, 1059, 998, 
920, 901, 827 cm-1.  
1H NMR (600 MHz, CDCl3): δ 7.50 (br s, 1H), 6.29 (s, 1H), 6.17 (s, 1H), 6.09 (s, 1H), 5.54 (d, J = 6.4 
Hz, 1H), 2.48 – 2.41 (m, 1H), 2.26 – 2.22 (m, 1H), 2.21 (s, 3H), 2.03 – 1.95 (m, 2H), 1.87 – 1.83 (m, 
1H), 1.57 (s, 3H), 1.47 – 1.41 (m, 1H), 1.39 (s, 3H) ppm. 
13C NMR (150 MHz, CDCl3): δ 157.5, 152.4, 140.7, 134.9, 113.2, 109.9, 109.3, 104.4, 84.3, 69.9, 
46.9, 39.4, 35.9, 24.7, 23.8, 21.5, 15.0 ppm. 
































Aldehyde 2.81 (305 mg, 1.12 mmol, 1.0 equiv.) was dissolved in THF (18 mL) and cooled to 0 °C. 
NaH (60% wt./ wt., 90 mg, 2.24 mmol, 2.0 equiv.) was then added in small portions and the 
reaction was stirred at room temperature for 4 h. The solution was then quenched with sat. 
NH4Cl(aq) and extracted with Et2O (3 x 10 mL). Combined organic extracts were dried with MgSO4, 
concentrated and purified via flash chromatography on SiO2 (6:1 hexanes/ EtOAc) to give enol 
ether 2.82 as the major diastereoisomer (205 mg, 67%) and 2.83 as the minor diastereoisomer 












































To a solution of enol ether 2.82 (56 mg, 0.210 mmol, 1.0 equiv.) in MeOH (3 mL) was added p-
toluenesulfonic acid (5 mg, 0.020 mmol, 10 mol%). The reaction was stirred at room temperature 
for 4 h, then distilled water was added (5 mL) and the product was extracted with Et2O (3 x 5 mL). 
The combined organic layers were dried with MgSO4, filtered, and concentrated. Purification via 
flash chromatography on SiO2 (6:1 hexanes/ EtOAc) then gave acetal 2.86 (35 mg, 54%) as an 
orange solid.  
 
Data for 2.86: 
Rf: 0.40 (3:1 hexanes/ EtOAc).  
FTIR (neat): 3344, 2950, 1630, 1575, 1497, 1450, 1354, 1316, 1293, 1206, 1176, 1129, 1100, 1077, 
1057, 999, 982, 948, 908, 824, 736 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.45 (br s, 1H), 6.26 (m, J = 6.4 Hz, 2H), 4.29 (s, 1H), 3.68 (s, 3H), 3.66 
(s, 3H), 3.28 (d, J = 9.9 Hz, 1H), 2.63 (t, J = 7.5 Hz, 1H), 2.56 (m, 1H), 2.22 (s, 3H), 1.94 (m, 1H), 1.71 
– 1.62 (m, 3H), 1.39 (s, 3H), 0.84 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 155.6, 153.9, 138.4, 114.4, 110.2, 108.7, 105.2, 82.5, 59.6, 58.8, 47.2, 
40.9, 39.2, 37.9, 29.8, 28.1, 25.4, 21.5, 10.6 ppm. 
































Enol ether 2.82 (191 mg, 0.667 mmol, 1.0 equiv.) was dissolved in CH2Cl2 (20 mL) and m-CPBA 
(77%, 173 mg, 1.00 mmol, 1.5 equiv.) was added. The resulting solution was stirred at room 
temperature for 1 h, then p-toluenesulfonic acid (250 mg, 1.31 mmol, 2.0 equiv.) was added and 
the solution was stirred for a further for 1 h. The reaction was then quenched with sat. NaSO3(aq.) 
(20 mL), the organic layer was then further washed with sat. NaHCO3(aq.) (2 x 20 mL) and extracted 
with CH2Cl2 (2 x 20 mL), dried with MgSO4 and filtered. Concentration afforded furan 2.92 (155 
mg, 81%), which was used without further purification.     
 
Data for 2.92: 
Rf: 0.40 (7:1 hexanes/ EtOAc).  
FTIR (neat): 3443, 2971, 2935, 1734, 1630, 1585, 1458, 1378, 1272, 1195, 1134, 1069, 998 cm-1. 
1H NMR (500 MHz, CDCl3): δ 9.75 (s, 1H), 6.48 (br s, 1H), 6.39 (s, 1H), 6.34 (s, 1H), 5.18 (d, J = 8.3 
Hz, 1H), 2.92 – 2.86 (m, 2H), 2.25 (s, 3H), 1.96 – 1.89 (m, 1H), 1.77 – 1.69 (m, 1H), 1.66 – 1.59 (m, 
1H), 1.52 – 1.47 (m, 1H), 1.45 (s, 3H), 1.41 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 203.9, 155.9, 152.6, 140.8, 110.7, 109.8, 106.4, 89.3, 83.0, 70.3, 52.6, 
51.2, 36.2, 27.1, 24.8, 21.7, 21.6 ppm. 































To a solution of furan 2.92 (250 mg, 0.870 mmol, 1.0 equiv.) under N2 in dry CH2Cl2 (20 mL) was 
added 1,3-propanedithiol (0.29 mL, 2.88 mmol, 3.0 equiv.) and BF3·OEt2 (400 mg, 0.35 mL, 2.82 
mmol, 3.0 equiv.) at 0 °C. The reaction mixture was stirred for 30 min at room temperature and 
quenched by the addition of sat. NaHCO3(aq) (20 mL). The organic layer was then separated and 
the aqueous phase was further extracted with CH2Cl2 (2 x 20 mL). The combined organic layers 
were dried with MgSO4, filtered and concentrated in vacuo. Purification by flash chromatography 
on SiO2 (9:1 hexanes/ EtOAc) then afforded dithiane 2.142 (93 mg, 40%) as a yellow solid. 
 
Data for 2.142: 
Rf: 0.30 (9:1 hexanes/ EtOAc).  
FTIR (neat): 3435, 2972, 1635, 1583, 1459, 1378, 1359, 1459, 1378, 1359, 1275, 1194, 1146, 1104, 
1129, 1065, 997, 908, 831, 774, 730 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.96 (br s, 1H), 6.36 (s, 1H), 6.29 (s, 1H), 4.96 (d, J = 9.1 Hz, 1H), 4.28 
(s, 1H), 2.95 – 2.73 (m, 6H), 2.23 (s, 3H), 1.90 – 1.76 (m, 4H), 1.50 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 156.1, 151.8, 140.2, 110.2, 109.9, 107.3, 86.6, 82.7, 69.6, 56.1,51.6, 
51.6, 35.4, 31.1, 30.8, 27.9, 26.1, 24.3, 22.8, 21.6 ppm. 

































To a solution of dithiane 2.142 (52 mg, 0.136 mmol, 1.0 equiv.) in dry EtOH (10 mL) was added 
Raney® Nickel (0.6 mL, 2400 slurry in H2O). H2 was sparged through the solution for 10 min, then 
the reaction was heated at reflux under H2 for 6 h and filtered through Celite (washed with EtOAc). 
The solution was then concentrated to give rhodonoid D (2.93) (37 mg, 0.130 mmol, quant.) as a 
white solid. Data for rhodonoid D (2.93) matched that previously reported in literature.33 
 
Data for rhodonoid D (2.93): 
Rf: 0.55 (2:1 hexanes/ EtOAc).  
MP: 162 – 165 °C. 
FTIR (neat): 3435, 2970, 2921, 2853, 1636, 1586, 1460, 1370, 1326, 1299, 1190 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.92 (s, 1H), 6.35 (s, 1H), 6.29 (s, 1H), 4.92 (d, J = 9.1 Hz, 1H), 2.82 (t, 
J = 8.5 Hz, 1H), 2.56 (ddd, J = 9.9, 8.0, 3.8 Hz, 1H), 2.23 (s, 3H), 1.85 – 1.78 (m, 1H), 1.75 – 1.72 (m, 
1H), 1.67 – 1.61 (m, 1H), 1.48 (s, 3H), 1.44 – 1.40 (m, 1H), 1.33 (s, 3H), 1.29 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 156.1, 151.7, 139.9, 110.0, 109.2, 107.3, 83.2, 82.9, 68.8, 51.6, 51.5, 
34.9, 28.0, 27.5, 24.13, 24.07, 21.5 ppm. 


































To aldehyde 2.92 (30 mg, 0.10 mmol, 1.0 equiv.) in pyridine (2 mL) was added dropwise at room 
temperature Ac2O (0.02 mL, 0.22 mmol, 2.2 equiv.). After 3 h the reaction was quenched upon 
addition of sat. brine (5 mL) and product was extracted EtOAc (3 x 5 mL), dried with MgSO4, filtered 
and concentrated. Purification by column chromatography on SiO2 (20:1 hexanes/ EtOAc) then 
gave 2.94 (11 mg, 33%) as a 1:1 mixture of epimers.  
 
Partial Data for 2.94: 
Rf: 0.40 (20:1 hexanes/ EtOAc).  
FTIR (neat): 2931, 1771, 1735, 1200, 1134 cm-1. 
1H NMR (500 MHz, CDCl3): δ 9.71 (s, 2H), 6.64 (s, 1H), 6.60 (s, 1H), 6.58 (s, 1H), 6.51 (s, 1H), 5.06 
(d, J = 8.6 Hz, 1H), 4.89 (d, J = 8.6 Hz, 1H), 2.88 (q, J = 8.6 Hz, 1H), 2.78 (t, J = 8.6 Hz, 1H), 2.74 – 
2.69 (m, 1H), 2.65 – 2.61 (m, 1H) 2.30 (s, 6H), 2.28 (s, 6H), 2.09 – 2.05 (m, 1H), 1.82 – 1.70 (m, 4H), 
1.62 – 1.55 (m, 4H), 1.37 (s, 3H), 1.32 (s, 3H), 1.32 (s, 3H), 1.26 (s, 3H) ppm.  
13C NMR (125 MHz, CDCl3): δ 205.4, 169.6, 154.9, 149.9, 140.7, 117.1, 116.4, 112.2, 87.8, 86.1, 

































To a solution of 2.82 (100 mg, 0.476 mmol, 1.0 equiv.) in CHCl3 (20 mL) at −10 °C was added NBS 
(37 mg, 0.428 mmol, 0.9 equiv.). The solution was left to warm to room temperature over 4 h, 
then quenched with NH4Cl(aq) (20 mL) and product extracted CHCl3 (3 x 20 mL), dried with MgSO4, 
filtered and concentrated. Purification by flash chromatography on SiO2 (9:1 hexanes/ EtOAc) then 
afforded bromide 2.95 (87 mg, 68%) and the recovered starting material 2.82 (14 mg, 14%). Data 
for 2.82 matched that previously obtained.  
 
Data for 2.95: 
Rf: 0.10 (4:1 hexanes/ EtOAc).  
FTIR (neat): 3384, 2961, 1675, 1618, 1572, 1451, 1360, 1304, 1170, 995, 836 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.84 (br s, 1H), 6.40 (s, 1H), 6.27 (s, 1H), 5.19 (d, J = 6.6 Hz, 1H), 2.81 
– 2.61 (m, 1H), 2.48 (dd, J = 10.1, 6.6 Hz, 1H), 2.32 (s, 3H), 2.07 – 2.01 (m, 1H), 1.87 – 1.78 (m, 1H), 
1.77 – 1.72 (m, 1H), 1.66 – 1.60 (m, 2H), 1.34 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 155.0, 151.2, 139.4, 137.7, 115.7, 112.1, 108.7, 104.5, 86.2, 65.7, 
46.5, 39.3, 37.9, 28.6, 27.0, 23.3, 16.3 ppm. 
































To a solution of 2.78 (5.11 g, 9.00 mmol, 1.0 equiv.) in acetone (150 mL) was added K2CO3 (6.45 g, 
46.8 mmol, 5.2 equiv.) and dimethyl sulfate (1.70 mL, 17.9 mmol, 2.0 equiv.). The solution was 
heated to reflux for 2 h, then cooled and distilled water (150 mL) added. The product was 
extracted with EtOAc (3 x 150 mL), dried MgSO4, filtered and concentrated. Purification by flash 
chromatography on SiO2 (9:1 hexanes/ EtOAc) then afforded chromene 2.96 (4.64 g, 86%) as a 
clear oil.  
 
Data for 2.96: 
Rf: 0.50 (9:1 hexanes/ EtOAc).  
FTIR (neat): 2967, 1613, 1572, 1453, 1387, 1229, 1144, 1024, 814 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.66 (d, J = 10.0, 1H), 6.28 (s, 1H), 6.22 (s, 1H), 5.46 (d, J = 10.0 Hz, 
1H), 5.10 (t, J = 1.3 Hz, 1H), 3.80 (s, 3H), 2.27 (s, 3H), 2.16 – 2.05 (m, 2H), 1.76 – 1.61 (m, 2H), 1.73 
(s, 3H), 1.37 (s, 3H) ppm.  
13C NMR (125 MHz, CDCl3): δ 155.2, 154.0, 139.5, 131.7, 126.9, 124.5, 117.4, 110.1, 108.0, 104.0, 
78.2, 55.7, 41.3, 26.4, 25.8, 22.9, 22.1, 17.8 ppm. 

























Chromene 2.96 (4.02 g, 14.7 mmol, 1.0 equiv.) was dissolved in CH2Cl2 (150 mL), SeO2 (420 mg, 
2.94 mmol, 20 mol%) and t-BuO2H (9.4 mL, 51.5 mmol, 3.5 equiv.) was added. The reaction was 
left to stir for 14 h at room temperature then quenched with sat. NH4Cl(aq) (150 mL) and product 
extracted CH2Cl2 (3 x 150 mL) and concentrated. The crude was then purified via flash column 
chromatography on SiO2 (9:1 hexanes/ EtOAc) to afford 2.97 (4.00 g, 94%) as an orange oil.  
 
Data for 2.97: 
Rf: 0.40 (9:1 hexanes/ EtOAc).  
FTIR (neat): 2966, 1683, 1612, 1572, 1462, 1388, 1226, 1017 cm-1. 
1H NMR (500 MHz, CDCl3): δ 9.35 (s, 1H), 6.70 (d, J = 10.0 Hz, 1H), 6.49 (t, J = 1.5 Hz, 1H), 6.25 (s, 
1H), 6.22 (s, 1H), 5.42 (d, J = 10.0 Hz, 1H), 3.80 (s, 3H), 2.57 – 2.43 (m, 2H), 2.26 (s, 3H), 1.92 – 1.76 
(m, 2H), 1.69 (s, 3H), 1.40 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 195.4, 155.3, 154.8, 153.6, 139.9, 139.4, 125.8, 118.2, 109.9, 104.2, 
77.9, 55.7, 39.7, 26.7, 25.9, 24.3, 22.1, 9.2 ppm. 


























A solution of 2.97 (232 mg, 0.810 mmol, 1.0 equiv.) in xylene (20 mL) was heated at reflux. After 
3 h the reaction was concentrated in vacuo. The crude was then purified via flash column 
chromatography on SiO2 (20:1 hexanes/ EtOAc) to afford 2.98 (40 mg, 17%) as an orange solid.  
 
Data for 2.98: 
Rf: 0.60 (20:1 hexanes/ EtOAc).  
FTIR (neat): 2925, 1674, 1617, 1590, 1463, 1227, 1124, 823 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.42 (s, 2H), 6.35 (s, 1H), 5.02 (d, J = 4.7 Hz, 1H), 3.81 (s, 3H), 2.70 (t, 
J = 8.2 Hz, 1H), 2.30 (s, 3H), 2.23 (ds, J = 9.2, 4.7 Hz, 1H), 2.08 – 2.01 (m, 1H), 1.83 (dd, J = 12.3, 4.9 
Hz, 1H), 1.78 – 1.67 (m, 2H), 1.61 (s, 3H), 1.27 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 157.2, 156.3, 141.2, 141.2, 140.5, 116, 112.4, 112.4, 112.4, 111.7, 
105.3, 105.2, 105.2, 85.7, 64.1, 64.0, 55.8, 55.8, 49.1, 38.6, 28.5, 27.8, 22.1, 16.7 ppm. 






























Enol ether 2.98(149 mg, 0.460 mmol, 1.0 equiv.) was dissolved in CH2Cl2 (40 mL) and m-CPBA (77% 
wt./ wt., 159 mg, 0.920 mmol, 2.0 equiv.) was added. The resulting solution was stirred at room 
temperature for 1 h, then p-toluenesulfonic acid (132 mg, 0.700 mmol, 1.5 equiv.) was added and 
the solution was stirred for a further for 1 h. The reaction was then quenched with sat. NaSO3(aq.) 
(20 mL), the organic layer was then further washed with sat. NaHCO3(aq.) (2 x 20 mL) and extracted 
with CH2Cl2 (2 x 40 mL), dried with MgSO4 and filtered. Concentration afforded furan 2.98 (134 
mg, 85%) as a clear oil, which was used without further purification.     
 
Data for 2.98: 
Rf: 0.20 (9:1 hexanes/ EtOAc).  
FTIR (neat): 2966, 1734, 1618, 1591, 1464, 1373, 1231, 1137, 1110, 982 cm-1. 
1H NMR (600 MHz, CDCl3): δ 9.76 (s, 1H), 6.38 (s, 1H), 6.37 (s, 1H), 5.43 (d, J = 8.6 Hz, 1H), 3.85 (s, 
3H), 2.88 (q, J = 7.7 Hz, 1H), 2.80 (t, J = 8.9 Hz, 1H), 2.30 (s, 3H), 2.11 (ddd, J = 12.9, 6.0, 2.5 Hz, 1H), 
1.89 – 1.79 (m, 1H), 1.76 – 1.68 (m, 1H), 1.64 – 1.58 (m, 1H), 1.37 (s, 3H), 1.25 (s, 3H) ppm. 
13C NMR (150 MHz, CDCl3): δ 206.0, 158.2, 155.9, 140.8, 112.5, 108.3, 105.2, 87.5, 87.3, 66.9, 56.9, 
56.0, 52.8, 42.3, 26.7, 24.9, 22.1, 21.1 ppm. 


















rt, 1 h, then; 













To a solution of 2,7-dihydroxynaphthalene (2.102) (5.00 g, 31.2 mmol, 1.0 equiv.) in PhMe (150 
mL) was added citral (5.32 mL, 31.2 mmol, 1.0 equiv.) and EDDA (170 mg, 0.030 mmol, 10 mol%). 
The reaction mixture was heated to reflux at 110 °C for 16 h, then cooled to room temperature 
and concentrated in vacuo. The residue was purified via flash chromatography on SiO2 (8:1 
hexanes/ EtOAc) to give chromene 2.101 (6.71 g, 73%) as a brown oil. Data for 2.101 matched that 
previously reported in the literature.34 
 
Data for 2.101: 
Rf: 0.20 (8:1 hexanes/ EtOAc). 
FTIR (neat): 3370, 2969, 2023, 1700, 1621, 1517, 1449, 1376, 1283, 1212, 1181, 1088, 915 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.62 (d, J = 8.8 Hz, 1H), 7.55 (d, J = 8.8 Hz, 1H), 7.23 (d, J = 2.5 Hz, 1H), 
6.97 – 6.85 (m, 3H), 5.63 (d, J = 10.0 Hz, 1H), 5.15 (bs, 1H), 5.11 (t, J = 7.2 Hz,  1H), 2.19 – 2.11 (m, 
2H), 1.79 (m, 2H), 1.66 (s, 3H), 1.58 (s, 3H), 1.44 (s, 3H) ppm.           
13C NMR (125 MHz, CDCl3): δ 154.3, 152.0, 131.9, 131.5, 130.6, 129.3, 128.1, 124.7, 124.3, 118.8, 
116.2, 114.9, 112.5, 104.0, 78.5, 41.0, 26.2, 25.8, 22.9, 17.8 ppm. 























To a solution of chromene 2.101 (4.84 g, 16.0 mmol, 1.0 equiv.) in CH2Cl2 (50 mL) at room 
temperature was added SeO2 (180 mg, 1.60 mmol, 10 mol%) and t-BuO2H (11.9 mL, 5.50 M in 
decane, 4.0 equiv.). The reaction was stirred at room temperature for 16 h, then quenched by 
addition of sat. Na2SO4(aq) (50 mL). The organic layer was separated, washed with brine (2 x 50 mL) 
and the aqueous phase was further extracted with CH2Cl2 (2 x 50 mL). The organic layers were 
combined, then dried with MgSO4, filtered, concentrated and purified via flash chromatography 
on SiO2 (2:1 hexanes/ EtOAc) to give alcohol 2.104 (2.44 g, 48%) as an orange oil and aldehyde 
2.100 (830 mg, 16%) as a red oil.  
 
Data for 2.104: 
Rf: 0.05 (9:1 hexanes/ EtOAc). 
FTIR (neat): 3294, 2975, 2867, 1621, 1517, 1449, 1379, 1285, 1219, 1182, 1100, 1013, 915 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.58 (d, J = 8.7 Hz, 1H), 7.52 (d, J = 8.7 Hz, 1H), 7.21 (d, J = 2.4 Hz, 1H), 
6.92 (dd, J = 8.7, 2.4 Hz, 1H), 6.86 (d, J = 8.7 Hz, 1H), 6.83 (d, J = 10.0 Hz, 1H), 5.53 (d, J = 10.0, 1H), 
5.45 (t, J = 7.1 Hz, 1H), 3.98 (s, 2H), 2.21 – 2.16 (m, 2H), 1.78 – 1.66 (m, 2H), 1.61 (s, 3H), 1.40 (s, 
3H) ppm.  
13C NMR (125 MHz, CDCl3): δ 154.9, 151.7, 134.6, 131.5, 130.5, 129.4, 127.7, 127.7, 126.4, 124.5, 
119.0, 115.8, 112.3, 103.9, 78.4, 69.0, 40.5, 26.2, 22.6, 13.7 ppm. 
HRMS (ESI) m/z: [M+H]+ Calcd for C20H23O3 311.1642; found 311.1636. 
 
Data for 2.100: 
Rf: 0.10 (2:1 hexanes/ EtOAc). 
FTIR (neat): 3350, 2924, 2971, 1665, 1634, 1620, 1516, 1451, 1377, 1284, 1238, 1216, 1183, 1133, 
1082, 916, 820, 781, 729 cm-1. 
1H NMR (600 MHz, CDCl3): δ 9.36 (s, 1H), 7.62 (d, J = 8.8 Hz), 7.56 (d, J = 8.8 Hz, 1H), 7.24 (d, J = 
2.3 Hz, 1H), 6.95 – 6.94 (m, 2H), 6.86 (d, J = 8.8 Hz), 6.51 (tt, J = 7.5, 1.4 Hz, 1H), 5.64 (bs, 1H), 5.60 
(d, J = 10.0 Hz, 1H), 2.62 – 2.46 (m, 2H), 1.97 – 1.85 (m, 2H), 1.70 (s, 3H), 1.47 (s, 3H) ppm.         
13C NMR (150 MHz, CDCl3): δ 195.7, 155.1, 154.7, 151.7, 139.4, 131.5, 130.6, 129.7, 127.0, 124.7, 
119.6, 115.8, 115.3, 112.1, 103.9, 78.2, 39.4, 26.4, 24.3, 9.3 ppm. 























To a solution of DMSO (0.34 mL, 4.82 mmol, 3.0 equiv.) in CH2Cl2 (45 mL) at –78 °C was added 
dropwise (COCl)2 (0.16 mL, 1.93 mmol, 1.2 equiv.). The reaction mixture was stirred for 10 min at 
–78 °C, then alcohol 2.104 (500 mg, 1.58 mmol, 1.0 equiv.) was added as a solution in CH2Cl2 (5 
mL) and the solution was stirred for a further 10 min. Et3N (2.20 mL, 15.8 mmol, 10.0 equiv.) was 
then added dropwise and the reaction was stirred for a further 20 min. The reaction mixture was 
quenched upon addition of distilled water (100 mL), extracted with CH2Cl2 (2 x 50 mL), washed 
with sat. brine (4 x 50 mL) and dried with MgSO4. The resultant mixture was filtered, concentrated 
in vacuo and purified via flash chromatography on SiO2 (2:1 hexanes/ EtOAc) to give aldehyde 

































A solution of aldehyde 2.100 (67 mg, 0.215 mmol, 1.0 equiv.) in PhMe (10 mL) was heated to reflux 
at 110 °C. After 24 h the reaction was cooled to room temperature, concentrated in vacuo, and 
purified via flash chromatography (9:1 hexanes/ EtOAc) to afford enol ether 2.103 (29 mg, 43%) 
as a yellow solid.  
 
Data for 2.103: 
Rf: 0.70 (2:1 hexanes/ EtOAc). 
FTIR (neat): 3296, 2974, 2249, 1675, 1624, 1518, 1452, 1376, 1238, 1218, 1186, 1134, 907 cm-1. 
1H NMR (600 MHz, d6-acetone): δ 8.51 (bs, 1H), 7.75 – 7.55 (m, 2H), 7.36 (s, 1H), 6.97 (dd, J = 8.8, 
1.4 Hz), 6.83 (d, J = 8.7, 1H), 6.30 (s, 1H), 5.21 (d, J = 5.7 Hz), 2.80 – 2.69 (m, 1H), 2.47 (dd, J = 9.7, 
5.7 Hz, 1H), 2.02 – 1.95 (m, 1H), 1.86 – 1.72 (m, 2H), 1.71 – 1.64 (m, 1H), 1.59 (s, 3H), 1.26 (s, 3H) 
ppm.      
13C NMR (150 MHz, d6-acetone): δ 157.1, 154.8, 140.9, 135.0, 130.9, 130.7, 125.4, 117.3, 116.3, 
116.0, 115.7, 105.1, 85.9, 66.6, 48.8, 39.3, 38.8, 28.7, 27.9, 16.6 ppm. 


































Enol ether 2.103 (332 mg, 1.07 mmol, 1.0 equiv.) was dissolved in CH2Cl2 (50 mL) and m-CPBA 
(77%, 360 mg, 1.30 mmol, 2.0 equiv.) was added. The resultant solution was stirred at room 
temperature for 30 min, then p-toluenesulfonic acid (300 mg, 1.58 mmol, 1.5 equiv.) was added 
and the reaction mixture was stirred for a further 30 min. The reaction mixture was then quenched 
by addition of distilled water (50 mL) and extracted with CH2Cl2 (2 x 50 mL), dried with MgSO4, 
filtered and concentrated. Crystallisation from acetone then afforded furan 2.106 (227 mg, 65%) 
as a white solid.     
 
Data for 2.106: 
Rf: 0.60 (2:1 hexanes/ EtOAc).  
FTIR (neat): 3372, 2971, 1733, 1691, 1625, 1517, 1449, 1375, 1286, 1241, 1217, 1199, 1134, 967, 
836, 711 cm-1. 
1H NMR (600 MHz, CDCl3): δ 9.65 (s, 1H), 8.60 (s, 1H), 7.65 (dd, J = 8.8, 5.6 Hz, 2H), 7.49 (d, J = 2.4 
Hz, 1H), 6.97 (dd, J = 8.7, 2.4 Hz, 1H), 6.83 (d, J = 8.8 Hz, 1H), 5.46 (d, J = 8.3 Hz, 1H), 2.97 – 2.90 
(m, 2H), 2.01 – 1.97 (m, 1H), 1.72 – 1.64 (m, 2H), 1.55 (dd, J = 12.3, 6.2 Hz, 1H), 1.42 (s, 3H), 1.37 
(s, 3H) ppm. 
13C NMR (150 MHz, CDCl3): δ 205.0, 157.1, 152.3, 136.1, 130.8, 130.7, 125.1, 117.1, 116.3, 112.6, 
106.5, 88.5, 84.7, 70.0, 54.4, 50.7, 38.7, 26.6, 25.7, 20.9 ppm. 



















rt, 30 min then;










Enol ether 2.103 (69 mg, 0.207 mmol, 1.0 equiv.) was dissolved in MeOH (5.0 mL) and p-TsOH (4 
mg, 0.020 mmol, 10 mol%) added. The solution was stirred at room temperature for 7 h, then 
reaction quenched upon addition of sat. NaHCO3(aq) (10 ml). Product was extracted with CH2Cl2 (3 
x 5 mL) and combined organic extracts were washed with distilled water (10 mL), dried with 
MgSO4, filtered and concentrated. Purification via flash chromatography (2:1 hexanes/ EtOAc) 
gave acetal 2.105 (47 mg, 63%) as a white solid. 
 
Data for 2.105: 
Rf: 0.50 (1:1 hexanes/ EtOAc). 
FTIR (neat): 2971, 2929, 1682, 1619, 1514, 1464, 1429, 1381, 1224, 1181, 1102, 1031, 916 cm-1. 
1H NMR (500 MHz, CDCl3): δ 9.36 (s, 1H), 7.63 (d, J = 8.9 Hz, 1H), 7.57 (d, J = 8.7 Hz, 1H), 7.21 (d, J 
= 2.4 Hz, 1H), 7.08 – 6.95 (m, 2H), 6.88 (dd, J = 8.8, 0.7 Hz, 1H), 6.49 (t, J = 7.4, 1H), 5.64 (d, J = 10.0 
Hz, 1H), 3.93 (s, 3H), 2.61 – 2.47 (m, 2H), 1.97 – 1.88 (m, 2H), 1.70 (s, 3H), 1.49 (s, 3H) ppm.    
13C NMR (125 MHz, CDCl3): δ 195.3, 158.7, 154.5, 151.7, 139.5, 131.3, 130.2, 129.5, 127.1, 
124.7,119.6, 115.7, 112.5, 100.5, 78.1, 55.4, 39.4, 26.3, 24.2, 9.23 ppm. 




































Chromene 2.101 (3.34 g, 11.3 mmol, 1.0 equiv.) was dissolved in acetone (60 mL), K2CO2 (8.15 g, 
58.9 mmol, 5.2 equiv.) and dimethyl sulfate (6.61 mL, 69.8 mmol, 6.2 equiv.) was added. The 
reaction was then headed to reflux for 4 h. The product was then cooled to room temperature 
quenched by addition of sat. brine (60 mL) and product extracted with EtOAc (3 x 60 mL), dried 
with MgSO4, filtered and concentrated. Purification via flash chromatography on SiO2 (20:1 
hexanes/ EtOAc) gave 2.107 (2.22 g, 63%) as a yellow oil. 
 
Data for 2.107: 
Rf: 0.60 (9:1 hexanes/ EtOAc). 
FTIR (neat): 2924, 1620, 1514, 1429, 1225, 1033, 913, 726 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.62 (d, J = 8.9 Hz, 1H), 7.55 (d, J = 8.7 Hz, 1H), 7.21 (d, J = 2.4 Hz, 1H), 
7.04 – 6.96 (m, 2H), 6.90 (dd, J = 8.7, 0.8 Hz, 1H), 5.66 (d, J = 10.0 Hz, 1H), 5.15 – 5.06 (m, 1H), 3.93 
(s, 3H), 2.23 – 2.08 (m, 2H), 1.84 – 1.69 (m, 2H), 1.66 (s, 3H), 1.58 (s, 3H), 1.44 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 158.6, 152.0, 131.8, 131.3, 130.2, 129.2, 128.1, 124.7, 124.3, 118.9, 
116.1, 115.5, 112.9, 100.5, 78.4, 55.4, 41.0, 26.2, 25.8, 22.9, 17.8 ppm. 






























To a solution of chromene 2.107 (5.01 g, 16.2 mmol) in CH2Cl2 (100 mL) was added t-BuO2H (10.6 
mL, 3.24 mmol, 5.5 M in decane, 20 mol%) and SeO2 (0.36 g, 58.3 mmol, 3.6 equiv.) the reaction 
was left to stir at room temperature. After 16 h the solution was quenched sat. Na2SO4(aq) (100 
mL), product extracted CH2Cl2 (3 x 100 mL), dried with MgSO4, filtered and concentrated. 
Purification via flash column chromatography on SiO2 (9:1 hexanes/ EtOAc) then afforded 2.108 
(2.58 g, 48%) as an orange oil. 
 
Data for 2.108: 
Rf: 0.20 (9:1 hexanes/ EtOAc). 
FTIR (neat): 2972, 1683, 1620, 1381, 1224, 1031, 915, 729 cm-1. 
1H NMR (500 MHz, CDCl3): δ 9.36 (s, 1H), 7.63 (d, J = 8.9 Hz, 1H), 7.57 (d, J = 8.7 Hz, 1H), 7.21 (d, J 
= 2.5 Hz, 1H), 7.04 (d, J = 10.0 Hz, 1H), 7.00 (dd, J = 8.9, 2.5 Hz, 1H), 6.88 (d, J = 8.9 Hz, 1H), 6.49 (t, 
J = 7.4 Hz, 1H), 5.64 (d, J = 10.0 Hz, 1H), 3.93 (s, 3H), 2.61 – 2.49 (m, 2H), 1.99 – 1.86 (m, 2H), 1.70 
(d, J = 1.1 Hz, 3H), 1.49 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 195.3, 158.7, 154.4, 151.6, 139.5, 131.3, 130.2, 129.5, 127.1, 
124.7, 119.6, 115.7, 115.7, 112.5, 100.5, 78.1, 55.4, 39.4, 26.3, 24.2, 9.2 ppm. 





























A solution of aldehyde 2.108 (80 mg, 0.215 mmol, 1.0 equiv.) in xylene (5 mL) was heated to reflux 
at 140 °C. After 3 h the reaction was cooled to room temperature, concentrated in vacuo, and 
purified via flash chromatography on SiO2 (9:1 hexanes/ EtOAc) to afford enol ether 2.109 (27 mg, 
33%) as an orange solid and 2.110 (1 mg, 1%) as the minor product. 
 
Data for 2.109: 
Rf: 0.50 (9:1 hexanes/ EtOAc). 
FTIR (neat): 2961, 1610, 1516, 1464, 1224, 1032, 922, 833, 667 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.68 (dd, J = 8.8, 6.0 Hz, 2H), 7.34 (d, J = 2.5 Hz, 1H), 7.05 – 7.01 (m, 
1H), 6.99 (d, J = 8.7 Hz, 1H), 6.42 (s, 1H), 5.33 (d, J = 5.5 Hz, 1H), 3.94 (s, 3H), 2.82 (t, J = 8.2 Hz, 
1H), 2.48 (dd, J = 9.5, 5.5 Hz, 1H), 2.15 (td, J = 13.7, 12.6, 7.7 Hz, 1H), 1.93 – 1.75 (m, 4H), 1.66 (s, 
3H), 1.34 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 158.8, 154.2, 140.6, 133.5, 130.3, 130.2, 125.2, 117.6, 116.0, 115.9, 
114.8, 101.0, 85.6, 66.2, 55.5, 48.8, 38.7, 38.4, 28.3, 27.9, 16.7 ppm. 
HRMS (ESI) m/z: [M+H]+ Calcd for C21H23O3 323.1642; found 323.1634. 
 
Partial Data for 2.110: 
Rf: 0.60 (9:1 hexanes/ EtOAc). 
FTIR (neat): 2950, 1725, 1622, 1515, 1461, 1237, 1132 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.79 (d, J = 2.5 Hz, 1H), 7.61 (d, J = 8.8 Hz, 1H), 7.57 (d, J = 8.8 Hz, 1H), 
6.99 (dd, J = 8.9, 2.4 Hz, 1H), 6.81 (d, J = 8.7 Hz, 1H), 6.16 (s, 1H), 5.75 (d, J = 7.3 Hz, 1H), 3.95 (s, 
3H), 2.65 – 2.58 (m, 1H), 2.35 – 2.26 (m, 1H), 2.11 – 1.97 (m, 4H), 1.58 (s, 3H), 1.39 (s, 3H) ppm. 





































To a solution of 2.108 (108 mg, 0.394 mmol, 1.0 equiv.) in CH2Cl2 (10 mL) at room temperature 
was added ethyl (triphenylphosphoranylidene)acetate (274 mg, 0.788 mmol, 2.0 equiv.). After 16 
h the reaction was quenched with sat. brine (10 mL) and product extracted with CH2Cl2 (3 x 10 
mL), dried with MgSO4, filtered and concentrated in vacuo. Purification by flash column 
chromatography on SiO2 (9:1 hexanes/ EtOAc) then gave 2.112 (88 mg, 66%) as an oil. 
 
Data for 2.112: 
Rf: 0.30 (20:1 hexanes/ EtOAc). 
FTIR (neat): 3383, 2923, 1684, 1610, 1578, 1447, 1381, 1268, 1185, 1060, 824 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.29 (d, J = 15.6 Hz, 1H), 6.67 (d, J = 9.8, 1H), 6.21 (s, 1H), 6.14 (s, 1H), 
5.88 (t, J = 7.5 Hz, 1H), 5.80 (br s, 1H), 5.77 (d, J = 15.7 Hz, 1H), 5.44 (d, J = 10.0 Hz, 1H), 4.21 (q, J 
= 7.1 Hz, 2H), 2.38 – 2.29 (m, 2H), 2.18 (s, 3H), 1.82 – 1.70 (m, 2H), 1.73 (s, 3H), 1.38 (s, 3H), 1.30 
(t, J = 7.1 Hz, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 167.9, 154.0, 151.4, 149.8, 141.9, 139.9, 133.1, 126.6, 117.5, 115.6, 
109.8, 108.6, 106.7, 78.1, 60.4, 40.3, 26.6, 23.9, 21.7, 14.5, 12.2 ppm. 



































To a solution of 2.112 (55 mg, 0.158 mmol, 1.0 equiv.) in PhMe (5 mL) was added BHT (13 mg, 
0.032 mmol, 20 mol%) and the reaction was heated to reflux. After 1 h the reaction was 
concentrated and the crude residue purified by flash column chromatography on SiO2 (20:1 
hexanes/ EtOAc) to give 2.111a (12 mg, 25%) as an orange oil.  
 
Data for 2.111a: 
Rf: 0.30 (20:1 hexanes/ EtOAc). 
FTIR (neat): 2963, 1760, 1633, 1591, 1444, 1332, 1216, 1083, 879 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.36 (s, 1H), 6.34 (s, 1H), 5.08 (m, 1H), 3.53 – 3.48 (m, 1H), 3.38 (t, J 
= 5.9 Hz, 1H), 2.50 (d, J = 6.6 Hz, 2H), 2.23 (s, 3H), 2.11 (dd, J = 12.7, 5.4 Hz, 1H), 1.94 – 1.89 (m, 
1H), 1.72 – 1.65 (m, 1H), 1.58 (s, 3H), 1.51 (s, 3H), 1.36 – 1.30 (m, 1H) ppm. 
13C NMR (125 MHz, CDCl3): δ 170.5, 155.0, 150.5, 141.0, 138.9, 114.0, 112.0, 108.0, 102.4, 85.4, 
41.8, 41.2, 40.6, 40.4, 29.7, 25.8, 23.5, 21.5, 21.3 ppm. 




































To a solution of aldehyde 2.108 (255 mg, 769 mmol, 1.0 equiv.) in PhMe (30 mL) was added BHT 
(41 mg, 0.153 mmol, 20 mol%) and ethyl (triphenylphosphoranylidene)acetate (820 mg, 1.92 
mmol, 2.5 equiv.), the solution was heated to reflux. After 24 h sat. brine (60 mL) was added and 
the product was extracted with EtOAc (3 x 60 mL), dried with MgSO4, filtered and concentrated. 
Purification via flash chromatography on SiO2 (20:1 hexanes/ EtOAc) then gave 2.111a (32 mg, 















































To a solution of Na2S2O4 (190 g, 1.09 mol, 8.7 equiv.) in H2O (500 mL), was added EtOAc (500 mL) 
and 1,4-napthoquinone (2.114) (20 g, 0.126 mmol, 1.0 equiv.). The reaction was left to stir at room 
temperature for 3 h, then organic layer was separated and aqueous layer further extracted with 
EtOAc (2 x 500 mL). The combined organic layers were then concentrated in vacuo and the crude 
residue dissolved in acetone (250 mL). K2CO3 (92 g, 0.665 mmol, 5.3 equiv.) was then added, 
followed by dimethylsulfate (60 mL, 0.665 mmol, 5.3 equiv.) and the solution was left to reflux. 
After 48 h, sat. brine (500 mL) was added and product extracted with EtOAc (3 x 250 mL), dried 
with MgSO4, filtered and concentrated. Purification by flash column chromatography on SiO2 (9:1 
hexanes/ EtOAc) then gave 2.115 (22.3 g, 94%) as a white solid. Data for 2.115 matched that 
previously reported in the literature.28 
 
Data for 2.115: 
Rf: 0.80 (CHCl3).  
MP: 86 – 88 °C (lit. 84 – 86 °C).28 
FTIR (neat): 2955, 1630, 1593, 1463, 1446, 1383, 1269, 1237, 1023 cm-1. 
1H NMR (500 MHz, CDCl3): δ 8.37 – 8.13 (m, 2H), 7.54 (ddd, J = 6.5, 3.3, 2.2 Hz, 2H), 6.72 (s, 2H), 
3.98 (s, 6H) ppm. 
13C NMR (125 MHz, CDCl3): δ 149.7, 126.5, 126.5, 126.0, 121.9, 121.9, 121.9, 103.3, 103.3, 55.8 
ppm. 
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To a solution of 2.115 (10.0 g, 53.1 mmol, 1.0 equiv.) in dry THF (250 mL) was added B2Pin2 (13.5 
g, 53.1 mmol, 1.0 equiv.), dtbpy (0.04 g, 1.06 mmol, 2 mol%), Ir(COD)OMe2 (40 mg, 0.531 mmol, 
1 mol%) and pinacol borane (0.8 mL, 5.31 mmol, 10 mol%). The solution was left to stir at reflux 
for 24 h, then cooled to room temperature and filtered through a pad of Celite® (THF) and 
concentrated in vacuo. The crude pinacol ester was dissolved in THF (250 mL), cooled to 0 °C and 
H2O2 (100 mL, 30% wt./ wt. in H2O) added followed by 1M NaOH(aq) (100 mL). After 30 mins, EtOAc 
(250 mL) was added and the organic layer extracted, dried with MgSO4, filtered and concentrated 
in vacuo. Purification via flash column chromatography on SiO2 (2:1 hexanes/ EtOAc) then gave 
2.116 (6.53 g, 60%) as a brown oil. Data for 2.116 matched that previously reported in the 
literature.28 
 
Data for 2.116: 
Rf: 0.70 (CH2Cl2).  
FTIR (neat): 3352, 2999, 2937, 2836, 1631, 1602, 1519, 1461, 1379, 1262, 1216, 1194, 1155, 1095, 
1000, 972, 917, 863, 798, 711, 665 cm-1. 
1H NMR (500 MHz, CDCl3): δ 8.13 (d, J = 9.0 Hz, 1H), 7.52 (d, J = 2.6 Hz, 1H), 7.12 (dd, J = 9.1, 2.6 
Hz, 1H), 6.68 (d, J = 8.3 Hz, 1H), 6.55 (d, J = 8.3 Hz, 1H), 5.78 (br s, 1H), 3.93 (d, J = 7.5 Hz, 6H) ppm. 
13C NMR (125 MHz, CDCl3): δ 154.1, 148.6, 127.9, 124.2, 121.7, 117.3, 117.2, 104.5, 104.4, 101.1, 
56.0, 55.9 ppm. 
















    dtbpy, B2Pin2
    pinacol borane
    THF, 24 h, 80 ºC
2. H2O2, NaOH







To a solution of 2.116 (1.14 g, 5.58 mmol, 1.0 equiv.) in CHCl3 (50 mL) was added NBS (1.09 g, 6.14 
mmol, 1.1 equiv.) at room temperature. The reaction was left to stir for 4 h then quenched upon 
addition of sat. Na2SO4(aq) (50 mL) and product extracted CHCl3 (3 x 50 mL), dried MgSO4, filtered 
and concentrated. Purification via flash chromatography (4:1 hexanes/ EtOAc) then gave 2.117 
(1.29 g, 65%) as an orange solid. Data for 2.117 matched that previously reported in the 
literature.28 
 
Data for 2.117: 
Rf: 0.20 (9:1 hexanes/ EtOAc).   
MP: 108 – 109 °C. 
FTIR (neat): 3425, 3350, 2933, 1627, 1608, 1588, 1566, 1458, 1439, 1383, 1321, 1281, 1241, 1191, 
1076, 1004, 970, 823, 777, 744 cm-1. 
1H NMR (600 MHz, CDCl3): δ 7.97 (d, J = 9.0 Hz, 1H), 7.49 (d, J = 2.6 Hz, 1H), 7.16 (dd, J = 9.0, 2.6 
Hz, 1H), 6.84 (s, 1H), 5.33 (br s, 1H), 3.94 (s, 6H) ppm. 
13C NMR (150 MHz, CDCl3): δ 153.9, 151.3, 147.1, 127.3, 124.4, 124.3, 118.9, 109.1, 108.7, 105.3, 
61.7, 56.0 ppm. 





























To a stirred solution of 2.117 (1.62 g, 5.75 mmol, 1.0 equiv.) in acetone/ DMF (12:1, 30 mL) was 
added K2CO3 (3.16 g, 22.9 mmol, 4.0 equiv.), TBAI (211 mg, 0.572 mmol, 10 mol%) and 2-
bromopropane (0.54 mL, 5.75 mmol, 1.0 equiv.). The reaction was heated to reflux for 16 h then 
cooled to room temperature, quenched with 1M HCl(aq) (30 mL) and product extracted with CH2Cl2 
(3 x 30 mL). The combined organic extracts were dried with MgSO4, filtered, and concentrated in 
vacuo. The residue was filtered through a short pad of SiO2 and Celite® (CH2Cl2) to afford 2.118 
(1.90 g, 81%) as an orange oil. Data for 2.118 matched that previously reported in the literature.28 
 
Data for 2.118: 
Rf: 0.50 (20:1 hexanes/ EtOAc).  
FTIR (neat): 2976, 1620, 1579, 1463, 1347, 1238, 1112, 997 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.97 (d, J = 9.1 Hz, 1H), 7.52 (d, J = 2.4 Hz, 1H), 7.19 (dd, J = 9.1, 2.5 
Hz, 1H), 6.86 (s, 1H), 4.81 – 4.69 (m, 1H), 3.95 (d, J = 2.7 Hz, 6H), 1.42 (d, J = 6.1 Hz, 6H) ppm. 
13C NMR (125 MHz, CDCl3): δ 156.2, 151.4, 147.1, 127.2, 124.2, 123.8, 120.9, 108.8, 108.5, 103.6, 





























To a solution of 2.118 (2.00 g, 6.15 mmol, 1.0 equiv.) in THF (40 mL) under N2 was added dropwise 
at –78 °C t-BuLi (7.3 mL, 12.3 mmol, 1.7M in hexane, 2.0 equiv.). The reaction was left to stir for 
10 min, followed by a dropwise addition of ethyl chloroformate (3.3 mL, 12.3 mmol, 1.7 M in 
hexane, 2.0 equiv.). After 5 min the reaction was warmed to room temperature and left to stir 16 
h. The reaction was then quenched sat. NH4Cl(aq) (40 mL), product extracted with EtOAc (3 x 40 
mL), dried with MgSO4, filtered and concentrated in vacuo. Purification via flash chromatography 
(19:1 → 9:1 hexanes/ EtOAc, gradient elution) then gave 2.119 (342 mg, 18%) as a yellow solid. 
Data for 2.119 matched that previously reported in the literature.28 
 
Data for 2.119: 
Rf: 0.50 (10:1 hexanes/ EtOAc).  
FTIR (neat): 2978, 1719, 1621, 1463, 1372, 1272, 983, 792 cm-1. 
1H NMR (500 MHz, CDCl3): δ 8.11 (d, J = 9.1 Hz, 1H), 7.52 (d, J = 2.6 Hz, 1H), 7.20 – 7.16 (m, 2H), 
4.78 (p, J = 6.1 Hz, 1H), 4.44 (q, J = 7.1 Hz, 2H), 4.00 (s, 3H), 3.98 (s, 3H), 1.45 (t, J = 7.2 Hz, 3H), 
1.41 (d, J = 6.0 Hz, 6H) ppm. 
13C NMR (125 MHz, CDCl3): δ 166.6, 157.9, 152.6, 150.4, 130.6, 125.6, 124.2, 120.5, 116.5, 104.5, 
103.0, 70.0, 63.4, 61.1, 55.8, 22.1, 14.5 ppm. 
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To a stirred solution of 2.119 (72 mg, 0.226 mmol, 1.0 equiv.) in CH2Cl2 (5 mL) at 0 °C was added 
AlCl3 (300 mg, 2.26 mmol, 10.0 equiv.) portion wise over 5 min. The reaction was left to stir for 30 
min, then diluted with CH2Cl2 (5 mL) and quenched with sat. NH4Cl(aq) (10 mL). The organic layer 
was separated, then aqueous layer was further extracted with CH2Cl2 (2 x 10 mL). The combined 
organic layers were dried with MgSO4, filtered and concentrated in vacuo. Purification via flash 
chromatography (9:1 → 1:1 hexanes/ EtOAc, gradient elution) then gave 2.113 (15 mg, 70%) as an 
orange solid. Data for 2.113 matched that previously reported in the literature.28 
 
Data for 2.113: 
Rf: 0.60 (1:1 hexanes/ EtOAc).  
FTIR (neat): 3420, 1627, 1600, 1526, 1469, 1396, 1375, 1336, 1249, 1240, 1199, 1158, 
1088, 1022, 994, 945, 853, 944, 788, 779, 713 cm-1. 
1H NMR (500 MHz, CDCl3): δ 11.73 (s, 1H), 8.30 (d, J = 9.0 Hz, 1H), 7.48 (d, J = 2.6 Hz, 1H), 7.13 (dd, 
J = 9.0, 2.6 Hz, 1H), 7.01 (s, 1H), 5.38 (s, 1H), 4.45 (q, J = 7.1 Hz, 2H), 3.95 (s, 3H), 1.45 (t, J = 7.1 Hz, 
3H) ppm. 
13C NMR (125 MHz, d6-acetone): δ 172.1, 159.7, 156.9, 147.7, 133.1, 126.7, 120.5, 118.9, 105.6, 
103.0, 101.9, 62.2, 56.1, 14.7 ppm. 































To solution of phenol 2.116 (854 mg, 4.18 mmol) in PhMe (10 mL) was added portion wise NaH 
(170 mg, 4.18 mmol, 60 wt./ wt., 1.0 equiv.) at room temperature and reaction was left to stir for 
1 h. The solution was then cooled to 0 °C and geranyl bromide (0.74 mL, 0.9 equiv.) added 
dropwise, the reaction was left to warm to room temperature. After 24 h the reaction was 
quenched upon addition of distilled H2O (10 mL) and products extracted with EtOAc (3 x 10 mL). 
The combined organic layers were then dried with MgSO4, filtered and concentrated in vacuo. 
Purification via flash chromatography (9:1 hexanes/ EtOAc) then gave 2.121 (182 mg, 13%) as a 
yellow oil and 2.143 (205 mg, 10%) as yellow oil.  
  
Data for 2.121: 
Rf: 0.20 (20:1 hexanes/ EtOAc).  
FTIR (neat): 3382, 2932, 2838, 1664, 1606, 1590, 1481, 1440, 1412, 1378, 1274, 1166, 1194, 1106, 
1081, 1050, 1000, 946, 800, 732, 717 cm-1. 
1H NMR (500 MHz, CDCl3): δ 8.12 (d, J = 9.0 Hz, 1H), 7.11 (d, J = 9.0 Hz, 1H), 6.75 (d, J = 8.4 Hz, 1H), 
6.58 (d, J = 8.4 Hz, 1H), 5.43 (br s, 1H), 5.38 (m, 1H), 5.09 – 5.04 (m, 1H), 4.16 (d, J = 6.5 Hz, 2H), 
3.94 (s, 3H), 3.88 (s, 3H), 2.17 – 2.05 (m, 4H), 1.89 (d, J = 1.5 Hz, 3H), 1.68 (d, J = 1.5 Hz, 3H), 1.61 
(d, J = 1.4 Hz, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 153.6, 151.3, 150.3, 136.0, 131.8, 126.5, 124.2, 124.1, 123.3, 122.0, 
119.7, 117.6, 106.5, 101.2, 56.2, 55.9, 39.8, 27.1, 26.7, 25.8, 17.8, 16.4 ppm. 
HRMS (ESI) m/z: [M+H]+ Calcd for C22H29O3 341.2111; found 341.2110. 
 
Data for 2.143: 
Rf: 0.45 (20:1 hexanes/ EtOAc).  
FTIR (neat): 2914, 2853, 1651, 1591, 1475, 1437, 1390, 1295, 1240, 1229, 1198, 1096, 947, 886, 
834, 799, 719 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.94 (d, J = 10.1 Hz, 1H), 6.87 (d, J = 9.0 Hz, 1H), 6.76 (d, J = 9.0 Hz, 
1H), 6.11 (d, J = 10.1 Hz, 1H), 4.86 (m, 2H), 4.58 (m, 2H), 3.82 (d, J = 2.8 Hz, 6H), 3.27 (dd, J = 13.7, 

























13C NMR (125 MHz, CDCl3): δ 205.3, 151.9, 151.0, 138.9, 136.8, 133.5, 131.1, 129.0, 125.3, 124.5, 
122.4, 119.8, 113.2, 109.3, 56.0, 55.5, 39.8, 37.7, 26.8, 25.7, 17.7, 16.1 ppm. 





































To a solution of 6-methylhept-5-en-2-one (2.144) (1.05 mL, 7.11 mmol, 1.0 equiv.) in THF (20 mL) 
at 0 °C was added ethynyl magnesium bromide (21.4 mL, 10.7 mmol, 1.5 equiv.) and solution was 
stirred for 2 h. The reaction was then quenched sat. NH4Cl(aq) (20 mL) and product extracted with 
Et2O (3 x 40 mL), dried with MgSO2, filtered and concentrated. Purification via flash 
chromatography (9:1 hexanes/ EtOAc) then gave 2.123 (672 mg, 62%) as a yellow oil. Data for 
2.123 matched that previously reported in literature.31 
 
Data for 2.123: 
FTIR (neat): 3403, 2930, 1726, 1450, 1375, 1119, 907 cm-1. 
1H NMR (500 MHz, CDCl3): δ 5.19 – 5.06 (m, 1H), 2.47 – 2.33 (m, 1H), 2.42 (s, 1H), 2.29 – 2.21 (m, 
1H), 2.18 – 2.11 (m, 1H), 1.70 – 1.64 (m, 2H), 1.66 (s, 3H), 1.61 (s, 3H), 1.46 (s, 3H) ppm.    
13C NMR (125 MHz, CDCl3): δ 132.5, 123.8, 87.8, 71.5, 68.3, 43.3, 29.8, 25.7, 23.6, 17.8 ppm. 



























A solution of the propargyl 2.123 (600 mg, 1.7 mmol, 1.0 equiv.) in MeCN (10 mL) was cooled to 
−10 °C and DBU (0.34 mL, 2.2 mmol, 1.3 equiv.) added. Trifluoracetic acid (TFAA) (0.25 mL, 1.7 
mmol, 1.0 equiv.) was then added dropwise over 25 min at 0 °C. The resulting solution was left to 
stir for 30 min, then added dropwise to a solution of 2.116 (500 mg, 1.7 mmol, 1.0 equiv.) in MeCN 
(10 mL) at −10 °C to room temperature. After 16 h the reaction was quenched upon addition of 
sat. NH4Cl(aq) (20 mL), and the product extracted with EtOAc (3 x 20 mL), dried with MgSO4, filtered 
and concentrated. Purification via flash chromatography (9:1 hexanes/ EtOAc) then gave 2.124 
(174 mg, 30%) as a yellow oil. 
 
Partial Data for 2.124: 
Rf: 0.80 (9:1 hexanes/ EtOAc).  
1H NMR (500 MHz, CDCl3): δ 8.12 (d, J = 9.1 Hz, 1H), 7.99 (d, J = 2.4 Hz, 1H), 7.39 (dd, J = 9.1, 2.5 
Hz, 1H), 6.68 (d, J = 8.3 Hz, 1H), 6.60 (d, J = 8.2 Hz, 1H), 5.23 – 5.16 (m, 1H), 3.95 (s, 6H), 2.63 (s, 


































A solution of 2.124 (56 mg, 0.165 mmol, 1.0 equiv.) in DMF (5 mL) was heated to reflux. After 5 h 
the solution was cooled to room temperature and EtOAc (20 mL) added. The solution was then 
washed with sat. brine (5 x 20 mL) and the organic layer dried with MgSO4, filtered and 
concentrated. Purification by flash column chromatography on SiO2 (20:1 hexanes/ EtOAc) then 
afforded 2.122 (38 mg, 68%) as a yellow oil.  
 
Data for 2.122: 
Rf: 0.60 (20:1 hexanes/ EtOAc).  
FTIR (neat): 2934, 1616, 1457, 1411, 1336, 1240, 1229, 1059, 1010, 800 cm-1. 
1H NMR (500 MHz, CDCl3): δ 8.07 (d, J = 9.0 Hz, 1H), 7.80 (dd, J = 10.3, 0.8 Hz, 1H), 7.04 (dd, J = 9.0, 0.8 
Hz, 1H), 6.75 (d, J = 8.4 Hz, 1H), 6.56 (d, J = 8.4 Hz, 1H), 5.55 (d, J = 10.3 Hz, 1H), 5.14 – 5.05 (m, 1H), 3.93 (s, 
3H), 3.89 (s, 3H), 2.20 – 2.10 (m, 2H), 1.79 – 1.72 (m, 2H), 1.65 (s, 3H), 1.58 (s, 3H), 1.43 (s, 3H). 
13C NMR (125 MHz, CDCl3): δ 152.6, 151.2, 150.3, 131.7, 126.5, 124.4, 123.7, 123.6, 123.2, 122.8, 
118.3, 114.5, 107.2, 101.4, 77.1, 56.3, 55.9, 40.5, 25.8, 25.6, 22.9, 17.8 ppm. 



































To a solution of dimethoxy chromene 2.122 (75 mg, 0.222 mmol. 1.0 equiv.) in CHCl3 (10 mL) was 
added NBS (40 mg, 0.222 mmol, 1.0 equiv.) at 0 °C. The solution was left to stir and slowly warmed 
to room temperature over 3 h and quenched upon addition of sat. brine (10 mL). The organic layer 
was separated and the aqueous layer further extracted with CHCl3 (2 x 10 mL). The combined 
organic layers were dried (MgSO4), filtered and concentrated in vacuo. Purification via flash 
column chromatography on SiO2 (9:1 hexanes/ EtOAc) then gave 2.126 (21 mg, 23%) as an orange  
solid.  
 
Data for 2.126: 
Rf: 0.50 (20:1 hexanes/ EtOAc).  
FTIR (neat): 2930, 2851, 1726, 1604, 1456, 1441, 1413, 1376, 1340, 1323, 1260, 1244, 1217, 1147, 
1094, 1042, 1001, 958, 930, 885, 822, 795, 727, 703 cm-1. 
1H NMR (500 MHz, CDCl3): δ 8.13 (d, J = 9.2 Hz, 1H), 7.07 (d, J = 9.2 Hz, 1H), 6.62 (d, J = 8.4 Hz, 1H), 
6.52 (d, J = 8.4 Hz, 1H), 5.46 (t, J = 3.3 Hz, 1H), 4.58 (d, J = 3.4 Hz, 1H), 4.38 – 4.35 (m, 1H), 3.96 – 
3.95 (m, 1H), 3.91 (s, 3H), 3.77 (s, 3H), 2.52 (dt, J = 13.1, 3.3 Hz, 1H), 2.27 (ddd, J = 13.9, 4.4, 2.1 
Hz, 1H), 1.73 (dd, J = 13.7, 4.9 Hz, 1H), 1.62 – 1.55 (m, 1H), 1.54 (s, 3H), 1.49 (s, 3H), 1.38 – 1.33 
(m, 1H) ppm.  
13C NMR (125 MHz, CDCl3): δ154.7, 151.6, 150.0, 146.6, 127.5, 122.7, 122.4, 117.2, 112.1, 111.0, 
































To a solution 6-methylhept-5-en-one (2.144) (2.94 mL, 20.0 mmol, 1.0 equiv.) in THF (20 mL) at 
−78 °C was added a solution of ethynyl magnesium bromide (51 mL, 25.5 mmol, 0.5M in THF, 1.3 
equiv.) in THF (50 mL). The mixture was slowly warmed to room temperature and stirred for 2.5 
h, then cooled back to −78 °C. Methyl chloroformate (3.06, 32.0 mmol, 1.6 equiv.) was then added 
dropwise over a period of 5 min. The solution was then warmed to room temperate and left for a 
further 2 h. Finally the reaction was quenched upon addition of sat. NaHCO3(aq) (50 mL), and 
product extracted with Et2O (3 x 50 mL), dried with MgSO4, filtered and concentrated. Purification 
via flash chromatography (100:1 → 20:1 hexanes/ Et2O, gradient elution) then gave 2.134 (2.75 g, 
56%) as a yellow oil. Data for 2.134 matched that previously reported in the literature.35 
 
Partial Data for 2.134: 
Rf: 0.45 (9:1 hexanes/ EtOAc).  
FTIR (neat): 3289, 1754, 1440, 1230, 1167, 1074, 912, 994, 732 cm-1. 
1H NMR (500 MHz, CDCl3): δ 5.11 (ddt, J = 8.6, 5.7, 1.5 Hz, 1H), 3.76 (s, 3H), 2.59 (s, 1H), 2.27 – 
2.13 (m, 2H), 2.04 – 1.94 (m, 1H), 1.87 (s, 1H), 1.72 (s, 3H), 1.68 (s, 3H), 1.62 (s, 3H) ppm. 
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To a solution of bromide 2.126 (500 mg, 1.7 mmol, 1.0 equiv.) in MeCN (100 mL) was added 
dropwise at 0 °C DBU (0.52 mg, 3.4 mmol, 2.0 equiv.) and CuCl (16 mg, 0.085 mmol, 5 mol%). A 
dropwise addition of 2.134 (550 mg, 2.6 mmol, 1.5 equiv.) in MeCN (100 mL) and reaction left to 
warm slowly to room temperature and stirred for 16 h. Reaction was then quenched with sat. 
NH4Cl(aq) (200 mL) and extracted with EtOAc (3 x 200 mL), dried with MgSO4, filtered and 
concentrated in vacuo. Purification via flash chromatography on SiO2 (20:5 hexanes/ EtOAc) then 
gave 2.133 (1.18 mg, 64%) as a yellow oil. 
 
Partial Data for 2.133: 
Rf: 0.45 (20:1 hexanes/ EtOAc).  
FTIR (neat): 3291, 2967, 1737, 1580, 1462, 1347, 1233, 1196, 1168, 1096, 975, 823 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.99 – 7.94 (m, 2H), 7.42 (dd, J = 9.1, 2.4 Hz, 1H), 6.85 (s, 1H), 5.24 – 
5.10 (m, 1H), 3.95 (s, 6H), 2.64 (s, 1H), 2.38 – 2.26 (m, 2H), 2.03 – 1.95 (m, 1H), 1.95 – 1.88 (m, 
1H), 1.70 (s, 3H), 1.66 (s, 3H), 1.65 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 153.9, 151.9, 147.0, 132.4, 126.8, 125.5, 123.8, 123.6, 123.2, 112.0, 




































A solution of 2.134 (459 mg, 1.10 mmol, 1.0 equiv.) in DMF (5 mL) was heated to reflux. After 5 h 
the solution was cooled to room temperature and EtOAc (20 mL) added. The solution was then 
washed with sat. brine (5 x 20 mL) and the organic layer dried with MgSO4, filtered and 
concentrated. Purification by flash column chromatography on SiO2 (20:1 hexanes/ EtOAc) then 
afforded 2.135 (190 mg, 41%) as a yellow oil.  
 
Data for 2.135: 
Rf: 0.45 (9:1 hexanes/ EtOAc).  
FTIR (neat): 2030, 1589, 1564, 1455, 1326, 1198, 1982, 1045, 991, 822 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.81 (d, J = 9.0 Hz, 1H), 7.62 (d, J = 10.3 Hz, 1H), 7.00 (d, J = 9.0 Hz, 
1H), 6.78 (s, 1H), 5.47 (d, J = 10.3 Hz, 1H), 5.01 (t, J = 7.2 Hz, 1H), 3.82 (s, 6H), 2.09 – 2.01 (m, 2H), 
1.72 – 1.62 (m, 2H), 1.56 (s, 3H), 1.48 (s, 3H), 1.34 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 153.9, 152.5, 147.5, 131.8, 127.1, 125.8, 124.3, 123.6, 123.3, 122.6, 
119.9, 115.3, 110.6, 108.6, 77.3, 61.5, 56.0, 40.6, 25.8, 25.7, 22.9, 17.7 ppm. 

































To a solution of 2.125 (200 mg, 0.479 mmol, 1.0 equiv.) in THF (10 mL) was added at −78 °C t-BuLi 
(0.98 mL, 1.68 mmol, 1.7 M, 3.5 equiv.) and the reaction was left to stir 10 min. CO2 (bubbled 
through phosphorus pentoxide) was then passed through the solution at 1 atm for 30 min. The 
reaction was then slowly warmed to room temperature and quenched upon addition of sat. 
NH4Cl(aq) (10 mL) and product extracted with EtOAc (3 x 10 mL), dried with MgSO4, filtered and 
concentrated. Purification via flash chromatography (20:1 CH2Cl2/ MeOH) then gave 2.136 (83 mg, 
16%) as an orange solid and 2.122 (77 mg, 42%).  
 
Data for 2.136: 
Rf: 0.60 (20:1 hexanes/ EtOAc).  
FTIR (neat): 2926, 1685, 1607, 1454, 1344, 1262, 1221, 1049, 995, 830 cm-1. 
1H NMR (500 MHz, CDCl3): δ 11.32 (br s, 1H), 7.92 (d, J = 9.0 Hz, 1H), 7.76 (d, J = 10.4 Hz, 1H), 7.36 
(s, 1H), 7.16 (d, J = 9.0 Hz, 1H), 5.60 (d, J = 10.3 Hz, 1H), 5.10 (tt, J = 7.1, 1.4 Hz, 1H), 4.05 (s, 3H), 
3.99 (s, 3H), 2.19 – 2.11 (m, 2H), 1.77 (ddd, J = 16.9, 10.3, 6.2 Hz, 2H), 1.66 (s, 3H), 1.58 (s, 3H), 
1.45 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 166.0, 154.8, 154.2, 151.7, 132.0, 127.4, 126.7, 124.3, 124.1, 123.7, 
123.1, 120.3, 115.7, 114.7, 105.8, 78.0, 64.49, 56.0, 40.8, 26.0, 25.8, 22.9 ppm. 
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2. CO2, –78 ºC 





To a solution of 2.136 (28 mg, 0.073 mmol, 1.0 equiv.) in CH2Cl2 (5 mL) was added SeO2 (2 mg, 
0.015 mmol, 0.2 equiv.) and t-BuO2H (0.05 mL, 0.263 mmol, 3.6 equiv.) at room temperature. The 
reaction was left to stir for 16 h then quenched upon addition of sat. Na2SO4(aq) (10 mL) and 
product extracted CH2Cl2 (3 x 10 mL), dried MgSO4, filtered and concentrated in vacuo. Purification 
via flash chromatography (20:1 CH2Cl2/ MeOH) then gave 2.137 (9 mg, 30%) as an orange oil.  
 
Partial Data for 2.137: 
Rf: 0.90 (20:1 CH2Cl2/ MeOH).  
FTIR (neat): 2924, 2851, 1720, 1608, 1456, 1378, 1258, 1207, 1128 cm-1. 
1H NMR (500 MHz, CDCl3): δ 9.36 (s, 1H), 8.31 (d, J = 9.6 Hz, 1H), 7.76 (d, J = 10.3 Hz, 1H), 7.03 (d, J = 9.5 
Hz, 1H), 6.73 (s, 1H), 6.50 (t, J = 7.4 Hz, 1H), 5.51 (d, J = 10.2 Hz, 1H), 3.94 (s, 6H), 2.58 – 2.51 (m, 2H), 1.96 – 
1.91 (m, 2H), 1.48 (s, 4H), 1.27 (s, 3H) ppm. 




































To a solution of 2.135 (38 mg, 0.091 mmol, 1.0 equiv.) in THF (3 mL) was added at −78 °C t-BuLi 
(0.25 mL, 0.319 mmol, 1.7 M, 3.5 equiv.) and the reaction was left to stir 10 min. CO2 (bubbled 
through phosphorus pentoxide) was then passed through the solution at 1 atm for 30 min. The 
reaction was then slowly warmed to room temperature and quenched upon addition of sat. brine 
(10 mL) and product extracted with EtOAc (3 x 10 mL), dried with MgSO4, filtered and 
concentrated. Purification via flash chromatography (20:1 CH2Cl2/ MeOH) then gave 2.139 (9 mg, 
25%) as an orange solid and 2.122 (6 mg, 17%).  
 
Data for 2.139: 
Rf: 0.45 (9:1 CH2Cl2/ MeOH).  
FTIR (neat): 2925, 1694, 1454, 1368, 1267, 1209, 1139, 1089, 1030, 825 cm-1. 
1H NMR (500 MHz, CDCl3): δ 8.28 (d, J = 9.6 Hz, 1H), 7.69 (d, J = 10.3 Hz, 1H), 7.02 (d, J = 9.5 Hz, 
1H), 6.70 (s, 1H), 5.51 (d, J = 10.3 Hz, 1H), 5.10 (td, J = 7.1, 3.6 Hz, 1H), 3.91 (s, 3H), 2.18 – 2.10 (m, 
J = 5.6 Hz, 2H), 1.78 – 1.72 (m, J = 7.1 Hz, 2H), 1.65 (s, 3H), 1.57 (s, 3H), 1.42 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 185.7, 179.3, 155.1, 151.7, 137.0, 131.8, 130.3, 129.6, 128.0, 125.9, 
124.5, 124.2, 117.4, 114.9, 105.7, 77.1, 55.6, 40.5, 33.2, 25.8, 25.6, 22.9 ppm. 


























    –78 ºC, 10 min
2. CO2, –78 ºC 





To a solution of 2.139 (20 mg, 0.053 mmol, 1.0 equiv.) in CH2Cl2 (5 mL) was added SeO2 (1 mg, 
0.009 mmol, 20 mol%) and t-BuO2H (0.03 mL, 0.191 mmol, 3.6 equiv.) at room temperature. The 
reaction was left to stir for 16 h then quenched upon addition of sat. Na2SO4(aq) (10 mL) and 
product extracted CH2Cl2 (3 x 10 mL), dried with MgSO4, filtered and concentrated in vacuo. 
Purification via flash chromatography (20:1 CH2Cl2/ MeOH) then gave 2.140 (7 mg, 35%) as an 
orange oil.  
 
Data for 2.140: 
Rf: 0.15 (20:1 CH2Cl2/ MeOH).  
FTIR (neat): 2965, 2927, 1687, 1607, 1458, 1365, 1263, 1137, 1087, 1016 cm-1. 
1H NMR (500 MHz, CDCl3): δ 9.36 (s, 1H), 8.31 (d, J = 9.5 Hz, 1H), 7.76 (d, J = 10.3 Hz, 1H), 7.03 (d, 
J = 9.5 Hz, 1H), 6.74 (s, 1H), 6.50 (td, J = 7.4, 1.5 Hz, 1H), 5.51 (d, J = 10.3 Hz, 1H), 3.93 (s, 3H), 2.57 
– 2.52 (m, 2H), 1.96 – 1.91 (m, 2H), 1.48 (s, 3H), 1.26 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 195.4, 177.4, 155.1, 154.7, 151.4, 139.5, 137.0, 130.4, 129.9, 128.2, 
125.0, 124.9, 124.5, 117.2, 114.6, 105.9, 76.8, 55.7, 39.0, 29.8, 24.3, 9.3 ppm. 



































2.4.3 NMR Comparison Data 
 
 
Table 2.4 – 1H and 13C NMR Comparison of Natural and Synthetic Rhodonoid D 
 
Assignment Natural Sample  
1H NMR 
 (400 MHz, CDCl3)  
Hou et al.33  
Synthetic Sample 
1H NMR  
(600 MHz, CDCl3) 
Natural  
Sample 
 1H NMR  
(150 MHz, CDCl3) 
Hou et al.33 
Synthetic  
Sample  
13C NMR  
(125 MHz, CDCl3) 
1 -- -- 155.7 155.6 
2 6.30 (br s) 6.30 (br s) 108.6 108.5 
3 -- -- 140.4 140.2 
4 6.26 (br s) 6.26 (s) 110.0 109.8 
5 -- -- 152.8 152.6 
6 -- -- 108.0 107.8 
7 5.04  
(d, J = 4.3 Hz) 
5.05  
(d, J = 4.2 Hz) 
69.1 68.9 
8 1.83  
(d, J = 4.3 Hz) 
1.87 – 1.81 (m) 51.3 51.1 
9 -- -- 77.7 77.5 
10 1.82  
(dd, J = 13.7, 6.0 
Hz) 
1.49  
(dd, J = 13.7, 6.0 
Hz) 
1.87 – 1.81 (m) 
1.49  
(dd, J = 14.6, 5.7 
Hz) 
27.7 27.6 
11 1.71 (m) 1.73 – 1.69 (m) 27.1 27.0 
12 3.85 (br s) 3.85 (s) 82.2 82.0 
13   42.8 42.6 
14 1.29 (s) 1.29 (s) 28.1 27.9 
15 1.26 (s) 1.26 (s) 23.1 23.0 
16 1.63 (s) 1.64 (s) 30.3 30.1 
17 2.23 (s) 2.23 (s) 21.6 21.5 

































2.4.4 NMR Spectra 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.4.5 Single Crystal X-Ray Data 
A single crystal of 2.83 was mounted in paratone-N oil on a plastic loop and X-ray diffraction data 
were collected at 150(2) K on an Oxford X-calibur single crystal diffractometer using Mo Ka 
radiation. The data set was corrected for absorption using a multi-scan method, and the structures 
solved by direct methods using SHELXS-2008 and refined by full-matrix least squares on F2 by 
SHELXL-2015,36 interfaced through the programs X-Seed37 and Olex2 (Table 2.5 – 2.11).38 Unless 
otherwise stated, non-hydrogen atoms were refined anisotropically and hydrogen atoms were 
included as invariants at geometrically estimated positions. Full data for the structure 
determination have been deposited with the Cambridge Crystallographic Data Centre as CCDC 
1944007. Copies of this information may be obtained free of charge from The Director, CCDC, 12 
Union Street, Cambridge CB2 1EZ, U.K. (fax, +44-1223-336-033; e-mail, deposit@ccdc.cam.ac.uk). 
Compound 2.83 is a racemic mixture and so the isomer that matches best to that of the natural 




Figure 2.4 − A perspective view of 2.83 with thermal ellipsoids shown at the 50% probability 











Table 2.5 − Crystal data and structure refinement for 2.83. 
 
Identification code 15-HP-80 
CCDC number 1944007 
Empirical formula C17H20O3 
Formula weight 272.33 
Temperature/K 150(2) 
Crystal system monoclinic 












Crystal size/mm3 0.57 × 0.47 × 0.06 
Radiation MoKα (λ = 0.71073) 
2θ range for data collection/° 7.316 to 58.424 
Index ranges -13 ≤ h ≤ 12, -12 ≤ k ≤ 12, -21 ≤ l ≤ 20 
Reflections collected 13296 
Independent reflections 3260 [Rint = 0.0304, Rsigma = 0.0252] 
Data/restraints/parameters 3260/0/185 
Goodness-of-fit on F2 1.039 
Final R indexes [I>=2σ (I)] R1 = 0.0431, wR2 = 0.1077 
Final R indexes [all data] R1 = 0.0527, wR2 = 0.1140 




Table 2.6 −  Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement 
Parameters (Å2×103) for 15. Ueq is defined as 1/3 of the trace of the orthogonalised UIJ tensor. 
 
Atom x y z U(eq) 
O1' 5412.3(9) 2733.4(10) 9100.5(5) 19.4(2) 
C1 3125.9(12) 3878.1(14) 7634.4(8) 18.4(3) 
C1' 3986.2(13) 2469.9(13) 9028.5(8) 16.7(2) 
C2 4684.8(12) 3751.9(14) 7660.0(7) 16.5(2) 
C2' 2845.2(13) 2949.2(14) 8335.1(8) 17.1(2) 
O3' 267.1(9) 3030.6(12) 7688.5(6) 27.5(2) 
C3 5771.9(12) 3841.8(14) 8541.4(8) 17.3(3) 
C3' 1441.8(13) 2587.1(14) 8343.8(8) 20.1(3) 
C4 7154.4(12) 3261.9(15) 8367.4(8) 19.2(3) 
C4' 1185.7(14) 1791.3(15) 9008.8(9) 23.3(3) 
C5 6672.7(13) 2307.8(16) 7542.1(8) 23.1(3) 
C5' 2336.1(14) 1310.6(14) 9687.8(8) 22.5(3) 
C6 5022.4(12) 2233.3(14) 7335.5(8) 17.3(3) 
C6' 3733.2(14) 1647.2(14) 9692.6(8) 19.8(3) 
C7 4065.3(13) 2021.6(15) 6439.7(8) 19.6(3) 
C7' 2075.8(17) 412.9(17) 10406.6(10) 32.3(3) 
C8 2751.5(13) 2616.3(15) 6248.7(8) 22.0(3) 
O9 2179.3(9) 3429.3(12) 6794.6(6) 25.4(2) 
C10 5901.9(14) 5349.8(15) 8978.0(9) 24.9(3) 
C11 4555.3(15) 1125.5(16) 5801.3(8) 25.3(3) 
  
Table 2.7 −Anisotropic Displacement Parameters (Å2×103) for 15. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
 
Atom U11 U22 U33 U23 U13 U12 
O1' 16.2(4) 24.5(5) 15.7(4) 4.1(3) 1.9(3) -0.3(3) 
C1 16.9(5) 19.4(6) 16.8(6) 1.2(5) 1.6(5) 2.1(5) 
C1' 17.8(5) 15.4(6) 17.1(6) -3.7(4) 5.4(5) -0.2(4) 
C2 15.8(5) 17.7(6) 14.8(6) 2.8(4) 2.6(4) -0.1(4) 
C2' 18.8(5) 15.9(6) 17.0(6) -2.4(4) 5.6(5) 0.3(4) 
O3' 15.9(4) 38.5(6) 27.1(5) 1.8(4) 4.8(4) 2.0(4) 
C3 16.8(5) 17.4(6) 16.3(6) 1.5(4) 2.6(4) -1.5(4) 
C3' 17.9(6) 20.0(6) 22.6(6) -4.4(5) 6.2(5) 1.3(5) 
C4 15.2(5) 22.2(6) 18.8(6) 0.7(5) 2.6(5) -0.7(5) 
C4' 22.5(6) 21.4(6) 29.8(7) -4.2(5) 13.6(5) -3.2(5) 
C5 16.4(6) 33.5(7) 18.6(6) -2.6(5) 4.0(5) 1.7(5) 
C5' 31.1(7) 16.9(6) 23.7(7) -2.9(5) 14.4(5) -1.3(5) 
C6 16.7(5) 20.2(6) 13.9(6) 1.3(4) 2.7(4) 0.9(4) 
C6' 26.3(6) 17.0(6) 16.5(6) -1.4(5) 7.0(5) 1.7(5) 
C7 21.6(6) 21.8(6) 14.0(6) 1.0(5) 3.0(5) -3.3(5) 
C7' 42.1(8) 28.8(8) 32.7(8) 5.4(6) 21.1(7) -0.2(6) 
C8 21.4(6) 29.1(7) 13.2(6) 3.0(5) 1.2(5) -2.7(5) 
O9 16.6(4) 40.7(6) 16.0(5) 1.9(4) 0.0(3) 3.9(4) 
C10 25.3(6) 21.0(6) 25.7(7) -4.7(5) 3.3(5) -1.1(5) 
C11 28.6(7) 27.8(7) 17.8(6) -3.1(5) 4.0(5) -1.3(6) 
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Table 2.8 − Bond Lengths for 2.83. 
 
Atom Atom Length/Å Atom Atom Length/Å 
O1' C1' 1.3740(14) C3 C10 1.5139(18) 
O1' C3 1.4597(14) C3' C4' 1.3840(19) 
C1 C2 1.5048(16) C4 C5 1.5514(18) 
C1 C2' 1.5056(17) C4' C5' 1.3935(19) 
C1 O9 1.4697(15) C5 C6 1.5378(16) 
C1' C2' 1.4016(17) C5' C6' 1.3861(18) 
C1' C6' 1.3940(17) C5' C7' 1.5070(19) 
C2 C3 1.5214(16) C6 C7 1.5023(16) 
C2 C6 1.5279(17) C7 C8 1.3309(18) 
C2' C3' 1.4035(17) C7 C11 1.5016(18) 
O3' C3' 1.3760(15) C8 O9 1.3887(16) 
C3 C4 1.5404(17) 
   
 
Table 2.9 − Bond Angles for 2.83. 
 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C1' O1' C3 118.83(9) O3' C3' C2' 120.64(12) 
C2 C1 C2' 110.02(10) O3' C3' C4' 117.68(11) 
O9 C1 C2 110.66(10) C4' C3' C2' 121.67(12) 
O9 C1 C2' 111.19(10) C3 C4 C5 106.87(9) 
O1' C1' C2' 123.61(11) C3' C4' C5' 120.09(12) 
O1' C1' C6' 115.25(11) C6 C5 C4 104.13(10) 
C6' C1' C2' 121.13(11) C4' C5' C7' 120.70(12) 
C1 C2 C3 115.72(10) C6' C5' C4' 119.38(12) 
C1 C2 C6 111.90(10) C6' C5' C7' 119.92(12) 
C3 C2 C6 102.60(9) C2 C6 C5 101.56(10) 
C1' C2' C1 120.74(11) C7 C6 C2 108.56(10) 
C1' C2' C3' 117.34(11) C7 C6 C5 121.76(10) 
C3' C2' C1 121.85(11) C5' C6' C1' 120.38(12) 
O1' C3 C2 109.52(9) C8 C7 C6 117.05(11) 
O1' C3 C4 105.61(9) C8 C7 C11 121.73(12) 
O1' C3 C10 108.01(10) C11 C7 C6 121.18(11) 
C2 C3 C4 101.85(10) C7 C8 O9 126.39(11) 
C10 C3 C2 115.77(10) C8 O9 C1 119.26(9) 
C10 C3 C4 115.51(10) 




Table 2.10 − Torsion Angles for 2.83. 
 
A B C D Angle/˚ A B C D Angle/˚ 
O1' C1' C2' C1 -3.44(18) O3' C3' C4' C5' 179.81(11) 
O1' C1' C2' C3' 179.42(11) C3 O1' C1' C2' 14.45(17) 
O1' C1' C6' C5' -179.89(11) C3 O1' C1' C6' -166.98(10) 
O1' C3 C4 C5 91.89(11) C3 C2 C6 C5 -47.78(11) 
C1 C2 C3 O1' 53.96(14) C3 C2 C6 C7 -177.22(9) 
C1 C2 C3 C4 165.43(10) C3 C4 C5 C6 -6.34(13) 
C1 C2 C3 C10 -68.42(14) C3' C4' C5' C6' 0.49(19) 
C1 C2 C6 C5 -172.46(10) C3' C4' C5' C7' -178.60(12) 
C1 C2 C6 C7 58.10(13) C4 C5 C6 C2 32.59(12) 
C1 C2' C3' O3' 2.35(18) C4 C5 C6 C7 153.17(12) 
C1 C2' C3' C4' -176.99(12) C4' C5' C6' C1' 0.55(19) 
C1' O1' C3 C2 -37.83(14) C5 C6 C7 C8 -150.44(13) 
C1' O1' C3 C4 -146.81(10) C5 C6 C7 C11 31.91(18) 
C1' O1' C3 C10 89.07(12) C6 C2 C3 O1' -68.18(11) 
C1' C2' C3' O3' 179.45(11) C6 C2 C3 C4 43.30(11) 
C1' C2' C3' C4' 0.12(18) C6 C2 C3 C10 169.44(11) 
C2 C1 C2' C1' 17.77(16) C6 C7 C8 O9 0.7(2) 
C2 C1 C2' C3' -165.23(11) C6' C1' C2' C1 178.07(11) 
C2 C1 O9 C8 16.71(15) C6' C1' C2' C3' 0.94(18) 
C2 C3 C4 C5 -22.51(13) C7 C8 O9 C1 8.8(2) 
C2 C6 C7 C8 -33.29(15) C7' C5' C6' C1' 179.65(12) 
C2 C6 C7 C11 149.06(12) O9 C1 C2 C3 -166.73(10) 
C2' C1 C2 C3 -43.47(14) O9 C1 C2 C6 -49.70(13) 
C2' C1 C2 C6 73.57(13) O9 C1 C2' C1' 140.72(11) 
C2' C1 O9 C8 -105.87(12) O9 C1 C2' C3' -42.28(15) 
C2' C1' C6' C5' -1.29(18) C10 C3 C4 C5 -148.83(11) 




Table 2.11 − Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement Parameters 
(Å2×103) for 2.83. 
 
Atom x y z U(eq) 
H1 2920 4948 7734 22 
H2 4908 4555 7293 20 
H3' 529 3223 7255 33 
H4A 7720 2645 8851 23 
H4B 7760 4110 8290 23 
H4' 224 1572 9002 28 
H5A 6957 2791 7073 28 
H5B 7102 1294 7639 28 
H6 4781 1439 7701 21 
H6' 4523 1315 10151 24 
H7'A 2980 315 10867 48 
H7'B 1718 -583 10198 48 
H7'C 1359 924 10622 48 
H8 2146 2470 5683 26 
H10A 6663 5307 9523 37 
H10B 4984 5604 9080 37 
H10C 6143 6114 8613 37 
H11A 3799 1128 5253 38 
H11B 4751 94 6005 38 
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Chapter Three – Synthesis of Rhodonoids A, B, E and F 
 Enabled by Singlet Oxygen 
3.1 Introduction 
3.1.1 Isolation of the Rhodonoid Family of Natural Products 
Rhododendron is a genus of woody plants belonging to the Ericaceae family and is famous for 
possessing a diverse range of phytochemicals. One species, Rhododendron capitatum is a 
flowering plant containing the polycyclic meroterpenoids rhodonoids A – G (3.1 – 3.7) isolated 
from the aerial part of the plant (Figure 3.1).1, 2 Despite the stereochemically rich nature of these 
structures, the rhodonoids were all isolated as partial racemates. This implies that the key steps 




Figure 3.1 – Rhodonoids A – G Isolated from Rhododendron Capitatum1, 2 
 
Biomimetic approaches towards the total synthesis of rhodonoids A – G (3.1 – 3.7) have all been 
previously achieved from commercially available orcinol (3.8) (Scheme 3.1).3 - 5 Knoevenagel 
condensation and oxa-6𝜋-electrocyclization with either citral (3.9) or farnesal (3.10) affords the 
corresponding chromenes 3.11 and 3.12 respectively. Perhaps unsurprisingly, both chromenes 
are natural products themselves with 3.11 being an unnamed natural product isolated from a 
plant of the same genus Rhododendron anthopogonides.6 While confluentin (3.12) was first 
isolated as a novel metabolite from the fungi Albatrellus ovinus.7 Further functionalization of the 
prenyl moiety via either epoxidation or electrophilic addition reactions then affords rhodonoids A 






















































Scheme 3.1 – Total Synthesis of Rhodonoids (A – G) via Chromenes 3.11 and 3.123 - 5 
 
3.1.2 The Total Synthesis of the Rhodonoids C, D and G  
In 2017, Wu et al. reported the first total synthesis of rhodonoid G (3.7) (Scheme 3.2).3 This was 
achieved through treatment of chromene 3.11 with p-TsOH to afford the o-QM 3.13. Formation 
of the corresponding carbocation 3.14 via a 6-exo-trig cyclization followed by the addition of 
water then gave rhodonoid G (3.7) in 40% (pathway A). Interestingly, formation of the citran 
natural product ranhuadujuanine B (3.15) also occurred presumably via a stepwise hetro-Diels-
Alder reaction (pathway B), whilst an ene reaction afforded the elimination products 3.16 and 









R = Me (3.11) 82%






































































3.9: citral or 
3.10: farnesal
Day et al., Org. Lett., 2017, 19, 2463.
Wu et al., Org. Lett.,  2017, 19, 3505. Wu et al., Org. Lett.,  2017, 19, 3505.




Scheme 3.2 – Wu and Co-Workers Total Synthesis of rhodonoid G3 
 
Our group has reported the divergent synthesis of rhodonoids C and D (3.3 and 3.4) again via 
biomimetic cascade reactions (Scheme 3.3).4 This involved the regioselective epoxidation of 
chromene 3.11 to afford 3.18 (dr 1:1). Treatment with SnCl4 resulted in an acid catalyzed 6-endo-
tet ring opening, most likely via the SN1 mechanism 3.19. Cyclization of the corresponding o-QM 
3.20 then afforded rhodonoid C (3.3) in 32% (pathway A). Simultaneously a 5-exo-tet ring opening 
of 3.21 (leading to inversion at C12) also occurred, this time via the SN2 mechanism to afford o-
QM 3.22. Nucleophilic attack of the tertiary alcohol to the o-QM 3.22 then resulted in 
































































Scheme 3.3 – Total Synthesis of Rhodonoids C and D by Day et al.4 
 
3.1.3 The Total Syntheses of the Rhodonoids A, B, E and F 
Wu and co-workers also reported the total synthesis of rhodonoid A (3.1) in 2017. This began with 
Knoevenagel condensation and oxa-6𝜋-electrocyclization of orcinol (3.8) and citral (3.9) to give 
chromene 3.11 (Scheme 3.4).5 Benzyl protection of the free phenol then afforded 3.23, followed 
by epoxidation with m-CPBA to give 3.24 in 53% (dr 1:1). Ring opening of epoxide 3.24 with the 
Lewis acid Al(Oi-Pr)3 provided access to the allylic alcohol 3.25, which was oxidized using Dess-
Martin periodinane conditions to give the 𝛼, 𝛽-unsaturated ketone 3.26 in 62% over 2-steps. A 
[2+2] cycloaddition of the enone 3.26 under UV light, and subsequent benzyl deprotection then 
afforded rhodonoid A (3.1). Overall, this sequence had a low total yield of 8% and required 7-




































































Scheme 3.4 – The Total Synthesis of Rhodonoid A by Wu and Co-Workers5 
 
Similarly, to rhodonoids A, C, D, and G, rhodonoids E and F (3.5 and 3.6) were also synthesized 
from a chromene precursor. However this time Wu and co-workers employed the C15 
merosesquiterpenoid E-confluentin (3.12) (Scheme 3.5).3 A cationic [2+2] cycloaddition with 
Fe(OTf)3 afforded the tetracycle 3.28 in a 70% yield. TBS protection of the free phenol 3.28 then 
gave 3.29, followed by epoxidation with m-CPBA and a Lewis acid catalyzed ring opening to afford 
the C12 epimers 3.30 and 3.31. Finally, TBAF deprotection then gave the desired natural products 















































































Scheme 3.5 – Wu and Co-Workers Total Synthesis of Rhodonoids E and F3 
 
The total synthesis of rhodonoid B (3.2) also began from confluentin (3.12), however this time 
from the Z isomer (derived from 6Z-farnesal) (Scheme 3.6).5 A cationic [2+2] cycloaddition of this 
isomer with Fe(OTf)3 afforded tetracycle 3.32 as the major diastereoisomer in 60% (epimer of 
3.28). Acetate protection followed by electrophilic addition of benzenesulphenyl chloride and 
substitution with sodium acetate provided tertiary acetoxy sulphide 3.33 in 83%. A 2-step 
oxidation with H2O2 followed by desulfurization then gave 3.34 in 69%. 3.34 was converted to the 
monoacetate protected phenol 3.35, then a TEMPO+BF4- oxidative allylic transposition and 
subsequent deacylation afforded rhodonoid B (3.2) in a 28% yield over 2-steps. In total, the 
synthesis of rhodonoid B (3.2) was achieved in a lengthy 11-step route, with an overall yield of 
4%.  
 
The high step count required for the synthesis of rhodonoids A, B, E and F (as described) in 
combination with the low yielding nature of these reactions prompted us to consider our own 
biomimetic route. We envisaged that one solution to achieve this would be through various 
unique photooxygenation cascade reactions, which we hoped could be employed to gain access 


































    CH2Cl2
2. Al(Oi-Pr)3













3.5: rhodonoid E, 91%
C12 ― C15 anti
3.6: rhodonoid F, 89%
C12 ― C15 syn
3.30: 32% (over 2-steps)
C12 ― C15 anti 
3.31: 31% (over 2-steps)























Scheme 3.6 – 11-Step Total Synthesis of Rhodonoid B from Wu et al.5 
 
3.1.4 Photooxygenation Reactions 
Photooxygenation reactions refer to any reaction that occurs with oxidation, light, and the 
incorporation of molecular oxygen. These reactions are initiated through a photosensitiser, 
usually a dye or pigment that often contains aromatic functionality (i.e. rose bengal (3.37), 






























1.  Ac2O, DMAP, CH2Cl2













































































Figure 3.2 – Common Photosensitisers for Photooxygenation Reactions 
 
These photosensitisers (sens) enter an excited singlet state (1Sens*) when exposed to a specific 
wavelength of light. Intersystem crossing (ISC) then occurs converting this singlet state to a more 
stable triplet state (3Sens*). The resultant sensitizer is then able to convert its energy via a series 
of reaction cascades to either molecular oxygen (3O2) or to the substrate of the photooxygenation 




Figure 3.3 – Photooxygenation Reactions with Photosensitisers 
 
There are three types of photooxygenation reactions (Type I, II, and III) based according to the 
order of transient intermediates formed. In type I reactions the photoactivated sensitiser (3sens*) 
interacts to afford a radical substrate, typically through homolytic bond cleavage. This substrate 
then reacts with ground state molecular oxygen (3O2) to yield the photooxygenation product 
(Scheme 3.7).10  
 
In type II reactions, the triplet state photosensitiser (3sens*) acts directly with molecular oxygen 
(3O2) to generate the reactive oxygen species (ROS), singlet oxygen (1O2). Singlet oxygen can then 
add to the substrate in a variety of ways, including Schenck-ene reactions to give hydroperoxides 
and cycloadditions to afford endoperoxides (Scheme 3.7). 
 







































During type III reactions an electron transfer between (3sens*) and the substrate results in 
formation of both a radical anionic photosensitiser and cationic substrate. The resulting anionic 
photosensitiser then transfers an electron to molecular oxygen (3O2) affording a superoxide anion 
(O2•—). Further reaction of the superoxide anion and cationic substrate then gives the oxygenated 
product (Scheme 3.7). 
 
 
Scheme 3.7 – Type I, II, and III Photooxygenation Reactions 
 
All three types of photooxygenation reactions have been applied in the context of total 
synthesis.11 - 14 However notably, type II photooxygenation reactions have been the most 
extensively used (presumably due to the low energy thresholds required to generate singlet 
oxygen). 
 
Of course, in nature the most abundant photosensitisers are chlorophylls, present in all plants 
(and some cyanobacteria) that undergo photosynthesis.15 Photooxygenation reactions are 
ubiquitous to nature, occurring in the presence of sunlight and atmospheric oxygen. These 
reactions are ideal for use in biomimetic synthesis, as they can be mimicked synthetically in a 
laboratory with use of the appropriate reaction conditions.  
 
The first reported example of a photooxygenation reaction was in 1867 by Carl J. Fritzsche, who 
observed the reversible formation of a precipitate in a solution of tetracene (3.41) that was 
exposed to air and ambient light (Scheme 3.8).16 At the time, the structure of the reagent and 
product was unknown, and it was not until some 60 years later with the help of chemists Charles 


























molecular oxygen was reported. Only in 1968 was the structure of singlet oxygen unequivocally 
established by Christopher S. Foote.20  
 
 
Scheme 3.8 – The First Example of Photooxygenation by Fritzsche in 186716 
 
In 1944, Schenck and Ziegler reported the first example into the use of singlet oxygen (1O2) in total 
synthesis.21 Irradiation of  𝛼-terpinene (3.43) in the presence of the photosensitiser eosin (3.40), 
afforded ascaridole (3.44). In the following years this synthesis was improved by the choice of a 





Scheme 3.9 – Schenck and Ziegler’s Total Synthesis of ascaridole22 
 
3.1.5 Schenck-Ene (Singlet Oxygen-Ene) Reactions 
In 1948, Schenck also reported the first dye sensitized singlet oxygen-ene reaction of terpenes 
(known today as the Schenck-ene reaction).23 Later work then focused on the photooxygenation 
of tetramethylethylene with a variety of photosensitisers (i.e. rose bengal (3.37), methylene blue 
(3.38), and chlorophyll) (Scheme 3.10).24  
 
 
Scheme 3.10 – Schenck’s 1958 Singlet Oxygen-Ene Reaction24 
 
Efforts towards the elucidation of the Schenk-ene reaction mechanism have been extensively 
studied. This ranges from the identification of the reactive intermediates via spectral,25, 
































isotope effects20, 27 and solvent dependence studies have been performed.28 Theoretical models 
have also been used to analyse these reactions ranging from frontier molecular orbital theory29 to 
more sophisticated ab initio methods.30 Of course, predicting the reaction coordinate of 
electronically excited molecules such as singlet oxygen using current theoretical methods is 
somewhat limited (even with the best models). Instead, this reaction mechanism is better 
elucidated through experimental data.  
 
On account of the reactive nature of the Schenck-ene reaction, a diverse range of mechanisms 
have been suggested. Arguments in favour of a concerted pathway via the transition state 3.47,31 
or a stepwise mechanism via the biradical intermediate 3.48 have both been proposed.30 
Furthermore, zwitterionic intermediates (i.e. 3.49)32 and perepoxide like intermediates (i.e. 
3.50),33 through the formation of a reversible exciplex 3.51 have also been implicated in this 
mechanism (Figure 3.4).34 
 
 
Figure 3.4 – Proposed Transition States Intermediates for the Schenck-ene Reaction31 - 34 
 
Kinetic data clearly favours a stepwise mechanism32 while the suprafacial selectivity and lack of 
Markovnikov orientation rules out the intermediary of any longer lived diradical (i.e. 3.48) and 
zwitterionic intermediates (i.e. 3.49).32, 35  
 
To date, the majority of experimental data accumulated suggest that the first identifiable step in 
the sequence is the reversible formation of an exciplex 3.51, formed from an excited state charge 
transfer complex of singlet oxygen (1O2) and the alkene 3.52.32, 34 Conversion of this complex 3.51 
into the perepoxide 3.50 then occurs as the rate limiting step, which is dependent on the electron 
density of the alkene. This perepoxide intermediate 3.50 was first proposed by D. B. Sharp in 
1960.36 Provided the presence of an allylic 𝛾-hydrogen atom (ideally perpendicular to the alkene) 
a 1,3-allylic transposition and ring opening of the perepoxide (ene reaction) then occurs to afford 
hydroperoxide 3.54. The products of the Schenk-ene reaction can then undergo subsequent 
transformations to afford a wide range of chemical structures and building blocks (3.55 – 3.60) 
(Scheme 3.11).9, 37, 38 In this chapter we hope to further explore some of these transformations, 


















rearrangement (i.e. 3.56) and reduction reactions. The mechanisms of these reactions will be 
discussed later in this chapter (vide infra).  
 
 
Scheme 3.11 – The Schenck-ene Reaction and Subsequent Transformations32 – 38 
 
Another example in the use of the Schenck-ene reaction in total synthesis includes the synthesis 
of (+)-okramine N (3.64) reported by Baran et al. in 2003 (Scheme 3.12).39 In this sequence 
diketopiperazine 3.64 is synthesized in 3-steps from commercially available (S)-tryptophan methyl 
ester. A one-pot indole protection with N-methyltriazolinedione (MTAD), followed by a Schenck-
ene reaction, reduction and aminal formation then afforded intermediate 3.63. Finally, indole 












































































































Not only does the Schenck-ene reaction exhibit high sustainability, with 100% atom economy, but 
it also employs relatively cheap and abundant reagents such as O2, metal-free catalysts, alkenes 
and visible light. Additionally, these reactions also occur with good regio-, and stereochemical 
control, allowing for the synthesis of complex molecules with stereochemical complexity.38 
 
Today, Schenck-ene reactions have become a powerful avenue enabling direct access to a diverse 
set of allylic alcohol and oxidized derivatives. Photooxygenation represents one of the most 
important hydrocarbon functionalization reactions available to the synthetic organic chemist. It is 
hoped that a Schenck-ene reaction could be employed in the biomimetic total synthesis of 
rhodonoids A, B, E, and F.  
 
3.1.6 Proposed Biogenic Relationship Between Rhodonoids A, B, E and F 
Given that chromene 3.11 has previously been shown via biomimetic synthesis to be the probable 
precursor of  the monoterpenoids rhodonoids C, D, G and ranhuadujuanine B (being synthesized 
in 1-step from 3.11) we thought it likely that it would could also be the precursor of rhodonoid A 
(3.1).3, 4 A singlet oxygen-ene reaction of the prenyl chromene 3.11 could give hydroperoxide 3.65 
(Scheme 3.13). We then envisaged a Kornblum-DeLaMare rearangement would give 3.66, via a 
base catalyzed 𝛼-proton abstraction and O-O cleavage to form a ketone. A subsequent 




Scheme 3.13 – The Proposed Biosynthesis of Rhodonoid A 
Singlet oxygen-ene reactions could also be implicated in the biosynthesis of rhodonoids B, E and 
































a [2+2] photocycloaddition to afford the cyclobutane diasteromers 3.28 and 3.32 (epimers at C12) 
(Scheme 3.14). 
 
Scheme 3.14 – [2+2] cycloaddition of confluentin to afford 3.28 and 3.32 
 
A Schenck-ene reaction of the cyclobutane 3.28 could form the diasteromeric hydroperoxides 
3.67 and 3.68, which after reduction would afford rhodonoid E (3.5) and rhodonoid F (3.6) 




Scheme 3.15 – Proposed Biosynthesis of Rhodonoids E and F 
 
We also proposed that Rhodonoid B (3.2) could be synthesized from a singlet oxygen-ene reaction 
of cyclobutane 3.32 to afford the peroxy radical 3.69 (Scheme 3.16). A Schenck rearangement of 
this reactive radical intermediate via the disassocitative 𝜂3 radical 3.70, would give a 1,3-
transposition, followed by a H atom abstraction to give the hydroperoxide 3.71. A base catalyzed 










































































Scheme 3.16 – The Proposed Biosynthesis of Rhodonoid B 
 
3.1.7 Project Aims 
We aimed to test the proposal of this biosynthesis through a total synthesis of rhodonoids A, B, E 
and F from the polyketide derived and comercially available orcinol (3.8). The ideal outcome 
would be to synthesize rhodonoid A (3.1) in 1-step from chromene (3.11) through a one-pot 
Schenk-ene, Kornblum-DeLaMare,  and [2+2] cycloaddition cascade. As irradiation with light is 
required for both the synthesis of singlet oxygen (necessary for the Schenck-ene reaction) and the 
[2+2] cycloaddition this was thought to be a plausible (Scheme 3.17). If this direct approach was 

































































































It was also hoped that a one-pot cascade via a Schenk-ene and reduction of tetracycle 3.68 could 
afford rhodonoids E and F (3.5 and 3.6). Whilst rhodonoid B (3.2) could be acessed through a 
formal total synthesis of the intermediate hydroperoxide 3.35 which following literature 




Scheme 3.18 – Proposed Biomimetic Syntheis of Rhodonoids B, E and F 
 
3.2 Results and Discussion 
3.2.1 The Biomimetic Total Synthesis of Rhodonoid A 
The synthesis of rhodonoid A (3.1) began with chromene 3.11, which was prepared from orcinol 
(3.8) using catalytic EDDA and citral (3.9) according to known procedure.4 A Schenck-ene reaction 
of 3.11 in the presence of O2, visible light and TPP (3.39) then afforded the hydroperoxide 3.74 in 














































































Scheme 3.19 – Synthesis of Chromene 3.11 and hydroperoxides 3.65 and 3.74 
 
Treatment of hydroperoxide 3.65 with Et3N in CH2Cl2 at room temperature then gave the 
Kornblum-DeLaMare product 3.66 in a low yield of 8%. Dissappointingly, reaction with either 
pyridine or piperidine only afforded trace amounts of the desired product. The best results were 
obtained upon reaction of 3.65 with acetyl chloride, pyridine and DMAP. Presumably this reaction 
occured through the peroxy intermediate 3.75, with DMAP acting as a nucleophillic catalyst to 
activate the Kornblum-DeLaMare rearrangement.38 Unsuprisingly, the formation of the acetate 




Scheme 3.20 – Kornblum-DeLaMare Rearrangement of hydroperoxide 3.65 
 
With 3.66 in hand, attempts towards a photocatalyzed [2+2] cycloaddition were investigated 
(Table 3.1). An initial attempt using identical conditions to that previously reported by Hsung and 
Tang in their [2+2] cycloadition of a Bn protected varient 3.20 was attempted (entry 1).5 
















































3.75 R = H (3.66) 26%







no reaction was observed. Of course, these types of [2+2] cycloaddition reactions do not have to 
occur exclusively through direct excitation with UV light, but can also be induced through an 
energy transfer from a photoexcited  sensitizer.40 Due to the ability of acetone to act as a triplet 
sensetizer, we attempted this reaction with acetone and UV light at room temperature (entries 2 
and 3). Again, no reaction was observed after 8 h and only decomposition after 24 h. Further 
attempts with the thioxanthone photosensitizers 3.77 and the pyrylium photosensitizer 3.78 also 
gave no reaction (entries 4 – 6). A more biomimetic attempt through the use of sunlight rather 
than UV light was also attempted, this time using the methylene blue photosensitizer 3.38, 




Table 3.1 – Conditions Screened for the Photochemical [2+2] Cycloaddition of 3.66 
 
Entry Photosensitizer  
(2 mol%) 
Light Source Conditions Result 
1 -- UVA hexane, rt, 12 h NR 
2 -- UVA acetone, rt, 8 h NR 
3 -- UVA acetone, rt, 24 h decomp. 
4 3.77: 
thioxanthone 
UVA THF, rt, 16 h NR 
5 3.77: 
thioxanthone 
UVA acetone, rt, 48 h decomp. 
6 3.78: 4-MeO-TPT Blue LED DCE, 0 °C, 5 h decomp. 
7 3.38: methylene 
blue 
sunlight CDCl3, rt, 4 h NR 
 
Having already serendipitously gained access to the acetate protected 𝛼, 𝛽-unsaturated ketone 
3.76 the attempted [2+2] photocyclization was attempted again. Gratifyingly, exposure of 3.76 to 
UV light in hexane afforded intermediate 3.79, direct treatment with K2CO3 and MeOH then 
afforded rhodonoid A (3.1) in 51% over 2-steps. Alternatively, use of acetone instead of hexane 
















Scheme 3.21 – Photochemical [2+2] Cycloaddition of 3.80 to Rhodonoid A 
 
Having achieved the synthesis of rhodonoid A (3.1), our efforts turned towards the development 
of a one-pot, photochemical method for the direct conversion of 3.11 into 3.1. Reaction of 
chromene 3.11 with TPP (3.39), O2, Ac2O, DMAP and pyridine in the presence of UVA light was 
undertaken. These reaction conditions were first disclosed by Laroche and Nay in their 
investigations of the photooxygenation of resinic diterpenes.38 Addition of K2CO3 was then added 
in the hope of an acetate deprotection to afford rhodonoid A (3.1) (Scheme 3.22). Regrettably, 
we only observed formation of the 𝛼, 𝛽-unsaturated ketone 3.76 in 28%. This suggeted that the 
desired Schenck-ene and Kornblum-DeLaMare cascade were infact occuring, but that the reaction 
was not undergoing the desired [2+2] cycloaddition or deprotection.  
 
 
Scheme 3.22 – Attempts Towards a One-Pot Synthesis of Rhodonoid A 
 
Although our initial attempt at a one-pot transformation proved elusive, efforts towards a more 
efficient two-step sequence were investigated. Gratifyingly it was found that a one-pot Schenck-
ene/ Kornblum-DeLaMare rearrangement of chromene 3.11 was successful this time with visible 
light to afford the 𝛼, 𝛽-unsaturated ketone 3.76 in 51% after flash chromatography. Enone 3.76 
was then disolved in MeOH and left under UV light at room temperature to form 3.79, which was 
subsequently deprotected by direct addition of K2CO3 to afford rhodonoid A (3.1) in 60% yield 
(Scheme 3.23). This 2-step (31% overall yield) sequence compares favourably to the previous 
synthesis of rhodonoid A (3.1) by to Wu and co-workers, who reported a 6-step (11% overall yield) 








































1O2, 3.39: TPP 
UV light, Ac2O
DMAP, pyr., CH2Cl2








Scheme 3.23 – 2-Step Sequence from Chromene 3.11 to Rhodonoid A 
 
3.2.2 The Biomimetic Total Synthesis of Rhodonoids B, E and F 
The Schenck-ene reaction was also invoked in the biomimetic synthesis of rhodonoids B, E and F. 
Confluentin (3.12) was synthesized as a 1.4:1 mixture of E and Z alkene isomers, through reaction 
of orcinol (3.8) with farnesal (3.10, as mixture of isomers) and catalytic EDDA.3 Wu et al. previously 
reported the diastereoselective synthesis of confluentin (3.12) through preparation of farnesal as 
single Z and E alkenes. Instead we decided to carry out a divergent intramolecular Lewis acid 
catalyzed [2+2] cycloaddition with Fe(OTf)3 on the mixture to give 3.28 and 3.32 in 43% and 28% 
respectively (Scheme 3.24). Cyclobutanes 3.28 and 3.32 were separable by careful flash 
chromatography on SiO2. Frustratingly, all attempts towards a photochemical [2+2] cycloadditions 
of Confluentin (3.12) using UVA light gave only decomposition.  
 
 
























































110 °C, 16 h
84%
3.8: orcinol 3.12: confluentin
Fe(OTf)3
































Alternatively, the desired [2+2] cycloaddition could also be achieved through acetate protection 
to afford chromene 3.80, as 1:1.4 mixture of Z and E alkene isomers. Subsequent [2+2] 
cycloaddition in the presence of the triarylpyrylium organic photocatalyst 4-MeO-TPT (3.78). 
Subsequent deprotection then afforded tetracycles 3.28 and 3.32 in 44% and 30% respectively 




Scheme 3.25 – Photoredox [2+2] Cycloaddition of Confluentin 
 
A Schenck-ene reaction of cyclobutane 3.28 using TPP (3.78) as a photosensitizer followed by 
direct reduction of the hydroperoxide intermediates with PPh3 afforded rhodonoid E (3.5) and 
rhodonoid F (3.6) in 23% and 16% yield respectively (Scheme 3.26). The tertiary alcohol and 
proposed natural product 3.81 was also obtained in 40%. Interestingly, 3.81 completes a formal 
total synthesis of a related natural product fastinoid B (epi-3.35), which is an epimer of rhodonoid 
B (3.35). These compounds were separable by careful flash chromatography using SiO2 
impregnated with 1% silver nitrate.41 In comparison Wu and co-workers converted 3.28 into 


















































Scheme 3.26 – The Total Synthesis of Rhodonoids E and F 
 
Next, we employed singlet oxygen chemistry in the formal synthesis of rhodonoid B (3.2), which 
was achieved by formation of a tertiary alcohol 3.35. This intermediate has been converted to 3.2 
by Wu et al. in 2 further steps.5 First, cyclobutane 3.32 was acylated to afford 3.73, followed by 
Schenck-ene reaction and reduction of the hydroperoxide using PPh3 to give 3.35 in 45%, 
alongside the secondary allylic alcohol diastereomers 3.82 which were isolated as an inseparable 
mixture (Scheme 3.27). Wu’s previous synthesis of rhodonoid B (3.2) used 7-steps (37% yield) to 
convert 3.32 into 3.2, compared to our 2-step synthesis (36% yield).5 
 
 
Scheme 3.27 – Formal Total Synthesis of Rhodonoid B 














3.39: TPP, 1O2 
visible light 
CH2Cl2, rt, 6 h









































































3.2.3 Synthesis of Rhodonoid E and F Analogues 
In addition to the synthesis of rhodonoids E and F, we through it might also be useful to synthesize 
both analogues of these natural products with epimerization at C12. It is hoped that in doing this 
these structures not only showcase our methodology (allowing us divergent access to a wide 
range of substrates in a small number of steps) but might also prove useful for future isolation 
work, as we suspect these compounds may be undiscovered natural products.  
 
A Schenck-ene reaction of cyclobutane 3.32 using TPP (3.39) as a photosensitizer followed by 
reduction of the hydroperoxide intermediates with PPh3 gave access to analogues 3.83, 3.84 and 




Scheme 3.28 – Synthesis of Rhodonoid E and F analogues 
 
 
Efforts towards the synthesis of the hydroperoxide natural product precursors were also 
undertaken on both cyclobutane 3.28 (precursors to rhodonoid E (3.5), rhodonoid F (3.6) and 
3.81) and 3.32 (precursors to 3.83, 3.84 and 3.85). Reaction of 3.28 with TPP (3.39) using Schenck-
ene conditions afforded hydroperoxide 3.86 in 20%. Unfortunately, 3.87 and 3.88 proved 




3.39: TPP, CH2Cl2 
visible light, 1O2 










































Scheme 3.29 – Synthesis of Rhodonoid E and F hydroperoxide precursors 
 
Alternatively, the same reaction conditions were employed using cyclobutane 3.32 to afford the 
hydroperoxide 3.89 in 16% and 3.90 and 3.91 in 30% as an inseparable mix (1.7:1) (Scheme 3.30).  
 
 
Scheme 3.30 – Synthesis of hydroperoxides 3.89, 3.90 and 3.91 
 
3.3 Conclusion 
By employing bio-inspired singlet oxygen-ene chemistry as a selective and mild oxidant we have 
reduced the step count of previous total syntheses of rhodonoids A, B, E and F. The 3-step total 
synthesis of rhodonoid A (3.1) features a one-pot Schenck-ene reaction and Kornblum-DeLaMare 
rearrangement, followed by an intramolecular [2+2] photocycloaddition. While the total synthesis 






























































































3.4.1 General Methods 
All chemicals used were purchased from commercial suppliers and used as received. All reactions 
were performed under an inert atmosphere of N2 unless otherwise stated. Thin layer 
chromatography was performed using aluminium sheets coated with silica gel. Visualization was 
aided by viewing under a UV lamp and staining with the appropriate stain followed by heating. All 
Rf values were measured to the nearest 0.05. Flash chromatography was performed using 40-63 
micron grade silica gel. Melting points were recorded on a digital melting point apparatus and are 
uncorrected. Infrared spectra were recorded using an FT-IR spectrometer as the neat compounds. 
High field NMR was recorded using a 600 MHz spectrometer (1H at 600 MHz, 13C at 150 MHz) or a 
500 MHz spectrometer (1H at 500 MHz, 13C at 125 MHz). The solvent used for NMR spectra was 
CDCl3 unless otherwise specified. 1H chemical shifts are reported in ppm on the δ-scale relative to 
TMS (δ 0.0) and 13C{1H} NMR are reported in ppm relative to chloroform (δ 77.16). Multiplicities 
are reported as (br) broad, (s) singlet, (d) doublet, (t) triplet, (q) quartet and (m) multiplet. All J-
values were rounded to the nearest 0.1 Hz. ESI high resolution mass spectra were recorded on a 
Q-TOF mass spectrometer. Photochemistry with UVA light was performed using a generic brand 
commercial LED UV light globe; wavelength: 365 nm. Photochemistry with UVC light was 
performed using a generic brand commercial LED UV light globe; wavelength: 254 nm. 
Photochemical reactions with visible light were performed with a conventional commercial LED 
desk lamp at 240 V with a 4 W 5000 K 32 mÅ globe. Reactions conducted under 470 nm blue LED 


















To a solution of orcinol (3.8) (10.0 g, 80.6 mmol, 1.0 equiv.) in PhMe (250 mL) at room temperature 
was added citral (3.9) (12.3 mL, 80.6 mmol, 1.0 equiv.) and EDDA (430 mg, 2.42 mmol, 3 mol%). 
The reaction was stirred at reflux for 3 h. The mixture was cooled to room temperature, then 
concentrated in vacuo and purified via flash column chromatography on SiO2 (8:1 hexanes/ EtOAc) 
to afford chromene 3.11 (17.2 g, 66.6 mmol, 82%) as an orange oil. Data for 3.11 matched that 
previously reported in the literature.4  
 
Data for 3.11:  
Rf: 0.40 (5:1 hexanes/ EtOAc). 
FTIR (neat): 3387, 2923, 1625, 1449, 1376, 1329, 1250, 1196, 1142, 1084, 1060, 907 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.61 (d, J = 10.0 Hz, 1H), 6.24 (s, 1H), 6.11 (s, 1H), 5.49 (d, J = 10.0 Hz, 
1H), 5.10 (t, J = 7.1 Hz, 1H), 4.71 (br s, 1H), 2.20 (s, 3H), 2.13 – 2.07 (m, 2H), 1.72 (dd, J = 10.7, 5.9 
Hz, 1H), 1.66 (s, 3H), 1.66 – 1.63 (m, 1H), 1.58 (s, 3H), 1.37 (s, 3H) ppm.  
13C NMR (125 MHz, CDCl3): δ 154.1, 151.0, 139.5, 131.6, 127.2, 124.2, 117.0, 109.9, 108.3, 106.7, 
78.2, 41.1, 26.2, 25.7, 22.7, 21.5, 17.6 ppm.  






















Chromene 3.11 (230 mg, 0.890 mmol, 1.0 equiv.) was dissolved in CH2Cl2 (10 mL), followed by 
addition of tetraphenylporphyrin (TPP) (3.39) (10 mg, 0.016 mmol, 2 mol%). The reaction was 
stirred at room temperature in a borosilicate glass test tube while exposed to visible light and with 
O2 bubbled through the solution for 20 h. The reaction was then concentrated and purified via 
flash chromatography on SiO2 (9:1 CH2Cl2/ EtOAc) to give the desired hydroperoxide 3.65 (130 mg, 
50%) as a 1:1 mixture of diastereoisomers and the tertiary hydroperoxide 3.74 (95 mg, 37%). 
 
Data for 3.65: 
Rf: 0.25 (20:1 EtOAc/ CH2Cl2). 
FTIR (neat): 3393, 2924, 1625, 1578, 1450, 1376, 1330, 1199, 1139, 1067, 992, 905 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.82 (m, 1H), 6.62 (d, J = 10.0 Hz, 1H), 6.22 (s, 1H), 6.11 (s, 1H), 5.44 
(dd, J = 10.0 Hz, 1H), 5.01 – 4.99 (m, 2H), 4.83 (br s, 1H), 4.31 (t, J = 6.6 Hz, 1H), 2.20 (s, 3H), 1.71 
(m, 7H), 1.36 (s, 1H) ppm.  
13C NMR (126 MHz, CDCl3): δ 154.0, 154.0, 151.2, 151.2, 143.6, 143.5, 139.8, 126.8, 126.7, 117.4, 
117.3, 114.7, 114.5, 109.9, 108.6, 108.6, 108.6, 106.7, 89.8, 89.7, 78.2, 78.0, 37.3, 37.0, 26.6, 26.4, 
25.6, 25.3, 21.6, 17.4, 17.4 ppm. 
HRMS (ESI) m/z: [M+H]+ Calcd for C17H23O4 291.1591, found 291.1591.  
 
Data for 3.74: 
Rf: 0.15 (20:1 EtOAc/ CH2Cl2). 
FTIR (neat): 3384, 2927, 1624, 1579, 1452, 1377, 1262, 1201 cm-1. 
1H NMR (600 MHz, CDCl3): δ 7.34 (br s, 1H), 6.64 (d, J = 10.0, 1H), 6.21 (s, 1H), 6.11 (s, 1H), 5.80 – 
5.70 (m, 1H), 5.60 – 5.50 (m, 1H), 5.47 – 5.42 (m, 1H), 5.17 (br s, 1H), 2.45 – 2.35 (m, 2H), 2.18 (s, 
3H), 1.40 (s, 3H), 1.26 (s, 6H) ppm.  
13C NMR (125 MHz, CDCl3): δ 154.2, 151.34, 140.0, 137.0, 126.6, 126.4, 117.5, 109.5, 108.7, 
107.0, 82.4, 78.0, 44.4, 26.8, 24.3, 24.3, 21.6 ppm. 
























Hydroperoxide 3.65 (275 mg, 0.947 mmol, 1.0 equiv.) was dissolved in pyridine (20 mL) and 4-
dimethylaminopyridine (DMAP) (12 mg, 0.095 mmol, 10 mol%) added, followed by a dropwise 
addition of AcCl (0.081 mL, 1.13 mmol, 1.2 equiv.). The reaction was left to stir at room 
temperature for 24 h, then quenched upon addition of H2O (30 mL), and product extracted with 
EtOAc (2 x 20 mL). The combined organic layers were then washed with 0.5 M CuSO4(aq) (3 x 60 
mL), dried with MgSO4, filtered and concentrated in vacuo. Purification via flash chromatography 
on SiO2 (9:1 hexanes/ EtOAc) then afforded acetate protected enone 3.76 (143 mg, 48%) as a 
white solid and enone 3.66 (53 mg, 26%) as a yellow oil.  
 
Data for 3.66: 
Rf: 0.55 (8:2 hexanes/ EtOAc). 
FTIR (neat): 3395, 2926, 1665, 1625, 1579, 1451, 1375, 1329, 1139, 992 cm-1. 
1H NMR (600 MHz, CDCl3): δ 6.64 (d, J = 9.9 Hz, 1H), 6.22 (s, 1H), 6.13 (s, 1H), 5.93 (s, 1H), 5.72 (s, 
1H), 5.44 (d, J = 9.9 Hz, 1H), 4.85 (br s, 1H), 2.85 (dddd, J = 61.9, 16.9, 9.7, 5.9 Hz), 2.20 (s, 3H), 
2.01 (dd, J = 5.9, 1.7 Hz, 2H), 1.85 (s, 3H), 1.38 (s, 3H) ppm.  
13C NMR (150 MHz, CDCl3): δ 202.1, 154.0, 151.3, 144.5, 139.9, 126.6, 124.9, 117.7, 109.9, 108.6, 
106.6, 78.0, 35.8, 32.7, 26.7, 21.6, 17.8 ppm. 
HRMS (ESI) m/z: [M+H]+ Calcd for C17H21O3 273.1485, found 273.1488.  
 
Data for 3.76: 
Rf: 0.30 (9:1 hexanes/ EtOAc). 
FTIR (neat): 2925, 1769, 1676, 1451, 1190 cm-1. 
1H NMR (600 MHz, CDCl3): δ 6.48 (s, 1H), 6.41 (s, 1H), 6.33 (d, J = 10.0 Hz, 1H), 5.92 (s, 1H), 5.71 
(d, J = 1.6 Hz, 1H), 5.49 (d, J = 10.0 Hz, 1H), 2.83 (dddd, J = 69.0, 17.1, 10.1, 5.4 Hz, 2H), 2.29 (s, 
3H), 2.25 (s, 3H), 2.08 – 1.93 (m, 2H), 1.90 – 1.79 (m, 3H), 1.38 (s, 3H) ppm. 
13C NMR (150 MHz, CDCl3): δ 201.6, 169.3, 153.8, 146.3, 144.3, 139.7, 128.6, 124.9, 117.4, 115.0, 
114.7, 111.3, 78.3, 35.8, 32.5, 26.9, 21.6, 20.9, 17.7 ppm.  






















A solution of enone 3.76 (68 mg, 0.216 mmol, 1.0 equiv.) in acetone (3 mL) was left in a borosilicate 
sealed vial placed within a water condenser and irradiated from beneath with UV light at a 
distance of 5 cm for 24 h at room temperature. The resultant solution was then concentrated, and 
the crude mixture dissolved in MeOH (3 mL) and K2CO3 (49 mg, 0.354 mmol, 1.6 equiv.) was then 
added in one portion. The reaction was then stirred for 1 h at room temperature. Distilled H2O (5 
mL) was then added, and the product was extracted with CH2Cl2 (3 x 10 mL). The combined organic 
layers were then dried with MgSO4, filtered and concentrated. Purification via flash 
chromatography (9:1 hexanes/ EtOAc) afforded rhodonoid A (3.1) as a white solid (45 mg, 86%). 
Data for rhodonoid A (3.1) matched that previously reported in the literature.2 
 
Data for rhodonoid A (3.1): 
Rf: 0.20 (8:2 hexanes/ EtOAc). 
MP: 179.6 – 180.2 °C (recryst. MeOH) (lit. 180.0 – 181.0 °C).1 
FTIR (neat): 2965, 1687, 1625, 1514, 1420, 1187, 1069 cm-1.  
1H NMR (600 MHz, CDCl3): δ 6.34 (s, 1H), 6.21 (s, 1H), 4.59 (s, 1H), 3.80 - 3.73 (m, 1H), 2.78 (ddd, 
J = 18.1, 10.9, 7.1 Hz, 1H), 2.59 (d, J = 9.5 Hz, 1H), 2.42 (ddd, J = 18.3, 6.8, 3.4 Hz, 1H), 2.39 – 2.33 
(m, 1H), 2.33 – 2.30 (m, 1H), 2.22 (s, 3H), 2.16 (dd, J = 12.2, 7.1 Hz, 1H), 2.03 (ddd, J = 14.0, 10.9, 
6.8 Hz, 1H), 1.44 (s, 3H), 1.16 (s, 3H) ppm.  
13C NMR (150 MHz, CDCl3): δ 216.5, 154.1, 152.8, 137.5, 112.6, 112.0, 109.3, 73.5, 51.1, 43.9, 39.0, 
34.1, 33.7, 25.4, 24.9, 21.9, 21.3 ppm. 























Using modified conditions reported by Laroche and Nay et al.,38 chromene 3.11 (69 mg, 0.275 
mmol, 1.0 equiv.) was dissolved in CH2Cl2 (4 mL), followed by addition of tetraphenylporphyrin 
(TPP) (3.39) (3 mg, 0.005 mmol, 2 mol%), pyridine (0.13 mL, 16.5 mmol, 60.0 equiv.), Ac2O (2.61 
mL, 27.5 mmol, 100 equiv.) and DMAP (1 mg, 0.006 mmol, 2 mol%). The reaction was stirred at 
room temperature in a borosilicate glass test tube while exposed to UV light at a distance of 10 
cm from the irradiation vessel and with O2 bubbled through the solution for 36 h. K2CO3 (114 mg, 
0.825 mmol, 3.0 equiv.) was then added to the solution and reaction left to stir further for 5 h. 
The reaction was then quenched by addition of distilled H2O (10 mL). The organic phase was then 
separated, and the aqueous phase further extracted with CH2Cl2 (2 x 10 mL). The combined 
organic layers were then washed with 0.5 M CuSO4(aq) (3 x 10 mL), dried over MgSO4, filtered and 
concentrated in vacuo. The residue was purified via flash chromatography on SiO2 (CH2Cl2) to give 


































Using modified conditions reported by Laroche and Nay et al.,38 chromene 3.11 (450 mg, 1.80 
mmol, 1.0 equiv.) was dissolved in CH2Cl2 (30 mL), followed by addition of tetraphenylporphyrin 
(TPP) (3.39) (22 mg, 0.036 mmol, 2 mol%), pyridine (8.70 mL, 108 mmol, 60 equiv.), Ac2O (17.0 
mL, 180 mmol, 100 equiv.) and DMAP (4 mg, 0.036 mmol, 2 mol%). The reaction was stirred at 
room temperature in a borosilicate glass test tube while exposed to visible light at a distance of 
10 cm from the irradiation vessel and with O2 bubbled through the solution for 36 h. The reaction 
was then quenched by addition of distilled H2O (40 mL). The organic phase was then separated, 
and the aqueous phase further extracted with CH2Cl2 (2 x 40 mL). The combined organic layers 
were then washed with 0.5 M CuSO4(aq) (3 x 60 mL), dried over MgSO4, filtered and concentrated 
in vacuo. The residue was purified via flash chromatography on SiO2 (CH2Cl2) to give the desired 












































A solution of enone 3.76 (57 mg, 0.181 mmol, 1.0 equiv.) in MeOH (3 mL) was left in a borosilicate 
sealed vial placed within a water condenser and irradiated from beneath with UV light at a 
distance of 5 cm for 24 h at room temperature. K2CO3 (62 mg, 0.450 mmol, 2.5 equiv.) was then 
added in one portion and the reaction was stirred for 1 h. H2O (5 mL) was added, and the product 
extracted with CH2Cl2 (3 x 10 mL). The combined organic layers were then dried with MgSO4, 
filtered and concentrated. Purification via flash chromatography on SiO2 (9:1 hexanes/ EtOAc) 
afforded rhodonoid A (3.1) as a white solid (30 mg, 60%). Data for rhodonoid A (3.1) matched that 




































To a solution of orcinol (3.8) (12.9 g, 103.9 mmol, 1.0 equiv.) in PhMe (300 mL) at room 
temperature was added farnesal (3.10) (mixture of isomers, 22.9 g, 103.9 mmol, 1.0 equiv.) and 
EDDA (190 mg, 10.4 mmol, 10 mol%). The reaction was stirred at reflux for 16 h. The mixture was 
cooled to room temperature, then concentrated in vacuo. Purification via flash column 
chromatography on SiO2 (10:1 hexanes/ EtOAc) then afforded confluentin (3.12) as a 1:1.4 mixture 
of Z:E isomers (28.6 g, 84%). Data for confluentin (3.12) matched that previously reported in the 
literature.3 
 
Data for confluentin (3.12): 
Rf: 0.50 (8:2 hexanes/ EtOAc). 
FTIR (neat): 2967, 1626, 1578, 1448, 1249, 1197, 1091 cm-1.  
1H NMR (600 MHz, CDCl3): δ 6.60 (d, J = 9.9 Hz, 1H), 6.24 (d, J = 4.0 Hz, 1H), 6.11 (s, 1H), 5.49 (dd, 
J = 10.0, 8.4 Hz, 1H), 5.17 – 5.04 (m, 2H), 4.70 (s, 1H), 2.20 (s, 3H), 2.15 – 1.94 (m, 6H), 1.76 – 1.70 
(m, 2H), 1.67 (s, 3H), 1.62 – 1.57 (m, 6H), 1.38 (s, 3H) ppm. 
13C NMR (150 MHz, CDCl3): δ 154.3, 151.2, 139.7, 139.7, 135.5, 135.4, 131.5, 127.4, 127.3, 125.0, 
124.5, 124.2, 116.9, 116.8, 110.0, 110.0, 108.4, 106.9, 78.4, 78.3, 41.5, 41.2, 39.8, 32.0, 26.8, 
26.7, 26.4, 26.4, 25.9, 25.8, 23.5, 22.8, 22.6, 21.6, 17.8, 17.8, 16.1 ppm. 






























   
Using a modified procedure from Tang et al.,3 Fe(OTf)3 (50 mg, 0.099 mmol, 0.3 equiv.) was added 
in one portion to a solution of a 1:1.4 Z:E mixture of 3.12 (100 mg, 0.306 mmol, 1.0 equiv.) in 
CH2Cl2 (20 mL) under N2 at –78 °C. The reaction was warmed to room temperature and left to stir 
for 12 h, then quenched with sat. NaHCO3(aq) (30 mL). The product was extracted with CH2Cl2 (3 x 
20 mL) and the combined organic extracts were washed with brine (60 mL). The organic phase 
was dried over MgSO4, filtered and concentrated in vacuo. Careful flash chromatography on SiO2 
(50:1 hexanes/ EtOAc) then afforded 3.28 as a white solid (42 mg, 43%) followed by 3.32 as an off 
white solid (28 mg, 28%). Data for 3.28 and 3.32 matched that previously reported in literature.3 
 
Data for 3.32: 
Rf: 0.20 (20:1 hexanes/ EtOAc). 
FTIR (neat): 2950, 1626, 1452, 1375, 1054 cm-1.  
1H NMR (600 MHz, CDCl3): δ 6.32 (s, 1H), 6.18 (s, 1H), 4.94 (t, J = 4.9 Hz, 1H), 4.46 (br s, 1H), 3.12 
(d, J = 9.7 Hz, 1H), 2.57 (dd, J = 9.8, 8.2 Hz, 1H), 2.42 (td, J = 8.3, 3.6 Hz, 1H), 2.22 (s, 3H), 2.05 (dt, 
J = 12.9, 7.5 Hz, 1H), 1.86 – 1.61 (m, 5H), 1.60 (s, 3H), 1.49 (s, 3H), 1.38 (s, 3H), 1.32 (s, 3H), 1.28 – 
1.11 (m, 2H) ppm. 
13C NMR (150 MHz, CDCl3): δ 154.7, 153.9, 137.5, 130.7, 125.4, 111.6, 108.7, 108.3, 83.7, 46.2, 
42.4, 40.2, 38.6, 36.1, 31.2, 30.5, 26.4, 26.1, 25.8, 23.5, 21.4, 17.7 ppm.  
HRMS (ESI) m/z: [M+H]+ Calcd for C22H31O2 327.2319, found 327.2319.  
 
Data for 3.28: 
Rf: 0.20 (20:1 hexanes/ EtOAc). 
FTIR (neat): 2927, 1625, 1584, 1453, 1251, 1052 cm-1.  
1H NMR (600 MHz, CDCl3): δ 6.32 (s, 1H), 6.17 (s, 1H), 5.17 (t, J = 7.0 Hz, 1H), 4.48 (s, 1H), 3.06 (d, 
J = 9.6 Hz, 1H), 2.56 (dd, J = 9.6, 7.7 Hz, 1H), 2.47 (t, J = 7.5 Hz, 1H), 2.22 (s, 3H), 2.18 – 2.04 (m, 
1H), 2.03 – 1.91 (m, 2H), 1.76 (ddd, J = 13.3, 11.6, 5.1 Hz, 1H), 1.71 (s, 3H), 1.70 – 1.59 (m, 4H), 
1.63 (s, 3H), 1.36 (s, 3H), 0.76 (s, 3H) ppm.  
13C NMR (150 MHz, CDCl3): δ 154.6, 154.1, 137.6, 131.4, 125.1, 111.5, 108.5, 108.2, 83.5, 46.8, 
44.4, 42.4, 39.1, 38.6, 35.6, 27.4, 25.9, 25.7, 22.9, 21.3, 17.8, 15.1 ppm.  




























To a solution of confluentin 3.12 (500 mg, 1.53 mmol, 1.0 equiv.) in CH2Cl2 (100 mL) at room 
temperature, was added pyridine (0.015 mL, 0.982 mmol, 0.5 equiv.), Ac2O (0.23 g, 2.30 mmol, 
1.5 equiv.) and then DMAP (18 mg, 0.153 mmol, 0.10 equiv.). The solution was left to stir for 30 
min, and reaction quenched upon addition of 0.5 M CuSO4 (aq) (100 mL). The organic layer was 
separated then further washed with 0.5 M CuSO4 (aq) (2 x 100 mL). The organic layer was dried with 
MgSO4, filtered and concentrated in vacuo. Purification via flash chromatography on SiO2 (20:1 
hexanes/ EtOAc) then afforded chromene 3.80 (542 mg, 97%) as an orange oil. 
  
Data for 3.80: 
Rf: 0.60 (9:1 hexanes/ EtOAc). 
FTIR (neat): 2967, 1701, 1625, 1566, 1448, 1368, 1198, 1057, 775 cm-1.  
1H NMR (600 MHz, CDCl3): δ 6.51 – 6.49 (m, 1H), 6.41 (s, 1H), 6.32 (d, J = 10.0 Hz, 1H), 5.56 – 5.52 
(m, 1H), 5.14 – 5.07 (m, 2H), 2.30 (s, 3H), 2.26 (s, 3H), 2.16 – 1.91 (m, 7H), 1.78 – 1.56 (m, 10H), 
1.37 (s, 3H) ppm.  
13C NMR (150 MHz, CDCl3): δ 169.4, 169.4, 154.0, 146.3, 139.5, 139.5, 135.6, 135.5, 131.7, 131.5, 
129.4, 129.4, 124.9, 124.5, 124.0, 116.8, 116.7, 114.8, 114.8, 114.8, 114.8, 111.6, 111.6, 78.7, 78.6, 
41.5, 41.3, 39.8, 32.0, 26.8, 26.7, 26.5, 26.4, 25.9, 25.8, 23.5, 22.7, 22.6, 21.6, 21.0, 17.8, 17.8, 16.1 
ppm. 




























Chromene 3.80 (52 mg, 0.159 mmol, 1.0 equiv.) was dissolved in DCE (16 mL, 0.01 M) and 4-MeO-
TPT (3.79) (2 mg, 0.003 mmol, 2 mol%) was added. The reaction was then cooled to 0 °C, O2 was 
then bubbled through the solution and the reaction was left to stir while exposed to a 470 nm 
blue LED lamp for 4 h. After this time the reaction was concentrated in vacuo, and the crude 
residue dissolved in MeOH (10 mL). K2CO3 (46 mg, 0.334 mmol, 2.1 equiv.) was added in one 
portion and the solution left to stir for 1 h. H2O (20 mL) and CH2Cl2 (20 mL) was then added, and 
organic layer separated, dried with MgSO4 and filtered. The solution was concentrated in vacuo 
and purified via careful flash chromatography on SiO2 (50:1 hexanes/ EtOAc) to afford 3.28 as a 
white solid (23 mg, 44%) followed by 3.32 as an off white solid (15 mg, 30%). Data for 3.28 and 
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To a borosilicate glass test tube containing 3.28 (188 mg, 0.661 mmol, 1.0 equiv.) in CH2Cl2 (20 
mL) was added TPP (3.39) (8 mg, 0.013 mmol, 2 mol%). O2 was bubbled through the solution while 
it was stirred at room temperature and exposed to visible light at a distance of 10 cm from the 
irradiation vessel for 6 h. PPh3 (350 mg, 1.32 mmol, 2.0 equiv.) was then added and the reaction 
was stirred for a further 16 h under N2. The solution was then concentrated in vacuo and purified 
via flash chromatography on SiO2 (9:1 CH2Cl2/ EtOAc) to give rhodonoid E (3.5) as a white solid (49 
mg, 23%) and a mixture of rhodonoid F (3.6) and allylic alcohol 3.81 (133 mg, 63%). The mixture 
was then further purified via flash chromatography using 1% wt./ wt. AgNO3 impregnated SiO2 
(7:3 hexanes/ EtOAc) with early fractions containing the allylic alcohol 3.81 (86 mg, 40%) as a red 
oil and later fractions containing rhodonoid F (3.6) as a white solid (35 mg, 16%). Data for 
rhodonoid E (3.5) and rhodonoid F (3.6) matched that previously reported in literature.3 
 
Data for rhodonoid E (3.5): 
Rf: 0.40 (9:1 CH2Cl2/ EtOAc). 
MP: 123.7 – 125.0 °C (recryst. CHCl3) (lit. 86 – 87 °C). 
FTIR (neat): 2925, 1621, 1415, 1259, 1118, 1055 cm-1.  
1H NMR (600 MHz, CDCl3): δ 6.32 (s, 1H), 6.16 (s, 1H), 4.99 (s, 1H), 4.87 (s, 1H), 4.61 (br s, 1H), 4.10 
(t, J = 5.0 Hz, 1H), 3.09 (d, J = 9.6 Hz, 1H), 2.56 (dd, J = 9.6, 7.8 Hz, 1H), 2.43 (td, J = 7.8, 4.1 Hz, 1H), 
2.22 (s, 3H), 2.07 – 1.94 (m, 1H), 1.76 (s, 3H), 1.73 – 1.59 (m, 6H), 1.54 – 1.49 (m, 1H), 1.35 (s, 3H), 
0.73 (s, 3H) ppm. 
13C NMR (150 MHz, CDCl3): δ 154.6, 154.1, 147.7, 137.6, 111.5, 111.3, 108.6, 108.2, 83.6, 76.6, 
44.5, 42.3, 42.0, 39.2, 38.8, 35.3, 29.4, 27.3, 25.7, 21.4, 17.8, 15.3 ppm.  
HRMS (ESI) m/z: [M+H]+ Calcd for C22H31O3 343.2268, found 343.2280.  
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Data for rhodonoid F (3.6): 
Rf: 0.20 (8:2 hexanes/ EtOAc). 
MP: 149.2 – 150.6 °C (lit. 152 – 153 °C).1 
FTIR (neat): 2944, 1624, 1419, 1260, 1137 cm-1.  
1H NMR (600 MHz, CDCl3): δ 6.31 (s, 1H), 6.17 (s, 1H), 4.98 (s, 1H), 4.87 (s, 1H), 4.79 (br s, 1H), 4.10 
(t, J = 6.2 Hz, 1H), 3.11 (d, J = 9.6 Hz, 1H), 2.55 (dd, J = 9.6, 7.9 Hz, 1H), 2.41 (td, J = 7.4, 3.5, Hz, 
1H), 2.21 (s, 3H), 2.02 – 1.95 (m, 1H), 1.87 – 1.80 (m, 1H), 1.76 (s, 3H), 1.70 – 1.50 (m, 6H), 1.34 (s, 
3H), 0.73 (s, 3H) ppm.  
13C NMR (150 MHz, CDCl3): δ 154.6, 154.2, 147.6, 137.5, 111.5, 111.4, 108.7, 108.3, 83.6, 76.7, 
44.7, 42.4, 42.2, 39.2, 38.8, 35.2, 29.5, 27.2, 25.6, 21.4, 17.7, 15.2 ppm. 
HRMS (ESI) m/z: [M+H]+ Calcd for C22H31O3 343.2268, found 343.2272.  
 
Data for 3.81: 
Rf: 0.20 (8:2 hexanes/ EtOAc). 
FTIR (neat): 2968, 1624, 1585, 1455, 1328, 1137 cm-1.  
1H NMR (600 MHz, CDCl3): δ 6.30 (s, 1H), 6.21 (s, 1H), 5.89 – 5.87 (m, 2H), 5.01 (br s, 1H), 3.05 (d, 
J = 9.7 Hz, 1H), 2.59 (dd, J = 9.7, 7.7 Hz, 1H), 2.44 – 2.37 (m, 2H), 2.32 (dd, J = 12.5, 3.2 Hz, 1H), 
2.21 (s, 3H), 2.0 – 1.96 (m, 1H), 1.75 – 1.56 (m, 3H), 1.36 (s, 9H), 0.79 (s, 3H) ppm. 
13C NMR (150 MHz, CDCl3): δ 154.4, 154.3, 143.3, 138.0, 123.3, 111.2, 108.4, 107.6, 83.1, 71.0, 
48.9, 45.7, 42.4, 38.7, 38.2, 33.2, 29.9, 29.7, 27.4, 25.5, 21.4, 15.3 ppm. 

















Following a modified procedure from Wu et al.,3 Ac2O (0.04 mL, 0.367 mmol, 2.0 equiv.) was added 
dropwise to a solution of 3.32 (60 mg, 0.184 mmol, 1.0 equiv.) and DMAP (33 mg, 0.275 mmol, 
1.5 equiv.) in CH2Cl2 (10 mL). The resulting mixture was stirred at room temperature for 30 min, 
then quenched by addition of sat. NaHCO3(aq) (20 mL). The resultant mixture was extracted with 
CH2Cl2 (3 x 20 mL). The combined organic extracts were dried over MgSO4, filtered, and 
concentrated in vacuo. Purification via flash chromatography on SiO2 (19:1 hexanes/ EtOAc) 
afforded acetate 3.73 (55 mg, 81%) as a colourless oil.  
 
Data for 3.73: 
Rf: 0.30 (19:1 hexanes/ EtOAc). 
FTIR (neat): 2949, 1768, 1626, 1451, 1371, 1052 cm-1.  
1H NMR (600 MHz, CDCl3): δ 6.60 (s, 1H), 6.48 (s, 1H), 4.94 (t, J = 7.8 Hz, 1H), 2.99 (d, J = 9.8 Hz, 
1H), 2.55 (t, J = 9.1 Hz, 1H), 2.42 (td, J = 8.5, 5.8 Hz, 1H), 2.29 (s, 3H), 2.27 (s, 3H), 2.04 (dt, J = 13.1, 
6.6 Hz, 1H), 1.84 – 1.67 (m, 4H), 1.66 – 1.58 (m, 1H), 1.61 (s, 3H), 1.50 (s, 3H), 1.32 (s, 3H), 1.29 (s, 
3H), 1.21 – 1.12 (m, 1H), 1.01 (ddd, J = 14.0, 12.1, 5.8 Hz, 1H) ppm. 
13C NMR (150 MHz, CDCl3): δ 169.2, 154.8, 149.1, 137.4, 130.7, 125.2, 116.8, 115.2, 114.7, 84.1, 
46.1, 42.7, 40.7, 38.9, 36.5, 31.3, 30.6, 26.1, 25.8, 25.7, 23.3, 21.4, 21.3, 17.6 ppm. 

































To a solution of 3.73 (101 mg, 0.311 mmol, 1.0 equiv.) in CH2Cl2 (20 mL) in a 25 mL borosilicate 
glass test tube was added TPP (3.39) (4 mg, 0.007 mmol, 2 mol%) and O2 was sparged through the 
solution for 10 min. Visible light was applied to the solution at a distance of 10 cm from the 
irradiation vessel which was stirred for 6 h at room temperature. PPh3 (163 mg, 0.621 mmol, 2.0 
equiv.) was then added to the solution in one portion and the reaction was stirred at room 
temperature under N2 for 8 h. The reaction was concentrated in vacuo and purified via flash 
chromatography on SiO2 (9:1 CH2Cl2/ EtOAc) to afford 3.35 (53 mg, 45%) as a yellow oil and 3.82 
(42 mg, 44%) as a yellow solid and as a 1:1 mixture of diastereomers. Data for 3.35 matched that 
previously reported.3 
 
Data for 3.35: 
Rf: 0.35 (9:1 CH2Cl2/ EtOAc). 
FTIR (neat): 948, 1768, 1750, 1626, 1576, 1371, 1198 cm-1.  
1H NMR (600 MHz, CDCl3): δ 6.61 (s, 1H), 6.47 (s, 1H), 5.43 (d, J = 16.0 Hz, 1H), 5.38 – 5.31 (m, 1H), 
3.05 (d, J = 9.5 Hz, 1H), 2.54 (t, J = 9.2 Hz, 1H), 2.45 (dt, J = 8.9, 4.2 Hz, 1H), 2.28 (s, 6H), 2.08 – 1.97 
(m, 2H), 1.94 – 1.84 (m, 1H), 1.76 – 1.70 (m, 2H), 1.64 – 1.59 (m, 1H), 1.28 (s, 6H), 1.22 (s, 6H) ppm.  
13C NMR (150 MHz, CDCl3): δ 169.3, 154.9, 149.0, 140.2, 137.6, 123.7, 117.0, 115.3, 114.8, 84.3, 
70.7, 46.4, 42.2, 40.8, 39.4, 36.1, 34.8, 31.1, 30.0, 29.9, 26.0, 25.6, 21.4, 21.3 ppm.  
HRMS (ESI) m/z: [M+NH4]+ Calcd for C24H36O4N 402.2639, found 402.2639.  
 
Data for 3.82: 
Rf: 0.50 (9:1 CH2Cl2/ EtOAc). 
FTIR (neat): 2970, 1771, 1466, 1306, 1160, 1107 cm-1.  
1H NMR (600 MHz, CDCl3): δ 6.61 (s, 1H), 6.47 (s overlapped, J = 6.8 Hz, 1H), 4.80 (d, J = 4.7 Hz, 
1H), 4.73 (d, J = 4.7 Hz, 1H), 3.78 – 3.73 (m, 1H), 3.01 (t, J = 9.3 Hz, 1H), 2.54 (t, J = 9.3 Hz, 1H), 2.44 
– 2.39 (m, 1H), 2.27 (s, 6H), 2.08 – 2.01 (m, 1H), 1.90 – 1.82 (m, 1H), 1.74 – 1.67 (m, 2H), 1.63 (s, 
3H), 1.59 (s, 3H), 1.59 – 1.55 (m, 1H), 1.30 (s, 3H), 1.28 (s, 3H), 1.10 – 1.09 (m, 1H), 1.00 – 0.92 (m, 































13C NMR (150 MHz, CDCl3): δ 169.3, 169.2, 154.9, 154.9, 149.0, 149.0, 147.8, 147.7, 137.5, 137.5, 
116.9, 116.8, 115.3, 115.2, 114.9, 114.8, 110.8, 110.7, 84.3, 84.2, 76.6, 76.5, 46.3, 46.2, 42.5, 42.4 
41.0, 40.8, 39.3, 39.2, 36.4, 36.3, 30.7, 30.4, 30.2, 27.7, 27.7, 25.9, 25.7, 25.6, 25.5, 21.4, 21.4, 
21.3, 17.8, 17.6 ppm.  





























To a solution of 3.32 (61 mg, 0.214 mmol, 1.0 equiv.) in CH2Cl2 (10 mL) in a 25 mL borosilicate glass 
test tube was added TPP (3.39) (3 mg, 0.004 mmol, 2 mol%) and O2 was sparged through the 
solution for 10 min. Visible light was applied to the solution at a distance of 10 cm from the 
irradiation vessel which was stirred for 6 h at room temperature. PPh3 (112 mg, 0.428 mmol, 2.0 
equiv.) was then added to the solution in one portion and the reaction was stirred at room 
temperature under N2 for 8 h. The reaction was concentrated in vacuo and purified via flash 
chromatography on SiO2 (9:1 CH2Cl2/ EtOAc) to afford 3.83 (7 mg, 10%) and an inseparable mixture 
of 3.84 and 3.85. The mixture was then further purified by flash chromatography (7:3 hexanes/ 
EtOAc) to afford 3.84 (26 mg, 37%) as a yellow oil and 3.85 (12 mg, 17%) as a yellow oil.  
 
Data for 3.83:  
Rf: 0.40 (9:1 CH2Cl2/ EtOAc). 
FTIR (neat): 3357, 2949, 1624, 1587, 1451, 1374, 1129, 1057, 996, 902, 732 cm-1.  
1H NMR (600 MHz, CDCl3): δ 6.33 (s, 1H), 6.16 (s, 1H), 4.81 – 4.72 (m, 1H), 4.73 – 4.71 (m, 1H), 
4.61 (br s, 1H), 3.72 (dd, J = 7.7, 4.0 Hz, 1H), 3.16 (d, J = 9.7 Hz, 1H), 2.56 (t, J = 9.1 Hz, 1H), 2.44 
(td, J = 8.43, 3.77 Hz, 1H), 2.21 (s, 3H), 2.06 (dd, J = 13.0, 6.8 Hz, 1H), 1.84 (dd, J = 6.7, 3.9 Hz, 1H), 
1.72 – 1.59 (m, 2H), 1.35 (s, 3H), 1.30 (s, 3H) ppm. 
13C {1H} NMR (150 MHz, CDCl3): δ 154.9, 153.7, 147.9, 137.5, 111.7, 110.6, 109.2, 108.4, 83.9, 
76.7, 46.5, 42.2, 40.5, 39.1, 35.7, 30.6, 30.3, 27.7, 26.0, 25.6, 21.4, 17.7 ppm. 
HRMS (ESI) m/z: [M+H]+ Calcd for C22H31O3 343.2268, found 343.2269.  
 
Data for 3.84:  
Rf: 0.20 (4:1 hexanes/ EtOAc). 
FTIR (neat): 3359, 1623, 1586, 1512, 1449, 1373, 1329, 1056, 996, 906, 825, 733 cm-1.  
1H NMR (600 MHz, CDCl3): δ 6.32 (s, 1H), 6.15 (s, 1H), 5.02 (br s, 1H), 4.97 – 4.80 (m, 1H), 4.72 – 
4.70 (m, 1H), 3.72 (dd, J = 7.8, 3.9 Hz, 1H), 3.16 (d, J = 9.7 Hz, 1H), 2.55 (t, J = 9.1 Hz, 1H), 2.43 (d, 
J = 3.9 Hz, 1H), 2.20 (s, 3H), 2.10 – 2.02 (m, 1H), 1.87 – 1.80 (m, 1H), 1.70 – 1.58 (m, 3H), 1.56 (s, 









































13C NMR (150 MHz, CDCl3): δ 154.9, 153.8, 147.7, 137.4, 111.6, 111.6, 110.7, 109.3, 108.5, 83.9, 
46.5, 42.1, 40.5, 39.1, 35.7, 30.5, 30.2, 27.6, 26.0, 25.6, 21.3, 17.6 ppm. 
HRMS (ESI) m/z: [M+H]+ Calcd for C22H31O3 343.2268, found 343.22577.  
 
Data for 3.85:  
Rf: 0.25 (7:3 hexanes/ EtOAc). 
1H NMR (600 MHz, CDCl3): δ 6.33 (s, 1H), 6.18 (s, 1H), 5.42 – 5.38 (m, 2H), 4.84 (br s, 1H), 3.18 (d, 
J = 9.7 Hz, 1H), 2.57 (dd, J = 9.7, 8.3 Hz, 1H), 2.46 (m, 1H), 2.22 (s, 3H), 2.09 – 1.98 (m, 2H), 1.70 – 
1.52 (s, 3H), 1.35 (s, 3H), 1.37 – 1.36 (m, 1H), 1.32 (s, 3H), 1.24 (s, 3H), 1.23 (s, 3H) ppm.  
13C NMR (150 MHz, CDCl3): δ 154.8, 153.9, 139.8, 137.7, 124.4, 111.7, 109.0, 108.5, 83.7, 71.0, 
46.6, 42.0, 40.2, 38.9, 35.7, 34.8, 31.0, 30.0, 29.8, 26.3, 25.9, 21.4 ppm. 






















To a solution of tetracycle 3.28 (226 mg, 0.687 mmol, 1.0 equiv.) in CH2Cl2 (20 mL), in a 25 mL 
borosilicate glass test tube was added TPP (3.39) (10 mg, 0.014 mmol, 2 mol%) and O2 was sparged 
through the solution for 10 min. Visible light was applied to the solution at a distance of 10 cm 
from the irradiation vessel which was stirred for 6 h at room temperature. The reaction was 
concentrated in vacuo and purified via flash chromatography on SiO2 (9:1 EtOAc/ hexanes) to 
afford 3.86 (51 mg, 20%) as a yellow oil and 3.87 and 3.88 (135 mg, 52%) as a yellow oil and a 
1:1.7 mixture of isomers.  
 
Data for 3.86: 
Rf: 0.50 (9:1 hexanes/ EtOAc). 
FTIR (neat): 3390, 2951, 1625, 1585, 1453, 1327, 1253, 1137, 1053, 1137, 1053, 996 cm-1.  
1H NMR (600 MHz, CDCl3): δ 7.77 (s, 1H), 6.32 (s, 1H), 6.14 (s, 1H), 5.06 (m, 2H), 4.44 (m, J = 1.2 
Hz, 1H), 4.33 (t, J = 6.7 Hz, 1H), 3.05 (d, J = 9.6 Hz, 1H), 2.56 (dd, J = 9.7, 7.7 Hz, 1H), 2.43 – 2.40 
(m, 1H), 2.21 (s, 3H), 2.02 – 1.93 (m, 1H), 1.76 (s, 3H), 1.75 – 1.59 (m, 5H), 1.56 (s, 2H), 1.35 (s, 3H), 
0.72 (s, 3H) ppm. 
13C NMR (150 MHz, CDCl3): δ 154.7, 154.0, 143.8, 137.6, 114.6, 111.6, 108.5, 108.1, 90.5, 83.5, 
44.5, 42.2, 42.2, 39.1, 38.6, 35.4, 27.3, 25.6, 25.6, 21.3, 17.4, 15.0 ppm. 
HRMS (ESI) m/z: [M+H]+ Calcd for C22H31O4 359.2248, found 359.2218.  
 
Data for 3.87 and 3.88: 
Rf: 0.40 (9:1 hexanes/ EtOAc). 












































1H NMR (500 MHz, CDCl3): (mix of isomers) δ 8.44 (s, 1H), 8.17 (s, 1.7H), 6.32 (s, 1.7H), 6.30 (s, 
1H), 6.21 (s, 1.7H), 6.15 (s, 1H), 5.96 – 5.89 (m, 1.7H), 5.76 – 5.71 (m, 1.7H), 5.39 (br s, 1.7H), 5.32 
– 5.29 (m, 1H), 5.05 (m, 2.0), 4.33 (t, J = 6.7 Hz, 1.7H), 3.11 – 3.04 (m, 2.7H), 2.58 – 2.50 (m, 2H), 
2.47 – 2.29 (m, 5H), 2.19 (s, 5H), 2.0 – 1.97 (m, 3H), 1.76 (s, 3H), 1.73 – 1.51 (11H), 1.38 ( s, 5H), 
1.37 (s, 5H), 1.34 (s, 6H), 0.79 (s, 5H), 0.71 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): (mix of isomers) δ 154.4, 154.3, 154.2, 154.1, 143.8, 143.7, 137.7, 
137.4, 137.3, 128.3, 114.8, 114.5, 111.4, 111.2, 108.7, 108.4, 108.3, 90.5, 83.6, 83.4, 49.2, 45.3, 
44.5, 42.3, 42.2, 42.0, 39.1, 38.9, 38.5, 38.3, 35.3, 35.2, 33.6, 27.2, 25.5, 25.4, 24.7, 24.4, 21.3, 
17.1, 15.5, 15.0 ppm. 



























To a solution of tetracycle 3.32 (126 mg, 0.443 mmol, 1.0 equiv.) in CH2Cl2 (10 mL), in a 25 mL 
borosilicate glass test tube was added TPP (3.39) (5 mg, 0.009 mmol, 2 mol%) and O2 was sparged 
through the solution for 10 min. Visible light was applied to the solution at a distance of 10 cm 
from the irradiation vessel which was stirred for 6 h at room temperature. The reaction was 
concentrated in vacuo and purified via flash chromatography on SiO2 (9:1 CH2Cl2/ EtOAc) to afford 
3.89 (26 mg, 16%) as a yellow oil and 3.90 and 3.91 (61 mg, 39%) as a yellow oil and a 1.7:1 mixture 
of isomers.  
 
Data for 3.89: 
Rf: 0.60 (9:1 CH2Cl2/ EtOAc). 
FTIR (neat): 3392, 2951, 1625, 1586, 1452, 1375, 1330, 1133, 1056, 996 cm-1.  
1H NMR (600 MHz, CDCl3): δ 7.68 (br s, 1H), 6.33 (s, 1H), 6.16 (s, 1H), 4.93 – 4.89 (m, 1H), 4.85 – 
4.84 (m, 1H), 4.55 (br s, 1H), 4.02 (dd, J = 7.1, 5.5 Hz, 1H), 3.15 (d, J = 9.7 Hz, 1H), 2.55 (t, J = 9.1 
Hz, 1H), 2.42 (td, J = 8.4, 3.7 Hz, 1H), 2.22 (s, 3H), 2.09 – 2.01 (m, 1H), 1.83 – 1.75 (m, 1H), 1.69 – 
1.60 (m, 2H), 1.58 (s, 3H), 1.35 – 1.18 (m, 4H), 1.32 (s, 3H), 1.30 (s, 3H) ppm.  
13C NMR (150 MHz, CDCl3): δ 154.9, 153.7, 144.2, 137.6, 113.6, 111.8, 109.0, 108.4, 90.5, 83.90, 
46.4, 42.1, 40.4, 39.0, 35.7, 30.3, 27.7, 26.5, 26.1, 25.6, 21.3, 17.3 ppm.  
HRMS (ESI) m/z: [M+H]+ Calcd for C22H31O4 359.2217, found 359.2218.  
 
Data for 3.90 and 3.91: 
Rf: 0.50 (9:1 CH2Cl2/ EtOAc). 
FTIR (neat): 3391, 2949, 1625, 1585, 1419, 1375, 1329, 1138, 1054, 995 cm-1.  
1H NMR (500 MHz, CDCl3): (mix of isomers) δ 7.86 (br s, 1H), 7.66 (br s, 1.7H), 6.35 (s, 1.7 H), 6.32 
(s, 1H), 6.21 (s, 1.7H), 6.17 (s, 1H), 5.51 – 5.45 (m, 1.7H), 5.20 (br s, 1.7H), 5.17 (d, J = 15.3 Hz, 
1.7H), 5.05 – 5.03 (br s, 1H), 4.92 – 4.90 (m, 1H), 4.87 – 4.87 (m, 1H), 4.00 – 3.97 (m, 1H), 3.23 (d, 










































– 1.58 (m, 7H), 1.88 – 1.33 (m, 2H), 1.73 – 1.53 (m, 8H), 1.37 – 1.36 (m, 5H), 1.35 (s, 5H), 1.33 (s, 
3H), 1.30 (s, 10H), 1.27 (s, 5H), 1.21 (s, 3H) ppm.  
13C NMR (125 MHz, CDCl3): (mix of isomers) δ 154.9, 154.8, 153.9, 153.7, 144.2, 137.7, 137.5, 
134.8, 129.6, 113.8, 111.9, 111.5, 109.4, 109.0, 108.7, 108.5, 90.4, 83.9, 83.8, 82.4, 46.8, 46.2, 
42.0, 40.5, 40.4, 39.3, 38.9, 35.8, 35.5, 35.2, 30.9, 30.3, 27.6, 26.2, 26.0, 25.9, 25.8, 25.7, 24.8, 
24.1, 21.4, 17.5 ppm. 



























3.4.3 NMR Comparison Data 
 
  




Synthetic sample (CDCl3) 
Yu Tang et al. (2017)5  
(500 MHz) 
Natural Sample (CDCl3) 




George et al. (2019) 
(600 MHz) 
3 2.58  
(d, J = 9.5 Hz) 
2.59 (d, J = 9.5 Hz) 2.59 (d, J = 9.5 Hz) 
4 3.71 – 3.80 (m) 3.75  
(td, J = 9.5, 7.0 Hz) 
3.75 (m) 
6 6.32 (s) 6.33 (br s) 6.34 (s) 
8 6.21 (s) 6.21 (br s) 6.21 (s) 
9 1.98 – 2.07 (m) 
2.29 – 2.38 (m) 
2.03  
(ddd, J = 14.0,  
11.0, 7.0 Hz)  
2.33  
(ddd, J = 14.0, 7.0, 3.5 Hz) 
2.03  
(ddd, J = 14.0,  
10.9, 6.8 Hz) 
2.32 (m) 
10 2.74 – 2.84 (m) 
2.39 – 2.44 (m) 
2.78  
(ddd, J = 18.0,  
11.0, 7.0 Hz) 
2.42  
(ddd, J = 18.0, 7.0, 3.5 Hz) 
2.78  
(ddd, J = 18.1, 10.9, 
7.1 Hz) 
2.42  
(ddd, J = 18.3,  
6.8, 3.4 Hz) 
13 2.14 - 2.18 (m) 
2.39 – 2.44 (m) 
2.18 
(dd, J = 12.0, 7.0 Hz) 
2.36 
(br dd, J = 12.0, 9.5 Hz) 
2.16  
(dd, J = 12.2, 7.1 Hz) 
2.36 (m) 
14 1.43 (s) 1.44 (s) 1.44 (s) 
15 1.15 (s) 1.15 (s) 1.16 (s) 
16 2.20 (s) 2.21 (s) 2.22 (s) 






























(CDCl3) Yu Tang  
et al. (2017)5  
(125 MHz) 
Natural Sample 
 (CDCl3) Ai-Jun 
Hou et al. (2017)2  
(125 MHz) 
Synthetic sample  
(CDCl3) George  
et al. (2019) 
 (600 MHz) 
2 73.5 73.6 73.5 
3 51.1 51.2 51.1 
4 21.8 21.9 21.9 
4a 112.5 112.6 112.6 
5 154.1 154.3 154.1 
6 112.5 112.3 112.0 
7 137.4 137.6 137.5 
8 109.3 109.3 109.3 
8a 152.7 152.6 152.8 
9 34.1 34.2 34.1 
10 33.6 33.7 33.7 
11 216.2 215.7 216.5 
12 43.8 43.9 43.9 
13 38.9 39.0 39.0 
14 24.9 25.0 24.9 
15 25.4 25.6 25.4 













   





(CDCl3) Yu Tang  
et al. (2017)3 
(500 MHz) 
Natural Sample 
(CDCl3) Ai-Jun Hou  
et al. (2015)1  
(500 MHz) 
Synthetic sample  
(CDCl3) George  
et al. (2019) 
 (600 MHz) 
3 2.52 – 2.58 (m) 2.56  
(dd, J = 9.6, 7.8 Hz) 
2.56  
(dd, J = 9.6, 7.8 Hz) 
4 3.09 (d, J = 9.5 Hz) 3.09 (d, J = 9.6 Hz) 3.09 (d, J = 9.6 Hz) 
6 6.16 (s) 6.16 (br s) 6.16 (s) 
8 6.31 (s) 6.31 (br s) 6.32 (s) 
9 1.94 – 2.00 (m) 





10 1.60 – 1.74 (m) 1.64 (m) 1.64 (m) 
11 2.43  
(td, J = 8.0, 3.5 Hz) 
2.43  
(td, J = 7.8, 3.0 Hz) 
2.43  
(td, J = 7.8, 4.1 Hz) 




14 1.48 – 1.53 (m) 





15 4.10 (t, J = 5.5 Hz) 4.10 (br t, J = 5.7 Hz) 4.10 (t, J = 5.0 Hz) 
17 4.87 (s) 
4.99 (s) 
4.87 (br s) 
4.99 (br s) 
4.87 (s) 
4.99 (s) 
18 1.76 (s) 1.76 (br s) 1.76 (s) 
19 0.73 (s) 0.73 (s) 0.73 (s) 
20 1.35 (s) 1.35 (s) 1.35 (s) 
21 2.22 (s) 2.22 (s) 2.22 (s) 



































(CDCl3) Yu Tang  
et al. (2017)3  
(125 MHz) 
Natural Sample 
(CDCl3) Ai-Jun Hou 
et al. (2015)1  
(125 MHz) 
Synthetic sample 
(CDCl3) George  
et al. (2019) 
 (150 MHz) 
2 83.4 83.5 83.6 
3 39.0 39.1 39.2 
4 35.1 35.3 35.3 
4a 108.4 108.6 108.6 
5 153.9 154.1 154.1 
6 108.1 108.2 108.2 
7 137.4 137.6 137.6 
8 111.3 111.5 111.5 
8a 154.5 154.6 154.6 
9 38.6 38.7 38.8 
10 25.5 25.6 25.7 
11 44.4 44.5 44.5 
12 42.1 42.3 42.3 
13 41.8 41.9 42.0 
14 29.3 29.4 29.4 
15 76.5 76.6 76.6 
16 147.5 147.7 147.7 
17 111.3 111.3 111.3 
18 17.7 17.8 17.8 
19 15.1 15.3 15.3 
20 27.1 27.3 27.3 


















(CDCl3) Yu Tang et 
al. (2017)3 
(500 MHz) 
Natural Sample  
(CDCl3) Ai-Jun Hou 
et al. (2015)1  
(500 MHz) 
Synthetic sample 
 (CDCl3) George  
et al. (2019) 
(600 MHz) 
3 2.52 – 2.57 (m) 2.55  
(dd, J = 9.6, 7.8 Hz) 
2.55  
(dd, J = 9.6, 7.9 Hz) 
4 3.11 (d, J = 9.5 Hz) 3.10  
(d, J = 9.6 Hz) 
3.11  
(d, J = 9.6 Hz) 
6 6.16 (s) 6.17 (br s) 6.17 (s) 
8 6.31 (s) 6.31 (br s) 6.31 (s) 
9 1.95 – 2.00 (m) 





10 1.50 – 1.70 (m) 1.65 (m) 1.65 (m) 
11 2.43 (td, J = 3.5, 8 
Hz) 
2.41  
(td, J = 7.8, 3.0 Hz) 
2.41  
(td, J = 7.4, 3.5 Hz) 
13 1.50 – 1.70 (m) 









15 4.10 (t, J = 6.5 Hz) 4.10  
(br t, 6.0) 
4.10  
(t, J = 6.2 Hz) 
17 4.87 (s) 
4.98 (s) 
4.88 (br s) 
4.98 (br s) 
4.87 (s) 
4.98 (s) 
18 1.76 (s) 1.76 (br s) 1.76 (s) 
19 0.72 (s) 0.73 (s) 0.73 (s) 
20 1.34 (s) 1.34 (s) 1.34 (s) 
21 2.21 (s) 2.22 (s) 2.21 (s) 




































(CDCl3) Yu Tang et 
al. (2017)3  
(125 MHz) 
Natural Sample 13C 
(CDCl3) Ai-Jun Hou 
et al. (2015)1  
(125 MHz) 
Synthetic sample 
(CDCl3) George  
et al. (2019) 
 (150 MHz) 
2 83.4 83.6 83.6 
3 39.1 39.2 39.2 
4 35.1 35.2 35.2 
4a 108.6 108.7 108.7 
5 154.1 154.1 154.2 
6 108.2 108.3 108.3 
7 137.4 137.6 137.5 
8 111.2 111.4 111.5 
8a 154.5 154.6 154.6 
9 38.7 38.8 38.8 
10 25.5 25.6 25.6 
11 44.6 44.7 44.7 
12 42.2 42.4 42.4 
13 42.1 42.2 42.2 
14 29.3 29.5 29.5 
15 76.9 76.7 76.7 
16 147.4 147.6 147.6 
17 111.4 111.5 111.4 
18 17.5 17.7 17.7 
19 15.1 15.3 15.2 
20 27.0 27.2 27.2 















3.4.4 NMR Spectra 
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Chapter Four – Biomimetic Total Synthesis of the Rubiginosins  
*This work was completed with assistance from Mr. Aaron Day who helped with key chromenylation 
reactions and Postdoctoral researcher Dr. Oussama Yahiaoui who brought through material for us* 
 
4.1 Introduction 
4.1.1 Isolation of the Rubiginosin and Anthopogochromane Natural Products 
Rhododendron plants are a diverse source of stereochemically complex, polycyclic 
meroterpenoids. Amongst the various possible scaffolds, the 6-6-5-4 ring system is relatively 
abundant in plant natural products (Figure 4.1). Perhaps one of the most well-known example is 
cannabicyclol (CBL) (4.1),1 synthesized via intramolecular [2+2] cycloadditions using 
photochemical,2 thermal,3 or acidic conditions.4 Rhododendron natural products with this scaffold 
have been explored extensively in this thesis, including the synthesis of fastinoid B (4.2), rhodonoid 




Figure 4.1 – Rhododendron Tetracyclic Chromanes with the 6-6-5-4 Ring System 
 
Another scaffold found belonging to the Rhododendron family includes the 6-6-6-4 ring system 
(Figure 4.2). Interestingly however, this ring system is comparatively rare in natural products. The 
simplest natural product with this structure is the monoterpenoid rhodonoid A (4.5), isolated from 
Rhododendron capitatum.5 Additionally there are also five merosesquiterpenoids with this ring 
system. The first, rubiginosin G (4.6) was reported in 2009 and isolated from Rhododendron 
adamsii, however at the time its relative configuration was not assigned and it was not named.6 
It was later re-isolated in 2018, this time from Rhododendron rubiginosum alongside rubiginosin 
A and B (4.7 and 4.8).7 Other natural products with this scaffold include anthopogochromane (4.9) 
isolated from Rhododendron anthopogonoides,8 and fastinoid C (4.10) isolated from 


































Figure 4.2 – Rhododendron Tetracyclic Chromanes with the 6-6-6-4 Ring System 
 
Despite the stereochemically rich nature of the 6-6-6-4 and 6-6-5-4 ring systems, these structures 
were all isolated as partial racemates, suggesting that their biosynthesis is not under enzymatic 
control, making them ideal targets towards a biomimetic synthesis. 
 
4.1.2 Total Synthesis of Natural Products Through Functionalized Hydrocarbons 
One strategy towards the synthesis of natural products is through functionalized hydrocarbons 
derived from C10 monoterpenoids. There are many advantages to this approach, including the 
direct access to cheap and abundant starting materials allowing for the synthesis of large 
quantities of natural products. Additionally, the synthesis of decorated hydrocarbons is often 
synthetically straightforward, and the electronics of these compounds can be carefully tuned, 
priming these substrates to undergo unusual cascade reactions and allowing the late-stage 
diversification of whole families of natural products.  
 
Notable examples include Marshall and Lebreton’s synthesis of (R,R)-isopiperitenol (4.11) 
(Scheme 4.1).10 Riley oxidation of neryl acetate (4.12) followed by a Collington-Meyers chloride 
reaction,10 gave the corresponding chloride 4.13. Deprotection and cyclization of the resultant 
alcohol 4.14 through treatment with EtMgBr and HMPA then afforded the diallylic cyclized ether 
4.15 in 65%. Finally, a base-induced [2,3]-Wittig rearrangement with (S,S)-BPEA gave (R,R)-























































Scheme 4.1 – Marshall and Lebreton’s Total Synthesis of (R,R)-isopiperitenol10 
 
Another example includes the total synthesis of the sesquiterpene lactone 6-oxodendrolasinolide 
(4.17) reported by Li et al. in 2007 (Scheme 4.2).11 This begins with Riley oxidation of the THP 
protected geraniol 4.18. An Appel reaction then affords the allylic chloride 4.19, which undergoes 
a 2-step Corey-Seebach reaction to give 4.20 in 85%. Functional group manipulation involving 
reduction, PMB protection, THP deprotection, and oxidation then gives the key functionalized 
aldehyde 4.21 (in 4-steps). Oxidative lactonization and deprotection then affords 4.22 and finally 











THF, rt, 36 h
SeO2, t-BuO2H
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4.24 R2 = PMB
4.22 R2 = H, 85% (over 2-steps)
DMP
















4.1.3 Bio-Inspired Cascade Reactions of Functionalized Hydrocarbons 
Functionalized hydrocarbons have also emerged as a powerful strategy in bio-inspired cascade 
reactions. This can be seen in Jamison and Katcher’s efforts towards the C, D, E, F and G ring of 
brevisulcenal F (4.25) through epoxide ring opening cascades (Scheme 4.3).12  
 
Coupling of the allylic bromide 4.26 to the Grignard reagent 4.27 afforded diene 4.28 as a single 
isomer in 58%. An Appel reaction of the allylic alcohol then then gave the bromide 4.29, followed 
by another Cu mediated allylation with 4.26 to afford the triene 4.30. The alcohol was then 
protected as the MOM ether 4.31 and a 1,2-addition with aldehyde 4.32 afforded 4.33 followed 
by a 2-step epimerization. Next, a series of Sharpless and Shi epoxidation followed by a Bn 
protection afforded the key triepoxide 4.34.  
 
Unfortunately, all attempts towards the target C, D, and E rings of 4.38 were unsuccessful. The 
key reaction cascade was attempted with KHMDS, however this was only partially successful 
affording the diepoxide 4.36. Presumably due to the sterically hindered tertiary alkoxide impeding 
attack of this nucleophile onto the second epoxide. Formation of the diol 4.37 was also observed, 
via the elimination and subsequent ring opening of 4.36. Reaction with NaHMDS as a base gave 
similar results affording 4.36 and 4.37 in a 2:1 ratio. While reaction with LiHMDS afforded the 
pentad 4.38, indicating that the C ring had cyclized in a 5-exo manner rather than the desired 6-
endo cyclization.  
 
Although the desired product 4.35 was not observed, this impressive attempt towards 
brevisulcenal (4.25) highlights the role of functionalized hydrocarbons in bio-inspired cascade 
reactions. It is expected that these efforts will provide future insight for the optimization of marine 






























































































Me4.26, CuBr, THF–50 ºC → –30 ºC
58%
4.28: R1 = OH










4.30: R2 = H
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Work within our group, has also featured bio-inspired cascade reactions of functionalized 
hydrocarbons. In 2017, Lam and co-workers reported the total synthesis of (±)-
verrubenzospirolactone (4.39) (Scheme 4.4).13 This 5-step total synthesis features a 2-step Riley 
oxidation to aldehyde 4.40, followed by a Horner-Wadsworth-Emmons reaction with 
phosphonate 4.41 to give the triene E-4.42 in 79%.  Heating of E-4.42 at 50 °C gave the 
intramolecular Diels-Alder product verrubenzospirolactone (4.39) in 41% alongside the C9 epimer 
4.43 in 38%. Clearly, some isomerization of E-4.44 into the more stable Z-4.46 occurred, leading 
to a greater yield of 4.43 than expected. Alkene isomerization using catalytic (MeCN)2PdCl2 in DMF 
gave a 7.5:1 mixture in favour of the desired Z-4.43. Heating of Z-4.46  at 50 °C gave 
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DMF, rt, 40 h
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Next, the structure of 4.39 was used as motivation for a multibond-forming, quadruple cascade 
reaction (Scheme 4.5). Incorporation of the triene unit into a functionalized aldehyde inspired the 
synthesis of 4.49 in 6-steps from geraniol 4.50. Next, the key reaction cascade with phloroglucinol 
4.51 involving a Knoevenagel condensation, oxa-6𝜋-electrocyclization, intramolecular Diels-Alder and 
oxa-Michael sequence. Treatment of 4.49 and 4.51 with Ca(OH)2 generated a 3:1 mixture of 4.52 and 
4.53 (C11 epimers) in 46%. This impressive cascade results in the formation of 7 stereocentres, 4 rings, 




Scheme 4.5 – Cascade Reaction Inspired by Verrubenzospirolactone13 
 
4.1.4 Proposed Biosynthesis of the Rubiginosins  
Given the co-isolation of the 6-6-5-4 ring system meroterpenoids with the related 6-6-6-4 
meroterpenoids and simpler chromene natural products (i.e. daurichromenic acid (4.57)),6 a unified 
biosynthesis to access both scaffolds was envisaged involving alkene isomerization as the key point of 
















































































We propose that in nature a C14 oxidation and decarboxylation of daurichromenic acid (4.57) could 
afford the chromene natural product rubiginosin E (4.58). A subsequent [2+2] cycloaddition of 4.58 
would then give access to the 6-6-5-4 scaffold. Provided the alkene stereochemistry of 4.58 is retained, 
this cycloaddition would afford fastinoid B (4.2), while rhodonoid B (4.3) would presumably be 
biosynthesized through the Z-alkene. Additionally, alkene isomerization of 4.58 (possibly occurring in 
nature via a photochemical [1,3]-H shift) from ∆11 to ∆12 would give the 2H-chromene rubiginosin D 
(4.59). Due to the conjugation of the 𝛼, 𝛽-unsaturated enone 4.59, we thought a stepwise [2+2] 
cycloaddition to provide access to 6-6-6-4 ring systems (i.e. rubiginosin A (4.7)) could be possible.   
 
It was envisaged that most direct route towards a divergent biomimetic synthesis of both chromene 
natural products, and the 6-6-5-4 and 6-6-6-4 ring systems, would be through the synthesis of a 
functionalized aldehyde. In this case, the synthesis of a pre-oxidised terpene (i.e. 4.60), which could 
undergo a Knoevenagel condensation with orcinol 4.61, and subsequent oxa-6𝜋-electrocyclization to 
afford the chromene natural products rubiginosin D (4.59) and rubiginosin E (4.58). It was hoped that 
subsequent [2+2] cycloadditions could provide direct access to the whole family of Rhododendron 









































































This approach would ideally be accompanied by a second challenge, a one-step cascade combining 
Knoevenagel condensation, oxa-6𝜋-electrocyclization, alkene isomerization and a formal [2+2] 
cycloaddition of orcinol 4.61 and aldehyde 4.60 (Scheme 4.7). It is hoped that this bio-inspired cascade 
reaction will allow a short total synthesis of racemic rubiginosin A (4.7) forming 5 stereocentres, 3 C-




Scheme 4.7 – Bio-inspired Cascade Synthesis of Rubiginosin A 
 
4.2 Results and Discussion 
4.2.1 Synthesis of Key Functionalized Aldehydes 
Synthesis of two key 𝛼, 𝛽-unsaturated aldehydes (4.60 and 4.64) commenced from geranyl acetate 
(4.65) (Scheme 4.8). Following a known procedure from Yeom et al. a SeO2 mediated Riley oxidation 
afforded 8-hydroxygeraniol 4.66 in 43% yield, alongside the aldehyde 4.67 in 23%.14 Next, an Appel 


































































Scheme 4.8 – Synthesis of the allylic bromide 4.68 
 
Substitution of 4.68 with the alkynyl copper derived from the acetylene 4.69 was achieved following 
a modified procedure by Oehlschlager and co-workers (Scheme 4.9).15 This involved addition of 4.69 
to stoichiometric CuI and Et3N, followed by addition of the bromide 4.68 at 0° C to afford alkynol 4.70. 
Unfortunately, a competing SN2’ substitution at C6 was observed resulting in formation of the by-
product 4.71. All attempt to supress the formation of 4.71 by screening different thermal conditions 
and addition rates of the bromide 4.68 were unsuccessful. Instead, the inseparable mixture of 4.70 
and 4.71 (as a 1.2:1 mixture) was taken on in the next step without further purification. 
 
 
Scheme 4.9 – CuI Mediated Coupling of bromide 4.68 and alkyne 4.6915 
 
A Meyer-Schuster rearrangement of alkynol 4.70 and 4.71 then afforded the enone 4.72 in 46%, and 
4.73 in 8% (over 2-steps) (Scheme 4.10). This was achieved using conditions developed by Hodgson 





















































Scheme 4.10 – Meyer-Schuster Rearrangement of alkynol 4.70 and 4.71 
 
Alternatively, following a modified procedure from Li et al. a one-pot umpolung coupling with bromide 
4.68 and the prenal derived TMS 4.74 in the presence of LDA at –78 °C gave direct access to enone 
4.72 in 44% (Scheme 4.11).17 Unfortunately, this result was not reproducible, and reaction gave poor 




Scheme 4.11 – Umpolung coupling of bromide 4.68 and 4.74 
 
Acetate hydrolysis of 4.72, afforded 4.75 in 76% alongside the conjugate addition by-product 4.76 in 
15% (Scheme 4.12). Subsequent Dess-Martin oxidation of the allylic alcohol 4.75 then afforded the 


















































–78 ºC, 16 h







































The isomeric aldehyde E-4.64 was also be synthesized this time by employing a DBU catalyzed alkene 
isomerisation of 4.72, which afforded the dienone 4.77 in 95% yield as a 2.2:1 mixture of E- and Z- 
isomers (Scheme 4.13). Deacylation and oxidation of 4.77 then gave the desired aldehyde E-4.64 as a 
single stereoisomer in 26% over 2-steps (after careful purification by flash column chromatography), 





Scheme 4.13 – DBU Alkene Isomerisation of 4.72 to Afford the Key Aldehyde E-4.64 
 
With the 𝛼, 𝛽-unsaturated aldehydes 4.60 and 4.64 in hand, our attention turned toward the synthesis 
of rubiginosins A, D, E, and G, fastinoid B, C, and Rhodonoid B.  
 
4.2.2 Synthesis of Rubiginosins A, D, E, and G, Fastinoid B, and Rhodonoid B 
We began our investigation focusing on a less ambitious, stepwise approach that would enable the 
divergent synthesis of several natural products (Scheme 4.14). Chromenylation of 4.61 with aldehyde 
E-4.64 was achieved using 10 mol% EDDA in PhMe following conditions developed by Lee and co-
workers,18 giving rubiginosin D (4.59) as a single regioisomer in 66% yield. Intrestingly, we observed a 
trace of rubiginosin A (4.7) in the crude NMR spectra. Next, following a modified procedure from Wu 
et al., a cationic Fe(OTf)3 [2+2] cycloaddition of 4.59 then afforded rubiginosin A (4.7) in 72% yield as 
a single diastereoisomer.19 Hydrogenation of the 𝛼, 𝛽-unsaturated alkene 4.7 then afforded rubiginosin 










































Additionally, a chromenylation of 4.61 with aldehyde 4.60 in the presence of catalytic EDDA afforded 
rubiginosin E (4.58) in 56% yield. Rubiginosin E was then treated to the analogous Fe(OTf)3 cationic 
[2+2] cycloaddition conditions, which proceeded non-stereoselective manner forming both fastinoid 
B (4.8, 42% yield) and rhodonoid B (4.3, 11% yield), while photochemical and basic conditions were 
unsuccessful. All attempted conversion of rubiginosin E (4.58) to rubiginosin A (4.7) via UV, 




Scheme 4.14 – Total Synthesis of Rubiginosins A, D, E, and G, Fastinoid B, and Rhodonoid B 
 
Various conditions towards the synthesis of fastinoid C (4.10) through a Michael addition from 
rubiginosin A (4.7) were screened (Table 4.1). Unfortunately, reaction of 4.7 with base conditions gave 
no reaction, while reactions with acid in aqueous conditions only resulted in decomposition (entries 
1 – 4). Refluxing in water gave no reaction (entry 5) and oxy-mercuriation conditions afforded 



































































0 ºC → rt
Fe(OTf)3
CH2Cl2, 



















Table 4.1 – Efforts Towards the Total Synthesis of Fastinoid C 
 
Entry Conditions Solvent Temperature Time Result 
1 K2CO3 THF/ H2O rt 3 d RSM 37% 
2 p-TsOH PhMe/ H2O 100 °C 6 h decomp. 
3 H2SO4 THF/ H2O 66 °C 5 h decomp. 
4 oxalic acid DMSO/ H2O 100 °C 3 h decomp. 
5 -- H2O 100 °C 3 h NR 
6 Hg(OAc)2 
then NaBH4, NaOH 
THF/ H2O 66 °C 2 h decomp. 
 
 
4.2.3 Bio-Inspired Cascade Reactions of Rubiginosin A 
A variety of conditions for the key bio-inspired cascade reaction of rubiginosin A (4.7) were 
investigated (Table 4.2). Reaction of the key aldehyde 4.60 with orcinol (4.61) was attempted using 
Ca(OH)2, pyridine, piperidine and Ac2O conditions (entries 1 - 3). Unfortunately, these conditions only 
gave either decomposition or no reaction. Reaction with Ti(Oi-Pr)4 only afforded the bis-chromene 
4.79 in 39% (entry 4). Reaction with 10 mol% EDDA afforded rubiginosin E (4.58) in 56%, however was 
not successful in pushing the key cascade to completion even when left for a longer period of time 
(entry 5). Gratifyingly, employing modified chromenylation conditions from Chauder et al. using AcOH 
and PhB(OH)2 gave rubiginosin A (4.7) in 10% with the regio-isomer “iso-rubiginosin A”(4.80) in 31%.20 
Interestingly a 2% yield of Ar-turmerone (4.81) was observed. (entry 6). It was found that increasing 
the amount of acetic acid led to a diminished yield of rubiginosin A and an increase in Ar-turmerone 





























Presumably, synthesis of “iso-rubiginosin A” (4.80) occurs through an analogous route to rubiginosin 
A (4.7) (vide supra, Scheme 4.8) (i.e. Knoevenagel condensation, oxa-6𝜋-electrocyclization, alkene 
isomerisation and a stepwise [2+2] cycloaddition), however this time with Knoevenagel condensation 





Scheme 4.15 – One-Pot Reaction Cascade of “Iso-Rubiginosin A” 
 
The synthesis of the Ar-turmerone (4.81) most likely occurs through an acid catalyzed alkene 
isomerization of 4.60 to form 4.86, followed by a vinylogous Aldol condensation to give 4.87. Finally, 
alkene isomerization to 4.88 and aromatization to afford Ar-turmerone (4.81) in 22%, from reaction 





































































Scheme 4.16 – Proposed Mechanism for Ar-turmerone 
 
To determine if the alkene isomerization step was responsible for the low overall yield of rubiginosin 
A (4.7), orcinol (4.61) was condensed with the pre-isomerized aldehyde E-4.64 (Scheme 4.17). 











































































PhMe, 110 ºC, 24 h





























4.2.4 Structural Revision of Anthopogochromane 
To date all Rhododendron natural products with the 6-6-6-4 ring system, possess the same relative 
configuration around the cyclobutane core, except for anthopogochromane (4.9) which has the 
opposite configuration at C13. Prompting us to pursue the synthesis of a revised structure of 




Figure 4.3 – Proposed Structural Revision of anthopogochromane 
 
First, an attempt to epimerize the key C13 carbon was undertaken using LDA at –78 °C. Unfortunately, 





Scheme 4.18 – Attempted Epimerization of Rubiginosin A 
 
Reaction of the key aldehyde 4.60 and with o-orsellinic acid 4.95 unfortunately gave the 
decarboxylated rubiginosin E (4.58) presumably due to harsh thermal conditions. While the one-pot 
reaction cascade conditions (stoichiometric PhB(OH)2 in AcOH/ PhMe) only afforded rubiginosin A 
(4.7) (Scheme 4.19).20 Based on this observation, these same conditions with the lower boiling point 


























































Scheme 4.19 – Reaction of o-orsellinic acid with Aldehyde 4.60 
 
In an attempt to avoid the observed decarboxylation, an alternative route using commercially 
available ethyl orsellinate (4.96) was investigated (Scheme 4.20). The key Knoevenagel/ oxa-6𝜋-
electrocyclization/ alkene isomerisation and formal [2+2] cycloaddition proceeded smoothly to afford 
4.97 in 10%. Reduction of the resulting enone using Pd/C hydrogenation conditions then afforded the 
corresponding ethyl ester 4.98 in 93%. Surprisingly, hydrolysis of the ethyl ester proved difficult. 














4.58: rubiginosin E4.95: o-orsellinic acid
5%
4.60, PhB(OH)2































































































With limited access to 4.98, partially due to the low yielding nature in the synthesis of 4.97 we 
abandoned this approach and consulted that literature. Similar results by Kang et al. also observed 
the difficult in removing the ethyl ester protected acids, leading us to attempt the key step with a 
more labile TMS protected ester 4.99.21 Unfortunately, reaction conditions with PhB(OH)2 and AcOH 
only afforded Ar-turmerone (4.81). While reaction with Ca(OH)2 gave decomposition of the starting 
materials. Reflux of the TMS protected acid 4.99 and aldehyde 4.60 with catalytic EDDA gave a 3% 
yield of the corresponding chromene 4.100, making it challenging to explore further derivatization to 
anthopogochromane (4.93) (Scheme 4.21). 
 
 
Scheme 4.21 – Reactions of Aldehyde 4.60 with TMS Protected Ester 4.99 
 
Finally, a two-step formylation/ oxidation of rubiginosin G (4.6) was attempted following a modified 
procedure by Luo and co-workers.22 Gratifyingly, Vilsmeier-Haack conditions afforded the desired 
aldehyde 4.101 albeit as a 2:1 mixture of 4.61:4.101. All attempts to force this reaction to completion 
through addition of excess oxalyl chloride and use of high temperature conditions was not successful. 
Unfortunately, attempted oxidation of this mixture to anthopogochromane (4.93) only resulted in 
decomposition (Scheme 4.22).  
 
 
Scheme 4.22 – Attempted Oxidation of Rubiginosin G to Anthopogochromane 
 
Despite our best efforts, attempts towards the synthesis of 4.93 remained elusive. Instead, we 
compared the reported 1H NMR spectra of anthopogochromane to rubiginosin B (4.8), whose 










































































NMR spectra to be almost identical, including diagnostic chemical shifts and coupling constants for 








Rubiginosin B (CDCl3)  
Yang et al. (2018)7 
Anthopogochromane (CDCl3) 
Kitanaka et al. (2010)8 








2 -- 77.4 -- 77.2 
3 1.89 (d, J = 9.8 Hz) 46.5 1.88 
(d, J = 9.1 Hz) 
46.3 
4 4.27  
(dd, J = 9.8, 8.9 Hz) 
24.0 4.24  
(dd, J = 9.1, 8.5 Hz) 
23.8 
4a -- 114.0 -- 113.3 
5 -- 161.1 -- 160.3 
6 -- 105.2 -- 104.7 
7 -- 142.5 -- 142.3 
8 6.35 s 114.8 6.33 (s) 114.6 
8a -- 160.7 -- 160.9 
9 1.35 (m) 
2.08 (m) 
36.3 2.15 (m) 36.2 
10 1.64 (m) 
1.98 (m) 
17.2 1.38 (m) 17.2 
11 1.25 (m) 
1.84 (m) 
34.1 1.61 (m) 34.0 
12 -- 39.0 -- 38.8 
13 3.01 (d, J = 8.9 Hz) 57.5 3.00 (d, J = 8.5 Hz) 56.4 
14 -- 200.2 -- 210.2 
15 5.97 (s) 123.5 2.25 (m) 51.9 
16 -- 155.9 2.13 (m) 24.1 
17 2.14 (s) 21.1 0.84 (d, J = 6.2 Hz) 22.8 
18 1.85 (s) 28.0 0.84 (d, J = 6.2 Hz) 22.8 
19 1.06 (s) 29.0 1.05 (s) 29.0 
20 1.12 (s) 25.5 1.13 (s) 25.4 
21 2.54 (s) 24.3 2.52 (s) 24.4 
































































































The primary argument for the originally proposed anthopogochromane 4.9 was based on an observed 
NOE interaction between H13 and H4 (Figure 4.4). However, in our obtained NMR spectra we also 
noticed a weak NOE interaction between the H13 and H4 protons of synthetic rubiginosin A (4.7) and 
rubiginosin G (4.6). However, we observed a stronger, more diagnostic interaction between H13 and 
H10 which confirms the relative configuration. We therefore propose a structural revision of 
anthopogochromane to 4.93. This reassignment is also supported by our biosynthetic proposal of 





Figure 4.4 – Structural Revision of Anthopogochromane 
 
4.3 Conclusion 
In summary, we report the synthesis of 6 members of the rubiginosin family of Rhododendron 
merosesquiterpenoids using a bio-inspired strategy. Synthesis of functionalized aldehydes 4.60 and 
4.64 allowed us direct access to both 6-6-6-6 and 6-6-5-4 ring systems in both stepwise and cascade 
sequences. Unfortunately, efforts towards synthesizing a revised structure of anthopogochromane 
4.93 proved elusive. However, re-evaluation of the NMR data for anthopogochromane indicates that 















































dH 3.00 (d, 8.5)
3
13
dH 3.01 (d, 8.9)
dH 4.24 (dd, 9.1, 8.5)
dH 4.27 (dd, 9.8, 8.9)
dH 1.88 (d, 9.1)
















= weak NOE correlation
 337 
4.4 Experimental 
4.4.1 General Methods 
All chemicals used were purchased from commercial suppliers and used as received. All reactions were 
performed under an inert atmosphere of N2 unless otherwise stated. Thin layer chromatography was 
performed using aluminium sheets coated with silica gel. Visualization was aided by viewing under a 
UV lamp and staining with the appropriate stain followed by heating. All Rf values were measured to 
the nearest 0.05. Flash chromatography was performed using 40-63 micron grade silica gel. Melting 
points were recorded on a digital melting point apparatus and are uncorrected. Infrared spectra were 
recorded using an FT-IR spectrometer as the neat compounds. High field NMR was recorded using a 
600 MHz spectrometer (1H at 600 MHz, 13C at 150 MHz) or a 500 MHz spectrometer (1H at 500 MHz, 
13C at 125 MHz). The solvent used for NMR spectra was CDCl3 unless otherwise specified. 1H chemical 
shifts are reported in ppm on the δ-scale relative to TMS (δ 0.0) and 13C{1H} NMR are reported in ppm 
relative to chloroform (δ 77.16). Multiplicities are reported as (br) broad, (s) singlet, (d) doublet, (t) 
triplet, (q) quartet and (m) multiplet. All J-values were rounded to the nearest 0.1 Hz. ESI high 
resolution mass spectra were recorded on a Q-TOF mass spectrometer. Photochemistry with UVA light 
was performed using a generic brand commercial LED UV light globe; wavelength: 365 nm. 
Photochemistry with UVC light was performed using a generic brand commercial LED UV light globe; 
wavelength: 254 nm. Photochemical reactions with visible light were performed with a conventional 
commercial LED desk lamp at 240 V with a 4 W 5000 K 32 mÅ globe. Reactions conducted under 470 




















To a solution of geranyl acetate (4.65) (20.0 g, 102 mmol, 1.0 equiv.) in CH2Cl2 (500 mL) at room 
temperature was added SeO2 (4.53 g, 40.8 mmol, 40 mol%), and t-BuO2H (55.6 mL, 306 mmol, 5.50 M 
in decane, 30 mol%). The reaction was stirred at room temperature for 1.5 h, then quenched with sat. 
Na2S2O3(aq) (500 mL). The organic layer was separated, and further extracted with CH2Cl2 (2 × 100 mL). 
The combined organic layers were filtered, then washed with brine (400 mL) and the organic layer 
dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by flash column 
chromatography on SiO2 (5:1 → 1:1 hexanes/ Et2O, gradient elution) to afford aldehyde 4.67 (4.94 g, 
23%) and the desired allylic alcohol 4.66 (9.05 g, 43%) as yellow oils. Data for 4.66 and 4.67 matched 
that previously reported in the literature.14 
 
Data for 4.66: 
Rf: 0.40 (2:1 hexanes/ EtOAc).  
FTIR (neat): 3428, 2921, 1738, 1444, 1366, 1233, 1022, 954 cm-1. 
1H NMR (500 MHz, CDCl3): δ 5.36 – 5.33 (m, 2H), 4.58 (d, J = 7.1 Hz, 2H), 3.99 (s, 2H), 2.18 – 2.16 (m, 
2H), 2.10 – 2.08 (m, 2H), 2.05 (s 3H), 1.70 (s, 3H), 1.66 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 171.3, 141.8, 135.4, 125.5, 118.9, 69.1, 61.6, 39.2, 25.8, 21.2, 16.5, 13.8 
ppm. 
HRMS (ESI) m/z: [M-H]- Calcd for C12H19O3 211.1340; found 211.1344. 
 
Data for 4.67: 
Rf: 0.75 (2:1 hexanes/ EtOAc). 
FTIR (neat): 2417, 2977, 1736, 1075, 1445, 1381, 1364, 1231, 1024, 845 cm-1. 
1H NMR (500 MHz, CDCl3): δ 9.34 (s, 1H), 6.40 (t, J = 6.9 Hz, 1H), 5.34 (t, J = 7.5 Hz, 1H), 4.54 (d, J = 7.0 
Hz, 2H), 2.45 (q, J = 7.5 Hz, 2H), 2.19 (t, J = 7.6 Hz, 2H), 2.00 (s, 3H), 1.70 (s, 3H), 1.70 (s, 6H) ppm. 
13C NMR (125 MHz, CDCl3): δ 195.1, 171.0, 153.4, 140.4, 139.7, 119.7, 61.1, 37.8, 27.0, 21.0, 16.4, 9.2 
ppm. 


















To a solution of allylic alcohol 4.66 (24.0 g, 113 mmol, 1.0 equiv.) in CH2Cl2 (400 mL) was added PPh3 
(38.5 g, 147 mmol, 1.3 equiv.). The mixture was cooled to 0 °C, then NBS (26.2 g, 147 mmol, 1.3 equiv.) 
was added portion-wise. The reaction was stirred at 0 °C for 5 min, then warmed to room temperature 
and stirred for a further 10 min. The reaction was quenched by addition of sat. Na2S2O3(aq) (300 mL), 
and the organic layer separated and concentrated in vacuo. The residue was dissolved in 
dichloromethane (30 mL), then Et2O (200 mL) and hexanes (400 mL) were added. The resultant 
suspension was filtered through celite, removing excess triphenylphosphine oxide, and succinamide. 
The filtrate was then concentrated, and residue purified by flash column chromatography on SiO2 
(10:1 → 6:1 hexanes/ Et2O, gradient elution) to afford the allylic bromide 4.68 (25.0 g, 80%) as a clear 
oil. Data for 4.68 matched that previously reported in literature.24 
 
Data for 4.68: 
Rf: 0.40 (4:1 hexanes/ EtOAc). 
FTIR (neat): 3424, 2964, 1738, 1444, 1366, 1220, 1024, 756 cm-1. 
1H NMR (500 MHz, CDCl3): δ 5.56 (t, J = 7.0 Hz, 1H), 5.35 – 5.33 (m, 1H), 4.58 (dd, J = 7.1, 2.1 Hz, 2H), 
3.96 (s, 2H), 2.19 – 2.15 (m, 2H), 2.10 – 2.09 (m, 2H), 2.06 (s, 3H), 1.76 (s, 3H), 1.70 (s, 3H) ppm.  

























Using modified conditions from Oehlschlager et al.,15 CuI (13.0 g, 68.2 mmol, 1.2 equiv.) was added to 
a solution of 2-methylbut-3-yn-2-ol (4.69) (6.60 mL, 68.2 mmol, 1.2 equiv.) and Et3N (9.50 mL, 68.2 
mmol, 1.2 equiv.) in DMF (80 mL) and Et2O (80 mL) and the reaction mixture was stirred for 1 h at 
room temperature. A solution of allylic bromide 4.68 (14.8 g, 56.7 mmol, 1.0 equiv.) in Et2O (80 mL) 
was added to the reaction mixture and stirred for a further 16 h at room temperature. The reaction 
mixture was quenched with sat. NH4Cl(aq) (80 mL). The aqueous layer was extracted with Et2O (3 × 80 
mL) and the combined organic extracts were dried with MgSO4, concentrated under reduced pressure 
and purified by flash column chromatography on SiO2 (4:1 hexanes/ EtOAc) to give a yellow oil of the 
propargylic alcohols 4.70 and 4.71 (9.97 g, 77%) as a 1.2:1 mixture. These products were then taken 
on as a crude mixture and used without further purification.  
 
Data for 4.70: 
Rf: 0.20 (20:1 hexanes/ EtOAc).  
FTIR (neat): 3428, 2981, 1736, 1443, 1365, 1232, 1167, 1023, 949, 754, 667 cm-1. 
1H NMR (500 MHz, CDCl3): δ 5.35 – 5.34 (m, 2H), 4.59 (d, J = 7.0 Hz, 2H), 2.87 (s, 1H), 2.14 (t, J = 7.2 
Hz, 2H), 2.07 – 2.05 (m, 2H), 2.05 (s, 3H), 1.71 (s 3H), 1.65 (s, 3H), 1.51 (s, 6H) ppm. 
13C NMR (125 MHz, CDCl3): δ 171.3, 141.7, 130.5, 125.1, 118.7, 112.2, 87.6, 80.0, 65.4, 61.5, 39.3, 
31.9, 28.7, 26.2, 21.1, 19.8, 16.2 ppm. 






























Using modified conditions from Hodgson et al.,16 MoO2(acac)2 (712 mg, 1.66 mmol, 5 mol%), 
AuCl(PPh3) (1.07 mg, 2.18 mmol, 5 mol%) and AgOTf (560 mg, 2.18 mmol, 5 mol%) were added 
successively to a 1.2:1 mixture of alkyne 4.70 and 4.71 (9.97 g, 43.7 mmol, 1.0 equiv.) in dry toluene 
(350 mL) at 0 °C. The reaction mixture was stirred at room temperature for 3 h, filtered through a pad 
of Celite and washed with Et2O (500 mL). The filtrate was concentrated and purified by flash column 
chromatography on SiO2 (9:1 hexanes/ EtOAc) to afford 4.73 (904 mg, 8% over 2-steps) and 4.72 (5.94 
g, 46% over 2-steps) as a yellow oil. 
 
Data for 4.72: 
Rf: 0.20 (9:1 hexanes/ EtOAc).  
FTIR (neat): 2975, 1738, 1685, 1618, 1446, 1380, 1333, 1233, 1024, 915, 732 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.11 – 6.10 (m, 1H), 5.36 – 5.33 (m, 1H), 5.26 – 5.22 (m, 1H), 4.58 (d, J = 
6.9 Hz, 2H), 3.04 (s, 2H), 2.21 – 2.15 (m, 2H), 2.14 (d, J = 1.3 Hz, 2H), 2.10 – 2.07 (m, 2H), 2.05 (s, 3H), 
1.88 (d, J = 1.3 Hz, 3H), 1.71 (s, 3H), 1.62 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 199.4, 171.3, 155.8, 142.1, 130.3, 128.6, 123.0, 118.7, 61.5, 55.5, 39.3, 
27.8, 26.5, 21.2, 20.8, 16.6, 16.6 ppm. 
HRMS (ESI) m/z: [M+Na]+ Calcd for C17H26O3Na 301.1774; found 301.1777. 
 
Data for 4.73: 
Rf: 0.30 (9:1 hexanes/ EtOAc).  
FTIR (neat): 2936, 1737, 1685, 1621, 1440, 1367, 1230, 1022, 967, 912 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.11 – 6.10 (m, 1H), 5.30 (t, J = 7.3 Hz, 1H), 4.90 (t, J = 1.6 Hz, 1H), 4.86 – 
4.87 (m, 1H), 4.54 (d, J = 7.0 Hz, 2H), 3.03 – 3.00 (m, 1H), 2.10 (s, 3H), 2.01 (s, 3H), 1.92 – 1.90 (m, 3H), 
1.84 (s, 3H), 1.65 (s, 3H), 1.60 (s, 3H), 1.61 – 1.55 (m, 1H) ppm.  
13C NMR (125 MHz, CDCl3): δ 200.1, 171.1, 155.9, 143.2, 141.9, 122.9, 118.8, 114.7, 61.4, 60.9, 37.2, 
27.8, 26.5, 21.1, 20.8, 19.9, 16.4 ppm. 


























4.71 4.73 8% (over 2-steps)




Using modified conditions from Li and co-workers,17 TMSCN (1.61 g, 13.9 mmol, 1.2 equiv.) was added 
to prenal 4.103 (1.27 mL, 11.6 mmol, 1.0 equiv.) and K2CO3 (240 mg, 1.74 mmol, 15 mol%) at room 
temperature. The reaction was left to stir for 16 h, then concentrated in vacuo and purified via flash 
column chromatography on SiO2 (5:1 hexanes/ EtOAc) to afford 4.74 (2.21 g, quant.) as a yellow oil. 
Data for 4.74 matched that previously reported.17 
 
Data for 4.74 
1H NMR (500 MHz, CDCl3): δ 5.37 – 5.33 (m, 1H), 5.08 (d, J = 8.6 Hz, 1H), 1.78 (s, 3H), 1.73 (s, 3H), 0.20 
(s, 9H) ppm. 
































To a solution of diisopropyl amine (0.81 mL, 5.75 mmol, 1.5 equiv.) in dry THF (10 mL) at –78 °C was 
added n-BuLi (2.3 mL, 2.5M in hexane, 1.5 equiv.). The solution was warmed to 0 °C and left to stir for 
5 min, then cooled back to –78 °C and the TMSCN reagent 4.74 (760 mg, 5.75 mmol, 1.5 equiv.) added. 
Next, the allylic bromide 4.68 (1.0 g, 3.83 mmol, 1.0 equiv.) in THF (7 mL) was added dropwise to the 
solution and the reaction was left to stir at –78 °C for 3 h. The reaction was quenched with sat. NH4Cl(aq) 
(10 mL) and the organic layer extracted (3 x 10 mL), dried with MgSO4, filtered and concentrated.  
 
The crude residue was dissolved in THF (5 mL) and TBAF (3.83 mL, 1.0 M in THF, 1.0 equiv.) was added 
dropwise at room temperature. After 5 min the reaction was quenched with sat. brine (5 mL) and the 
product extracted CH2Cl2 (3 x 5 mL), dried with MgSO4, filtered and concentrated in vacuo. Purification 
via flash column chromatography on SiO2 (9:1 hexanes/ EtOAc) then afforded 4.72 (473 mg, 44%) as 





























–78 ºC, 16 h





To a solution of ketone 4.72 (1.01 g, 3.63 mmol, 1.0 equiv.) in MeOH (20 mL) at 0 °C was added K2CO3 
(501 mg, 3.63 mmol, 1.0 equiv.) portion-wise. The reaction was stirred at 0 °C for 1 h, brine (50 mL) 
was added and the mixture was extracted with Et2O (30 mL × 3). The combined organic extracts were 
washed with brine (30 mL × 3), dried over MgSO4, filtered, and concentrated in vacuo. The residue 
was purified by flash column chromatography on SiO2 (4:1 → 2:1 hexanes/ EtOAc) to afford 4.75 as a 
clear colourless oil (654 mg, 76%) and the Michael addition product 4.76 (77 mg, 8%) as a yellow oil.  
 
Data for 4.75: 
Rf: 0.20 (4:1 hexanes/ EtOAc). 
FTIR (neat): 3500, 2915, 1685, 1618, 1445, 1007 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.08 – 6.07 (m, 1H), 5.40 – 5.37 (m, 1H), 5.20 – 5.17 (m, 1H), 4.12 (d, J = 
6.9 Hz, 2H), 3.02 (s, 2H), 2.18 – 2.14 (m, 2H), 2.11 (s, 3H), 2.05 (t, J = 7.6 Hz, 2H), 1.86 (s, 3H), 1.65 (s, 
3H), 1.59 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 199.5, 155.9, 138.9, 130.0, 128.8, 124.1, 123.1, 59.4, 55.3, 39.2, 27.8, 
26.4, 20.8, 16.6, 16.3 ppm. 
HRMS (ESI) m/z: [M+Na]+ Calcd for C15H24O2Na 259.1669; found 259.1670. 
 
Data for 4.76: 
Rf: 0.10 (7:3 hexanes/ EtOAc). 
FTIR (neat): 3358, 2973, 1708, 1380, 1367, 1226, 1184, 1068, 1002 cm-1. 
1H NMR (500 MHz, CDCl3): δ 5.39 (t, J = 1.3 Hz, 1H), 5.19 (t, J = 7.0 Hz, 1H), 4.13 (d, J = 6.9 Hz, 2H), 3.20 
(s, 3H), 3.09 (s, 2H), 2.58 (s, 2H), 2.23 – 2.13 (m, 2H), 2.09 – 2.05 (m, 2H), 1.66 (s, 3H), 1.59 (s, 3H), 1.24 
(s, 6H) ppm. 
13C NMR (125 MHz, CDCl3): δ  208.6, 138.8, 129.5, 129.4, 124.4, 74.6, 59.4, 55.9, 51.5, 49.2, 39.2, 26.2, 
24.8, 24.0, 16.6, 16.2 ppm. 

























To a solution of 4.75 (654 mg, 2.77 mmol, 1.0 equiv.) in CH2Cl2 (20 mL) at 0 °C was added NaHCO3 (465 
mg, 5.53 mmol, 2.0 equiv.), followed by DMP (1.76 g, 4.15 mmol, 1.5 equiv.). The reaction was stirred 
at 0 °C for 1 h, then hexanes (80 mL) was added. The resultant suspension was filtered, and the filtrate 
was concentrated in vacuo. The residue was purified by flash column chromatography on SiO2 (4:1 
hexanes/ EtOAc) to afford aldehyde 4.60 as a pale, light yellow oil (573 mg, 88%).  
 
Data for 4.60: 
Rf: 0.40 (7:3 hexanes/ EtOAc).  
FTIR (neat): 2915, 1673, 1619, 1445, 1383, 1194, 1121 cm-1. 
1H NMR (500 MHz, CDCl3): δ 9.99 (d, J = 8.0 Hz, 1H), 6.08 (s, 1H), 5.88 (d, J = 8.0 Hz, 1H), 5.22 – 5.20 
(m, 1H), 3.04 (s, 2H), 2.29 – 2.26 (m, 4H), 2.17 (s, 3H), 2.14 (s, 3H), 1.88 (s, 3H), 1.63 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 199.1, 191.4, 163.5, 156.2, 131.4, 127.7, 127.3, 123.0, 55.2, 40.4, 27.9, 
25.9, 20.9, 17.7, 16.7 ppm. 
































To a solution of 4.72 (1.21 g, 4.35 mmol, 1.0 equiv.) in CHCl3 (20 mL) was added DBU (0.80 mL, 5.21 
mmol, 1.2 equiv.) and the reaction was left to stir at reflux for 2 d. The resulting solution was then 
concentrated and purified by flash column chromatography on SiO2 (4:1 hexanes/ Et2O) to afford a 
yellow oil of E-4.77 and Z-4.77 as a 2.2:1 mixture of diastereomers (1.15 g, 95%). Although these 
products were then taken on as a crude mixture and used without further purification, it was found 
that a small sample of pure material could be isolated for analytical characterisation purposes.  
 
Data for E-4.77: 
Rf: 0.25 (4:1 hexanes/ EtOAc).  
FTIR (neat): 2936, 1737, 1672, 1443, 1380, 1229, 1108, 1022, 955, 877, 756 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.05 (m, 1H), 6.01 (m, 1H), 5.36 – 5.30 (m, 1H), 4.57 (dd, J = 7.2, 2.4 Hz, 
2H), 2.15 (s, 3H), 2.14 (s, 3H), 2.10 – 2.06 (m, 2H), 2.04 (s, 3H), 2.04 – 2.00 (m, 2H), 1.88 (s, 3H), 1.63 – 
1.58 (m, 2H) ppm. 
13C NMR (125 MHz, CDCl3): δ 191.7, 171.2, 157.5, 154.5, 141.8, 126.4, 125.9, 119.0, 61.4, 40.8, 39.1, 
27.9, 25.5, 21.1, 20.7, 19.2, 16.4 ppm.  
HRMS (ESI) m/z: [M+Na]+ Calcd for C17H26O3Na 301.1774; found 301.1773. 
 
Data for Z-4.77: 
Rf: 0.30 (4:1 hexanes/ EtOAc).  
FTIR (neat): 2936, 1736, 1672, 1623, 1444, 1378, 1228, 1112, 1023, 1023, 955, 870 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.02 (m, 2H), 5.36 – 5.30 (m, 1H), 4.56 (d, J = 6.8 Hz, 2H), 2.61 – 2.54 (m, 
2H), 2.14 (s, 3H), 2.11 – 2.05 (m, 2H), 2.03 (s, 3H), 1.86 (dd, J = 5.6, 1.3 Hz, 6H), 1.69 (s, 3H), 1.59 (m, 
2H) ppm. 
13C NMR (125 MHz, CDCl3): δ 191.7, 171.2, 157.5, 154.5, 142.0, 126.6, 126.4, 118.7, 61.5, 39.3, 34.4, 
27.8, 26.5, 25.5, 21.1, 20.7, 16.5 ppm. 






















To a solution of E-4.77 and Z-4.77 as a 2.2:1 mixture of diastereomers (1.15 g, 4.13 mmol, 1.0 equiv.) 
in MeOH (20 mL) was added portion-wise K2CO3 (0.57 g, 4.13 mmol, 1.0 equiv.) at 0 °C. The reaction 
was left to stir for 1 h, then quenched upon addition of distilled water (30 mL). Extraction with CHCl3 
(3 x 30 mL) was performed, and the solution was dried with MgSO4, concentrated and purified by flash 
column chromatography on SiO2 (3:1 hexanes/ EtOAc) to afford a yellow oil of E-4.78 and Z-4.78 as a 
2.2:1 mixture of diastereoisomers (502 mg, 51%). Although these products were then taken on as a 
crude mixture and used without further purification, it was found that a small sample of pure material 
could be isolated for analytical characterisation purposes. 
 
Data for E-4.78: 
Rf: 0.20 (3:1 hexane/ EtOAc).  
FTIR (neat): 3410, 2935, 1671, 1443, 1381, 1218, 1112, 1005, 875 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.04 – 6.04 (m, 2H), 5.41 – 5.38 (m, 1H), 4.14 (d,  J = 6.7 Hz, 1H), 2.175 (s, 
6H), 2.11 (t, J = 7.7 Hz, 2H), 2.02 (t, J = 7.6 Hz, 2H), 1.89 (s, 3H), 1.67 (s, 3H), 1.63 – 1.58 (m, 2H) ppm. 
13C NMR (125 MHz, CDCl3): δ 191.8, 157.7, 154.5, 139.1, 126.4, 125.9, 124.1, 59.4, 40.9, 39.1, 27.9, 
26., 25.6, 19.2, 16.3 ppm. 
HRMS (ESI) m/z: [M+Na]+ Calcd for C15H24O2Na 259.1669; found 259.1668. 
 
Data for Z-4.78: 
Rf: 0.20 (3:1 hexanes/ EtOAc).  
FTIR (neat): 3411, 2933, 1670, 1620, 1443, 1379, 1221, 1112, 1000, 870, 772 cm-1. 
1H NMR (500 MHz, CDCl3): δ 5.99 – 5.97 (m, 2H), 5.40 (t, J = 5.5 Hz, 1H), 4.14 (d, J = 7.0 Hz, 2H), 2.61 – 
2.57 (m, 2H), 2.21 – 2.14 (br s, 1H), 2.10 (s, 3H), 2.02 (t, J = 7.5 Hz, 2H), 1.84 – 1.81 (m, 6H), 1.63 (s, 
3H), 1.58 – 1.51 (m, 2H) ppm. 
13C NMR (125 MHz, CDCl3): δ 191.8, 157.7, 154.5, 139.1, 126.4, 123.9, 59.4, 59.4, 39.2, 32.8, 27.8, 
26.2, 25.5, 20.7, 16.3 ppm.  























To a solution of E-4.78 and Z-4.78 as a 2.2:1 mixture of diastereomers (502 mg, 2.12 mmol, 1.0 equiv.) 
in CH2Cl2 (30 mL) at 0 °C was added NaHCO3 (360 mg, 4.25 mmol, 2.0 equiv.) and Dess-Martin 
periodinane (1.35 g, 3.18 mmol, 1.5 equiv.). The solution was left to stir for 1.5 h then quenched upon 
addition of sat. NaHCO3(aq) (30 mL). The organic layer was extracted with CH2Cl2 (3 x 30 mL), dried with 
MgSO4 and concentrated in vacuo. Purification by flash column chromatography on SiO2 (4:1 hexanes/ 
Et2O) then afforded Z-4.64 (113 mg, 12% over 2-steps) and E-4.64 (252 mg, 26% over 2-steps) as yellow 
oils. If needed further recrystallisation of the trans isomer E-4.64 with hexanes at 0 °C could also be 
performed.  
 
Data for E-4.64: 
Rf: 0.15 (4:1 hexanes/ Et2O).  
FTIR (neat): 2941, 1671, 1625, 1443, 1382, 1217, 1195, 1109, 1044, 873 cm-1. 
1H NMR (500 MHz, CDCl3): δ 10.00 (d, J = 7.9 Hz, 1H), 6.07 – 6.06 (m, 1H), 6.03 – 6.02 (m, 1H), 5.89 
(dq, J = 7.9, 1.2 Hz, 1H), 2.23 – 2.19 (m, 2H), 2.19 – 2.13 (m, 8H), 1.90 (s, 3H), 1.73 – 1.70 (m, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 191.6, 191.3, 163.2, 156.4, 155.0, 127.7, 126.3, 126.3, 40.7, 40.0, 27.9, 
25.0, 20.7, 19.1, 17.7 ppm. 
HRMS (ESI) m/z: [M+H]+ Calcd for C15H23O2 235.1693; found 235.1696. 
 
Data for Z-4.64: 
Rf: 0.20 (4:1 hexanes/ Et2O).  
FTIR (neat): 2935, 1670, 1444, 1380, 1194, 1113, 1045, 872, 773 cm-1. 
1H NMR (500 MHz, CDCl3): δ 9.99 (d, J = 8.0 Hz, 1H), 6.06 – 6.04 (m, 2H), 5.89 (d, J = 8.1 Hz, 1H), 2.62 
(t, J = 7.8, 2H), 2.28 (t, J = 7.8 Hz, 2H), 2.19 (s, 3H), 2.15 (s, 3H), 1.88 (s, 6H), 1.69 (pent, J = 7.8 Hz, 2H) 
ppm. 
13C NMR (125 MHz, CDCl3): δ 191.5, 191.1, 164.2, 157.2, 154.8, 127.5, 126.9, 126.3, 40.7, 33.2, 27.9, 
25.8, 25.5, 20.7, 17.7 ppm. 





















To a solution of aldehyde E-4.61 (50 mg, 0.213 mmol, 1.0 equiv.) in PhMe (8 mL) was added orcinol 
monohydrate 4.61 (40 mg, 0.320 mmol, 1.5 equiv.), and EDDA (4 mg, 0.021 mmol, 10 mol%). The 
mixture was heated to reflux for 2 h, and the solvent was removed in vacuo. The residue was purified 
by flash column chromatography on a Biotage® IsoleraTM 1.2.1 (4:1 → 2:1 hexanes/ Et2O, gradient 
elution) to afford rubiginosin D (4.59) as a light brown oil (48 mg, 66%). Data for rubiginosin D (4.59) 
matched that previously reported in literature.7 
 
Data for rubiginosin D (4.59): 
Rf: 0.20 (2:1 hexanes/ Et2O).  
FTIR (neat): 3360, 2923, 1620, 1444, 1330, 1218, 1097, 992, 824, 775 cm-1. 
1H NMR (600 MHz, CD3OD): δ 6.64 (dd, J = 10.0, 0.7 Hz, 1H), 6.14 (s, 1H), 6.10 – 6.09 (m, 1H), 6.07 (s, 
1H), 6.06 – 6.05 (m, 1H), 5.45 (d, J = 10.0 Hz, 1H), 2.16 (s, 3H), 2.16 – 2.13 (m, 2H), 2.12 (s, 3H), 2.08 (s, 
3H), 1.90 (s, 3H), 1.63 – 1.62 (m, 4H), 1.32 (s, 3H) ppm.  
13C NMR (150 MHz, CD3OD): δ 193.8, 159.5, 156.2, 155.2, 154.2, 140.4, 127.3, 127.1, 126.8, 118.9, 
109.3, 109.2, 108.1, 78.9, 42.2, 41.4, 27.8, 26.6, 22.9, 21.7, 20.8, 19.3 ppm. 






























To a solution of rubiginosin D (4.59) (46 mg, 0.135 mmol, 1.0 equiv.) in CH2Cl2 (5 mL) at 0 °C was added 
Fe(OTf)3 (20 mg, 0.040 mmol, 0.3 equiv.) and the reaction was left to slowly warm to room 
temperature over 5 h. Then quenched upon addition of brine (10 mL) and the products extracted with 
CH2Cl2 (3 x 10 mL). The combined organic layers were then dried with MgSO4, filtered and 
concentrated in vacuo. Purification by flash column chromatography on SiO2 (19:1 hexanes/ EtOAc) 
then afforded rubiginosin A (4.7) (33 mg, 72%) as a white solid. Data for rubiginosin A (4.7) matched 
that previously reported in literature.7 
 
Data for rubiginosin A (4.7): 
MP: 137.5 – 138.9 °C (lit. 142 – 144 °C).7 
Rf: 0.40 (9:1 hexanes/ EtOAc). 
FTIR (neat): 2248, 2929, 1728, 1660, 1608, 1584, 1447, 1368, 1323, 1187, 1132, 1062 cm-1. 
1H NMR (600 MHz, CDCl3): δ 7.48 (br s, 1H), 6.40 (s, 1H), 6.30 (s, 1H), 5.87 (m, 1H), 3.82 (t, J = 9.3 Hz, 
1H), 2.96 (d, J = 9.3 Hz, 1H), 2.23 (s, 3H), 2.16 (s, 3H), 2.01 – 1.93 (m, 1H), 2.09 (dt, J = 13.9, 3.7 Hz) 
1.90 (s, 3H), 1.89 – 1.84 (m, 1H), 1.82 (d, J = 9.8 Hz, 1H), 1.70 – 1.62 (m, 1H), 1.37 – 1.24 (m, 2H), 1.15 
(s, 3H), 1.14 (s, 3H) ppm.  
13C NMR (150 MHz, CDCl3): δ 203.2, 158.1, 154.4, 153.4, 138.0, 122.4, 112.1, 111.5, 110.6, 75.3, 58.0, 
45.1, 39.5, 36.4, 34.4, 29.7, 28.2, 25.9, 24.0, 21.6, 21.5, 17.4 ppm. 
































To a solution of rubiginosin A (4.7) (30 mg, 0.059 mmol, 1.0 equiv.) in dry MeOH (15 mL) was added 
portion-wise Pd/C (55 mg, 0.005 mmol, 10% w/w, 10 mol%). The solution was then put under vacuum/ 
flushed with H2 three times and the reaction was left to stir at room temperature for 4 h. The reaction 
was then filtered through celite with EtOAc and concentrated to afford rubiginosin G (4.6) (29 mg, 
96%) as a clear oil. Data for rubiginosin G (4.6) matched that previously reported in literature.7  
 
Data for rubiginosin G (4.6): 
Rf: 0.20 (19:1 hexanes/ EtOAc). 
FTIR (neat): 3395, 2956, 2929, 1682, 1631, 1585, 1456, 1370, 1323, 1260, 1127, 1059, 908 cm-1. 
1H NMR (600 MHz, CDCl3): δ 6.83 (s, 1H), 6.40 (s, 1H), 6.31 (s, 1H), 3.81 (t, J = 9.4 Hz, 1H), 2.91 (d, J = 
9.4 Hz, 1H), 2.23 (s, 3H), 2.18 (dd, J = 13.5, 6.6 Hz, 1H), 2.15 – 2.10 (m, 1H), 2.09 – 2.05 (m, 1H), 2.00 – 
1.91 (m, 1H), 1.87 – 1.81 (m, 1H), 1.80 (d, J = 9.3 Hz, 1H), 1.70 - 1.63 (m), 1.37 – 1.33 (m, 1H), 1.33 – 
1.28 (m, 1H), 1.17 (s, 3H), 1.11 (s, 3H), 0.89 (d, J = 6.4 Hz, 3H), 0.86 (d, J = 6.4 Hz, 3H) ppm. 
13C NMR (150 MHz, CDCl3): δ 213.9, 154.5, 153.1, 138.1, 111.8, 111.7, 110.6, 75.3, 57.4, 50.9, 45.2, 
39.4, 36.6, 34.5, 29.6, 25.8, 24.2, 23.9, 23.0, 22.8, 21.6, 17.3 ppm. 

































To a solution of aldehyde 4.60 (287 mg, 1.22 mmol, 1.0 equiv.) in PhMe (10 mL) was added orcinol 
monohydrate 4.61 (228 mg, 1.84 mmol, 1.5 equiv.), and EDDA (22 mg, 0.122 mmol, 10 mol%). The 
mixture was heated to reflux for 2 h, and the solvent was removed in vacuo. The residue was purified 
by flash column chromatography on SiO2 (4:1 → 2:1 hexanes/ Et2O, gradient elution) to afford 
rubiginosin E (4.58) as a light brown oil (234 mg, 56%). Data for rubiginosin E (4.58) matched that 
previously reported in literature.7 
 
Data for rubiginosin E (4.58): 
Rf: 0.20 (2:1 hexanes/ Et2O).  
FTIR (neat): 3365, 2972, 2920, 1676, 1621, 1579, 1445, 1328, 1280, 1204, 1140, 1097, 1073 cm-1. 
1H NMR (600 MHz, CDCl3): δ 6.63 (d, J = 10.0 Hz, 1H), 6.18 (br s, 1H), 6.14 (s, 1H), 6.08 (s, 1H), 5.46 (d, 
J = 10.0 Hz, 1H), 5.29 (t, J = 7.2 Hz, 1H), 3.02 (s, 2H), 2.19 – 2.14 (m, 2H), 2.16 (s, 3H), 2.11 (s, 3H), 1.88 
(s, 3H), 1.73 – 1.64 (m, 2H), 1.56 (s, 3H), 1.33 (s, 3H) ppm. 
13C NMR (150 MHz, CD3OD): δ 201.9, 157.8, 155.2, 154.2, 140.4, 130.7, 130.6, 127.1, 123.9, 118.8, 
109.3, 109.2, 108.1, 78.9, 56.0, 41.7, 27.7, 26.6, 23.9, 21.7, 20.8, 16.3 ppm. 




























To a solution of rubiginosin E (4.58) (53 mg, 0.156 mmol, 1.0 equiv.) in CH2Cl2 (10 mL) at –40 °C was 
added Fe(OTf)3 (23 mg, 0.047 mmol, 0.3 equiv.) and reaction was left to stir 7 h. Brine (10 mL) was 
added and the solution extracted with CH2Cl2 (3 x 10 mL). The organic layers were dried with MgSO4, 
filtered and concentrated. Purification by flash chromatography on SiO2 (20:1 hexanes/ EtOAc) 
afforded fastinoid B (4.8) (22 mg, 42%) and rhodonoid B (4.3) (6 mg, 11%). Data for fastinoid B (4.8) 
and rhodonoid B (4.3) matched that previously reported in literature. 5,9 
 
Data for fastinoid B (4.8): 
Rf: 0.25 (20:1 hexanes/ EtOAc).  
FTIR (neat): 3250, 2947, 1678, 1613, 1574, 1490, 1444, 1376, 1177, 1057, 910, 827 cm-1. 
1H NMR (500 MHz, CDCl3): δ 9.25 (s, 1H), 6.39 (s, 1H), 6.27 (s, 1H), 6.11 (s, 1H), 3.38 (d, J = 9.6 Hz, 1H), 
2.97 (d, J = 17.7 Hz, 1H), 2.79 (d, J = 17.7 Hz, 1H), 2.68 (t, J = 8.8 Hz, 1H), 2.31 (td, J = 8.4, 2.9 Hz, 1H), 
2.23 (s, 3H), 2.20 (s, 3H), 2.08 – 2.02 (m, 1H), 1.92 (s, 3H), 1.80 – 1.73 (m, 1H), 1.66 – 1.59 (m, 1H), 1.56 
– 1.51 (m, 1H), 1.31 (s, 3H), 0.84 (s, 3H) ppm. 
13C NMR (150 MHz, CDCl3): δ 203.1, 159.6, 156.2, 154.6, 138.2, 124.1, 110.8, 110.4, 108.0, 83.0, 58.7, 
46.9, 41.7, 40.6, 38.5, 34.2, 28.2, 26.3, 24.8, 21.5, 21.3, 15.5 ppm. 
HRMS (ESI) m/z: [M+H]+ Calcd for C22H29O3 341.2111; found 341.2115. 
 
Data for rhodonoid B (4.3): 
Rf: 0.20 (20:1 hexanes/ EtOAc). 
MP: 145.3 – 149.8 °C (lit. 148 – 149 °C).5  
FTIR (neat): 3395, 2949, 1677, 1619, 1585, 1444, 1418, 1328, 1139, 1054, 907, 825 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.33 (s, 1H), 6.25 (s, 1H), 5.89 – 5.88 (m, 1H), 5.35 (s, 1H), 3.18 (d, J = 9.3 
Hz, 1H), 2.62 (td, J = 8.0, 2.6 Hz), 2.60 (dd, J = 9.0, 8.0 Hz, 1H), 2.47 (d, J = 18.3 Hz, 1H), 2.42 (d, J = 18.3 
Hz, 1H), 2.22 (s, 3H), 2.04 (s, 3H), 1.98 – 1.90 (m, 1H), 1.78 (s, 3H), 1.75 – 1.68 (m, 1H), 1.66 – 1.61 (m, 
1H), 1.60 – 1.56 (m, 1H), 1.54 (s, 3H), 1.32 (s, 3H) ppm. 
13C NMR (150 MHz, CDCl3): δ 201.6, 154.5, 154.4, 154.2, 137.8, 125.0, 111.9, 109.6, 109.6, 83.9, 47.0, 
45.6, 41.7, 39.5, 39.1, 36.5, 30.5, 27.7, 26.9, 26.4, 21.4, 20.7 ppm. 

































To a solution of aldehyde 4.60 (146 mg, 0.623 mmol, 1.0 equiv.) in PhMe (10 mL) was added orcinol 
monohydrate 4.61 (130 mg, 0.935 mmol, 1.5 equiv.), phenylboronic acid (110 mg, 0.935 mmol, 1.5 
equiv.) and acetic acid (0.04 mL, 0.623 mmol, 1.0 equiv.). The solution was heated to reflux and left to 
stir for 24 hours, then concentrated in vacuo. The residue was purified by flash chromatography on 
SiO2 (20:1 → 9:1 hexanes/ EtOAc, gradient elution) to afford Ar-turmerone (4.81) (3 mg, 2%) as a 
yellow solid, rubiginosin A (4.7) (22 mg, 10%) and “iso-rubiginosin A” (4.80) (39 mg, 31%) as a white 
solid. Data for rubiginosin A (4.7) and Ar-turmerone (4.80) matched that previously obtained and 
previously reported in the literature.7, 25 
 
Data for 4.80: 
Rf: 0.30 (3:1 hexanes/ EtOAc). 
FTIR (neat): 3407, 2930, 1667, 1615, 1445, 1379, 1328, 1130, 985 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.27 (d, J = 2.4 Hz, 1H), 6.24 (d, J = 2.4 Hz, 1H), 5.82 – 5.80 (m, 1H), 4.65 
(br s, 1H), 4.02 (t, J = 8.9 Hz, 1H), 3.19 (d, J = 9.1 Hz, 1H), 2.38 (s, 3H), 2.11 (s, 3H), 2.09 – 2.02 (m, 2H), 
1.84 (s, 3H), 1.84 – 1.81 (m, 1H), 1.78 (d, J = 8.9 Hz, 1H), 1.67 – 1.61 (m, 1H), 1.37 – 1.31 (m, 1H), 1.25 
– 1.17 (m, 1H), 1.08 (s, 3H), 0.99 (s, 3H) ppm. 
13C NMR (120 MHz, CDCl3): δ 200.0, 156.1, 154.5, 154.4, 137.2, 124.2, 120.4, 110.4, 104.0, 75.8, 
57.7, 47.7, 38.9, 37.1, 34.4, 28.8, 27.8, 26.6, 25.6, 20.9, 19.3, 17.3 ppm. 
HRMS (ESI) m/z: [M+H]+ Calcd for C22H29O3 341.2111, found 341.2114.  
 
Data for Ar-turmerone (4.81): 
Rf: 0.45 (9:1 hexanes/ EtOAc). 
FTIR (neat): 2962, 2925, 1686, 1619, 1515, 1446, 1378, 1112, 1011, 819 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.13 – 7.08 (m, 4H), 6.07 – 6.00 (m, 1H), 3.33 – 3.25 (m, 1H),  
2.71 (dd, J = 15.7, 6.1 Hz, 1H), 2.61 (dd, J = 15.7, 8.3 Hz, 1H), 2.31 (s, 3H), 2.11 (s, 3H), 1.86 (s, 3H), 1.25 
(s, 3H), 1.24 (s, 3H) ppm. 
13C NMR (120 MHz, CDCl3): δ 200.0, 155.2, 143.8, 135.7, 129.2, 126.8, 124.2, 52.8, 35.4, 27.8, 22.1, 
21.1, 20.9 ppm.  
HRMS (ESI) m/z: [M+H]+ Calcd for C15H20O 217.1587, found 217.1587.  
4.60, PhB(OH)2
AcOH, PhMe
































To a solution of aldehyde E-4.64 (146 mg, 0.623 mmol, 1.0 equiv.) in PhMe (10 mL) was added orcinol 
monohydrate 4.61 (130 mg, 0.935 mmol, 1.5 equiv.), phenylboronic acid (110 mg, 0.935 mmol, 1.5 
equiv.) and acetic acid (0.04 mL, 0.623 mmol, 1.0 equiv.). The solution was heated to reflux and left to 
stir for 24 hours, then concentrated in vacuo. The residue was purified by flash chromatography on 
SiO2 (20:1 → 9:1 hexanes/ EtOAc, gradient elution) to afford Ar-turmerone (4.81) (3 mg, 2%), 
rubiginosin A (4.7) (22 mg, 10%) and “iso-rubiginosin A” (4.80) (39 mg, 31%) as a white solid. Data for 
rubiginosin A (4.7), “iso-rubiginosin A” (4.80) and Ar-turmerone (4.81) matched that previously 




















































To a solution of diisopropyl amine (0.02 mL, 0.113 mmol, 2.5 equiv.) in THF (2.5 mL) at 0 °C was added 
dropwise n-BuLi (0.02 mL, 0.113 mmol, 11.0 M, 2.5 equiv.) and stirred for 5 min at room temperature. 
The solution was then cooled to 0 °C and rubiginosin A (4.7) (15 mg, 0.045 mmol, 1.0 equiv.) dissolved 
in THF (2.5 mL) was added dropwise and left to stir for 3 h. The reaction was then quenched sat. 
NH4Cl(aq) and product extracted with Et2O (3 x 5 mL), dried with MgSO4, filtered and concentrated. 
Purification via flash chromatography on SiO2 (20:1 → 9:1 hexanes/ EtOAc, gradient elution) afforded 
4.94 (2 mg, 13%) as a clear oil.  
 
Data for 4.94: 
Rf: 0.20 (19:1 hexanes/ EtOAc). 
FTIR (neat): 3501, 2927, 1690, 1653, 1636, 1584, 1457, 1325, 1183, 1130 cm-1. 
1H NMR (600 MHz, CDCl3): δ 6.61 (br s, 1H), 6.40 (s, 1H), 6.31 (s, 1H), 4.91 – 4.90 (m, 1H), 4.73 – 4.71 
(m, 1H), 3.83 (t, J = 9.3 Hz, 1H), 3.05 (d, J = 9.3 Hz, 1H), 3.03 – 3.02 (m, 2H), 2.23 (s, 3H), 2.10 – 2.05 
(m, 1H), 2.00 – 1.92 (m, 1H), 1.89 – 1.85 (m, 1H), 1.81 (d, J = 9.2 Hz, 1H), 1.70 (s, 3H), 1.69 – 1.63 (m, 
1H), 1.38 – 1.31 (m, 2H), 1.20 (s, 3H), 1.11 (s, 3H) ppm.  
13C NMR (150 MHz, CDCl3): δ 211.8, 154.6, 153.1, 138.3, 138.2, 115.6, 111.8, 111.7, 110.6, 75.3, 
56.7, 50.8, 45.3, 39.6, 36.6, 34.4, 29.5, 25.8, 24.0, 22.9, 21.6, 17.3 ppm.  
































To a solution of ethyl orsellinate (4.96) (128 mg, 0.653 mmol, 2.0 equiv.) in PhMe (3 mL) was added 
aldehyde (4.60) (77 mg, 0.327 mmol, 1.0 equiv.), PhB(OH)2 (60 mg, 0.491 mmol, 1.5 equiv.) and AcOH 
(0.02 mL, 0.327 mmol, 1.0 equiv.). The reaction was left to heat at reflux for 24 h. Then concentrated 
in vacuo. Purification by flash chromatography on SiO2 (9:1 hexanes/ EtOAc) afforded 4.97 (25 mg, 
10%) as a clear oil. 
 
Data for 4.97: 
Rf: 0.40 (19:1 hexanes/ EtOAc). 
FTIR (neat): 2972, 2934, 1652, 1619, 1315, 1297, 1284, 1248, 1176, 1133, cm-1. 
1H NMR (500 MHz, CDCl3): δ 11.89 (br s, 1H), 6.29 (s, 1H), 6.00 (s, 1H), 4.38 (d, J = 7.1 Hz, 2H), 4.30 (s, 
1H), 3.03 (d, J = 9.0 Hz, 1H), 2.47 (s, 3H), 2.13 (s, 3H), 2.08 – 1.96 (m, 3H), 1.87 – 1.80 (m, 2H), 1.84 (s, 
3H) 1.62 (t, J = 7.3 Hz, 3H), 1.34 – 1.29 (m, 2H), 1.12 (s, 3H), 1.02 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 200.0, 172.0, 160.7, 159.9, 155.1, 140.7, 123.7, 114.3, 114.2, 106.4, 71.9, 
61.3, 57.2, 46.9, 36.6, 34.2, 29.9, 28.9, 27.9, 25.5, 24.4, 24.3, 21.0, 17.3, 14.4 ppm.  


































Chromene 4.97 (10 mg, 0.024 mmol, 1.0 equiv.) was dissolved in dry MeOH (5 mL) and Pd/C (3 mg, 
0.002 mmol, 10% wt./ wt., 10 mol%) added. The reaction was placed under an atmosphere of vacuum/ 
H2 three times, then left to stir under an atmosphere of H2 at room temperature for 3 h. The solution 
was then filtered through celite with CHCl3 to afford 4.98 (9 mg, 93%) as a clear oil.  
 
Data for 4.98: 
Rf: 0.55 (CHCl3). 
FTIR (neat): 3501, 2927, 1690, 1653, 1636, 1584, 1457, 1325, 1183, 1130 cm-1. 
1H NMR (500 MHz, CDCl3): δ 11.90 (s, 1H), 6.30 (s, 1H), 4.39 (q, J = 7.1 Hz, 2H), 4.26 (t, J = 9.0 Hz), 2.97 
(d, J = 8.9 Hz, 1H), 2.48 (s, 3H), 2.23 (dd, J = 16.4, 5.8 Hz, 1H), 2.16 – 2.01 (m, 4H), 2.00 – 1.89 (m, 2H), 
1.87 (d, J = 9.1 Hz, 1H), 1.83 – 1.76 (m, 1H), 1.61 – 1.58 (m, 2H), 1.40 (t, J = 7.1 Hz, 3H), 1.14 (s, 3H), 
1.03 (s, 3H), 0.84 (t, J = 5.9 Hz, 6H) ppm.                
13C NMR (125 MHz, CDCl3): δ 209.6, 172.1, 160.9, 159.8, 140.8, 114.3, 113.8, 106.3, 72.0, 61.3, 56.4, 
51.9, 46.6, 36.2, 34.0, 28.9, 25.5, 24.5, 24.4, 24.0, 22.9, 22.8, 17.2, 14.4 ppm.  






































To a solution of o-orsellinic acid (4.95) (2.71 g, 16.1 mmol, 1.0 equiv.) in CH2Cl2 (30 mL) at room 
temperature was added PPh3 (6.30 g, 24.2 mmol, 1.5 equiv.), 2-(trimethylsilyl)ethanol (2.8 mL, 10.3 
mmol, 1.2 equiv.) and a dropwise addition of DIAD (4.75 mL, 24.2 mmol, 1.5 equiv.). The reaction 
mixture was left to stir for 48 h, then filtered and quenched sat. brine (30 mL). The product was 
extracted CH2Cl2 (3 x 30 mL), dried MgSO4, filtered and concentrated in vacuo. Purification via flash 
chromatography on SiO2 (9:1 hexanes/ EtOAc) afforded 4.99 (1.07 g, 25%). Data for 4.99 matched that 
previously reported in literature.21 
 
Data for 4.99:  
Rf: 0.15 (9:1, hexanes/ EtOAc). 
FTIR (neat): 3500, 2955, 1617, 1588, 1314, 1300, 1197, 1170, 1107, 1060, 995 cm-1. 
1H NMR (500 MHz, CDCl3): δ 11.89 (s, 1H), 6.28 (d,  J = 2.5 Hz, 1H), 6.24 – 6.20 (m, 1H), 5.54 (s, 1H), 
4.53 – 4.30 (m, 2H), 2.61 – 2.41 (m, 3H), 1.27 – 1.07 (m, 2H), 0.88 (s, 9H) ppm. 


































To a solution of 4.99 (407 mg, 1.52 mmol, 1.0 equiv.) in PhMe (4 mL) was added aldehyde 4.60 (356 
mg, 1.52 mmol, 1.0 equiv.) and EDDA (27 mg, 0.152 mmol, 10 mol%). The solution was left to stir at 
reflux for 3 h, after which time it was concentrated and purified via flash chromatography on SiO2 (9:1 
hexanes/ EtOAc) to afford 4.100 (22 mg, 3%) as a brown oil. 
 
Data for 4.100: 
Rf: 0.50 (9:1 hexanes/ EtOAc). 
FTIR (neat): 3025, 1646, 1566, 1454, 1420, 1383, 1314, 1250, 1117, 1057, 1009, 858 cm-1. 
1H NMR (500 MHz, CDCl3): δ 12.09 (s, 1H), 6.73 (d, J = 10.3 Hz, 1H), 6.16 (s, 1H), 6.06 – 5.96 (m, 1H), 
5.45 (d, J = 10.3 Hz, 1H), 5.23 (t, J = 7.2 Hz, 1H), 4.49 – 4.32 (m, 2H), 3.00 (s, 2H), 2.47 (s, 3H), 2.20 – 
2.14 (m, 2H), 2.13 (s, 3H), 1.86 (s, 3H), 1.76 – 1.65 (m, 2H), 1.58 (s, 3H), 1.39 (s, 3H), 1.19 – 1.12 (m, 
2H), 0.08 (s, 9H) ppm. 
13C NMR (125 MHz, CDCl3): δ 199.4, 172.2, 159.9, 157.7, 155.8, 143.0, 130.2, 128.9, 126.1, 123.0, 
117.1, 107.1, 105.4, 79.7, 63.7, 55.4, 41.4, 27.8, 27.2, 24.7, 23.0, 22.6, 21.9, 20.8, 20.7, 17.8, 16.5, − 
1.4 ppm. 
































Following a modified literature procedure from Luo and co-workers,22 dry DMF (1 mL) was cooled to 
0 °C and oxalyl chloride (0.175 mL, 2.04 mmol, 17 equiv.) was added dropwise. The solution was left 
to stir for 30 min then rubiginosin G (39 mg, 0.120 mmol, 1.0 equiv.) in MeCN (4 mL) was added 
dropwise. The reaction was then left to stir for a further 6 h at room temperature, then concentrated 
in vacuo and purified via flash chromatography on SiO2 (9:1 hexanes/ EtOAc) to afford the recovered 
starting material 4.6 and 4.101 (25.3 mg, 60%) as a (2.0:1) mixture. 
 
Partial Data for 4.101: 
1H NMR (500 MHz, CDCl3): δ 12.57 (s, 1H), 10.10 (brs, 1H), 6.98 (s, 1H), 4.36 (t, J = 8.8 Hz, 1H), 2.95 (d, 
J = 8.8 Hz, 1H), 2.52 – 2.49 (m, 2H), 2.28 (s, 3H), 2.01 (m, 2H), 1.89 (d, J = 9.6 Hz, 2H), 1.68 – 1.62 (m, 








































4.4.3 NMR Comparison Data 
 




Synthetic Sample (CD3OD)  
George et al. (2021) 
Natural Sample (CD3OD) 
Yang et al. (2018)7 








2 -- 78.9 -- 78.9 
3 5.45  
(d, J = 10.0 Hz) 
127.1 5.45  
(d, J = 9.8 Hz) 
127.1 
4 6.64  
(dd, J = 10.0, 0.7 Hz) 
118.9 6.64  
(d, J = 9.8 Hz) 
118.8 
4a -- 108.1 -- 108.1 
5 -- 155.2 -- 158.2 
6 6.07 (s) 109.2 6.14 (s) 109.3 
7 -- 140.4 -- 140.4 
8 6.14 (s) 109.3 6.08 (s) 109.3 
8a -- 154.2 -- 154.2 
9 1.63 – 1.62 (m) 41.4 1.63 (m) 41.4 
10 1.63 – 1.62 (m) 22.9 1.63 (m) 22.9 
11 2.16 – 2.13 (m) 42.2 2.16 (m) 42.2 
12 -- 159.5 -- 159.5 
13 6.06 – 6.05 (m) 126.8 6.09 (m) 126.8 
14 -- 193.8 -- 193.9 
15 6.10 – 6.09 (m) 127.3 6.10 (m) 127.3 
16 -- 156.2 -- 155.2 
17 2.12 (s) 20.8 2.12 (s) 20.7 
18 1.90 (s) 27.8 1.90 (s) 27.7 
19 1.32 (s) 26.6 1.33 (s) 26.6 
20 2.08 (s) 19.3 2.08 (s) 19.3 









































Synthetic Sample (CDCl3)  
George et al. (2021) 
Natural Sample (CDCl3) 
Yang et al. (2018)7 









2 -- 75.3 -- 75.3 
3 1.82  
(d, J = 9.8 Hz) 
45.1 1.82  
(d, J = 9.8 Hz) 
45.1 
4 3.82  
(t, J = 9.3 Hz) 
24.0 3.83  
(t, J = 9.3 Hz) 
24.0 
4a -- 112.1 -- 112.0 
5 -- 153.4 -- 154.4 
5-OH 7.48 (s) -- -- -- 
6 6.40 (s) 110.6 6.31 (s) 111.5 
7 -- 138.0 -- 137.9 
8 6.30 (s) 111.5 6.41 (s) 110.6 
8a -- 154.4 -- 153.4 
9 1.37 – 1.24 (m) 
2.09 
(dt, J = 13.9, 3.7 Hz) 
36.4 1.37 (m) 
2.07 (m) 
36.4 
10 1.70 – 1.62 (m) 
2.01 – 1.93 (m) 
17.4 1.66 (m) 
1.97 (m) 
17.4 
11 1.37 – 1.24 (m) 
1.89 – 1.84 (m) 
34.4 1.30 (m) 
1.88 (m) 
34.4 
12 -- 39.5 -- 39.4 
13 2.96  
(d, J = 9.3 Hz) 
58.0 2.97  
(d, J = 9.3 Hz) 
58.0 
14 -- 203.2 -- 203.2 
15 5.87 (m) 122.4 5.88 (m) 122.4 
16 -- 158.1 -- 158.0 
17 2.16 (s) 21.5 2.17 (s) 21.5 
18 1.90 (s) 28.2 1.91 (s) 28.2 
19 1.14 (s) 29.7 1.14 (s) 29.6 
20 1.15 (s) 25.9 1.16 (s) 25.8 




































Synthetic Sample (CDCl3)  
George et al. (2021) 
Natural Sample (CDCl3) 
Yang et al. (2018)7 









2 -- 75.3 -- 75.3 
3 1.80 (d, J = 9.3 Hz) 45.2 1.79 (d, J = 9.5 Hz) 45.2 
4 3.81 (t, J = 9.4 Hz) 23.9 3.81 (t, J = 9.5 Hz) 23.9 
4a -- 111.8 -- 111.9 
5 -- 153.1 -- 154.6 
5-OH 6.83 (s) -- -- -- 
6 6.40 (s) 110.6 6.30 (s) 111.8 
7 -- 138.1 -- 138.2 
8 6.31 (s) 111.7 6.40 (s) 110.6 
8a -- 154.5 -- 153.2 
9 1.37 – 1.33 (m) 
2.09 – 2.05 (m) 
36.6 1.34 (m) 
2.08 (m) 
36.6 
10 1.70 – 1.63 (m) 
2.00 – 1.91 (m) 
17.3 1.65 (m) 
1.95 (m) 
17.3 
11 1.33 – 1.28 (m) 
1.87 – 1.81 (m) 
34.5 1.30 (m) 
1.84 (m) 
34.5 
12 -- 39.4 -- 39.5 
13 2.91 (d, J = 9.4 Hz) 57.4 2.91 (d, J = 9.8 Hz) 57.4 
14 -- 213.9 -- 213.9 
15 2.18  
(dd, J = 13.5, 6.6 Hz) 
50.9 2.17 (m) 50.9 
16 2.15 – 2.10 (m) 24.2 2.11 (m) 24.3 
17 0.89 (d, J = 6.4 Hz) 23.0 0.89 (d, J = 6.7 Hz) 23.0 
18 0.86 (d, J = 6.4 Hz) 22.8 0.86 (d, J = 6.7 Hz) 22.8 
19 1.11 (s) 29.6 1.11 (s) 29.6 
20 1.17 (s) 25.8 1.17 (s) 25.9 






































Synthetic Sample (CD3OD)  
George et al. (2021) 
Natural Sample (CD3OD) 
Yang et al. (2018)7 








2 -- 78.9 -- 78.9 
3 5.46  
(d, J = 10.0 Hz) 
127.1 5.46  
(d, J = 9.9 Hz) 
127.1 
4 6.63  
(d, J = 10.0 Hz) 
118.8 6.63 
(d, J = 9.9 Hz) 
118.8 
4a -- 108.1 -- 109.2 
5 -- 155.2 -- 155.2 
6 6.08 (s) 109.3 6.14 (s) 109.4 
7 -- 140.4 -- 140.4 
8 6.14 (s) 109.2 6.08 (s) 109.2 
8a -- 154.2 -- 154.1 
9 1.73 – 1.64 (m) 41.7 1.68 (m) 41.7 
10 2.19 – 2.14 (m) 23.9 2.16 (m) 23.9 
11 5.29  
(t, J = 7.2 Hz) 
130.6 5.29 (m) 130.6 
12 -- 130.7 -- 130.7 
13 3.02 (s) 56.0 3.02 (s) 56.0 
14 -- 201.9 -- 201.9 
15 6.18 (br s) 123.9 6.18 (m) 123.9 
16 -- 157.8 -- 157.8 
17 2.11 (s) 20.8 2.11 (s) 20.8 
18 1.88 (s) 27.7 1.88 (s) 27.7 
19 1.33 (s) 26.6 1.33 (s) 26.6 
20 1.56 (s) 16.3 1.56 (s) 16.5 










































Synthetic Sample (CDCl3)  
George et al. (2021) 
Natural Sample (CDCl3) 
Hou et al. (2019)9 








2 -- 83.0 -- 83.0 
3 2.68 (t, J = 8.8 Hz) 40.6 2.68 (t, J = 8.8 Hz) 40.6 
4 3.38 (d, J = 9.6 Hz) 34.2 3.38 (d, J = 10.0 Hz) 34.3 
4a -- 108.0 -- 108.0 
5 -- 156.2 -- 156.2 
5-OH 9.25 (s) -- -- -- 
6 6.39 (s) 110.4 6.39 (br s) 110.4 
7 -- 138.2 -- 138.2 
8 6.27 (s) 110.8 6.27 (br s) 110.8 
8a -- 154.6 -- 154.6 
9 2.08 – 2.02 (m) 
1.56 – 1.51 (m) 
38.5 2.04 (m) 
1.54 (m) 
38.6 
10 1.80 – 1.73 (m) 
1.66 – 1.59 (m) 
24.8 1.76 (m) 
1.63 (m) 
24.8 
11 2.31  
(td, J = 8.4, 2.9 Hz) 
46.9 2.31  
(td, J = 8.4, 2.4 Hz) 
47.0 
12 -- 41.7 -- 41.8 
13 2.97 (d, J = 17.7 Hz) 
2.79 (d, J = 17.7 Hz) 
58.7 2.97 (d, J = 17.6 Hz) 
2.79 (d, J = 17.6 Hz) 
58.7 
14 -- 203.1 -- 203.1 
15 6.11 (s) 124.2 6.11 (br s) 124.2 
16 -- 159.6 -- 159.6 
17 1.92 (s) 28.2 1.93 (br s) 28.2 
18 2.20 (s) 21.5 2.21 (br s) 21.5 
19 0.84 (s) 15.5 0.84 (s) 15.5 
20 1.31 (s) 26.3 1.32 (s) 26.3 






































Synthetic Sample (CDCl3)  
George et al. (2021) 
Natural Sample (CDCl3) 
Hou et al. (2015)5 








2 -- 83.9 -- 83.9 
3 2.60  
(dd, J = 9.0, 8.0 Hz) 
39.1 2.59  
(dd, J = 9.0, 8.0 Hz) 
39.1 
4 3.18  
(d, J = 9.3 Hz) 
36.5 3.17  
(d, J = 9.0 Hz) 
36.6 
4a -- 109.6 -- 109.6 
5 -- 154.2 -- 154.2 
5-OH 5.35 (br s) -- 5.42 (br s) -- 
6 6.25 (s) 109.6 6.25 (br s) 109.6 
7 -- 137.8 -- 137.8 
8 6.33 (s) 111.9 6.33 (br s) 111.9 
8a -- 154.5 -- 154.6 
9 1.60 – 1.56 (m) 
1.98 – 1.90 (m) 
39.5 1.94 (m) 
1.58 (m) 
39.5 
10 1.66 – 1.61 (m) 
1.75 – 1.68 (m, 1H) 
26.9 1.72 (m) 
1.63 (m) 
26.9 
11 2.62  
(td, J = 8.0, 2.6 Hz) 
47.0 2.62 (m) 47.0 
12 -- 41.7 -- 41.7 
13 2.42 (d, J = 18.3 Hz) 
2.47 (d, J = 18.3 Hz) 
45.6 2.41 (d, J = 18.6 Hz) 
2.49 (d, J = 18.6 Hz) 
45.6 
14 -- 201.6 -- 201.6 
15 5.89 – 5.88 (m) 125.0 5.89 (br s) 125.0 
16 -- 154.4 -- 154.4 
17 1.78 (s) 27.7 1.78 (br s) 27.7 
18 2.04 (s) 20.7 2.04 (br s) 20.7 
19 1.54 (s) 30.5 1.53 (s) 30.5 
20 1.32 (s) 26.4 1.32 (s) 26.4 

































4.4.4 NMR Spectra 
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Chapter Five – Biomimetic Synthesis of Nyingchinoids A, B, D  
and Rasumatranin D 
*This work was completed with help from Mr Jacob Hart (who assisted the synthesis of Nyingchinoids A, B and 
D) and Mr. Aaron Day (for stereochemistry discussions). Biological testing was done by Ornella Romeo and Dr. 
Danny Wilson from the School of Biological Sciences, University of Adelaide* 
 
5.1 Introduction 
5.1.1 Isolation of Nyingchinoids A, B, D and Rasumatranin D 
In 2017, Wang et al. reported the bibenzyl-based meroterpenoids rasumatranins A – D (5.1 – 5.4) 
isolated from the Chinese liverwort Radula sumatrana (Figure 5.1).1 A year later the structurally 
similar Nyingchinoids A – H (5.5 – 5.8) isolated from the flowering plant Rhododendron nyingchiense 
were disclosed by Huang and co-workers.2 These natural products were each identified as scalemic 




Figure 5.1 – Rasumatranins A – D and Nyingchinoids A – H1, 2 
5.1: rasumatranin A 5.2: rasumatranin B 5.3: rasumatranin C
5.5: nyingchinoids A 5.6: nyingchinoids B
5.7: nyingchinoid C 5.8: nyingchinoid D 5.9: nyingchinoid E 3S
5.10: nyingchinoid H 3R




















































































5.1.2 Identification of Anthocyanidins in the Rhododendron Nyingchiense Species 
Continuing our investigations into compounds isolated from the Rhododendron genus, we began 
investigating other common co-isolated natural products. Specifically, we became interested in the 
pigment responsible for the red-purple flower colour in Rhododendron nyingchiense; one of the major 
ornamental characteristics of all Rhododendron plants) (Figure 5.2).3  
 
 
Figure 5.2 – Different Flowering Rhododendron Species (Image from Du et al.)3 
 
These pigments are largely derived from flavonol and anthocyanin compounds, isolated from the 
petals of a range of different Rhododendron species including Rhododendron agastum, fortunei, 
chihsinianum, strigosum and rubiginosum to name a few. In 2016, Liu and co-workers reported the 
co-isolation of 7 flavonols and 3 different anthocyanins from Rhododendron nyingchiense; cyanidin-3-
O-arabinoside (5.14), cyanidin-3-O-glucoside (5.15) and cyanidin-3-O-glucoside-5-O-arabinoside 
(5.16) (Figure 5.3).4 
 421 
 
Figure 5.3 – Cyanidins from Rhododendron nyingchiense4 
 
Recently, Guo et al. reported the first visible light induced decarboxylation alkylation of heterocycles 
5.17 and aliphatic carboxylic acids 5.18 using the simplest anthocyanidin analogue cyanidin (5.19) to 




Scheme 5.1 – First Reported Example of a Photocatalyzed Anthocyanin Reaction5 
 
This use of cyanidin (5.19) as a photoredox catalyst prompted us to question the role of analogous 
anthocyanidins (5.14 – 5.16) (co-isolated with the nyingchinoid family of natural products) both in 
broader plant metabolism and in providing insight into the possible biosynthesis of nyingchinoids A, 
B, and D and rasumatranin D via photoredox catalysis.  
 
5.1.3 Photoredox Catalysis 
Photoredox catalysis is the conversion of visible light into chemical energy through excitation of a 
sensitiser and a single electron transfer (SET) reaction.6 This leads to the formation of radical 
substrates which can access unique modes of reactivity that would not otherwise occur. Once this 
redox process has occurred, the catalyst relaxes back its ground state and can be regenerated to turn 


































































The simplified concept of photoredox catalysis is described below (Figure 5.4). Here visible light 
absorption, and a spin-allowed metal to ligand charge transfer (MLCT) allows the catalyst [Ru(bpy)3]2+ 
to enter an excited state. Intersystem crossing (ISC) then occurs to afford a highly reactive triplet 




Figure 5.4 – Reactivity of the Photoredox Catalyst [Ru(bpy)3]2+  
These photoredox catalysts can be classified into three major classes: transition metal complexes, 
organic dyes, and semiconductors.6 They can act as both strong oxidants and reductants providing 
unique reaction environments and facilitating the ability to access new chemical reactivities.  
In the case of transition metal photocatalysts, the oxidative or reductive power can be fine-tuned 
through careful choice of the metal (i.e. Ru, Ir, Ti, Cu) and ligands used (often polypyridyl) (Figure 5.5). 
As a general rule the oxidative and reductive power is largely influenced by the ligands.7 Indeed, the 
synthesis of these catalysts is typically synthetically straightforward, and a wide range of substitution 
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Figure 5.5 – Oxidative and Reductive Power of Ruthenium Based Photoredox Catalysts 
 
Organic photoredox catalysts have also been extensively reported in the literature, providing some 
advantage over transition metal photoredox catalysts; primarily due to their low toxicity, higher 
tolerance towards moisture, and not needing the presence of rare and precious metals.9, 10 Common 
examples include those photosensitisers previously described in chapter three; rose bengal (RB) 
(5.21), methylene blue (MB) (5.22), tetraphenyl porphyrin (TPP) (5.23), and fluorescein (5.24) (Figure 
5.6). Alongside more heavily developed photocatalysts such as the acridiniums (i.e. 5.25),11 perylene 
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Figure 5.6 – Common Examples of Organic Photoredox Catalysts 
 
5.1.4 A Brief History of Photoredox Catalysis 
Stories of scientific discovery often begin with a lightbulb moment. Ironically for photoredox catalysis 
this story begins with an actual lightbulb. In 1978 Hedstrand and co-workers reported a [Ru(bpy)3]Cl2 
visible light catalyzed reduction of sulfonium ions (5.28) into alkanes (5.29) using N-substituted 1,4-
dihydropyridines (5.30) (Scheme 5.2).14 
 
 
Scheme 5.2 – First Reported Example of Photoredox Catalysis14 
 
Shortly after, between the years 1981 and 1990 Fukuzumi, Hironaka, Ishitani and Pac reported similar 
[Ru(bpy)3]Cl2 photocatalyzed catalyzed reductions.15 - 17 While the first oxidative photoredox catalyzed 
reaction was discovered in 1984 by Deronzier and Cano-Yelo using an aryl diazonium salt 5.31 for the 
conversion of alcohols 5.32 into their corresponding aldehydes 5.33 (Scheme 5.3).18 Deronzier also 

































R1 = H, t-Bu, OMe












R4 = H, Br, F, Ph, OMe, NO2























went on to disclose the first photoredox redox neutral transformation through a [Ru(bpy)3Cl2] 
mediated Pschorr reaction.19  
 
 
Scheme 5.3 – First Reported Oxidative Photoredox Catalyzed Reaction18 
 
Further work by Okada, then described the preparation of N-(acyloxy)phthalimides 5.34 from 
carboxylic acids and their use as alkyl radical intermediates which can be intercepted for a diverse 
range of chemical transformations (Scheme 5.4).20 - 23 In these reactions a single electron reduction 
with a photoexcited catalyst affords phthalimide, CO2 and the carbon radical 5.35, which can undergo 
a variety of reactions including chlorination (i.e 5.36), phenyl-selenenylation (i.e. 5.37), hydro-
decarboxylation (via a hydrogen atom extraction from t-butyl thiol) (i.e. 5.38) and conjugate additions 


























































Remarkably, despite early demonstrations into the direct application of photoredox catalysis in 
organic synthesis this area remained relatively unexplored for the next 15 years, with ruthenium 
polypyridyl catalysts only being used in the area of solar cell research.24 It was not until 2008 when 
both MacMillan and Yoon independently published separate papers using visible light photoredox 
catalysis that its significance was fully realized. Work by MacMillan and his postdoctoral researcher 
David Nicewicz (whose catalysts will be explored later in this chapter, vide infra) focused on the 
formation of an enantioselective 𝛼-alkylation of aldehydes 5.40 (Scheme 5.5).25 This was achieved 
through a dual organocatalytic and photoredox catalytic cycle, combining two approaches in one 
sequence. Use of the ruthenium photoredox catalyst [Ru(bpy)3]Cl2 and an organic catalyst allowed the 




Scheme 5.5 – MacMillan and Nicewicz’s Enantioselective 𝜶-Alkylation of Aldehydes25 
 
In 2008, in a completely unrelated area of chemistry Yoon’s group reported a reversible photoredox 
catalyzed intramolecular [2+2] cycloaddition of the bis-styrenes 5.43 employing [Ru(bpy)3]Cl2 and the 




Scheme 5.6 – Intramolecular [2+2] Bis-enone Cycloaddition Reaction26 
 
Shortly after, Narayanam et al. disclosed a dehalogenation reaction of 𝛼-acyl and benzylic halides.27 





























63 – 93% yield

















54 – 98 % yield
4:1 → 10:1 dr
[2+2] cycloaddition
 427 
co-workers reported the reductive dehalogenation of C3 bromopyrrolindolines in the divergent 
synthesis of the drimentine alkaloids A, F, and G (5.45 – 5.47) (Scheme 5.7).28 This synthesis featured 
a uniquely effective intermolecular radical 1,4-addition of 5.48 with the conjugate acceptor 5.49 to 
afford 5.50. The divergent synthesis of drimentines A, F and G was then realized through deprotection 
and amidation to give 5.51, followed by deprotection/ annulation, reduction and dehydration.  
 
 
Scheme 5.7 – Total Synthesis of Drimentines A, F and G Through Photoredox Catalysis28 
 
Today photoredox catalysis is currently one of the most popular areas in organic chemistry, with the 
number of publications increasing by a factor of 10 in less than 5 years. Photoredox catalysis has 
become a powerful strategy for the activation of small molecules and generation of reactive radical 
intermediates, leading to the development of new chemical transformations and umpolung reactivity.  
 
5.1.5 Photoredox Catalyzed [2+2+2] Cycloadditions 
Both the Nicewicz and Yoon groups have employed photoredox catalyzed [2+2+2] cycloadditions of 
triplet oxygen with distonic cation radical intermediates in the synthesis of endoperoxides.29, 30 In the 
Yoon group this was achieved using polypyridyl ruthenium (II) catalysts to synthesise endoperoxides 





































5.45: drimentines A (R1 = i-Bu, R3 = H)
         23% (over 5-steps)
5.46: drimentines F (R1 = i-Pr, R3 = Me)
         25% (over 5-steps)
5.47: drimentines G (R1 = i-Pr, R3 = H) 





































Scheme 5.8 – Yoon’s Ru(bpz)32+ catalyzed [2+2+2] Cycloadditions of Bis(enone) substrates29 
 
Almost simultaneously, Nicewicz and Gesmundo disclosed similar [2+2+2] cycloadditions. They found 
that using the triarylpyrylium salt 5.56 catalyst, they were able to increase the substrate scope to non-
styrene compounds (Scheme 5.9). The authors also observed that electron rich arenes 5.57 were 





Scheme 5.9 – [2+2+2] Cycloadditions Using the Triarylpyrylium 5.6230 
 
Intrigued by these [2+2+2] cycloadditions obtained from readily oxidizable olefins, alongside the 
presence of the co-isolated and cyanidins (5.14 – 5.16) as potential photoredox catalysts we 
considered the possibility that a similar photoredox catalyzed reaction may be occurring in nature for 































































5.1.6 Biogenic Relationships Between Nyingchinoid A, B, D and Rasumatranin D 
We were particularly interested in the biosynthetic relationships between nyingchinoids A, B and D 
and the possible biosynthetic precursor, chromene 5.59. In chapter four the 6-6-5-4 ring system, was 
extensively discussed being arguably the most common scaffold in Rhododendron natural products. It 
is most likely that nyingchinoid D (5.8) is formed through a visible light catalyzed intramolecular [2+2] 




Scheme 5.10 – Proposed Biosynthesis of Nyingchinoid D Through a [2+2] Cycloaddition 
 
What is less clear is the biosynthetic link between nyingchinoids A, B and chromene 5.59. One 
possibility is the formation of a 1,2-dioxane 5.60 arising from a photoredox catalyzed [2+2+2] 
cycloaddition between triplet oxygen the chromene and prenyl alkene of 5.61 (Scheme 5.11). 
Dearomatization of endoperoxide 5.60 through O-O cleavage would then afford nyingchinoid B (5.6). 
While a nucleophilic attack to the spiroepoxide would afford the ring expansion product nyingchinoid 
A (5.5) through C-C bond scission. In nature, these types of reactions would most likely occur in 
chlorophyll photosystems which possess unique oxidative environments to facilitate cascades not 


























































We also suspect that the structurally similar rasumatranin D (5.4), might in fact be misassigned (Figure 
5.7). We were suspicious of the reported syn stereochemistry across the C3 and C11 ring junction in 
the NMR spectra, which was different to that of nyingchinoid A (5.5). Additionally, the bibenzyl 
substitution pattern around the aromatic ring seemed dubious due to its differing regiochemistry 
when compared to the other rasumatranin co-isolated natural products (5.1 – 5.3).  
 
 
Figure 5.7 – Proposed Structural Revision of Rasumatranin D 
 
Applying photocatalysts we hope to mimic our proposed biosynthesis and describe investigations into 
the biomimetic synthesis of nyingchinoids A, B, D and synthesis and structural revision of rasumatranin 
D. We also hoped that this synthesis could allow us to develop a bio-inspired approach towards some 
novel endoperoxides, which could possess some interesting antimalarial properties.    
 
5.1.7 A Bio-Inspired Approach Towards Antimalarial Endoperoxides 
Annually, there are approximately 228 million cases and 405,000 deaths due to malaria disease.31 
Current anti-malarial medications, including those treating the highly resistant Plasmodium 
falciparum, are heavily reliant on the natural product artemisinin (5.61) and artemisinin-based 
combination therapies (ACTs) (Figure 5.8).32 Recently, several Southeast Asian countries have 
reported parasites with decreased sensitivity to ACTs.33 Thus, the discover of new bio-inspired 
endoperoxides remains a significant interest.  
 
 




































































It is the unusual peroxide bridge in ACTs which acts as a pharmacophore, undergoing homolytic 
cleavage when exposed to haemoglobin.34 This results in the formation of reactive oxygen species 
(ROS) (i.e. hydroxyl radicals and superoxide anions) which exclusively damage malaria specific proteins 
and result in parasitic death.  
 
As we hope to generate chromene derived endoperoxides in the synthesizing nyingchinoids A, B, D 
and rasumatranin D, we envisaged that this project could be expanded through the synthesis of a 
diverse library of endoperoxide analogues (Scheme 5.12). Not only will this allow for the rapid 
generation of substrates, but it will also allow for the easy functionalization of these analogues based 
on resultant structure activity relationships (SAR). If successful we hope that these molecules could 
be used to improve drug treatment approaches for malaria.  
 
 
Scheme 5.12 – A Divergent Approach Towards the Synthesis of Endoperoxides  
 
 
5.2 Results and Discussion 
5.2.1 Total Synthesis of Nyingchinoids A, B and D 
The biomimetic synthesis of nyingchinoids A (5.5), B (5.6), and D (5.8) began with the synthesis of the 
racemic chromene 5.59 through a 1-step condensation of orcinol (5.67) with citral according to a 
literature procedure (Scheme 5.13).35 Conversion of chromene 5.59 into the endoperoxide 5.60 using 
a variety of oxidation conditions was attempted, however direct attempts to oxidise 5.59 to a phenoxy 
radical using standard photoredox conditions (in the presence of O2) only afforded decomposition. 
Instead, 5.59 was protected as the TBS-ether 5.68 in 75% through reaction with TBSCl and imidazole 
in DMF. 
 
Scheme 5.13 – Synthesis of the TBS Protected Chromene 5.68 






































Exposure of 5.68 to conditions known to generate singlet oxygen (e.g. methylene blue, O2, MeOH, 
visible light) gave products (5.69 and 5.70) formed exclusively by oxygenation of the prenyl motif, 
rather than reaction at the chromene (Scheme 5.14). This was perhaps unsurprising as similar results 
were previously observed in chapter three (vide supra).36 
 
 
Scheme 5.14 – Reaction of Chromene 5.68 With Singlet Oxygen 
 
Instead, treatment of 5.68 using conditions developed by Nicewicz (4-MeO-TPT (5.56) photocatalyst, 
1 atm O2, blue LED, DCE) gave, cyclobutane 5.71 after 20 minutes as the exclusive product observed 
in the crude 1H NMR spectrum (Figure 5.9). After purification, 5.71 was isolated in 87% yield. 
Treatment of 5.71 with TBAF the afforded nyingchinoid D (5.8) in 86% yield. Additionally, a one-pot, 
2-step procedure was successful for the direct conversion of 5.68 into 5.8, which was achieved in a 
51% yield. To our delight, on repeating this [2+2] cycloaddition we observed gradual formation of the 
key endoperoxide 5.72 (as a single diastereoisomer) when the reaction was run for 7 hours, allowing 
us access to 5.72 in 60% yield (Scheme 5.15). 
 



















































Pleasingly, treatment of endoperoxide 5.72 with TBAF formed nyingchinoid B (5.6) in 92% yield via 
deprotection through formation of an intermediate phenoxide anion, which dearomatized and 
underwent O-O cleavage to afford the spiroepoxide nyingchinoid B (5.6) (Scheme 5.15). An acid 
catalyzed C-C cleavage and aromatization using TFA in CH2Cl2 then gave nyingchinoid A (5.5) in 58% 
yield.  
 
Next our efforts turned towards the transformation of chromene 5.68 to form 5.6 and 5.5 in a one-
pot procedure. Gratifyingly, photoredox catalyzed aerobic [2+2+2] cycloaddition of 5.68 followed by 
the direct addition of TBAF afforded 5.6 in 61% yield, while addition of TBAF followed by TFA gave 5.5 
in 53%. The last sequence of 5.68 into 5.5 involves the construction of 2 rings, 3 stereocentres, 4 C-O 
bonds and 1 C-C bond, alongside the scission of 1 O-O bond and 1 C-C bond! 
 
 
Scheme 5.15 – Biomimetic Synthesis of Nyingchinoids A, B and D 
 
Pleasingly, our obtained NMR spectra of 5.5, 5.6 and 5.8 matched that previously reported by Hou 
and co-workers.2 Additionally, we obtained crystal structures of nyingchinoids A and B to 










































20 min: 5.71 (87%)





























Figure 5.10 – X-Ray Structure of Nyingchinoids A and B 
 
These results clearly indicated the photoredox catalyzed intramolecular [2+2] cycloaddition of 5.68 to 
be reversible. Indeed, we found that re-treating cyclobutane 5.71 to 4-MeO-TPT (5.56) under aerobic 
conditions formed enone 5.72 in 71% yield, with epimerization at C11 indicating that cycloreversion 
had occured before the [2+2+2] cycloaddition. In previous studies of photocatalytic, intermolecular 
[2+2] cycloadditions of electron-rich styrenes, Yoon has also observed the reversibility of similar 
cyclobutane reactions when using the highly oxidizing photocatalyst Ru(bpz)32+ (vide supra) (Scheme 
5.8).26  
With this in mind, a mechanistic cycle for the aerobic [2+2+2] cycloaddition of 5.68 that incorporates 
a reversible [2+2] cycloaddition is described herein (Scheme 5.16). First, we propose the photocatalyst 
5.59 is activated by blue LED light to afford the photoexcited 4-MeO-TPT*, containing a high oxidation 
potential (+1.74 V) capable of oxidizing the electron-rich chromene 5.68 through a single electron 
transfer (SET) to give radical cation 5.73. 5-exo-trig cyclization of 5.73 would then generate the 
diastereomeric, distonic radical cations 5.74 and 5.75. Diastereomer 5.74 has syn-stereochemistry 
across the C3 and C11 carbons and is primed to undergo further cyclization to give 5.76, followed by 
reduction to give 5.71 as the kinetic product. Based on experimental results, we believe these 
transformations to be reversible through re-oxidation of 5.71 by 4-MeO-TPT* and reversion to 5.73 
through a retro-[2+2] of 5.74. Alternatively, due to the anti-stereochemistry across the C3 and C11 
carbons 5.75 is unable to undergo reductive cyclization, instead 5.75 it is trapped by triplet oxygen to 
give 5 the peroxy radical cation 5.77. Single electron reduction of 5.78 then affords the 
thermodynamic product 5.72.  
 
With the assistance of Assoc. Prof. David M. Huang computational modeling using density functional 
theory (DFT) showed that this stepwise mechanistic pathway was supported, indicating both 5-exo-
trig cyclizations of radical cation 5.73 to be reversible, hence confirming 5.72 as the thermodynamic 
product.  
 




5.2.2 Total Synthesis and Structural Revision of Rasumatranin D 
Next, our efforts turned towards the total synthesis of rasumatranin D (5.4). Although there was no 
accompanying X-ray structure of 5.4, close inspection of the reported NMR spectra of nyingchinoid A 
(5.5) suggested two major areas of structural reassignments were required (Figure 5.11).  
 
 
Figure 5.11 – Proposed Structural Revision of Rasumatranin D 
 
Firstly, comparison of the NMR spectra of nyingchinoid A (5.5), whose structure has been 
unambiguously proven by X-ray crystallography, with that of the previously reported and co-isolated 
natural product o-bibenzyl-cannabicyclol (5.79), suggested that the substitution pattern around the 
aromatic ring was incorrect.37 In fact, rasumatranin D (5.4) is the only member of the rasumatranin 
family with differing regiochemistry regarding the chromene and the bibenzyl side chain. Careful 
examination of the HMBC spectra of the originally proposed rasumatranin D (5.4) shows discrepancies 
with the key correlations (Figure 5.12).  
 
Specifically, we were intrigued by the report of H6 to C16 coupling and suspicious lack of coupling 
between H8 and C16. As these two HMBC correlation should be equidistant it is unlikely looking at the 
originally proposed structure for 5.5 that the H8 and C16 correlation is absent. However, if the 
bibenzyl fragment was aligned with that the previous reported rasumatranin natural products the only 
interaction observed would indeed be the H6 to C16 correlation. Additionally, they also observed an 
unlikely long range 4J coupling between H8 and C5. Instead in our revised structure 5.13 this would be 
a more plausible 2J coupling between H8 and H7. These correlations provide evidence for a revised 
regiochemistry of rasumatranin D (5.13).  
 








































































Secondly, our mechanistic proposal for the [2+2] and [2+2+2] cycloadditions of the chromene 5.68, 
and the requirement of the anti-stereochemistry across the C3 and C11 carbons to impede reductive 
cyclization suggested that the relative configuration at C11 should be reassigned to as in 5.13 
(analogous to nyingchinoid A). Specifically, it was the coupling constant of 14 Hz between H3 and H11 
and the absence of a NOE interaction, which strongly indicated a trans relationship at this ring 
junction. We therefore proposed a structural reassignment of 5.4 to 5.13, which additionally provide 
more clarity into the proposed biosynthesis. 
 
Following known literature procedures by Svenson and co-workers, synthesis of the revised structure 
of rasumatranin D (5.13) commenced from reaction of benzyl bromide (5.80) with triphenyl phosphine 
to afford the phosphonium salt 5.81 in 75%.38 Wittig olefination between 5.81 and 3,5-
dimethoxybenzaldehyde (5.82) then gave E-3,5-dimethoxy stilbene (5.83) in 64%. Hydrogenation of 
5.83 using H2 and Pd/C afforded 5.84 in 91%, and deprotection with HBr afforded the bibenzyl 
resorcinol 5.85 in 66% (Scheme 5.17). 
 
 
Scheme 5.17 – Synthesis of the Bibenzyl Resorcinol 5.8538 
 
Next, conditions towards the chromenylation of 5.85 to give the ortho-bibenzyl chromene (5.86) were 
screened. Unfortunately reflux of 5.85 with citral, Ca(OH)2 in EtOH only gave decomposition, while 
reflux in PhMe with citral and 10 mol% EDDA afforded only the para-bibenzyl chromene (5.87) and 
the bis-chromene (5.88). Instead following a modified literature procedure from Crombie et al. 
PPh3 BrBr
PPh3, PhMe
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reaction of 5.85 with pyridine and citral at reflux afforded both 5.87 and a small amount of 5.86 in 
17% (Scheme 5.18).37 
 
Scheme 5.18 – Synthesis of the ortho-bibenzyl chromene 5.8637 
 
Next, 5.89 was synthesised by TBS-protection of chromene 5.86 through reaction with TBSOTf and 
catalytic 2,6-lutidine in 53% (Scheme 5.19).  
 
 
Scheme 5.19 – TBS protection of 5.86 to 5.89 
The key photoredox catalyzed aerobic [2+2+2] cycloaddition of 5.89, using the same conditions 
previously described, then afforded the endoperoxide 5.90 (Scheme 5.20). Treatment of 5.90 with 
TBAF formed the nyingchinoid B analogue 5.91 (presumably an undiscovered natural product), which 
gave rasumatranin D (5.13) on exposure to TFA. Gratifyingly the obtained NMR data for 5.13 showed 
excellent agreement with the published data for natural rasumatranin D, confirming our proposed 
structural revision.1 An efficent one-pot conversion of 5.89 into 5.13 was also achieved in 49% yield. 
 
In a similar vein to the nyingchinoid system, we found the photoredox catalyzed [2+2] cycloaddition 
of 5.89 using the 4-MeO-TPT (5.56) photocatalyst to be reversible. If the reaction was quenched and 
purified after 20 mins, we obtained 5.92 in 72%. Deprotection of 5.92 with TBAF at room temperature 
then gave the co-isolated natural product o-bibenzyl cannabicyclol 5.93 in 22%. However, we found 







































Scheme 5.20 – Synthesis of the Revised Structure of Rasumatranin D 
 
5.2.3 Investigation into the Reversibility of Photoredox [2+2] Cycloadditions 
After having successfully synthesized nyingchinoids A, B, D and rasumatranin D, our interest turned 
towards the reversibility of photoredox catalyzed [2+2] and aerobic [2+2+2] cycloadditions. We were 
especially interested in revisiting work by Yoon and Nicewicz to determine if these reactions were 
occurring as competing or reversible reactions.30, 31 This was in part driven by our findings into the 
reversible nature of [2+2] cycloadditions in both the nyingchinoid and rasumatranin systems.  
 
As a short mechanistic study, we gained access to the two bis(styrene) substrates (5.94), through 
coupling of an allylic bromide (5.95) with either the phenyl (a) or p-methoxy cinnamyl (b) alcohols 




Scheme 5.21 – Synthesis of bis(styrene) substrates 5.94 
 
With 5.94 in hand both bis(styrenes) were screened for reversibility (Table 5.1). The phenyl substrate 
5.94a was reacted following modified procedures from Yoon et al. employing the [Ru(bpz)3][PF6]2 











































20 min: 5.92 (72%)




























0 °C → rt, 16 h
5.94a R = H (12%)
5.94b R = OMe (45%)
R R
5.96a R = H
5.96b R = OMe
 440 
despite leaving this reaction for extended periods none of the expected reversibility was observed. 
Instead, these reactions gave slow decomposition rather than an increased yield of the endoperoxide 
5.97a (entries 1 − 4). Treatment of 5.94a following conditions developed by Nicewicz also showed 
comparable results, giving only a minor improvement in the yield of 5.97a when left for 4 h (entries 5 
– 7). The p-OMe bis(styrene) 5.94b showed similar results to 5.94A, albeit with slightly lower yields 




Table 5.1 – Key Investigations into the Reversibility of [2+2] Photoredox Cycloadditions 
 
 
Entry R Conditions Solvent Catalyst 5.97 5.98 5.99 RSM 
1 H O2, 1 h, 0 °C 
visible light 
MeNO2  [Ru(bpz)3][PF6]2 -- -- trace 91% 
2 H O2, 2 h, 0 °C 
visible light 
MeNO2  [Ru(bpz)3][PF6]2 44% 20% trace 17% 
3 H O2, 4 h, 0 °C 
visible light 
MeNO2  [Ru(bpz)3][PF6]2 10% 10% trace 40% 
4 H O2, 5 h, 0 °C 
visible light 
MeNO2  [Ru(bpz)3][PF6]2 13% 9% trace 11% 
5 H O2, 1 h 
−	41 °C 
blue LED 
CH2Cl2 5.56: 4-MeO-TPT 
(2 mol%) 
24% trace -- 26% 
6 H O2, 2 h 
−	41 °C 
blue LED 
CH2Cl2 5.56: 4-MeO-TPT 
(2 mol%) 
21% trace -- 25% 
7 H O2, 4 h 
−	41 °C 
blue LED 
CH2Cl2 5.56: 4-MeO-TPT 
(2 mol%) 
37% trace -- 0% 
8 OMe O2, 1 h, 0 °C 
visible light 
MeNO2  [Ru(bpz)3][PF6]2 4% 7% trace 53% 
9 OMe O2, 2 h, 0 °C 
visible light 
MeNO2  [Ru(bpz)3][PF6]2 19% 20% trace 20% 
10 OMe O2, 5 h, 0 °C 
visible light 






















a R = H




Interestingly it was observed that the crude 1H NMR using Yoon’s [Ru(bpz)3][PF6]2 photoredox 
catalyzed conditions showed trace of the aryl tetralones 5.99. Looking through the literature we found 
a previous report by Liu and co-workers who used a TiO4 photoredox cyclization of bis(styrenes) 5.100 




Scheme 5.22 – Liu’s TiO4 Mediated Cyclization of bis(styrenes) 5.10039 
 
Not long after our findings further work by Xiang et al. was disclosed showing more detailed insights 
into a similar photoredox catalyzed mechanism behind the synthesis of a related compound 5.102 
(Scheme 5.23).40 This reaction is proposed to occur through oxidation of 5.100 by the excited 
acridinium salt [(Mes-AcrMe)BF4-]* 5.103* to afford the radical cation 5.104. An intramolecular [2+2] 
cycloaddition would then give 5.105 which would go on to give the Z cyclobutane 5.106. A reversible 
re-oxidation with 5.103* could regenerate 5.105 which upon cleavage of the benzylic C-C bond would 
afford 5.107. Next cycloreversion would give 5.108 followed by a SET ring closure which would give 
the more thermodynamically stable reversible formation of E cyclobutane 5.109. Additionally, 5.107 
could also undergo an electrophilic or radical cyclization via the transition state 5.110 to provide the 
radical cation 5.111. Deprotonation of 5.111 through reaction with thiophenolate would then afford 
the radical 5.112. Finally, an intermolecular hydrogen atom abstraction would provide the endo-Diels-
Alder adduct 5.102 or in the case of our findings and work by Liu this species could be intercepted 

















X = O, C














Finally, the obtained cyclobutanes 5.98 were attempted to react under photoredox conditions in hope 
of forming the endoperoxides 5.97. Unfortunately, these reactions only gave decomposition proving 
unequivocally that these reactions were indeed not reversible (Scheme 5.24).  
 
 
Scheme 5.24 – Attempted Synthesis of Endoperoxides 5.97 from Cyclobutanes 5.98 
 
5.2.4 Synthesis and Evaluation of Antimalarial Endoperoxides 
Having achieved the total synthesis of nyingchinoids A, B, D and rasumatranin D, and having 
investigated the reversibility of these reactions, our investigations turned towards the synthesis of a 
library of endoperoxide analogues. Four different chromenes (5.113 – 5.116) were synthesized in good 
to excellent yields by employing standard chromenylation conditions through condensation of various 
phenols (5.117 – 5.119) with citral in the presence of either catalytic EDDA, or PhB(OH)2 and AcOH 
(Scheme 5.25).41 – 47 
 
 
Scheme 5.25 – Synthesis of Various Chromenes 5.113 – 5.115 
 
Next, the phenol chromenes (5.116 and 5.116), alongside the previously synthesised nyingchinoid 
chromene 5.59 and the resorcinol chromene 5.120* were protected using standard conditions either 
through benzylation, methylation or/ and TBS protection. This allowed us divergent access to a library 
of chromenes 5.121 – 5.130 (Scheme 5.26). 
 
*5.120 was synthesized according to a literature procedure from Katakawa and co-workers and a small sample was gifted to 












a R = H











AcOH, PhMe, 110 °C
5.117: (R1 = Bn, R2 = Bn)





5.119: olivetol (R2 = Am)
5.67:   orcinol (R2 = Me)
5.113: (R1 = Bn, R2 = OBn ) 60%
5.114: (R1 = Me, R2 = OMe) 89%
5.115: (R1 = H, R2 = Me) 82%
5.116: cannabichromene 












Scheme 5.26 – Synthesis of Various Protected Chromenes 5.121 – 5.130 
 
Subsequent treatment of these protected chromenes with the 4-MeO-TPT (5.56) photocatalyst in DCE 
and 1 atm O2 while irradiated with blue LED light afforded the endoperoxides 5.131a – 5.142a 
(Scheme 5.27). Intrestingly, we found no major trend between the electronics of these chromenes 
and the yields. We did however observe that three of the photoredox reactions afforded the 
cyclobutane products 5.133b, 5.134b and 5.142b, even when these reactions were left for extended 
time periods (over 6 h). This suggested that the initial 5-exo-trig reactions were occurring in a non-
reversible manner. It also became clear to us that the more sterically hindered benzyl and Amyl 
functional groups were not well tolerated.  
TBSCl, imidazole
CH2Cl2, 8 h, rt
OR
 TBSOTf, 2,6-lutidine 













5.121: (R1 = Me, R2 = OBn) quant.
5.122: (R1 = OBn, R2 = Me) quant.
5.123: (R1 = OBn, R2 = Am) 37%
benzyl protection
BnBr, TBAI
THF, 0 ºC → rt
5.128: (R1 = OTBS, R2 = H) 56%
5.129: (R1 = OTBS, R2 = Me) 70%





5.59:   (R1 = Me, R2 = OH)
5.115: (R1 = OH, R2 = Me)
5.120:  (R1 = OH, R2 = H)
5.116: cannabichromene
          (R1 = OH, R2 = Am)
5.124: (R1 = Me, R2 = OMe) 62%
5.125: (R1 = OMe, R2 = Am) 37%
5.126: (R1 = OMe, R2 = Me) 86%








Scheme 5.27 – Synthesis of Key Endoperoxides 5.131a – 5.142a and 5.72a 
 
Finally, a small sample of the endoperoxides 5.131a – 5.142a, alongside the cyclobutane products and 
a selection of the previously described natural products (from chapters two, three and four) were 
tested for antimalarial activity. This was performed in three separate rounds, done in collaboration 
with Ornella Romeo and Dr. Danny Wilson from the School of Biological Sciences, University of 
Adelaide. Initial testing (Figure 5.13) showed promising results, it was observed that the three 
endoperoxides 5.136a (LB15), 5.138a (LB17), 5.140a (LB16) had good ability at reducing parasitic 
growth, with 5.138a and 5.140a having a IC50 of approximately 1 𝜇M.  
 
 5.56: 4-MeO-TPT 
















































































































































Figure 5.13 – Testing of Key Endoperoxides for Antimalarial Activity 
 
In the second round of testing (Figure 5.13) we observed improved results, identifying 4 compounds 
(5.133a (LB35), 5.134a (LB39), 5.135a (LB33) and 5.139a (LB34)) which reduced parasitic growth 
>75% (Figure 5.14)! The IC50 values for these compounds were then compared to that of the 
commercially available drugs used for the treatment of malaria; dihydroartemisinin (DHA) (5.62) and 
chloroquine (5.143). To our delight, the endoperoxide 5.133a (LB35) had an IC50 ≈	0.5 𝜇M. Although 
this result is not as impressive as the commercial drugs, it represented a significant step forward in 
















































Figure 5.14 – Testing of Key Endoperoxides for Antimalarial Activity 
 
In our final testing round, we became interested in the cannabinoid endoperoxides, derived from the 
natural product cannabichromene (5.116) (Figure 5.15). Disappointingly, these endoperoxides did not 
afford as promising results as we had hoped. Only two endoperoxide candidates showing good 
antimalarial activities were observed (5.141a (LB51), and 5.142a (LB52)). These compounds had 











































































Figure 5.15 – Testing of Key Endoperoxides for Antimalarial Activity 
 
5.3 Conclusion 
5.3.1 Future Directions 
One future aim for this project is to expand our total synthesis to include rasumatranins A – C (5.1 – 
5.3) and nyingchinoids E – H (5.9 – 5.12). We serendipitously reported the synthesis of a similar 
scaffold containing this 6–6–6 ring system while working on the total synthesis of the parvinaphthols 
(chapter two, vide supra), and we propose that a similar approach through a selective oxidation could 
allow access to these class of natural products.  
 
This approach would begin from the epoxidation of the chromene ring 5.144 to afford diastereomers 
5.145 and 5.146 (Scheme 5.28). Next, ring opening and formation of the p-QM 5.147 and 5.148, 


















carbocations 5.149 and 5.150 are direct precursors to rasumatranins A – C and nyingchinoids E – H. 
Addition of water to the carbocations would give access to rasumatranin A (5.1) and rasumatranin C 
(5.3) (pathway A, pathway B). While an ene reaction of 5.149 would afford rasumatranin B (5.2), 
nyingchinoid E (5.9) and nyingchinoid H (5.10) (pathway C). Ideally this total synthesis would be 
accompanied by a second challenge, whether or not this could be achieved asymmetrically. Recent 























































5.2: rasumatranin B (R1 = bibenzyl)
5.9: nyingchinoid E (R1 = Me)


























In conclusion, we report the biomimetic synthesis of nyingchinoids A (5.5), B (5.6) and D (5.8), and 
confirm the structural revision of rasumatranin D (5.13). This was achieved through visible light 
photoredox catalyzed [2+2] and [2+2+2] cycloadditions of electron-rich chromenes and further multi-
step dearomatization and ring expansion cascades. Synthesis of nyingchinoids A (5.5) and B (5.6) from 
the common chromene intermediate (5.68) gives good insight into the biosynthesis of these natural 
products through predisposed and highly diastereoselective reactions. Although, investigations into 
the reversibility of related [2+2+2] cycloadditions with bis(styrene) substrates suggests these reactions 
are irreversible, we observed reversibility when performing more similar cycloadditions on chromene 
analogues. This has allowed us to synthesize a family of related endoperoxides, which were found to 


























5.4.1 General Methods 
All chemicals used were purchased from commercial suppliers and used as received. All reactions were 
performed under an inert atmosphere of N2 unless otherwise stated. Thin layer chromatography was 
performed using aluminium sheets coated with silica gel. Visualization was aided by viewing under a 
UV lamp and staining with the appropriate stain followed by heating. All Rf values were measured to 
the nearest 0.05. Flash chromatography was performed using 40-63 micron grade silica gel. Melting 
points were recorded on a digital melting point apparatus and are uncorrected. Infrared spectra were 
recorded using an FT-IR spectrometer as the neat compounds. High field NMR was recorded using a 
600 MHz spectrometer (1H at 600 MHz, 13C at 150 MHz) or a 500 MHz spectrometer (1H at 500 MHz, 
13C at 125 MHz). The solvent used for NMR spectra was CDCl3 unless otherwise specified. 1H chemical 
shifts are reported in ppm on the δ-scale relative to TMS (δ 0.0) and 13C{1H} NMR are reported in ppm 
relative to chloroform (δ 77.16). Multiplicities are reported as (br) broad, (s) singlet, (d) doublet, (t) 
triplet, (q) quartet and (m) multiplet. All J-values were rounded to the nearest 0.1 Hz. ESI high 
resolution mass spectra were recorded on a Q-TOF mass spectrometer. Photochemistry with UVA light 
was performed using a generic brand commercial LED UV light globe; wavelength: 365 nm. 
Photochemistry with UVC light was performed using a generic brand commercial LED UV light globe; 
wavelength: 254 nm. Photochemical reactions with visible light were performed with a conventional 
commercial LED desk lamp at 240 V with a 4 W 5000 K 32 mÅ globe. Reactions conducted under 470 



















To a solution of orcinol (5.67) (10.1 g, 81.4 mmol, 1.0 equiv.) in pyridine (6.70 mL, 6.58 g, 83.2 mmol, 
1.0 equiv.) was added citral (14.8 g, 97.2 mmol, 1.2 equiv.). The reaction was stirred at 80 °C for 22 h, 
then cooled to room temperature, concentrated in vacuo, and purified by flash chromatography on 
SiO2 (4:1 CHCl3/ cyclohexane) to give chromene 5.59 as a clear oil (2.61 g, 12%). Data for 5.59 matched 
that previously reported in the literature.32 
 
Data for 5.59: 
Rf: 0.40 (4:1 CHCl3/ cyclohexane). 
FTIR (neat): 3384, 2968, 1586, 1609, 1461, 1325, 1137, 838 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.47 (d, J = 10.1 Hz, 1H), 6.17 (s, 1H), 6.16 (s, 1H), 5.46 (d, J = 10.1 Hz, 1H), 
5.10 (t, J = 7.1 Hz, 1H), 4.72 (br s, 1H), 2.23 (s, 3H), 2.10 (dt, J = 16.8, 6.7 Hz, 2H), 1.76 – 1.67 (m, 2H), 
1.66 (s, 3H), 1.58 (s, 3H), 1.36 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 155.8, 154.7, 135.2, 131.6, 126.6, 124.2, 119.5, 113.2, 109.2, 101.4, 78.0, 
41.0, 26.2, 25.7, 22.7, 18.4, 17.6 ppm. 




























To a solution of chromene 5.65 (1.27 g, 4.92 mmol, 1.0 equiv.) in DMF (50 mL) was added TBSCl (1.76 
g, 11.6 mmol, 2.4 equiv.) and imidazole (800 mg, 11.6 mmol, 2.4 equiv.). Reaction was left to stir at 
room temperature for 4 h. EtOAc (50 mL) then added, and solution washed with 5% LiCl(aq) (2 × 30 mL), 
sat. NH4Cl(aq) solution (2 × 30 mL) and sat. brine (2 × 30 mL). The solution was dried with MgSO4, filtered 
and concentrated in vacuo. The residue was purified by flash chromatography on SiO2 (30:1 hexanes/ 
Et2O) to give the corresponding TBS chromene 5.68 as a colourless oil (1.38 g, 75%). 
 
Data for 5.68: 
Rf: 0.70 (4:1 hexanes/ EtOAc). 
FTIR (neat): 2957, 2929, 2858, 1604, 1482, 1330, 1252, 1151, 838, 779 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.47 (d, J = 10.0 Hz, 1H), 6.18 (d, J = 2.2 Hz, 1H), 6.16 (d, J = 2.2 Hz, 1H), 
5.46 (d, J = 10.0 Hz, 1H), 5.12 – 5.07 (m, 1H), 2.21 (s, 3H), 2.14 – 2.06 (m, 2H),  
1.73 – 1.67 (m, 2H), 1.66 (s, 3H), 1.58 (s, 3H), 1.36 (s, 3H), 0.97 (s, 9H), 0.19 (s, 6H) ppm. 
13C NMR (125 MHz, CDCl3): δ 155.9, 154.3, 134.7, 131.6, 126.8, 126.8, 124.2, 119.7, 114.2, 113.8, 
106.0, 77.8, 41.0, 26.2, 25.7, 22.7, 18.4, 18.2, 17.6, – 4.4 ppm. 

































5.68 (82 mg, 0.220 mmol, 1.0 equiv.) dissolved in MeOH (10 mL) and O2 was bubbled through the 
solution for 10 min. Methylene blue (1 mg, 0.004 mmol, 2 mol%) was then added and the solution 
was left to stir under 1 atm of O2 and irradiated with a 200 W incandescent bulb and left to stir for 16 
h. The solution was then concentrated in vacuo and purified by flash chromatography on SiO2 (3:2 
PhMe/ CH2Cl2) to give the 5.69 (20 mg, 23%) as a 1:1 mixture of diastereoisomers and 5.70 (18 mg, 
21%).  
  
Data for 5.69: 
Rf: 0.30 (3:2 PhMe/ CH2Cl2). 
FTIR (neat): 2929, 1605, 1567, 1483, 1330, 1253, 1152, 1004, 839 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.77 (d, J = 6.6 Hz, 1H), 6.48 (d, J = 10.0 Hz, 1H), 6.18 (s, 1H), 6.14 (s, 1H), 
5.41 (dd, J = 10.0, 4.9 Hz, 1H), 5.02 – 5.00 (m, 2H), 4.29 (m, 1H), 2.21 (s, 3H), 1.79 – 1.63 (m, 4H), 1.71 
(s, 3H), 1.34 (s, 3H), 0.96 (s, 9H), 0.19 (s, 6H). 
13C NMR (125 MHz, CDCl3): δ 156.0, 154.1, 154.1, 143.5, 143.4, 134.8, 134.8, 126.4, 126.2, 126.2, 
120.1, 114.5, 114.3, 113.6, 113.5, 106.0, 89.6, 89.6, 77.6, 77.4, 37.1, 36.7, 26.4, 26.1, 25.6, 25.5, 25.1, 
18.4, 18.4, 18.2, 17.3, 17.2, -4.4 ppm. 
HRMS (ESI) m/z: [M+H]+ Calcd for C23H37O4Si , found 405.2452. 
 
Data for 5.70: 
Rf: 0.20 (3:2 PhMe/ CH2Cl2). 
FTIR (neat): 2930, 1605, 1567, 1483, 1331, 1254, 1151, 1005, 770 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.28 (br s, 1H), 6.50 (d, J = 10.0 Hz, 1H), 6.20 (d, J = 2.3 Hz, 1H), 6.16 (d, J 
= 2.4 Hz, 1H), 5.82 – 5.72 (m, 1H), 5.61 – 5.53 (m, 1H), 5.45 (d, J = 10.0 Hz, 1H), 2.42 (ddd, J = 7.4, 3.6, 
1.2 Hz, 2H), 2.22 (s, 3H), 1.41 (s, 3H), 1.28 (s, 6H), 0.98 (s, 9H), 0.20 (s, 5H) ppm. 
13C NMR (125 MHz, CDCl3): δ 156.1, 154.3, 136.8, 134.9, 126.4, 126.1, 120.1, 114.5, 113.6, 105.9, 82.1, 
44.0, 26.5, 25.6, 24.3, 24.1, 18.4, 18.2, -4.4 ppm. 


























O2 gas was bubbled through a solution of 5.68 (109 mg, 2.93 mmol, 1.0 equiv.) in DCE (25 mL) for 10 
minutes. 4-MeO-TPT (5.56) (3 mg, 0.006 mmol, 2 mol%) was then added and the reaction mixture was 
stirred under 1 atm of O2 while exposed to a 470 nm blue LED lamp at 0 °C for 20 min. The reaction 
mixture was then concentrated in vacuo and purified by flash chromatography on SiO2 (30:1 hexanes/ 
Et2O) to give cyclobutane 5.71 as a colourless oil (95 mg, 87%). 
 
Data for 5.71: 
Rf: 0.70 (4:1 hexanes/ EtOAc). 
FTIR (neat): 2949, 2929, 2858, 1610, 1577, 1473, 1329, 1252, 1146, 837, 778 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.28 (d, J = 2.4 Hz, 1H), 6.25 (d, J = 2.4 Hz, 1H), 3.09 (d, J = 9.7 Hz, 1H), 
2.55 (t, J = 8.2 Hz, 1H), 2.40 (td, J = 7.9, 2.5 Hz, 1H), 2.10 (s, 3H), 2.00 – 1.95 (m, 1H), 1.76 – 1.70 (m, 
1H), 1.66 – 1.57 (m, 2H), 1.38 (s, 3H), 1.32 (s, 3H), 0.97 (s, 9H), 0.65 (s, 3H), 0.19 (s, 6H) ppm. 
13C NMR (125 MHz, CDCl3): δ 154.3, 154.2, 137.9, 116.6, 114.7, 107.4, 83.0, 46.5, 39.6, 39.3, 39.2, 
38.0, 34.0, 26.7, 25.7, 25.4, 20.1, 18.4, 18.1, – 4.4 ppm. 

































To a solution of 5.71 (95 mg, 2.55 mmol, 1.0 equiv.) in THF (4 mL) was added TBAF (1.0 M in THF, 0.25 
mL, 2.55 mmol, 1.0 equiv.) and the reaction was stirred at room temperature for 5 min. The mixture 
was then diluted with EtOAc (20 mL), washed with sat. brine (2 × 20 mL), dried over MgSO4, filtered 
and concentrated in vacuo. The residue was purified by flash chromatography on SiO2 (8:1 → 4:1 
hexanes/ EtOAc, gradient elution) to give nyingchinoid D (5.8) as a colourless oil (27 mg, 86%). Data 
for nyingchinoid D (5.8) matched that previously reported in literature. 2 
 
Data for nyingchinoid D (5.8): 
Rf: 0.40 (4:1 hexanes/ EtOAc). 
FTIR (neat): 3388, 2947, 1614, 1594, 1458, 1139, 840 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.28 (d, J = 2.6 Hz, 1H), 6.24 (d, J = 2.6 Hz, 1H), 4.70 (br s, 1H), 3.08 (d, J = 
9.7 Hz, 1H), 2.55 (dd, J = 9.7, 8.9, 1H), 2.41 (td, J = 8.1, 2.7 Hz, 1H), 2.11 (s, 3H), 2.01 – 1.95 (m, 1H), 
1.72 – 1.71 (m, 1H), 1.67 – 1.57 (m, 2H), 1.38 (s, 3H), 1.32 (s, 3H), 0.66 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 154.6, 154.2, 138.4, 116.0, 109.9, 102.8, 83.3, 46.5, 39.6, 39.4, 39.2, 
37.9, 34.0, 26.6, 25.4, 20.1, 18.5 ppm. 




































To a solution of 5.68 (115 mg, 0.300 mmol, 1.0 equiv.) in DCE (15 mL) was added 4-MeO-TPT (5.56) (2 
mg, 0.006 mmol, 2 mol%) and the reaction mixture was stirred under N2 while exposed to a 470 nm 
blue LED lamp at 0 °C for 20 min. TBAF (1.0 M solution in THF, 0.30 ml, 0.300 mmol, 1.0 equiv.) was 
then added to the mixture at room temperature and the reaction mixture was stirred for 5 min. The 
reaction mixture was then diluted with CH2Cl2 (10 mL), washed with sat. brine (2 × 10 mL), dried over 
MgSO4, filtered and concentrated in vacuo. The residue was purified by flash chromatography on SiO2 
(8:1 hexanes/ EtOAc) to give nyingchinoid D (5.6) (40 mg, 51% over 2-steps). Data for nyingchinoid D 













































O2 was bubbled through a solution of 5.68 (174 mg, 0.467 mmol, 1.0 equiv.) in DCE (45 mL). After 10 
minutes reaction was cooled to 0 °C, 4-MeO-TPT (5.56) (5 mg, 0.009 mmol, 2 mol%) was then added 
and the reaction mixture was stirred under 1 atm of O2 while exposed to a 470 nm blue LED lamp for 
7 h. The reaction mixture was then concentrated in vacuo and purified by flash chromatography on 
SiO2 (30:1 hexanes/ Et2O) to give the endoperoxide 5.72 (115 mg, 60%) as a colourless oil. 
 
Data for 5.72: 
Rf: 0.30 (40:1 hexanes/ EtOAc). 
FTIR (neat): 2958, 2930, 2858, 1607, 1578, 1473, 1331, 1254, 1150, 844, 781 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.28 (d, J = 2.4 Hz, 1H), 6.17 (d, J = 2.4 Hz, 1H), 5.54 (d, J = 8.7 Hz, 1H), 
2.53 (td, J = 12.5, 7.7 Hz, 1H), 2.33 (s, 3H), 2.27 – 2.23 (m, 1H), 2.07 (dd, J = 13.4, 8.7 Hz, 1H), 1.99 (ddd, 
J = 13.4, 11.5, 3.2 Hz, 1H), 1.84 – 1.81 (m, 1H), 1.50 – 1.42 (m, 1H), 1.32 (s, 3H), 1.27 (s, 3H), 1.12 (s, 
3H), 0.96 (s, 9H), 0.19 (s, 6H) ppm. 
13C NMR (125 MHz, CDCl3): δ 156.8, 155.6, 141.1, 115.6, 109.8, 107.3, 84.0, 82.7, 74.1, 46.1, 45.5, 
39.6, 26.9, 25.6, 22.8, 22.5, 19.3, 19.0, 18.1, – 4.4 ppm. 
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To a solution of endoperoxide 5.72 (41 mg, 0.102 mmol, 1.0 equiv.) in THF (1 mL) at room temperature 
was added TBAF (1.0 M solution in THF, 0.10 mL, 0.10 mmol, 1.0 equiv.) and the reaction mixture was 
stirred for 1 h. Further TBAF (1.0 M solution in THF, 0.10 mL, 0.10 mmol) was added, then the mixture 
was diluted with EtOAc (20 mL), washed with sat. brine (2 × 20 mL), dried over MgSO4, filtered and 
concentrated in vacuo. The residue was purified by flash chromatography on SiO2 (7:1 EtOAc/ 
hexanes) to give nyingchinoid B (5.6) (27 mg, 92%) as a colourless oil. Data for nyingchinoid B (5.6) 
matched that previously reported in literature.2  
 
Data for nyingchinoid B (5.6): 
Rf: 0.35 (7:1 EtOAc/ hexanes).   
FTIR (neat): 3413, 2969, 1658, 1600, 1421, 1219, 1128, 884 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.26 (t, J = 1.7 Hz, 1H), 5.97 (d, J = 2.0 Hz, 1H), 4.03 (d, J = 3.8 Hz, 1H), 
2.55 (dd, J = 17.0, 8.0 Hz, 1H), 2.20 (dd, J = 8.0, 3.8 Hz, 1H), 2.10 – 2.03 (m, 1H), 1.93 – 1.88 (m, 1H), 
1.88 – 1.85 (m, 1H), 1.84 (d, J = 1.5 Hz, 3H), 1.46 – 1.41 (m, 1H), 1.34 (s, 3H), 1.29 (s, 3H), 1.23 (s, 3H) 
ppm. 
13C NMR (125 MHz, CDCl3): δ 187.5, 167.1, 148.9, 131.7, 114.9, 90.7, 72.1, 63.6, 54.5, 53.7, 43.5, 40.3, 
30.2, 27.2, 25.9, 25.3, 15.8 ppm. 

































To a solution of nyingchinoid B (5.6) (35 mg, 0.121 mmol, 1.0 equiv.) in CH2Cl2 (3 mL) was added TFA 
(0.01 mL, 0.120 mmol, 1.0 equiv.) and the solution was stirred at room temperature for 20 min. The 
reaction mixture was quenched with sat. NaHCO3(aq) solution (10 mL) and the organic layer was 
separated and washed with sat. brine (2 × 10 mL), then dried over MgSO4, filtered and concentrated 
in vacuo. The residue was purified by flash chromatography on SiO2 (4:1 → 1:1 hexanes/ EtOAc, 
gradient elution) to give nyingchinoid A (5.5) as an orange oil (20 mg, 58%). Data for nyingchinoid A 
(5.5) matched that previously reported in literature. 2 
 
Data for nyingchinoid A (5.5): 
Rf: 0.75 (4:1 EtOAc/ hexanes). 
FTIR (neat): 3364, 2970, 1596, 1464, 1137, 1025, 904, 728 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.40 (d, J = 3.0 Hz, 1H), 6.32 (d, J = 3.0 Hz, 1H), 4.94 (br s, 1H), 4.92 (d, J = 
3.0 Hz, 1H), 3.42 (ddd, J = 14.4, 12.6, 6.0 Hz, 1H), 2.57 (dt, J = 14.7, 8.8 Hz, 1H), 2.37 (ddd, J = 14.7, 9.9, 
1.6 Hz, 1H), 2.22 (s, 3H), 2.13 (dd, J = 14.1, 3.1 Hz, 1H), 1.79 – 1.77 (m, 1H), 1.52 (s, 3H), 1.39 – 1.31 
(m, 1H), 1.28 (s, 3H), 1.17 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 151.7, 151.3 138.6, 133.8, 112.9, 109.5, 96.1, 81.2, 80.1, 64.1, 51.9, 47.3, 
29.7, 24.8, 22.7, 21.3, 16.4 ppm. 





































O2 was bubbled through a solution of 5.68 (124 mg, 0.333 mmol, 1.0 equiv.) in DCE (35 ml). After 10 
min the reaction was cooled to 0 °C and 4-MeO-TPT (5.56) (3.2 mg, 0.007 mmol, 2 mol%) was added. 
The reaction mixture was stirred under 1 atm of O2 while exposed to 470 nm blue LED lamp for 4 h. 
TBAF (1.0 M in THF, 0.33 ml, 0.333 mmol, 1.0 equiv.) was then added and the reaction mixture was 
stirred for 20 min at room temperature. The reaction mixture was quenched with sat. NH4Cl(aq) 
solution (35 mL) and the organic layer was separated and washed with sat. NaHCO3(aq) (35 mL) and sat. 
brine (35 mL), then dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by 
flash chromatography on SiO2 (4:1 → 1:1 hexanes/ EtOAc, gradient elution) to give nyingchinoid B 
(5.6) as a colourless oil (58 mg, 61%). Data for nyingchinoid B (5.6) matched that previously obtained 



























 blue LED, DCE 
0 ºC, 1 atm O2, 4 h;











O2 was bubbled through a solution of 5.68 (108 mg, 0.290 mmol, 1.0 equiv.) in DCE (30 mL). After 10 
minutes the reaction mixture was cooled to 0 °C, and 4-MeO-TPT (5.56) (3 mg, 0.006 mmol, 2 mol%) 
was added. The reaction mixture was then stirred under 1 atm of O2 while exposed to a 470 nm blue 
LED lamp for 4 h. TBAF (1.0 M in THF, 0.29 ml, 0.290 mmol, 1.0 equiv.) was added and the reaction 
mixture was stirred for 1 h, followed by TFA (0.04 ml, 0.58 mmol, 2.0 equiv.) and stirring was continued 
for 10 minutes. The reaction mixture was quenched with sat. NaHCO3(aq) solution (20 mL) and the 
organic layer was separated and washed with sat. NaHCO3(aq) solution (20 mL) and brine (20 mL), then 
dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by flash 
chromatography on SiO2 (4:1 → 1:1 hexanes/ EtOAc, gradient elution) to give nyingchinoid A (5.5) as 
a pale yellow solid (45 mg, 53%). Data for nyingchinoid A (5.5) matched that previously obtained and 








































blue LED, DCE 
0 ºC, 1 atm O2, 4 h;
then TBAF, rt, 1 h;





To a solution of benzyl bromide (5.80) (9.56 mL, 80.4 mmol, 1.0 equiv.) in PhMe (420 mL) was added 
PPh3 (21.1 g, 80.4 mmol, 1.0 equiv.) at room temperature, and the solution was heated to 120 °C for 
18 h. The resulting white precipitate was then filtered and further washed with PhMe (200 mL) and 
dried in vacuo to afford benzyltriphenylphosphonium bromide (5.81) (52.4 g, 75%) as a white solid. 
Data for 5.81 matched that previously reported in literature.35 
 
Data for 5.81: 
FTIR (neat): 3053, 1587, 1484, 1436, 1189, 1112, 995, 719 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.79 – 7.72 (m, 8H), 7.70 – 7.66 (m, 2H), 7.66 – 7.62 (m, 5H), 7.56 – 7.52 
(m, 1H), 7.49 – 7.43 (m, 3H), 7.22 – 7.20 (m, 1H), 5.44 (d, J = 14.4 Hz, 2H) ppm. 
13C NMR (125 MHz, CDCl3): δ 134.9, 134.9, 134.5, 134.4, 132.1, 132.1, 131.9, 131.9, 131.6, 131.5, 































Lithium hydroxide (410 mg, 17.1 mmol, 1.5 equiv.) was added to a stirred solution of 
benzyltriphenylphosphonium bromide (5.81) (5.00 g, 11.4 mmol, 1.0 equiv.) in i-PrOH (100 mL) and 
the reaction was left to stir for 15 min at room temperature. 3,5-dimethoxybenzaldehyde (5.82) (1.90 
g, 11.4 mmol, 1.0 equiv.) was then added and reaction heated to reflux for 16 h. The reaction was 
then cooled and quenched upon addition of brine (100 mL) and product was extracted with EtOAc (3 
x 100 mL) and purified via flash chromatography on SiO2 (4:1 hexanes/ EtOAc) to give the Wittig 
product (5.83) (1.76 g, 64%) as a white solid. Data for 5.83 matched that previously reported in the 
literature.35 
 
Data for 5.83: 
Rf: 0.45 (9:1 hexanes/ EtOAc). 
MP: 53 – 54 °C (lit. 53 – 55 °C).35 
FTIR (neat): 2837, 1712, 1590, 1457, 1424, 1350, 1295, 1203, 1060, 959, 826 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.48 (d, J = 8.1 Hz, 2H), 7.33 (t, J = Hz, 2H), 7.25 – 7.20 (m, 1H), 7.09 – 
6.97 (m, 2H), 6.65 (s, 2H), 6.38 (d, J = 2.2 Hz), 3.79 (s, 6H) ppm.  
13C NMR (125 MHz, CDCl3): δ 161.0, 139.3, 137.1, 129.2, 128.7, 128.6, 127.7, 126.5, 104.6, 100.0, 55.3 
ppm.  































To a solution of 5.83 (1.56 g, 6.50 mmol, 1.0 equiv.) in MeOH (150 mL) was added portion-wise Pd/C 
(10% wt./ wt., 700 mg, 0.65 mmol, 10 mol%). The reaction was purged with H2/ vacuum three times 
and reaction left to stir at room temperature for 16 h. The solution was then filtered through celite 
the concentrated in vacuo to afford a 5.84 (1.35 g, 86%). Data for 5.84 matched that previously 
reported in the literature.35 
 
Data for 5.84: 
Rf: 0.40 (9:1 hexanes/ EtOAc). 
FTIR (neat): 2935, 1736, 1594, 1455, 1428, 1349, 1295, 1203, 1060, 909, 731 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.36 – 7.28 (m, 2H), 7.25 – 7.19 (m, 3H), 6.38 (t, J = 2.0 Hz, 2H), 6.35 (q, J 
= 2.0 Hz, 1H), 3.79 (s, 6H), 2.92 (dd, J = 11.3, 1.6 Hz, 4H) ppm.  
13C NMR (125 MHz, CDCl3): δ160.7, 144.1, 141.7, 128.4, 128.3, 125.9, 106.5, 98.0, 38.2, 37.6 ppm.  

































To a solution of 5.84 (1.24 g, 5.1 mmol, 1.0 equiv.) in AcOH (10 mL) was added HBr (6.0 mL,1.0 mol, 
33% wt./ wt. in AcOH, 20 equiv.) and the reaction was left to reflux. After 16 h the solution was 
quenched with sat. brine (10 mL) and product extracted with EtOAc (3 x 10 mL), dried with MgSO4, 
filtered and concentrated. Purification via flash chromatography on SiO2 (4:1 hexanes/ EtOAc) gave 
the diol 5.85 (715 mg, 66%) as pale yellow oil. Data for 5.85 matched that previously reported in the 
literature.35 
 
Data for 5.85: 
Rf: 0.35 (3:2 hexanes/ EtOAc). 
FTIR (neat): 3342, 1698, 1599, 1495, 1453, 1143, 999, 974, 837, 748 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.24 (dd, J = 8.1, 6.8 Hz, 2H), 7.17 (d, J = 7.3 Hz, 1H), 7.14 – 7.09 (m, 2H), 
6.23 (d, J = 2.3 Hz, 2H), 6.16 (t, J = 2.2 Hz, 1H), 5.48 (br s, 2H), 2.85 – 2.71 (m, 4H) ppm.  
13C NMR (125 MHz, CDCl3): δ 156.3, 145.0, 141.5, 128.4, 128.3, 128.3, 125.9, 108.3, 100.6, 37.5, 37.2 
ppm.  






























To a solution of 5-phenylethylresorcinol (5.85) (1.15 g, 5.37 mmol, 1.0 equiv.) in pyridine (0.46 mL, 
5.37 mmol, 1.0 equiv.) was added citral (1.19 mL, 7.00 mmol, 1.3 equiv.) and the resultant mixture 
was stirred at 100 °C for 18 h. EtOAc (50 mL) was added, and the solution was washed with 1 M HCl(aq) 
(30 mL) and 1 M CuSO4(aq) (2 × 50 mL). The organic solution was then dried with MgSO4, filtered and 
concentrated in vacuo. The residue was purified by flash chromatography on SiO2 (4:1 CHCl3/ 
cyclohexane) then (9:1 → 4:1, hexanes/ EtOAc, gradient elution) to give chromene 5.87 (1.44 g, 76%) 
as a yellow oil alongside chromene 5.86 (313 mg, 17%) as a red oil. Data for 5.86 and 5.87 matched 
that previously reported in literature.37 
 
Data for 5.87: 
Rf: 0.20 (20:1 hexanes/ EtOAc). 
FTIR (neat): 3387, 2970, 2924, 1622, 1496, 1431, 1376, 1141, 1083, 1055, 821, 774 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.28 (dd, J = 7.1, 1.1 Hz, 2H), 7.24 – 7.14 (m, 3H), 6.64 (d, J = 10.0 Hz, 1H), 
6.31 (s, 1H), 6.11 (s, 1H), 5.52 (d, J = 10.0 Hz, 1H), 5.17 – 5.08 (m, 1H), 4.98 (br s, 1H), 2.93 – 2.83 (m, 
2H), 2.81 – 2.71 (m, 2H), 2.18 – 2.08 (m, 2H), 1.76 – 1.66, 2H), 1.69 (s, 3H), 1.60 (s, 3H), 1.40 (s, 3H) 
ppm. 
13C NMR (125 MHz, CDCl3): δ 154.1, 151.1, 143.5, 143.5, 141.7, 131.6, 128.4, 128.4, 128.3, 128.3, 
128.3, 127.4, 125.9, 124.2, 116.8, 109.1, 107.7, 107.3, 78.3, 41.1, 37.9, 37.4, 26.2, 25.6, 22.7, 17.6 
ppm. 
HRMS (ESI) m/z: [M+H]+ Calcd for C24H29O2 349.2162, found 349.2120.  
 
Data for 5.86: 
Rf: 0.30 (4:1 hexanes/ EtOAc). 
FTIR (neat): 3387, 2928, 1610, 1452, 1139 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.28 – 7.16 (m, 5H), 6.47 (d, J = 10.1 Hz, 1H), 6.18 (d, J = 2.3 Hz, 1H), 6.16 
(d, J = 2.5 Hz, 1H), 5.46 (d, J = 10.1 Hz, 1H), 5.10 (t, J = 7.8 Hz, 1H), 4.64 (br s, 1H), 2.85 – 2.83 (m, 4H), 
2.11 – 2.08 (m, 2H), 1.67 (s, 3H), 1.59 (s, 3H), 1.36 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 155.9, 154.9, 141.5, 139.0, 131.7, 128.4, 128.4, 126.9, 126.0, 124.2, 
119.1, 112.8, 108.4, 101.8, 77.9, 40.9, 37.4, 34.4, 26.2, 25.7, 22.7, 17.6 ppm. 





















To a solution of 5-phenylethylresorcinol (5.85) (1.06 g, 5.00 mmol, 1.0 equiv.) in PhMe (50 mL) and 
EDDA (180 mg, 0.980 mmol, 0.05 equiv.) was added citral (0.84 mL, 5.00 mmol, 1.0 equiv.) and the 
resultant mixture was stirred at 120 °C for 40 h. The solution was then cooled, concentrated in vacuo 
and residue was purified by flash chromatography on SiO2 (15:1 → 10:1 hexanes/ EtOAc, gradient 
elution) to give the bis-chromene 5.88 (43 mg, 3%) and chromene 5.87 (382 mg, 22%) as a red oil. 
Data for 5.87 matched that previously obtained and previously reported in the literature.37 
 
Data for 5.88: 
1H NMR (500 MHz, CDCl3): δ 7.31 – 7.26 (m, 2H), 7.22 – 7.17 (m, 3H), 6.70 (d, J = 10.0 Hz, 1H), 6.48 (d, 
J = 10.0 Hz, 1H), 6.21 (s, 1H), 5.51 – 5.46 (m, 2H), 5.12 (t, J = 5.7 Hz, 2H), 2.83 (s, 6H), 2.16 – 2.11 (m, 
4H), 1.75 – 1.61 (m, 4H), 1.68 (s, 6H), 1.40 -1.39 (m, 6H) ppm. 
13C NMR (125 MHz, CDCl3): δ 153.5, 149.0, 141.8, 138.2, 131.6, 131.6, 131.5, 128.4, 127.1, 127.1, 
126.6, 125.9, 124.3, 119.5, 117.2, 112.3, 109.0, 108.3, 78.3, 77.8, 41.2, 40.8, 37.4, 34.6, 26.4, 25.9, 
25.7, 25.7, 22.7, 22.7, 17.6, 17.6 ppm.  






























To a solution of chromene 5.86 (384 mg, 1.10 mmol, 1.0 equiv.) in dry CH2Cl2 (20 mL) was added 2,6-
lutidine (0.260 mL, 2.20 mmol, 2.0 equiv.), and TBSOTf (0.320 mL, 1.65 mmol, 1.5 equiv.). The reaction 
mixture was stirred at room temperature for 20 min. Then the reaction was quenched upon addition 
of a sat. NH4Cl(aq) (20 mL). The organic layer was separated and further extraction of the aqueous layer 
with CH2Cl2 (3 x 20 mL) performed. Combined organic extracts were dried with MgSO4, filtered, and 
concentrated in vacuo. The residue was purified by flash chromatography on SiO2 (30:1 hexanes/ Et2O) 
to give 5.89 as a colourless oil (270 mg, 53%). 
 
Data for 5.89: 
Rf: 0.75 (4:1 hexanes/ EtOAc). 
FTIR (neat): 2929, 2858, 1604, 1473, 1253, 1154, 842, 781 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.29 – 7.26 (m, 2H), 7.21 – 7.16 (m, 3H), 6.49 (d, J = 10.0 Hz, 1H), 6.48 (d, 
J = 10.0 Hz, 1H), 6.18 (d, J = 2.2 Hz, 1H), 6.15 (d, J = 2.2 Hz, 1H),  5.47 (d, J = 10.0 Hz, 1H), 5.09 (t, J = 7.3 
Hz, 1.0 Hz), 2.84 (m, 4H), 2.13 – 2.06 (m, 2H), 1.72 – 1.57 (m, 2H), 1.68 (s, 3H), 1.59 (s, 3H), 1.37 (s, 
3H), 0.97 (s, 9H), 0.17 (s, 6H) ppm. 
13C NMR (125 MHz, CDCl3): δ 156.0, 154.5, 141.6, 138.4, 131.6, 128.4, 128.4, 127.2, 125.9, 124.2, 
119.3, 113.5, 113.3, 106.5, 77.7, 40.9, 37.4, 34.3, 26.1, 25.7, 25.7, 22.7, 18.2, 17.6, – 4.4 ppm. 






























O2 gas was bubbled through a solution of 5.89 (60 mg, 0.130 mmol, 1.0 equiv.) in DCE (13 mL) for 10 
min. 4-MeO-TPT (5.56) (1 mg, 0.003 mmol, 2 mol%) was then added and the reaction mixture was 
stirred under 1 atm of O2 while exposed to a 470 nm blue LED lamp at 0 °C for 4 h. The reaction mixture 
was then concentrated in vacuo and purified by flash chromatography on SiO2 (30:1 hexanes/ Et2O) to 
give the endoperoxide 5.90 (45 mg, 69%) as a colourless oil. 
 
Data for 5.90: 
Rf: 0.40 (9:1 hexanes/ EtOAc). 
FTIR (neat): 2929, 1605, 1575, 1147, 837 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.24 (dd, J = 9.3, 3.6 Hz, 2H), 7.19 – 7.15 (m, 3H), 6.33 (d, J = 2.4 Hz, 1H), 
6.19 (d, J = 2.4 Hz, 1H), 5.35 (d, J = 8.7 Hz, 1H), 3.07 – 2.97 (m, 2H), 2.93 – 2.88 (m, 1H), 2.83 – 2.77 (m, 
1H), 2.51 (td, J = 12.5, 7.7 Hz, 1H), 2.25 – 2.19 (m, 1H), 1.98 (dd, J = 13.2, 8.6 Hz, 2H), 1.82 – 1.76 (m, 
1H), 1.45 – 1.39 (m, 1H), 1.31 (s, 3H), 1.19 (s, 3H), 1.09 (s, 3H), 0.97 (s, 9H), 0.18 (s, 6H) ppm. 
13C NMR (125 MHz, CDCl3): δ 156.9, 155.7, 144.8, 141.9, 128.6, 128.2, 125.7, 114.7, 109.7, 107.6, 83.8, 
82.6, 73.7, 46.1, 45.5, 39.5, 37.8, 34.1, 26.9, 25.7, 22.7, 22.4, 19.0, 18.1, – 4.4 ppm.  


























 blue LED, DCE





To a solution of endoperoxide 5.90 (42 mg, 0.085 mmol, 1.0 equiv.) in THF (2 mL) at room temperature 
was added TBAF (1.0 M solution in THF, 0.085 ml, 0.085 mmol, 1.0 equiv.) and the reaction mixture 
was stirred for 5 min. The mixture was diluted with EtOAc (10 mL), washed with sat. brine (2 × 10 mL), 
dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by flash 
chromatography on SiO2 (7:1 EtOAc/ hexanes) to give epoxide 5.91 as a colourless oil (30 mg, 93%). 
 
Data for 5.91: 
Rf: 0.45 (4:1 EtOAc/ hexanes).  
FTIR (neat): 3407, 2968, 1654, 1598, 1420, 1219, 888 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.28 (m, 2H), 7.18 (dd, J = 17.7, 7.3 Hz, 3H), 6.33 (d, J = 1.9 Hz, 1H), 6.00 
(d, J = 1.9 Hz, 1H), 3.90 (d, J = 3.9 Hz, 1H), 2.84 – 2.80 (m, 2H), 2.53 – 2.49 (m, 1H), 2.44 (ddd, J = 8.6, 
6.2, 2.9 Hz, 1H), 2.32 – 2.23 (m, 1H), 2.12 – 2.03 (m, 2H), 1.91 – 1.83 (m, 2H), 1.43 – 1.39 (m, 1H), 1.30 
(s, 3H), 1.27 (s, 3H), 1.21 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 187.5, 167.2, 151.9, 140.5, 130.8, 128.6, 128.4, 126.4, 115.0, 90.7, 72.1, 
63.5, 54.3, 53.6, 43.5, 40.3, 34.3, 30.1, 29.8, 27.1, 25.9, 25.3 ppm.  






























To a solution of 5.91 (39 mg, 0.103 mmol, 1.0 equiv.) in CH2Cl2 (5 mL) was added TFA (0.005 ml, 0.07 
mmol, 70 mol%) and the reaction mixture was stirred at room temperature for 5 min and then 
quenched with saturated sat. NaHCO3(aq) solution (10 mL). The organic layer was separated and 
washed with sat. NaHCO3(aq) solution (10 mL) and sat. brine (2 × 10 mL), dried over MgSO4, 
concentrated in vacuo and then purified by flash chromatography on SiO2 (4:1 → 1:1 hexanes/ EtOAc) 
to give rasumatranin D (5.4) as a white solid (28 mg, 70%). 
 
Data for rasumatranin D (5.4): 
Rf: 0.65 (4:1 EtOAc/ hexanes). 
FTIR (neat): 3348, 2970, 1602, 1554, 1136, 1027, 729 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.26 – 7.21 (m, 2H), 7.17 – 7.13 (m, 3H), 6.37 (d, J = 3.0 Hz, 1H), 6.35 (d, 
J = 3.0 Hz, 1H), 4.92 (br s, 1H), 4.65 (d, J = 3.0 Hz, 1H), 3.42 (ddd, J = 14.0, 12.6, 6.0 Hz, 1H), 2.97 – 2.92 
(m, 1H), 2.92 – 2.90 (m, 1H), 2.89 – 2.82 (m, 1H), 2.79 (ddd, J = 10.4, 7.4, 5.1 Hz, 1H), 2.57 (dt, J = 14.6, 
8.8 Hz, 1H), 2.36 (ddd, J = 14.6, 9.9, 1.6 Hz, 1H), 2.08 (dd, J = 14.6, 3.1 Hz, 1H), 1.76 (dddd, J = 11.2, 7.9, 
6.1, 1.5 Hz, 1H), 1.51 (s, 3H), 1.38 – 1.29 (m, 1H), 1.27 (s, 3H), 1.16 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 151.8, 151.3, 141.8, 138.5, 137.4, 128.7, 128.2, 125.8, 112.0, 109.9, 96.5, 
81.1, 79.9, 64.2, 51.9, 47.2, 36.7, 32.0, 29.7, 24.7, 22.7, 21.2 ppm. 



































O2 was bubbled through a solution of 5.89 (84 mg, 0.182 mmol, 1.0 equiv.) in DCE (20 mL, 0.01 M). 
After 10 minutes the reaction mixture was cooled to 0 °C, and 4-MeO-TPT (5.56) (2 mg, 0.004 mmol, 
2 mol%) was added. The reaction mixture was then stirred under 1 atm of O2 while exposed to a 470 
nm blue LED lamp for 4 h. TBAF (1.0 M in THF, 0.18 ml, 0.182 mmol, 1.0 equiv.) was added and the 
reaction mixture was stirred for 1 h, followed by TFA (0.030 ml, 0.26 mmol, 1.5 equiv.) and stirring 
was continued for 10 minutes. The reaction mixture was quenched with sat. NaHCO3(aq) (15 mL) and 
the organic layer was separated and washed with brine (15 mL), then dried over MgSO4, filtered and 
concentrated in vacuo. The residue was purified by flash chromatography on SiO2 (4:1 → 1:1, hexanes/ 
EtOAc, gradient elution) to give rasumatranin D (5.4) as a white solid (34 mg, 49%). Data for 5.4 























0 ºC, 1 atm O2 4 h;
then TBAF, rt, 1 h; 
















To a solution of 5.89 (130 mg, 0.280 mmol, 1.0 equiv.) in DCE (28 mL) was added 4-MeO-TPT (5.56) (2 
mg, 0.006 mmol, 2 mol%) and the reaction mixture was exposed to a 470 nm blue LED lamp at 0 °C 
for 20 min. The reaction mixture was then concentrated in vacuo and purified by flash 
chromatography on SiO2 (30:1 hexanes/ Et2O) to give the cyclol 5.92 as a colourless oil (94 mg, 72%). 
 
Data for 5.92: 
Rf: 0.80 (8:1 hexanes/ EtOAc). 
FTIR (neat): 2929, 2858, 1696, 1607, 1575, 1472, 1425, 1252, 1146, 1019, 812, 780 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.29 – 7.26 (m, 2H), 7.21 – 7.15 (m, 3H), 6.34 (d, J = 2.5 Hz, 1H), 6.29 (d, 
J = 2.5 Hz, 1H), 3.09 (d, J = 9.0 Hz, 1H), 2.80 (d, J = 7.3 Hz, 2H), 2.72 (t,  J = 8.0 Hz, 2H), 2.50 (t, J = 9.0 
Hz, 1H), 2.01 – 1.94 (m, 1H), 1.75 – 1.66 (m, 2H), 1.65 – 1.59 (m, 2H), 1.36 (s, 3H), 1.29 (s, 3H), 0.98 (s, 
9H), 0.62 (s, 3H), 018 (s, 6H) ppm.  
13C NMR (125 MHz, CDCl3): δ 154.6, 154.4, 141.9, 141.4, 128.5, 128.4, 128.4, 125.9, 113.7, 108.1, 83.3, 
46.5, 41.0, 39.9, 39.8, 37.4, 37.2, 34.8, 34.2, 26.1, 25.7, 25.7, 25.3, 18.8, −4.4 ppm. 




























To a solution of 5.92 (94 mg, 0.203 mmol, 1.0 equiv.) in THF (4 mL) at room temperature was added 
TBAF (1.0 M solution in THF, 0.20 ml, 0.203 mmol, 1.0 equiv.) and the reaction mixture was stirred for 
5 min. The mixture was diluted with EtOAc (10 mL), washed with sat. brine (2 × 10 mL), dried over 
MgSO4, filtered and concentrated in vacuo. The residue was purified by flash chromatography on SiO2 
(4:1 EtOAc/ hexanes) to give o-bibenzyl cannabicyclol (5.93) (22 mg, 22%). Data for o-bibenzyl 
cannabicyclol (5.93) matched that previously reported in the literature.34 
 
Data for o-bibenzyl cannabicyclol (5.93): 
Rf: 0.90 (3:2 hexanes/ EtOAc). 
FTIR (neat): 3382, 2947, 1615, 1593, 1453, 1331, 1115, 1032, 700 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.29 (t, J = 7.4 Hz, 2H), 7.22 – 7.18 (m, 3H), 6.36 (d, J = 2.6 Hz, 1H), 6.28 
(d, J = 2.6 Hz, 1H), 4.80 (br s, 1H), 3.10 (d, J = 9.6 Hz, 1H), 2.84 – 2.70 (m, 2H), 2.76 – 2.69 (m, 2H), 2.52 
(t, J = 9.0 Hz, 1H), 2.42 (dt, J = 8.0, 3.2 Hz), 1.74 – 1.58 (m, 4H), 1.37 (s, 3H), 1.30 (s, 3H), 0.63 (s, 3H) 
ppm. 
13C NMR (125 MHz, CDCl3): δ 154.9, 154.4, 142.0, 141.9, 128.4, 128.4, 125.9, 116.1, 108.8, 103.5, 83.5, 
46.5, 39.9, 39.9, 39.8, 37.3, 37.1, 34.9, 34.1, 26.0, 25.3, 18.8 ppm. 

























To a solution of 5.89 (67 mg, 0.145 mmol, 1.0 equiv.) in DCE (25 mL, 0.01 M) was added 4-MeO-TPT 
(5.56) (2 mg, 0.006 mmol, 2 mol%) and the reaction mixture was stirred under N2 while exposed to a 
470 nm blue LED lamp at 0 °C for 15 min. TBAF (1.0 M solution in THF, 0.14 ml, 0.145 mmol, 1.0 equiv.) 
was then added to the mixture at room temperature and the reaction mixture was stirred for 5 min. 
The reaction mixture was then diluted with CH2Cl2 (10 mL), washed with sat. brine (2 × 10 mL), dried 
over MgSO4, filtered and concentrated in vacuo. The residue was purified by flash chromatography on 
SiO2 (4:1 EtOAc/ hexanes) to give o-bibenzyl cannabicyclol (5.93) (28 mg, 54% over 2-steps). Data for 
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NaBH4 (2.68 g, 70.9 mmol, 1.15 equiv.) was added to a solution of E-para-methoxycinnamaldehyde 
5.151 (10.0 g, 61.7 mmol, 1.0 equiv.) in MeOH (250 mL) at 0 °C. After 1 h the reaction was quenched 
upon addition of sat. brine (250 mL) and diluted with CH2Cl2 (250 mL), the organic layer was separated 
and further extracted with CH2Cl2 (2 x 250 mL). The combined organic layers were dried with MgSO4, 
filtered and concentrated to give 4-methyl cinnamyl alcohol 5.96b (8.45 g, 83%) as an orange oil. Data 
for 5.96B matched that previously reported in literature.26, 30 
 
Data for 5.96b: 
Rf: 0.30 (6:4 hexanes/ EtOAc). 
FTIR (neat): 3356, 2839, 1654, 1605, 1510, 1458, 1305, 1269, 1250, 1174, 1127, 1085, 1006 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.33 (d, J = 8.6 Hz, 2H), 6.86 (d, J = 8.6 Hz, 2H), 6.56 (dt, J = 15.9, 1.6 Hz), 
6.24 (dt, J = 15.8, 5.9 Hz, 1H), 4.30 (d, J = 5.9 Hz, 2H), 3.81 (s, 3H) ppm.  
13C NMR (125 MHz, CDCl3): δ 159.3, 131.0, 129.4, 127.7, 126.3, 114.0, 63.9, 55.3 ppm.  



























To a stirring solution of the allylic alcohol 5.96b (6.0 g, 36.5 mmol, 1.0 equiv.) in Et2O (110 mL) at 0 °C 
was added PBr3 (1.37 mL, 14.6 mmol, 40 mol%) in the absence of light. The reaction was further stirred 
for 3 h, then poured over sat. NaHCO3(aq) (110 mL) and the organic layer separated. The aqueous layer 
was further extracted with Et2O (2 x 110 mL), dried with MgSO4, filtered and concentrated in vacuo to 
afford 5.95 (5.76 g, 70%) directly as a white solid. Data for 5.95 matched that previously reported in 
the literature.26, 30 
 
Data for 5.95: 
FTIR (neat): 2959, 1643, 1603, 1509, 1469, 1437, 1415, 1309, 1286, 1248, 1176, 1141, 1064, 1029, 
969, 826, 810, 829 cm-1. 
1H NMR (600 MHz, CDCl3): δ 7.33 (d, J = 8.8 Hz, 2H), 6.86 (d, J = 8.8 Hz, 2H), 6.60 (d, J = 15.5 Hz, 1H), 
6.26 (dt, J = 15.7, 7.9 Hz, 1H), 4.17 (dd, J = 7.9, 1.0 Hz, 2H), 3.82 (s, 3H) ppm.  
13C NMR (150 MHz, CDCl3): δ 159.8, 134.2, 128.0, 123.0, 114.1, 55.3, 34.2 ppm.  



























Alcohol 5.96a (1.47 g, 10.9 mmol, 1.0 equiv.) in THF (10 mL) was added dropwise to a solution of NaH 
(0.73 g, 17.5 mmol, 50% wt./ wt. 1.6 equiv.) in THF (15 mL). The solution was stirred at 0 °C for 30 min, 
then the bromide 5.95 (3.13 g, 13.1 mmol, 1.2 equiv.) in THF (10 mL) was added dropwise and reaction 
was warmed to room temperature and left to stir for 16 h. Solution was quenched upon addition of 
sat. NH4Cl(aq) (35 mL) and the organic layer was extracted with Et2O (3 x 35 mL), dried with MgSO4, 
filtered and concentrated. Purification by flash chromatography on SiO2 (9:1 hexanes/ EtOAc) gave 
5.94a (395 mg, 12%). Data for 5.94a matched that previously reported in the literature.26, 30 
 
Data for 5.94a: 
Rf: 0.55 (9:1 hexanes/ EtOAc). 
FTIR (neat): 3002, 2837, 1607, 1495, 1248, 1175, 1104, 1034, 967, 840 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.39 (d, J = 7.4 Hz, 2H), 7.36 – 7.28 (m, 4H), 7.25 (d, J = 8.7 Hz, 1H), 6.90 
– 6.80 (m, 2H), 6.64 (d, J = 15.9 Hz, 1H), 6.58 (d, J = 15.9 Hz, 1H), 6.33 (d, J = 15.9 Hz, 1H), 6.19 (d, J = 
15.9 Hz, 1H), 4.19 (ddd, J = 7.5, 6.1, 1.4 Hz), 3.81 (s, 3H) ppm.  
13C NMR (125 MHz, CDCl3): δ 159.3, 136.8, 132.5, 132.4, 129.5, 128.5, 127.7, 127.7, 126.5, 126.1, 
123.7, 114.0, 71.0, 70.6, 55.3 ppm.  



























Alcohol 5.96b (1.47 g, 8.95 mmol, 1.0 equiv.) in THF (10 mL) was added dropwise to a solution of NaH 
(50% wt./ wt., 0.68 g, 14.3 mmol, 1.6 equiv.) in THF (15 mL). The solution was stirred at 0 °C for 30 
min, then the bromide 5.95 (2.46 g, 10.8 mmol, 1.2 equiv.) in THF (10 mL) was added dropwise and 
reaction was warmed to room temperature and left to stir for 16 h. The solution was quenched upon 
addition of sat. NH4Cl(aq) (35 mL) and the organic layer was extracted with Et2O (3 x 35 mL), dried with 
MgSO4, filtered and concentrated to give a yellow solid 5.94b (1.25 g, 45%). Data for 5.94b matched 
that previously reported in the literature.26, 30 
 
Data for 5.94b: 
Rf: 0.80 (1:1 EtOAc/ hexanes). 
FTIR (neat): 2962, 1603, 1510, 1464, 1440, 1418, 1356, 1309, 1209, 1275, 1175, 1127, 1100, 1028, 
1053, 968, 840, 812 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.35 (d, J = 8.7 Hz, 4H), 6.87 (d, J = 8.7 Hz, 4H), 6.59 (d, J = 15.8 Hz, 2H), 
6.21 (dt, J = 15.8, 6.2 Hz, 2H), 4.19 (dd, J = 6.2, 1.4 Hz, 4H), 3.82 (s, 6H) ppm.  
13C NMR (125 MHz, CDCl3): δ 159.3, 132.3, 129.5, 127.7, 123.8, 114.0, 70.8, 55.3, 55.3 ppm.  





























Following a modified procedure from Nicewicz et al., 5.94b (108 mg, 0.348 mmol, 1.0 equiv.) in DCE 
(22 mL) was cooled to 0 °C. 4-MeO-TPT (5.56) (5 mg, 0.018 mmol, 5 mol%) and anthracene (34 mg, 
0.105 mmol, 30 mol%) was added and solution irradiated with a 470 nm blue LED lamp.25 The solution 
was left to stir for 1 h, then concentrated and product was purified by flash chromatography on SiO2 
(8:1 hexanes/ EtOAc) to afford 5.98b (72 mg, 64%) as a white solid. Data for 5.98b matched that 
previously reported in the literature.25 
 
Data for 5.98b: 
Rf: 0.75 (1:1 hexanes/ EtOAc). 
1H NMR (500 MHz, CDCl3): δ 6.85 (d, J = 8.4 Hz, 4H), 6.64 (d, J = 8.4 Hz, 4H), 4.08 (d, J = 9.3 Hz, 2H), 
3.70 (s, 6H), 3.65 (d, J = 3.9 Hz, 2H), 3.23 (br s, 2H) ppm. 
13C NMR (125 MHz, CDCl3): δ 157.5, 133.1, 129.0, 113.2, 74.0, 55.1, 46.5, 42.5 ppm. 




























O2 was bubbled through the solution of 5.94a (110 mg, 0.39 mmol, 1.0 equiv.) in CH2Cl2 (17 mL) at 
−41 °C for 10 min.  4-MeO-TPT (5.56) (3 mg, 0.008 mmol, 2 mol%) was then added and the reaction 
was left to stir under 1 atm of O2 for 4h while exposed to a 470 nm blue LED lamp. The solution was 
then concentrated and purified by flash chromatography on SiO2 (4:1 hexanes/ EtOAc) to afford the 
endoperoxide 5.98a (46 mg, 37%) as a yellow solid. Data for 5.98a matched that previously reported 
in literature.25  
 
Data for 5.98a: 
Rf: 0.30 (9:1 hexanes/ EtOAc). 
FTIR (neat): 2928, 1609, 1514, 1251, 1177, 1030, 967 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.51 (d, J = 8.7 Hz, 2H), 7.38 (t, J = 7.5 Hz, 2H), 7.36 – 7.29 (m, 3H), 6.92 
(d, J = 8.7 Hz, 2H), 5.57 (d, J = 5.8 Hz, 1H), 5.06 (d, J = 9.9 Hz, 1H), 4.18 (t, J = 7.3 Hz, 1H), 3.80 (s, 3H), 
3.78 (d, J = 9.6 Hz, 1H), 3.45 (dd, J = 10.8, 7.9 Hz, 1H), 3.26 (dd, J = 11.3, 7.6 Hz, 1H), 2.90 – 2.80 (m, 
1H), 2.68 – 2.57 (m, 1H) ppm.  
13C NMR (125 MHz, CDCl3): δ 160.3, 137.0, 129.0, 128.2, 128.2, 127.6, 127.0, 114.2, 87.4, 83.1, 83.1, 
68.9, 68.0, 55.3, 46.5, 41.2 ppm. 






















To a solution of the 5.94a (103 mg, 0.37 mmol, 1.0 equiv.) was added Ru[bpz]2[PF6] (2 mg, 0.007 mmol, 
2 mol%) and O2 was bubbled through the solution at room temperature for 10 min. The solution was 
then irradiated with a 200 W incandescent bulb and left to stir under 1 atm O2 for 2 h. The solution 
was then concentrated and purified by flash chromatography on SiO2 (4:1 hexanes/ EtOAc) to afford 
the cyclobutane 5.98a (20 mg, 20%) as a white solid, the endoperoxide 5.97A (51 mg, 44%) as a yellow 
solid. Data for 5.98a and 5.97a matched that previously obtained and previously reported in 
literature.25, 26 
 
Data for 5.98a: 
Rf: 0.70 (4:1 hexanes/ EtOAc). 
FTIR (neat): 2956, 2828, 1610, 1512, 1248, 1178, 1036, 830 cm-1. 
1H NMR (600 MHz, CDCl3): δ 7.09 (t, J = 7.6 Hz, 2H), 7.03 – 6.99  (m, 1H), 6.96 – 6.91 (m, 2H), 6.84 (d, 
J = 8.7 Hz, 2H), 6.62 (d, J = 8.7 Hz, 2H), 4.09 (d, J = 9.4 Hz, 2H), 3.69 (d, J = 9.5 Hz, 7H), 3.29 (d, J = 4.7 
Hz, 1H), 3.24 (s, 1H) ppm. 
13C NMR (150 MHz, CDCl3): δ 157.5, 140.9, 133.0, 129.0, 128.1, 127.7, 125.6, 113.1, 74.0, 74.0, 55.1, 



























To a solution of the 5.94b (100 mg, 0.320 mmol, 1.0 equiv.) was added Ru[bpz]2[PF6] (2 mg, 0.007 
mmol, 2 mol%) and O2 was bubbled through the solution at room temperature for 10 min. The solution 
was then irradiated with a 200 W incandescent bulb and left to stir under 1 atm O2 for 2 h. The solution 
was then concentrated and purified by flash chromatography on SiO2 (4:1 hexanes/ EtOAc) to afford 
the cyclobutane 5.98b (20 mg, 20%) as a white solid, the endoperoxide 5.97b (21 mg, 19%) as a yellow 
solid and recovered starting material 5.94b (20 mg, 20%). Data for 5.98b and 5.97b matched that 
previously obtained and previously reported in literature.25, 26 
 
Data for 5.97b: 
Rf: 0.50 (91:1 hexanes/ EtOAc). 
FTIR (neat): 2971, 1159, 1028, 732, 700 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.42 (d, J = 8.7 Hz, 2H), 7.32 (d, J = 8.7 Hz, 2H), 6.94 – 6.88 (m, 4H), 5.52 
(d, J = 5.7 Hz, 1H), 5.03 (d, J = 9.8 Hz, 1H), 4.14 (t, J =7.3 Hz, 1H), 3.82 – 3.79 (m, 7H), 3.44 (dd, J = 10.8, 
7.9 Hz, 1H), 3.23 (dd, J = 11.3, 7.6 Hz, 1H), 2.88 – 2.76 (m, 1H), 2.71 – 2.60 (m, 1H). 
13C NMR (125 MHz, CDCl3): δ 160.3, 159.0, 129.1, 129.0, 128.9, 128.4, 114.2, 113.6, 87.3, 82.9, 68.9, 
68.1, 55.3, 55.2, 46.7, 41.2 ppm. 






























To a solution of phloroglucinol (5.152) (5.0 g, 39.7 mmol, 1.0 equiv.) in DMF (80 mL) was 
added imidazole (801 mg, 11.9 mmol, 30 mol%) and TIPSCl (2.54 mL, 11.9 mmol, 30 mol%) at 
room temperature. After 48 h the reaction was diluted with Et2O (80 mL) and the organic 
layer was washed with distilled water (80 mL) and further washed with sat. brine (3 x 80 mL). 
The organic layer was then dried with MgSO4, filtered, concentrated in vacuo and purified via 
flash column chromatography on SiO2 (9:1 hexanes/ EtOAc) to afford 5.153 (92 mg, 8%) as a 
clear oil. Data for 5.154 matched that previously reported in literature.41 
 
Partial Data for 5.153: 
Rf: 0.30 (3:1 hexanes/ EtOAc). 
FTIR (neat): 3303, 2945, 2867, 1600, 1464, 1147, 1025, 998 cm-1. 
1H NMR (500 MHz, CDCl3): δ 5.98 (d, J = 2.1 Hz, 2H), 5.96 – 5.95 (m, 1H), 1.28 – 1.21 (m, 3H), 1.09 (d, 
J = 7.0 Hz, 18H) ppm. 



























To a solution of 5.153 (500 mg, 1.77 mmol, 1.0 equiv.) in MeCN (20 mL) was added Cs2CO3 (576 mg, 
1.77 mmol, 1.0 equiv.) and BnBr (0.45 mL, 3.71 mmol, 2.1 equiv.) at room temperature. After 24 h the 
reaction was diluted with Et2O (20 mL), washed with distilled water (20 mL) and sat. brine (20 mL). 
The organic layer was dried with MgSO4, filtered and concentrated in vacuo. The crude residue was 
redissolved in THF (20 mL) and TBAF (1.76 mL, 1.77 mmol, 1.0 M THF, 1.0 equiv.) was added at room 
temperature. After 15 min, the reaction was then diluted with Et2O (20 mL) and washed with sat. brine 
(40 mL). The organic layer was then dried with MgSO4, filtered and concentrated in vacuo. Purification 
via flash column chromatography on SiO2 (5:1 hexanes/ EtOAc) then afforded 5.117 (83 mg, 15%) as 
a clear oil. Data for 5.117 matched that previously reported in the literature.41 
 
Partial Data for 5.117: 
Rf: 0.30 (3:1 hexanes/ EtOAc). 
1H NMR (500 MHz, CDCl3): δ 7.43 – 7.36 (m, 8H), 7.34 (t, J = 6.9 Hz, 2H), 6.25 (t, J = 2.1 Hz, 1H), 6.12 
(d, J = 2.1 Hz, 2H), 5.28 (br s, 1H), 4.99 (s, 4H) ppm. 



















    MeCN, rt, 24 h
2.TBAF, THF







To a solution of 3,5-dibenzylphenol (5.117) (83 mg, 0.270 mmol, 1.0 equiv.) in PhMe (15 mL) was 
added citral (0.05 mL, 0.270 mmol, 1.0 equiv.), PhB(OH)2 (10 mg, 0.014 mmol, 5 mol%) and AcOH (0.05 
mL, 0.054 mmol, 20 mol%). The reaction was stirred at 110 °C for 16 h. The mixture was cooled to 
room temperature, then concentrated in vacuo. The residue was purified by flash column 
chromatography on SiO2 (9:1 hexanes/ EtOAc) to give chromene 5.113 (66 mg, 60%) as a yellow oil.  
 
Data for 5.113: 
Rf: 0.65 (9:1 hexanes/ EtOAc). 
FTIR (neat): 2966, 2922, 1610, 1575, 1434, 1373, 1100, 813 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.49 – 7.35 (m, 8H), 7.36 – 7.32 (m, 2H), 6.72 (d, J = 10.0 Hz, 1H), 6.18 (d, 
J = 2.3 Hz, 1H), 6.16 (d, J = 2.3 Hz, 1H), 5.40 (d, J = 10.0 Hz, 1H), 5.18 – 5.10 (m, 1H), 5.03 (s, 2H), 5.01 
(s, 2H), 2.18 – 2.11 (m, 2H), 1.78 – 1.64 (m, 2H), 1.70 (s, 3H), 1.61 (s, 3H), 1.41 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 160.2, 155.4, 155.1, 137.1, 137.0, 131.7, 128.7, 128.6, 128.1, 128.0, 
127.7, 127.5, 125.1, 124.4, 117.5, 104.8, 95.4, 93.5, 78.8, 70.4, 70.2, 41.3, 26.5, 25.8, 22.9, 17.8 ppm. 




























To a solution of 3,5-dimethoxyphenol (5.116) (1.00 g, 6.49 mmol) in PhMe (30 mL) was added citral 
(1.11 mL, 6.49 mmol, 1.5 equiv.), PhB(OH)2 (40 mg, 0.342 mmol, 5 mol%) and AcOH (0.08 mL, 1.29 
mmol, 20 mol%). The reaction was stirred at 110 °C for 24 h. The mixture was cooled to room 
temperature, then concentrated in vacuo. The residue was purified by flash column chromatography 
on SiO2 (9:1 hexanes/ EtOAc) to give chromene 5.114 (1.66 g, 89%) as an orange oil. Data for 5.114 
matched that previously reported in the literature.42 
 
Data for 5.114: 
Rf: 0.80 (9:1 hexanes/ EtOAc). 
FTIR (neat): 2966, 2925, 2840, 1611, 1578, 1495, 1202, 1146, 1113, 1050 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.61 (d, J = 10.0 Hz, 1H), 6.02 (d, J = 2.3 Hz, 1H), 5.99 (d, J = 2.3 Hz, 1H), 
5.37 (d, J = 10.0 Hz, 1H), 5.12-5.08 (m, 1H), 3.78 (s, 3H), 3.76 (s, 3H), 2.14-2.07 (m, 2H), 1.76-1.70 (m, 
1H), 1.66 (s, 3H), 1.65-1.61 (m, 1H), 1.58 (s, 3H), 1.37 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 161.1, 156.2, 155.1, 131.7, 125.0, 124.4, 117.3, 104.2, 94.0, 91.5, 78.7, 
55.7, 55.5, 41.3, 26.4, 25.8, 22.9, 17.8 ppm.  





























To a solution of 5.120 (1.50 g, 5.73 mmol, 1.0 equiv.)* in acetone (30 mL) was added K2CO3 (4.41 g, 
20.1 mmol, 5.2 equiv.) and dimethyl sulfate (1.16 mL, 11.5 mmol, 2.0 equiv.). The solution was heated 
to reflux for 4 h, then cooled and distilled water (30 mL) added. The product was extracted with EtOAc 
(3 x 30 mL), dried with MgSO4, filtered and concentrated in vacuo. Purification by flash column 
chromatography on SiO2 (19:1 hexanes/ EtOAc) then afforded chromene 5.127 (1.19 mg, 75%) as a 
clear oil.  
 
Data for 5.127: 
Rf: 0.60 (9:1 hexanes/ Et2O).  
FTIR (neat): 2950, 1601, 1466, 1252, 1098, 751 cm-1. 
1H NMR (600 MHz, CDCl3): δ 7.03 (t, J = 8.2 Hz, 1H), 6.69 (d, J = 10.0 Hz, 1H), 6.45 – 6.40 (d, J = 8.2 Hz, 
1H), 6.39 (d, J = 8.2 Hz, 1H), 5.52 (d, J = 10.0 Hz, 1H), 5.13 – 5.06 (m, 1H), 3.81 (s, 3H), 2.15 – 2.08 (m, 
2H), 1.78 – 1.62 (m, 2H), 1.66 (s, 3H), 1.57 (s, 3H), 1.38 (s, 3H) ppm. 
13C NMR (150 MHz, CDCl3): δ 155.4, 154.1, 131.8, 129.0, 128.0, 124.3, 117.4, 110.6, 109.5, 102.9, 78.2, 
55.8, 41.2, 26.4, 25.8, 22.9, 17.8 ppm. 












*5.120 was synthesized according to a literature procedure from Katakawa and co-workers, and a 

















To a solution of 5.120 (1.00 g, 4.10 mmol, 1.0 equiv.)* in CH2Cl2 (40 mL) was added imidazole (330 mg, 
4.92 mmol, 1.2 equiv.) and TBSCl (740 mg, 4.92  mmol, 1.2 equiv.) at room temperature. After 8 h the 
reaction was quenched upon addition of distilled H2O (40 mL) and the product was extracted with 
CH2Cl2 (2 x 40 mL), dried with MgSO4, filtered and concentrated in vacuo. Purification by flash 
chromatography on SiO2 (19:1 hexanes/ EtOAc) then afforded chromene 5.128 (812 mg, 56%) as a 
clear oil.  
 
Data for 5.128: 
Rf: 0.60 (19:1 hexanes/ EtOAc).  
FTIR (neat): 2958, 2929, 1634, 1600, 1472, 1459, 1387,1287, 1217, 1153, 1084, 1056, 922 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.92 (t, J = 8.1 Hz, 1H), 6.64 (d, J = 10.0 Hz, 1H), 6.41 (d, J = 8.2 Hz, 1H), 
6.32 (d, J = 8.2 Hz, 1H), 5.51 (d, J = 10.0 Hz, 1H), 5.14 – 5.06 (m, 1H), 2.13 – 2.08 (m, 2H), 1.77 – 1.59 
(m, 2H), 1.66 (s, 3H), 1.57 (s, 3H), 1.37 (s, 3H), 1.01 (s, 9H), 0.21 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 154.5, 151.59, 131.8, 128.7, 128.2, 124.4, 118.2, 113.5, 111.6, 109.7, 
78.1, 41.3, 26.4, 26.0, 25.8, 22.9, 18.5, 17.8, -4.1 ppm. 













*5.121 was synthesized according to a literature procedure from Katakawa and co-workers, and a 
















To a solution of orcinol (5.67) (10.0 g, 81.0 mmol, 1.0 equiv.) in PhMe (250 mL) at room temperature 
was added citral (12.3 mL, 81.0 mmol, 1.0 equiv.) and EDDA (500 mg, 2.43 mmol, 3 mol%). The reaction 
was stirred at 110 °C for 5 h. The mixture was cooled to room temperature, then concentrated in 
vacuo. The residue was purified by flash column chromatography on SiO2 (8:1 hexanes/ EtOAc) to give 
chromene 5.115 (17.2 g, 82%) as an orange oil. Data for 5.115 matched that previously reported in 
the literature.44 
 
Data for 5.115: 
Rf: 0.40 (5:1 hexanes/ EtOAc).  
FTIR (neat): 3387, 2970, 2924, 1625, 1578, 1509, 1450, 1377, 1330, 1250 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.61 (d, J = 10.0 Hz, 1H), 6.24 (s, 1H), 6.11 (s, 1H), 5.49 (d, J = 10.0 Hz, 1H), 
5.10 (t, J = 7.2 Hz, 1H), 4.73 (br s, 1H), 2.20 (s, 3H), 2.13 – 2.07 (m, 2H), 1.75 – 1.70 (m, 1H), 1.66 (s, 
3H), 1.65 – 1.61 (m, 1H), 1.58 (s, 3H), 1.37 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 154.3, 151.2, 139.7, 131.8, 127.4, 124.4, 116.9, 110.0, 108.5, 106.9, 78.4, 
41.3, 26.4, 25.8, 22.9, 21.7, 17.8 ppm. 



























To a solution of 5.115 (1.00 mg, 3.86 mmol, 1.0 equiv.) in THF (120 mL) was added NaH (240 mg, 4.63 
mmol, 50% wt./ wt. 1.2 equiv.), TBAI (1.84 g, 4.63 mmol, 1.2 equiv.) and benzyl bromide (0.60 mL, 
4.63 mmol, 1.2 equiv.) at 0 °C. The solution was then warmed to room temperature and left to stir. 
After 16 h, the reaction was quenched upon addition of distilled H2O (60 mL) and the product was 
extracted with CH2Cl2 (60 mL), dried with MgSO4, filtered and concentrated in vacuo. Purification via 
flash column chromatography on SiO2 (9:1 hexanes/ EtOAc) then afforded 5.121 (1.35 g, quant.) as a 
yellow oil.  
 
Data for 5.121: 
Rf: 0.70 (19:1 hexanes/ EtOAc).  
FTIR (neat): 2968, 2920, 1613, 1571, 1452, 1375, 1329, 1231, 1102 900 cm-1. 
1H NMR (600 MHz, CDCl3): δ 7.44 (d, J = 7.1 Hz, 2H), 7.39 (t, J = 7.5 Hz, 2H), 7.33 (t, J = 7.1 Hz, 1H), 6.73 
(d, J = 10.0 Hz, 1H), 6.30 (s, 2H), 5.45 (d, J = 10.0 Hz, 1H), 5.13 – 5.07 (m, 1H), 5.04 (s, 2H), 2.26 (s, 3H), 
2.15 – 2.05 (m, 2H), 1.73 – 1.61 (m, 2H), 1.66 (s, 3H), 1.58 (s, 3H), 1.37 (s, 3H) ppm. 
13C NMR (150 MHz, CDCl3): δ 154.4, 154.0, 139.5, 137.4, 131.7, 128.6, 128.0, 127.5, 126.9, 124.4, 
117.6, 110.3, 108.4, 105.3, 78.3, 70.4, 41.3, 26.5, 25.8, 22.9, 22.2, 17.8 ppm. 

























To a solution of 5.115 (5.11 g, 9.00 mmol, 1.0 equiv.) in acetone (150 mL) was added K2CO3 (6.45 g, 
46.8 mmol, 5.2 equiv.) and dimethyl sulfate (1.70 mL, 17.9 mmol, 2.0 equiv.). The solution was heated 
to reflux for 4 h, then cooled and distilled water (150 mL) added. The product was extracted with 
EtOAc (3 x 150 mL), dried with MgSO4, filtered and concentrated. Purification by flash column 
chromatography on SiO2 (9:1 hexanes/ EtOAc) then afforded chromene 5.126 (4.64 g, 86%) as a clear 
oil. Data for 5.126 matched that previously reported in the literature.45 
 
Data for 5.126: 
Rf: 0.50 (9:1 hexanes/ EtOAc).  
FTIR (neat): 2967, 1613, 1572, 1453, 1387, 1229, 1144, 1024, 814 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.66 (d, J = 10.0, 1H), 6.28 (s, 1H), 6.22 (s, 1H), 5.46 (d, J = 10.0 Hz, 1H), 
5.10 (t, J = 1.3 Hz, 1H), 3.80 (s, 3H), 2.27 (s, 3H), 2.16 – 2.05 (m, 2H), 1.76 – 1.61 (m, 2H), 1.73 (s, 3H), 
1.37 (s, 3H) ppm.  
13C NMR (125 MHz, CDCl3): δ 155.2, 154.0, 139.5, 131.7, 126.9, 124.5, 117.4, 110.1, 108.0, 104.0, 78.2, 
55.7, 41.3, 26.4, 25.8, 22.9, 22.1, 17.8 ppm. 





























To a solution of 5.115 (1.00 g, 3.87 mmol, 1.0 equiv.) in CH2Cl2 (40 mL) was added imidazole (310 mg, 
4.64 mmol, 1.2 equiv.) and TBSCl (700 mg, 4.64  mmol, 1.2 equiv.) at room temperature. After 8 h the 
reaction was quenched upon addition of distilled water (40 mL) and the product was extracted with 
CH2Cl2 (2 x 40 mL), dried with MgSO4, filtered and concentrated in vacuo. Purification by flash column 
chromatography on SiO2 (19:1 hexanes/ EtOAc) then afforded chromene 5.129 (1.00 g, 70%) as a clear 
oil.  
 
Data for 5.129: 
Rf: 0.15 (hexanes).  
FTIR (neat): 2929, 1614, 1566, 1461, 1387, 1252, 1096, 839, 779 cm-1. 
1H NMR (600 MHz, CDCl3): δ 6.60 (d, J = 10.0 Hz, 1H), 6.26 (s, 1H), 6.14 (s, 1H), 5.44 (d, J = 10.0 Hz, 1H), 
5.09 (ddt, J = 7.2, 5.7, 1.5 Hz, 1H), 2.20 (s, 3H), 2.15 – 2.04 (m, 2H), 1.75 – 1.61 (m, 2H), 1.66 (s, 3H), 
1.57 (s, 3H), 1.36 (s, 3H), 1.00 (s, 9H), 0.20 (s, 6H) ppm. 
13C NMR (150 MHz, CDCl3): δ 154.2, 151.4, 139.2, 131.7, 127.0, 124.4, 118.2, 112.5, 110.8, 110.4, 78.1, 
41.3, 26.4, 26.0, 25.8, 22.9, 21.8, 18.5, 17.8, -4.1 ppm. 


























To a solution of 5.59 (540 mg, 2.10 mmol, 1.0 equiv.) in THF (60 mL) was added NaH (120 mg, 2.52 
mmol, 50% wt./ wt., 1.2 equiv.), TBAI (920 mg, 2.52 mmol, 1.2 equiv.) and benzyl bromide (0.30 mL, 
2.52 mmol, 1.2 equiv.) at 0 °C. The solution was then warmed to room temperature. After 16 h, the 
reaction was quenched upon addition of distilled water (60 mL) and the product was extracted with 
CH2Cl2 (2 x 60 mL), dried with MgSO4, filtered and concentrated in vacuo. Purification via flash column 
chromatography on SiO2 (19:1 hexanes/ EtOAc) then afforded 5.121 (718 mg, quant.) as a yellow oil.  
 
Data for 5.121: 
Rf: 0.60 (19:1 hexanes/ EtOAc).  
FTIR (neat): 2968, 1607, 1328, 1146, 1028, 988 cm-1. 
1H NMR (600 MHz, CDCl3): δ 7.44 – 7.40 (m, 2H), 7.38 (t, J = 8.5, 2H), 7.32 (t, J = 7.2 Hz, 1H), 6.48 (d, J 
= 10.0 Hz, 1H), 6.34 (d, J = 2.5 Hz, 1H), 6.32 (d, J = 2.5 Hz, 1H), 5.47 (d, J = 10.1 Hz, 1H), 5.10 (t, J = 1.5 
Hz, 1H), 5.00 (s, 2H), 2.25 (s, 3H), 2.16 – 2.04 (m, 2H), 1.74 – 1.62 (m, 1H), 1.66 (s, 3H), 1.58 (s, 3H), 
1.37 (s, 3H) ppm. 
13C NMR (150 MHz, CDCl3): δ 159.3, 154.7, 137.2, 135.1, 131.8, 128.7, 128.0, 127.6, 126.8, 124.4, 
119.7, 113.5, 109.4, 1007, 78.1, 70.0, 41.2, 26.4, 25.8, 22.9, 18.8, 17.8 ppm. 




























To a solution of 5.59 (1.0 g, 3.87 mmol, 1.0 equiv.) in acetone (30 mL) was added K2CO3 (6.45 g, 20.1 
mmol, 5.2 equiv.) and dimethyl sulfate (1.70 mL, 20.1 mmol, 2.0 equiv.). The solution was heated to 
reflux for 4 h, then cooled and distilled water (30 mL) added. The product was extracted with EtOAc 
(3 x 30 mL), dried with MgSO4, filtered and concentrated in vacuo. Purification by flash 
chromatography on SiO2 (9:1 hexanes/ EtOAc) afforded chromene 5.124 (646 mg, 62%) as a clear oil.  
 
Data for 5.124: 
Rf: 0.65 (9:1 hexanes/ EtOAc).  
FTIR (neat): 2923, 1608, 1491, 1330, 1147, 1052, 838 cm-1. 
1H NMR (600 MHz, CDCl3): δ 6.66 (d, J = 10.0 Hz, 1H), 6.28 (s, 1H), 6.22 (s, 1H), 5.46 (d, J = 10.0 Hz, 1H), 
5.10 (t, J = 5.7 Hz, 1H), 3.80 (s, 3H), 2.27 (s, 3H), 2.17 – 2.09 (m, 2H), 1.78 – 1.63 (m, 2H), 1.66 (s, 3H), 
1.58 (s, 3H), 1.37 (s, 3H) ppm. 
13C NMR (150 MHz, CDCl3): δ 160.1, 154.7, 135.1, 131.8, 126.7, 124.4, 119.7, 113.2, 108.6, 99.7, 78.1, 
55.3, 41.2, 26.4, 25.8, 22.9, 18.8, 17.8 ppm. 






























To a solution of olivetol (5.119)(4.00 g, 22.2 mmol, 1.0 equiv.) in PhMe (150 mL) was added citral (4.60 
mL, 26.6 mmol, 1.2 equiv.) and EDDA (400 mg, 2.2 mmol, 10 mol%). The reaction mixture was stirred 
at 110 °C for 17 hr, cooled to room temperature, concentrated in vacuo, and purified by flash column 
chromatography on SiO2 (10:1 hexanes/ EtOAc) to afford cannabichromene (5.116) (5.73 g, 82%) as 
an orange oil. Data for 5.116 matched that previously reported in literature.46 
 
Data for 5.116: 
Rf: 0.20 (10:1 hexanes/ EtOAc). 
FTIR (neat): 3392, 2926, 1621, 1579, 1426, 1051, 754 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.61 (d, J = 10.0 Hz, 1H), 6.25 (s, 1H), 6.12 (s, 1H), 5.49 (d, J = 10.0 Hz, 1H), 
5.12-5.07 (m, 1H), 4.64 (br s, 1H), 2.45 (t, J = 7.7 Hz, 2H), 2.14-2.06 (m, 2H), 1.76-1.64 (m. 2H), 1.66 (s, 
3H), 1.58 (s, 3H), 1.58-1.54 (m, 2H), 1.38 (s, 3H), 1.36-1.31 (m, 2H), 1.31-1.25 (m, 2H), 0.88 (t, J = 6.9, 
3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 154.2, 151.0, 144.9, 131.7, 127.4, 124.3, 116.9, 109.3, 107.7, 107.1, 78.3, 
41.2, 36.1, 31.6, 30.8, 26.4, 25.8, 22.9, 22.7, 17.8, 14.2 ppm.  





















110 °C, 17 h
82%




To a solution of cannabichromene (5.116) (300 mg, 0.96 mmol, 1.0 equiv.) in THF (30 mL) was added 
NaH (50 mg, 1.11 mmol, 50% wt./ wt., 1.2 equiv.) at 0 °C, followed by TBAI (420 mg, 1.25 mmol) and 
BnBr (140 mg, 1.15 mmol). The reaction mixture stirred and warmed to room temperature over 4 hr. 
The reaction was quenched with distilled water (30 mL) and extracted with CH2Cl2 (3 x 20 mL). The 
combined organic extracts were dried with MgSO4, filtered, concentrated in vacuo, and purified by 
flash column chromatography on SiO2 (19:1 hexanes/ EtOAc) to afford 5.123 (157 mg, 37%) as a 
crystalline orange solid. 
 
Data for 5.123: 
Rf: 0.40 (19:1 hexanes/ EtOAc). 
FTIR (neat): 2960, 2927, 2857, 1612, 1589, 1428, 1110, 732, 695 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.45 (d, J = 7.8 Hz, 2H), 7.39 (t, J = 7.3 Hz, 2H), 7.35-7.30 (m, 1H), 6.74 (d, 
J = 10.0 Hz, 1H), 6.23 (s, 1H), 6.31 (s, 1H), 5.46 (d, J = 10.0 Hz, 1H), 5.11 (t, 7.0 Hz, 1H), 5.06 (s, 2H), 2.50 
(t, J = 7.7 Hz, 2H), 2.16-2.08 (m, 2H), 1.77- 1.62 (m, 2H), 1.67 (s, 3H), 1.60 (s, 3H), 1.39 (s, 3H), 1.58-
1.54 (m, 2H), 1.36-1.33 (m, 2H), 1.33-1.27 (m, 2H), 0.90 (t, J = 6.8 Hz, 3H) ppm.  
13C NMR (125 MHz, CDCl3): δ 154.4, 154.0, 144.7, 137.5, 131.7, 128.6, 127.9, 127.5, 127.0, 124.4, 
117.7, 109.6, 108.6, 104.8, 78.2, 70.4, 41.3, 36.5, 31.6, 31.0, 26.5, 25.8, 22.9, 22.7, 17.8, 14.2 ppm.  





























To a solution of cannabichromene (5.116) (300 mg, 0.95 mmol, 1.0 equiv.) in acetone (30 mL) was 
added K3CO3 (670 mg, 4.96 mmol, 5.0 equiv.) and dimethyl sulfate (180 mg, 1.91 mmol, 2.0 equiv.). 
The reaction mixture was stirred at 60 °C for 4 hr. The reaction was quenched with distilled water (30 
mL) and extracted with EtOAc (3 x 20 mL). The combined organic extracts were dried with MgSO4, 
filtered, concentrated in vacuo, and purified by flash column chromatography on SiO2 (19:1 hexanes/ 
EtOAc) to afford methoxy olivetol chromene (5.125) (250 mg, 81%) as a yellow oil. Data for 5.116 
matched that previously reported in the literature.47  
 
Data for 5.125: 
Rf: 0.60 (9:1 hexanes/ EtOAc). 
FTIR (neat): 2928, 2871, 2857, 1612, 1569, 1451, 1423, 1217, 1100, 908, 822, 774, 733 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.66 (d, J = 9.9 Hz, 1H), 6.29 (s, 1H), 6.21 (s, 1H), 5.45 (d, J = 10.0 Hz, 1H), 
5.12-5.07 (m, 1H), 3.80 (s, 3H), 2.50 (t, J = 7.6 Hz, 2H), 2.14-2.06 (m, 2H), 1.76-1.63 (m, 2H), 1.66 (s, 
3H), 1.61-1.58 (m, 2H), 1.60 (s, 3H), 1.37 (s, 3H), 1.36-1.32 (m, 2H), 1.32-1.29 (m, 2H), 0.89 (t, J = 6.8 
Hz, 3H) ppm.  
13C NMR (125 MHz, CDCl3): δ 155.2, 153.9, 144.7, 131.7, 126.9, 124.4, 117.4, 109.3, 108.2, 103.3, 78.2, 
55.7, 41.2, 36.6, 31.7, 31.0, 26.4, 25.8, 22.9, 22.7, 17.8, 14.2 ppm.  





























To a solution of cannabichromene (5.115) (300 mg, 0.95 mmol, 1.0 equiv.) in dry CH2Cl2 (20 mL) was 
added 2,6-lutidine (0.22 g, 1.9 mmol, 2.0 equiv.) and TBSOTf (0.33 g, 1.4 mmol, 1.5 equiv.). The 
reaction mixture was stirred at –78 °C and slowly warmed to room temperature over 1 hr. The reaction 
was quenched upon addition of sat. NH4Cl(aq) (3 x 20 mL) and the aqueous layer was extracted with 
CH2Cl2 (20 mL). The combined organic extracts were dried with MgSO4, filtered and concentrated in 
vacuo. Purification by flash column chromatography on SiO2 (30:1 hexanes/ EtOAc) then afforded 
5.130 (312 mg, 77%) as a yellow oil. 
 
Data for 5.130: 
Rf: 0.50 (19:1 hexanes/ EtOAc). 
FTIR (neat): 2929, 1612, 1563, 1462, 1426, 1387, 1253, 1214, 1103, 1005, 836, 778, 759 cm-1. 
1H NMR (500 MHz, CDCl3): δ 6.61 (d, J = 10.0 Hz, 1H), 6.28 (s, 1H), 6.16 (s, 1H), 5.45 (d, J = 10.0 Hz, 1H), 
5.13-5.08 (m, 1H), 2.45 (t, J = 7.7 Hz, 2H), 2.14-2.07 (m, 2H), 1.75-1.60 (m, 2H), 1.67 (s, 3H), 1.60 (s, 
3H), 1.57-1.53 (m, 2H), 1.37 (s, 3H), 1.35-1.32 (m, 2H), 1.32-1.28 (m, 2H), 1.01 (s, 9H), 0.89 (t, J = 6.7 
Hz, 3H), 0.21 (s, 6H) ppm. 
13C NMR (125 MHz, CDCl3): δ 151.1, 151.3, 144.3, 131.7, 127.1, 124.4, 118.3, 111.9, 111.0, 109.8, 78.1, 
41.3, 36.1, 31.6, 30.8, 26.4, 26.1, 26.0, 25.8, 22.9, 22.7, 18.5, 17.8, 14.2 ppm.  

























–78 ºC → rt, 1 h
77%
 501 
5.4.3 General Method for the Synthesis of Endoperoxides (5.131a – 5.142a) 
To a solution of chromene (1.0 equiv.) in DCE (0.01 M) was added 4-MeO-TPT (5.56) (2 mol %) and the 
reaction mixture was stirred at 0 °C under 1 atm of O2 while exposed to a 470 nm blue LED lamp. The 
reaction mixture was then concentrated in vacuo and purified by flash column chromatography on 
SiO2 (eluent as specified) to afford the corresponding endoperoxides and cyclobutane product (5.131 
– 5.42). 
 
5.131: Reaction left for 2 h. Purification by flash column chromatography on 
SiO2 (9:1 hexanes/ EtOAc) afforded (5.131a) (26 mg, 34%) as a clear oil. Data 
for 5.131a: Rf: 0.50 (9:1 hexanes/ EtOAc). FTIR (neat): 2969, 1612, 1587, 1498, 
1453, 1434, 1096, 734 cm-1. 1H NMR (500 MHz, CDCl3): δ 7.45 (d, J = 7.0 Hz, 
2H), 7.42 – 7.25 (m, 8H), 6.20 (d, J = 2.3 Hz, 1H), 6.12 (d, J = 2.3 Hz, 1H), 5.76 
(d, J = 8.8 Hz, 1H), 5.12 (d, J = 12.2 Hz, 1H), 5.01 (d, J = 12.1 Hz, 1H), 4.97 (d, J = 5.9 Hz, 2H), 2.60 – 2.52 
(m, 1H), 2.30 – 2.23 (m, 1H), 2.09 (dd, J = 13.4, 8.8 Hz, 1H), 2.04 – 1.97 (m, 1H), 1.85 – 1.77 (m, 1H), 
1.47 (dt, J = 12.0, 6.0 Hz, 1H), 1.35 (s, 3H), 1.29 (s, 3H), 1.12 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3): δ 
161.2, 159.9, 156.7, 137.2, 136.8, 128.7, 128.6, 128.2, 127.8, 127.7, 127.1, 100.8, 96.4, 94.7, 84.9, 
82.6, 72.0, 70.3, 70.3, 70.2, 70.2, 70.2, 46.1, 45.7, 39.7, 27.1, 22.9, 22.5, 19.3 ppm. HRMS: calculated 
for C30H33O5 [M+H]+ 473.2323, found 473.2325. 
 
5.132: Reaction left for 1 h. Purification by flash column chromatography on 
SiO2 (19:1 hexanes/ EtOAc) afforded (5.132a) (82 mg, 74%) as a white solid. 
Data for 5.132a: MP: 138 – 142 °C. Rf: 0.20 (9:1 hexanes/ EtOAc). FTIR (neat): 
3109, 1702, 1605, 1451, 1398, 1234, 1180, 1101, 870, 786 cm-1. 1H NMR (500 
MHz, CDCl3): δ 6.04 (d, J = 2.3 Hz, 1H), 6.00 (d, J = 2.3 Hz, 1H), 5.64 (d, J = 8.8 
Hz, 1H), 3.77 (s, 3H), 3.74 (s, 3H), 2.54-2.47 (m, 1H), 2.23 (ddd, J = 14.6, 9.3, 7.1 Hz, 1H), 2.05 (dd, J = 
13.4, 8.8 Hz, 1H), 1.99 (ddd, J = 14.6, 11.4, 3.3 Hz, 1H), 1.82-1.74 (m, 1H), 1.49-1.41 (m, 1H), 1.30 (s, 
3H), 1.27 (s, 3H), 1.08 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3): δ 162.0, 160.9, 156.5, 99.9, 94.9, 92.5, 
84.8, 82.5, 72.0, 55.8, 55.3, 45.9, 45.7, 39.7, 27.0, 22.9, 22.5, 19.1 ppm. HRMS: calculated for C18H25O5 
[M+H]+ 321.1697, found 321.1699. 
 
5.133: Reaction left for 5 h. Purification by flash column chromatography on SiO2 
(9:1 hexanes/ EtOAc) afforded (5.133a) (10 mg, 4%) as a clear oil and (5.134b) (42 
mg, 16%) as a clear oil. Data for 5.133a: Rf: 0.30 (9:1 hexanes/ EtOAc). FTIR (neat): 
2968, 1605, 1588, 1468, 1249, 1249, 1089 cm-1. 1H NMR (600 MHz, CDCl3): δ 7.16 

























2.56 – 2.50 (m, 1H), 2.30 – 2.23 (m, 1H), 2.09 (dd, J = 13.3, 8.7 Hz, 1H), 2.03 – 1.97 (m, 1H), 1.83 – 1.78 
(m, 1H), 1.51 – 1.38 (m, 2H), 1.31 (s, 3H), 1.28 (s, 3H), 1.11 (s, 3H) ppm. 13C NMR (150 MHz, CDCl3): δ 
160.1, 155.7, 130.6, 111.2, 107.2, 103.5, 84.6, 82.8, 72.2, 56.0, 55.4, 45.8, 39.7, 27.0, 22.9, 22.5, 19.1 
ppm. HRMS: calculated for C17H22O4 [M-H]- 289.1445, found 289.1420. 
 
Partial Data for 5.133b: Rf: 0.80 (9:1 hexanes/ EtOAc). FTIR (neat): 2958, 1674, 1581, 
1462, 1137, 1087, 912 cm-1. 1H NMR (600 MHz, CDCl3): δ 7.05 (t, J = 8.2 Hz, 1H), 6.50 
(dd, J = 8.2, 1.0 Hz, 1H), 6.41 (dd, J = 8.1, 1.0 Hz, 1H), 3.77 (s, 3H), 3.12 (d, J = 9.6 Hz, 
1H), 2.56 (dd, J = 9.7, 7.3 Hz, 1H), 2.38 (t, J = 7.3 Hz, 1H), 1.69 – 1.59 (m, 2H), 1.62 – 
1.57 (m, 2H), 1.38 (s, 3H), 1.35 (s, 3H), 0.70 (s, 3H) ppm. 13C NMR (150 MHz, CDCl3): δ 158.4, 154.1, 
127.1, 113.2, 111.0, 102.1, 83.3, 55.1, 46.5, 39.3, 38.0, 37.9, 36.6, 33.9, 27.9, 25.9, 17.9 ppm.  
 
5.134: Reaction left for 48 h. Purification by flash column chromatography on SiO2 
(19:1 hexanes/ EtOAc) afforded (5.134a) (16 mg, 8%) and (5.134b) (38 mg, 19%). 
Data for 5.134a: Rf: 0.50 (9:1 hexanes/ EtOAc). FTIR (neat): 2995, 1603, 1583, 
1470, 1375, 1361, 1243, 1171, 1046, 1059 cm-1. 1H NMR (600 MHz, CDCl3): δ 7.05 
(t, J = 8.2 Hz, 1H), 6.45 (d, J = 8.1 Hz, 1H), 6.41 (d, J = 8.1 Hz, 1H), 5.63 (d, J = 8.8 Hz, 1H), 2.59 – 2.49 
(m, 1H), 2.29 – 2.22 (m, 1H), 2.07 (dd, J = 13.4, 8.8 Hz, 1H), 2.58 – 2.50 (m, 1H), 2.28 – 2.23 (m, 1H), 
1.49 – 1.45 (m, 1H), 1.31 (s, 3H), 1.27 (s, 3H), 1.08 (s, 3H), 1.03 (s, 9H), 0.27 (s, 3H), 0.21 (s, 3H) ppm. 
13C NMR (150 MHz, CDCl3): δ 156.5, 156.0, 130.3, 111.9, 111.4, 110.3, 84.4, 82.4, 72.0, 46.3, 45.7, 
39.8, 27.1, 26.0, 22.9, 22.4, 19.4, 18.5, -4.1 ppm. HRMS: calculated for C22H35O4Si [M+H]+ 391.2299, 
found 391.2297. 
 
Data for 5.134b: Rf: 0.60 (9:1 hexanes/ EtOAc). FTIR (neat): 2951, 1582, 1459, 1245, 
1053, 838 cm-1. 1H NMR (600 MHz, CDCl3): δ 6.94 (t, J = 8.1 Hz, 1H), 6.50 (dd, J = 
8.2, 1.1 Hz, 1H), 6.40 (dd, J = 8.1, 1.1 Hz, 1H), 3.20 (d, J = 9.6 Hz, 1H), 2.55 (dd, J = 
9.6, 7.9 Hz, 1H), 2.43 – 2.35 (m, 1H), 2.05 – 1.94 (m, 1H), 1.75 – 1.66 (m, 1H), 1.65 
– 1.59 (m, 2H), 1.38 (s, 3H), 1.34 (s, 3H), 1.00 (s, 9H), 0.70 (s, 3H), 0.28 (s, 3H), 0.23 (s, 3H) ppm. 13C 
NMR (150 MHz, CDCl3): δ 154.7, 126.6, 116.4, 111.4, 110.9, 83.5, 46.7, 39.9, 39.1, 39.0, 36.4, 34.3, 
27.0, 26.3, 25.6, 18.8, 18.4, -2.8, -3.6 ppm. HRMS: calculated for C22H35O2Si [M+H]+ 359.2401, found 
359.32400. 
 
5.135: Reaction left for 5 h. Purification by flash column chromatography on 
SiO2 (19:1 hexanes/ EtOAc) afforded (5.135a) (35 mg, 16%). Data for 5.135a: Rf: 
0.40 (9:1 hexanes/ EtOAc). FTIR (neat): 2969, 1617, 1582, 1453, 1361, 1166, 




























Hz, 2H), 7.29 (d, J = 7.4 Hz, 1H), 6.34 (s, 1H), 6.31 (s, 1H),  5.77 (d, J = 8.6 Hz, 1H), 5.15 (d, J = 12.1 Hz, 
1H), 5.04 (d, J = 12.2 Hz, 1H), 2.58 – 2.51 (m, 1H), 2.25 (s, 3H), 2.09 (dd, J = 13.4, 8.7 Hz, 1H), 2.02 – 
1.96 (m, 1H), 1.82 – 1.77 (m, 1H), 1.50 – 1.41 (m, 2H), 1.33 (s, 3H), 1.27 (s, 3H), 1.11 (s, 3H) ppm. 13C 
NMR (150 MHz, CDCl3): δ 159.0, 155.6, 141.1, 137.5, 128.7, 128.6, 127.7, 127.1, 111.9, 108.5, 106.3, 
84.5, 82.6, 72.1, 70.4, 45.7, 39.7, 27.1, 22.9, 22.5, 22.0, 19.3 ppm. HRMS: calculated for C24H29O4 
[M+H]+ 381.2060, found 381.2060. 
 
5.136: Reaction left for 4 h. Purification by flash column chromatography on 
SiO2 (19:1 hexanes/ EtOAc) afforded (5.136) (42 mg, 11%) as a yellow oil. Data 
for 5.136: MP: 138 – 142 °C. Rf: 0.25 (19:1 hexanes/ EtOAc). Rf: 0.45 (9:1 
hexanes/ EtOAc). FTIR (neat): 2968, 1617, 1582, 1461, 1417, 1361, 1229, 1147, 
1055, 817 cm-1. 1H NMR (600 MHz, CDCl3): δ 6.29 (s, 1H), 6.27 (s, 1H), 5.67 (d, J 
= 8.7 Hz, 1H), 3.80 (s, 3H), 2.51 (td, J = 12.6, 7.6 Hz, 1H), 2.27 (s, 3H), 2.26 – 2.22 (m, 1H), 2.07 (dd, J = 
13.4, 8.8 Hz, 1H), 1.98 (ddd, J = 14.7, 11.4, 3.3 Hz, 1H), 1.82 – 1.76 (m, 1H), 1.49 – 1.41 (m, 1H), 1.30 
(s, 3H), 1.27 (s, 3H), 1.09 (s, 3H) ppm. 13C NMR (150 MHz, CDCl3): δ 159.9, 155.4, 141.1, 111.5, 104.7, 
104.2, 84.4, 82.6, 72.1, 55.9, 46.0, 45.7, 39.7, 27.0, 22.9, 22.5, 22.0, 19.1 ppm. HRMS: calculated for 
C18H25O4 [M+H]+ 305.1747, found 305.1745. 
 
5.137: Reaction left for 6 h. Purification by flash column chromatography on 
SiO2 (9:1 hexanes/ EtOAc) afforded (5.137a) (1.16 g, 44%) as a clear oil. Rf: 0.40 
(19:1 hexanes/ EtOAc). FTIR (neat): 2961, 1616, 1577, 1461, 1361, 1251, 1166, 
1085, 1003, 838, 780 cm-1. 1H NMR (600 MHz, CDCl3): δ 6.29 (d, J = 1.6 Hz, 1H), 
6.24 (d, J = 1.6 Hz, 1H), 5.60 (d, J = 8.8 Hz, 1H), 2.53 (ddd, J = 13.4, 11.9, 7.6 Hz, 
1H), 2.28 – 2.23 (m, 1H), 2.22 (s, 3H), 2.05 (dd, J = 13.4, 8.8 Hz, 1H), 1.99 (ddd, J = 14.7, 11.5, 3.3 Hz, 
1H), 1.82 – 1.75 (m, 1H), 1.50 – 1.42 (m, 1H), 1.32 (s, 3H), 1.27 (s, 3H), 1.08 (s, 3H), 1.04 (s, 9H), 0.27 
(s, 3H), 0.22 (s, 3H) ppm. 13C NMR (150 MHz, CDCl3): δ 156.2, 155.7, 140.7, 112.9, 112.0, 107.3, 84.2, 
82.3, 71.9, 46.2, 45.7, 39.8, 27.0, 22.9, 22.4, 21.7, 19.4, 18.5, -4.1, -4.1 ppm. HRMS: calculated for 
C23H37O4Si [M+H]+ 405.2456, found 405.2457. 
 
 
5.138: Reaction left for 6 h. Purification by flash column chromatography on 
SiO2 (19:1 hexanes/ EtOAc) afforded (5.138a) (60 mg, 45%) as a clear oil.  Data 
for 5.138a: Rf: 0.40 (9:1 hexanes/ EtOAc). FTIR (neat): 2969, 1609, 1582, 1453, 
1143, 840 732 cm-1. 1H NMR (600 MHz, CDCl3): δ 7.43 – 7.37 (m, 4H), 7.35 – 
























2H), 2.58 – 2.46 (m, 1H), 2.38 (s, 3H), 2.29 – 2.24 (m, 1H), 2.10 (dd, J = 13.4, 8.6 Hz, 1H), 2.01 (ddd, J = 
14.8, 11.4, 3.2 Hz, 1H), 1.85 – 1.80 (m, 1H), 1.51 – 1.41 (m, 1H), 1.33 (s, 3H), 1.30 (s, 3H), 1.14 (s, 3H) 
ppm. 13C NMR (150 MHz, CDCl3): δ 160.1, 155.9, 141.4, 137.0, 128.7, 128.0, 127.6, 111.0, 109.4, 101.6, 
84.2, 82.8, 74.1, 69.9, 45.6, 39., 26.9, 24.0, 23.0, 22.6, 19.6, 19.1 ppm. HRMS: calculated for C24H29O4 
[M+H]+ 381.2060, found 381.2060. 
 
5.139a: Reaction left for 5 h. Purification by flash column chromatography on 
SiO2 (19:1 hexanes/ EtOAc) afforded (5.139a) (65 mg, 29%) as a clear oil. Data 
for 5.139a: Rf: 0.25 (19:1 hexanes/ EtOAc). FTIR (neat): 2927, 1611, 1582, 
1143, 1048, 951, 839 cm-1. 1H NMR (600 MHz, CDCl3): δ 6.36 (d, J = 2.6 Hz, 1H), 
6.23 (d, J = 2.6 Hz, 1H), 5.55 (d, J = 8.6 Hz, 1H), 3.74 (s, 3H), 2.54 – 2.47 (m, 1H), 2.36 (s, 3H), 2.29 – 
2.21 (m, 1H), 2.09 (dd, J = 13.4, 8.6 Hz, 1H), 2.00 (ddd, J = 14.6, 11.4, 3.2 Hz, 1H), 1.86 – 1.77 (m, 1H), 
1.51 – 1.43 (m, 1H), 1.31 (s, 3H), 1.29 (s, 3H), 1.12 (s, 3H) ppm. 13C NMR (150 MHz, CDCl3): δ 160.8, 
155.9, 141.4, 110.3, 109.1, 100.7, 84.2, 82.8, 74.1, 55.2, 46.1, 45.7, 39.6, 26.9, 22.9, 22.6, 19.6, 19.1 
ppm. HRMS: calculated for C18H25O4 [M+H]+ 305.1747, found 305.1740. 
 
5.140: Reaction left for 5 h. Purification by flash column chromatography on 
SiO2 (19:1 hexanes/ EtOAc) afforded (5.140a) (11 mg, 6%) as a clear oil. Data for 
5.140a: Rf: 0.40 (19:1 hexanes/ EtOAc). FTIR (neat): 2931, 1165, 1150, 952, 825 
cm-1. 1H NMR (500 MHz, CDCl3): δ 7.48 (d, J = 7.7 Hz, 2H), 7.37 (t, J = 7.7 Hz, 2H), 
7.30 (t, J = 7.7 Hz, 1H), 6.35 (s, 1H), 6.32 (s, 1H), 5.77 (d, J = 8.7 Hz, 1H), 5.16 (d, J = 12.0 Hz, 1H), 5.04 
(d, J = 12.1 Hz, 1H), 2.60-2.53 (m, 1H), 2.51-5.47 (m, 2H), 2.26 (ddd, J = 14.5, 9.3, 7.1 Hz, 1H), 2.09 (dd, 
J = 13.4, 8.7 Hz, 1H), 2.00 (ddd, J = 14.7, 11.5, 3.3 Hz, 1H), 1.84-1.78 (m, 1H), 1.59-1.55 (m, 2H), 1.51-
1.42 (m, 2H), 1.34 (s, 3H), 1.32-1.28 (m, 3H), 1.28 (s, 3H) 1.12 (s, 3H), 0.88 (t, J = 7.0 Hz, 3H) ppm. 13C 
NMR (125 MHz, CDCl3): δ 158.9, 155.5, 146.2, 137.5, 128.6, 127.6, 127.2, 111.2, 105.8, 105.1, 84.5, 
82.6, 72.2, 70.4, 46.1, 45.7, 39.7, 36.4, 31.6, 30.7, 27.1, 22.9, 22.7, 22.5, 19.3, 14.2 ppm. HRMS: 
calculated for C28H36O4 [M+H]+ 437.2685, found 437.2686. 
 
5.141a: Reaction left for 6 h. Purification by flash column chromatography on 
SiO2 (19:1 hexanes/ EtOAc) afforded (5.141a) (88 mg, 35%) as a clear oil. Data 
for 5.141a: Rf: 0.20 (9:1 hexanes/ EtOAc). FTIR (neat): 2961, 2931, 2873, 2859, 
1166, 1147, 1090, 1025, 974, 931, 907, 826 cm-1. 1H NMR (500 MHz, CDCl3): δ 
6.30 (s, 1H), 6.28 (s, 1H), 5.68 (d, J = 8.7 Hz, 1H), 3.81 (s, 3H), 2.57-2.53 (m, 1H), 2.53-2.49 (m, 2H), 2.25 
(ddd, J = 14.5, 9.4, 7.1 Hz, 1H), 2.07 (dd, J = 13.4, 8.7 Hz, 1H), 1.99 (dd, J = 14.7, 11.4, 3.3 Hz, 1H), 1.80 

























3H), 1.27 (s, 3H), 1.10 (s, 3H), 0.89 (t, J = 6.8 Hz, 3H) ppm. 13C NMR (125 MHz, CDCl3): δ 159.9, 155.4, 
146.2, 110.8, 104.5, 104.1, 84.5, 82.7, 72.3, 55.9, 46.0, 45.7, 39.8, 36.4, 31.7, 30.8, 27.0, 23.0, 22.7, 
22.5, 19.2, 14.2 ppm. HRMS: calculated for C22H33O4 [M+H]+ 361.2373, found 361.2373. 
 
5.142: Reaction left for 6 h. Purification by flash column chromatography on 
SiO2 (19:1 hexanes/ EtOAc) afforded (5.142a) (25 mg, 13%) as a clear oil and 
(5.142b) (82 mg, 44%) as a white solid Data for 5.142a: Rf: 0.40 (19:1 hexanes/ 
EtOAc). FTIR (neat): 2956, 2929, 2858, 1615, 1575, 1463, 1429, 1362, 1252, 
1166, 1075, 839, 781cm-1. 1H NMR (500 MHz, CDCl3): δ 6.29 (d, J = 1.5 Hz, 1H), 6.24 (d, J = 1.5 Hz, 1H), 
5.60 (d, J = 8.9 Hz, 1H), 2.57-2.50 (m, 1H), 2.47 (td, J = 7.5, 2.4 Hz, 1H), 2.24 (ddd, J = 14.5, 9.4, 7.0 Hz, 
1H), 2.05 (dd, J = 13.5, 8.9 Hz, 1H), 1.98 (ddd, J = 14.7, 11.4, 3.3 Hz, 1H), 1.82-1.74 (m, 1H), 1.59-1.53 
(m, 2H), 1.50-1.42 (m, 2H), 1.35-1.31 (m, 2H), 1.31 (s, 3H), 1.30-1.28 (m, 2H), 1.26 (s, 3H), 1.08 (s, 3H), 
1.03 (s, 9H), 0.88 (t, J = 6.9 Hz, 3H), 0.26 (s, 3H), 0.21 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3): δ 156.2, 
155.6, 145.8, 112.4, 111.3, 107.5, 84.3, 82.3, 72.0, 46.3, 45.7, 39.8, 36.0, 31.6, 30.7, 27.1, 26.1, 22.9, 
22.7, 22.4, 19.4, 18.5, 14.2, -4.0 ppm. HRMS: calculated for C27H45O4Si [M+H]+ 461.3082, found 
461.3084. 
 
 Data for 5.142b: MP: 138 – 142 °C. Rf: 0.70 (19:1 hexanes/ EtOAc). FTIR (neat): 
2955, 2930, 2859, 1615, 1572, 1462, 1424, 1254, 1136, 1082, 1064, 907, 836, 
781 cm-1. 1H NMR (500 MHz, CDCl3): δ 6.34 (s, 1H), 6.22 (s, 1H), 3.41 (d, J = 9.6 
Hz, 1H), 2.53 (dd, J = 9.6, 7.8 Hz, 1H), 2.46 (t, 7.6 Hz, 2H), 2.36 (td, J = 7.8, 2.7 Hz, 
1H), 2.02-1.94 (m, 1H), 1.73-1.66 (m, 1H), 1.62-1.58 (m, 2H), 1.58-1.53 (m, 2H), 1.36 (s, 3H), 1.34 (s, 
3H), 1.32-1.29 (m, 2H), 1.29-1.26 (m, 2H), 0.99 (s, 12H), 0.88 (t, J = 6.8 Hz, 3H), 0.27 (s, 3H), 0.22 (s, 
3H) ppm. 13C NMR (125 MHz, CDCl3): δ 154.4, 141.8, 113.2, 111.4, 111.2, 83.3, 46.7, 39.8, 38.9, 38.8, 
36.4, 35.8, 34.3, 31.6, 30.9, 27.3, 26.4, 25.7, 22.7, 18.8, 18.3, 14.2, -2.7, -3.6 ppm. HRMS: calculated 

































Synthetic Sample (CDCl3) 
George et al. (2019) 
Natural sample (CDCl3) 









2  83.3 -- 83.4 
3 2.55  (dd, J = 9.7, 8.0 Hz) 39.2 
2.56  
(dd, J = 9.6, 8.0 Hz) 39.3 
4 3.08  (d, J = 9.7 Hz) 37.9 
3.08  
(d, J = 9.6 Hz) 38.0 
4a -- 116.0 -- 116.2 
5 -- 138.4 -- 138.6 
6 6.28  (d, J = 2.6 Hz) 109.9 
6.28  
(d, J = 2.4 Hz) 111.0* 
7 -- 154.2 -- 154.4 
8 6.24  (d, J = 2.6 Hz) 102.8 
6.24  
(d, J = 2.4 Hz) 102.9 
8a -- 154.6 -- 154.7 
9 1.98 (m) 1.60 (m) 39.4 
1.98 (m) 
1.60 (m) 39.5 
10 1.72 (m) 1.63 (m) 25.4 
1.72 (m) 
1.63 (m) 25.5 
11 2.41 (td, J = 8.1, 2.7 Hz) 46.5 
2.41  
(td, J = 8.0, 3.0 Hz) 46.6 
12 -- 39.6 -- 39.7 
13 1.38 (s) 34.0 1.38 (s) 34.1 
14 0.66 (s) 18.5 0.66 (s) 18.7 
15 1.32 (s) 26.6 1.32 (s) 26.8 
16 2.11 (s) 20.1 2.11 (s) 20.2 
7-OH 4.70 (br s) -- -- -- 
 































Synthetic Sample (CDCl3) 
George et al. (2019) 
Natural sample (CDCl3) 









2 -- 90.7  90.9 
3 2.20 (dd, J = 8.0, 3.8 Hz) 43.5 
2.20 
(dd, J = 8.0, 4.0 Hz) 43.7 
4 4.03 (d, J = 3.8 Hz) 63.6 
4.03 
(d, J = 4.0 Hz) 63.7 
4a -- 54.5 -- 54.7 
5 -- 148.9 -- 149.0 
6 6.26 (t, J = 1.7 Hz) 131.7 6.28 (br s) 131.9 
7 -- 187.5 -- 187.7 
8 5.97 (d, J = 2.0 Hz) 114.9 
6.00 
(d, J = 1.6 Hz) 115.3 
8a -- 167.1 -- 167.2 
9 2.07 (m) 1.86 (m) 40.3 
2.08 (m) 
1.88 (m) 40.5 
10 1.89 (m) 1.43 (m) 25.3 
1.91 (m) 
1.43 (m) 25.5 
11 2.55 (m) 53.7 2.55 (q, J = 8.0 Hz) 53.8 
12 -- 72.1 -- 72.4 
13 1.23 (s) 25.9 1.24 (s) 26.0 
14 1.34 (s) 30.2 1.35 (s) 30.4 
15 1.29 (s) 27.2 1.30 (s) 27.3 


































Synthetic Sample (CDCl3) 
George et al. (2019) 
Natural sample (CDCl3) 









2  81.2  81.3 
3 2.13 
(dd, J = 14.1, 3.1 Hz) 
64.1 2.13 
(dd, J = 14.4, 3.0 Hz) 
64.3 
4 4.92 
(d, J = 3.0 Hz) 
96.1 4.91 
(d, J = 3.0 Hz) 
96.3 
4a -- 138.6 -- 138.7 
5 -- 133.8 -- 134.0 
6 6.40 
(d, J = 3.0 Hz) 
112.9 6.40 
(d, J = 3.0 Hz) 
113.0 
7 -- 151.7 -- 151.9 
8 6.32, 
(d, J = 3.0 Hz) 
109.5 6.32 
(d, J = 3.0 Hz) 
109.7 
8a -- 151.3 -- 151.5 
9 2.57 
(dt, J = 14.7, 8.8 Hz) 
2.37 
(ddd, J = 14.7, 9.9, 1.6 Hz) 
47.3 2.57 
(dt, J = 15.0, 9.0 Hz) 
2.37 
(ddd, J = 15.0, 10.0, 1.2 Hz) 
47.4 
10 1.77 (m) 
1.34 (m) 




(ddd, J = 14.4, 12.6, 6.0 
Hz) 
51.9 3.42 
(ddd, J = 14.4, 12.6, 6.0 Hz) 
52.1 
12 -- 80.1 -- 80.2 
13 1.52 (s) 29.7 1.52 (s) 29.8 
14 1.17 (s) 22.7 1.17 (s) 22.9 
15 1.28 (s) 24.8 1.28 (s) 24.9 
16 2.22, s 16.4 2.23, s 16.6 













































Synthetic Sample (CDCl3) Natural sample (CDCl3) 









2 -- 83.5 -- 83.5 
3 2.52 (t, J = 9.0 Hz) 46.5 2.51 (t, J = 8.8 Hz) 46.6 
4 2.42  (dt, J = 8.0, 3.4 9 Hz) 37.3 
2.42  
(dt, J = 8.0, 3.4 Hz) 37.3 
4a -- 116.1 -- 126.6 
5 -- 141.9 -- 141.9 
6 6.36 (d, J = 2.6 Hz) 108.1 
6.35 
(d, J = 2.3 Hz) 108.1 
7 -- 154.9 -- 155.0 
8 6.28 (d, J = 2.6 Hz) 103.5 
6.27 
(d, J = 2.3 Hz) 103.4 
8a -- 154.4 -- 154.5 









11 3.10 (d, J = 9.6 Hz) 39.9 
3.09 
(d, J = 9.5 Hz) 40.0 
12 -- 39.8 -- 40.0 
13 1.37 (s) 25.3 1.25 (s) 25.3 
14 0.63 (s) 18.8 0.62 (s) 18.9 
15 1.30 (s) 34.1 1.36 (s) 34.1 
16 2.84 – 2.69 (m) 34.9 2.76 (s) 34.9 
17 2.84 – 2.69 (m) 37.1 2.76 (s) 37.2 
18 -- 142.0 -- 142.1 
19 7.22 – 7.18 (m) 128.4 7.33 – 7.13 (m) 128.4 
20 7.29 (t, J = 7.4 Hz) 128.4 7.33 – 7.13 (m) 128.4 
21 7.22 – 7.18 (m) 125.9 7.33 – 7.13 (m) 126.0 
































Synthetic Sample (d6-acetone) 
George et al. (2019) 
Natural sample (d6-acetone) 









2 -- 81.6 -- 81.6 
3 2.25  (dd, J = 14.1, 3.0 Hz) 64.7 
2.26  
(dd, J = 14.0, 3.0 Hz) 64.7 
4 4.72  (d, J = 3.0 Hz) 97.4 
4.71  
(d, J = 3.0 Hz) 97.5 
4a -- 138.7 -- 138.7 
5 -- 137.7 -- 137.8 
6 6.47  (d, J = 3.0 Hz) 112.6 
6.47 
 (d, J = 2.9 Hz) 112.6 
7 -- 152.4 -- 154.4 
8 6.33  (d, J = 3.0 Hz) 110.6 
6.32  
(d, J = 2.9 Hz) 110.6 
8a -- 154.4 -- 154.7 
9 
2.48  
(dt, J = 14.4, 8.7 Hz) 
2.39  
(ddd, J = 14.4, 9.9, 1.7 Hz) 
48.0 
2.48  
(dt, J = 14.4, 8.7 Hz) 
2.39  
(ddd, J = 14.4, 9.9, 1.5 Hz) 
48.0 
10 1.73 (m) 21.8 1.73 (m) 21.8 
11 3.36  (ddd, J = 14.1, 12.6, 6.0 Hz) 53.0 
3.36  
(ddd, J = 14.0, 12.8, 6.0 Hz) 53.0 
12 -- 79.7 -- 79.7 
13 1.14 (s) 23.0 1.13 (s) 23.0 
14 1.43 (s) 30.2 1.43 (s) 30.4 
15 1.29 (s) 24.7 1.28 (s) 24.8 
16 2.91 (m) 33.1 2.91 (m) 33.2 
17 2.80 (m) 37.7 2.80 (m) 37.7 
18 -- 143.0 -- 143.0 
19 7.27 (m) 129.0 7.27 (m) 129.1 
20 7.22 (m) 129.3 7.22 (m) 129.3 
21 7.17 (m) 126.6 7.17  (tt, J = 7.2, 1.3 Hz) 126.6 


































5.4.5 NMR Spectra 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.4.6 Single Crystal X-Ray Data 
A crystal of nyingchinoid B (5.6) was mounted under paratone-N oil on a nylon loop, and X-ray 
diffraction data were collected at 150(2) K with Mo Kα radiation (λ = 0.7107 Å) on an Oxford Diffraction 
X-calibur small molecule diffractometer.49 The data set was corrected for absorption and the structure 
solved by direct methods using SHELXS-2014 and refined by full matrix least-squares on F2 by SHELXL-
2014, interfaced through the program X-Seed.50 In general, all non-hydrogen atoms were refined 
anisotropically, and hydrogen atoms were included as invariants at geometrically estimated positions. 
Details of data collection and structure refinement are given below. CCDC number 1882907 contains 
the supplementary crystallographic data for this paper. These data can be obtained free of charge 
from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif. 
 
Crystal data for nyingchinoid B (5.6). C17H22O4, F.w. 290.34, monoclinic, P21/n, a 11.7425(5), b 
14.6257(5), c 17.7664(6) Å, b 95.029(3)°, V 3039.5(2) Å3, Z = 8, Dcalc = 1.269 Mg/m3, µ 0.089 mm-1, 
F(000) 1248, crystal size 0.30 × 0.30 × 0.30 mm3, q range for data collection 3.43 to 28.22°, Ind. reflns 
6484, Obs. reflns 4598, Rint 0.0424, GoF 1.024, R1 [I>2s(I)] 0.0468, wR2 (all data) 0.1117, largest diff. 
peak and hole 0.261 and -0.210 e.Å-3. In the structure of nyingchinoid B two molecules are present in 
the asymmetric unit.  These two molecules are enantiomers but are not related by symmetry due to 






















Figure 5.12 − A. A representation of the structure of nyingchinoid B with ellipsoids presented with 
50% probability level. Carbon - grey; hydrogen - white; and oxygen - red. B. A view of the hydrogen 
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Chapter Six – Efforts Towards the Total Synthesis of Hinckdentine A 
6.1 Introduction 
6.1.1 Hinckdentine A Isolation 
(+)-Hinckdentine A (6.1) is a tribrominated indole alkaloid, first isolated in 1987 by Blackman and co-
workers (Figure 6.1).1 It was collected from shallow waters off the eastern coast of Tasmania and 
extracted from the marine bryozoan Hincksinoflustra denticulate. (+)-Hinckdentine A (6.1) features a 
unique brominated indolo[1,2-c]quinazoline (6.2) core fused to a 7-membered lactam. It also 
possesses a synthetically challenging C2 quaternary centre, and its absolute stereochemistry has been 
unambiguously determined by single crystal X-ray diffraction. Due to its low abundance in nature 
(isolation yield of 0.0005% wt./ wt.) the biological activity of 6.1 has not been reported, however 
certain derivatives containing the quinazoline core (6.2) have been shown to exhibit potent 
cataleptogenic, antibacterial and antifungal activities.2 
 
Figure 6.1 – (+)-Hinckdentine A 
 
(+)-Hinckdentine A (6.1) presents itself as an intriguing target for synthetic chemists and although 
biosynthetic proposals have been put forward (see work by Ruan and co-workers),3 the exact 
biosynthetic pathway remains elusive. Despite this, the synthesis of 6.1 has been extensively reported 
in the literature (Scheme 6.1).4 In 1994, Billimoria and co-workers reported the first total synthesis of 
(±)-hinckdentine A (6.1) through a selenium initiated radical cyclization of 6.3 to form the lactam motif 
of 6.1 (Scheme 6.1).5 Unfortunately these attempts were unsuccessful, and it wasn’t until 2003 that 
the synthesis of the racemic 8-desbromohinckdentine A analogue (6.4) was achieved by Liu and 
McWhoter.6 Six years later Higuchi et al. disclosed the first reported synthesis of (±)-hinckdentine A 
(6.1) in 21-steps,7 while a formal 17-step total synthesis of the unnatural enantiomer (−)-hinckdentine 
A (6.1) was reported by Han and co-workers in 2014.8 In 2016, the first asymmetric synthesis of the 
natural (+)-hinckdentine A (6.1) was reported by the Fukuyama group.9 This featured an asymmetric 
dearomatization cyclization of a functionalized N-acyl tetrahydrocarbazole to give the enone 6.5. In 
2018, Torres-Ochoa et al. reported a 14-step total synthesis of (+)-hinckdentine A (6.1)10 and later that 
year the Xu group went on to publish a 12-step synthesis featuring a unique electrochemical 














described in 2021 by Jeon et al. featuring an imino-Stetter reaction.12 Herein, this introduction will 
attempt to summarize all 7 successful total syntheses of hinckdentine A (6.1).  
 
Scheme 6.1 – Previous Syntheses of Hinckdentine A and 8-desbromohinckdentine A5-12 
 
6.1.2 Total Synthesis of 8-Desbromohinckdentine A by Liu and McWhorter 
In 2003, Liu and McWhorter published a synthetic approach to (±)-hinckdentine A (6.1) which hinged 
on a late stage tribromination of the quinazoline (6.2) core (Scheme 6.2).6 This synthesis began 
following a 7-step synthesis of 6.7 from 2-bromoacetophenone (6.12), which underwent a [1,2]-alkyl 
shift under acidic conditions to afford 3-oxindole 6.13 in quantitative yield. Boc protection, ozonolysis 
and reductive amination with 2,4-dimethoxybenzylamine then afforded 6.14. Subsequent acetylation 
afforded 6.15 in 56% over 3-steps, followed by an intramolecular aldol reaction to give the 
azepinoindolone 6.16 in 92%. Next mesylation, elimination and reduction afforded 6.17 in 76% over 
2-steps. This was followed by amination to give 6.18, which underwent Boc deprotection and 
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gave 6.20. Finally, treatment with bromine afforded (±)-desbromohinckdentine A (6.4) in 92%. 
Unfortunately, all attempts to synthesize the tribrominated (±)-hinckdentine A (6.1) only gave 
inseparable mixtures of bromine regioisomers. Overall, the synthesis of 6.4 was achieved in 20-steps.  
 
 
Scheme 6.2 – Liu and McWhorter’s Synthesis of 8-Desbromohinckdentine A6 
 
6.1.3 Total Synthesis of (±)-Hinckdentine A by Higuchi and Co-workers 
In 2009, the first total synthesis of (±)-hinckdentine A (6.1) was reported by Higuchi and co-workers.7 
This began with a 2-step synthesis of 6.22 from 2-nitroacetephenone (6.23) following a literature 
procedure from MacPhillamy et al..13 PMB protection of 6.22 followed by oxidation then afforded 6.8. 
Reaction of 6.8 with the silyl enol ether 6.24 in the presence of CSA gave the Mannich addition product 
6.25 in 77%. Presumably, this reaction proceeded through the 𝛼-ketoiminium ion 6.26 allowing for 
the formation of the C2 quaternary centre. The aldehyde 6.25 was then reduced and TBS protected 
to give 6.27 in 89% over 2-steps. PMB deprotection and reduction of the nitro group afforded 6.28. 
Treatment of 6.28 with trimethyl orthoformate gave the quinazoline ring of 6.29 and a Horner-
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6.31. Boc and TBS deprotection then afforded alcohol 6.32, which was activated with mesyl chloride 
and substituted with NaN3 to afford 6.33. A Staudinger reduction and a ruthenium mediated 
lactamisation then gave 6.34 affording the key pentacyclic framework. Interestingly, the authors 
found that a late-stage bromination with NBS afforded the desired tribrominated product. This 
success was attributed to steric hinderance of the Boc group on the quinazoline ring, presumably 
precluding over bromination (unlike Liu and McWhorter’s observations).6 Deprotection and 
subsequent oxidation then gave (±)-hinckdentine A (6.1) in 47% over 3-steps. In total, this synthesis 
was achieved in 21-linear steps, featuring a unique Mannich reaction to form the key C2 quaternary 
centre and a ruthenium catalyzed lactamisation. 
  
 
Scheme 6.3 – Total Synthesis of Hinckdentine A by Higuchi et al.7 
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6.1.4 Formal Synthesis of (–)-Hinckdentine A by Han et al. 
Han and co-workers completed an asymmetric formal synthesis of the unnatural enantiomer of (–)-
hinckdentine A (6.1) in 2014 (Scheme 6.4).8 Although the author’s original intention involved the total 
synthesis of a family of trigonoliimines, the synthetic methodology developed facilitated an 
enantiomeric oxidation of 6.35 mediated by the aspartyl peptide catalyst 6.36. This afforded 6.9 in 
97% yield and 79% ee. A t-BuOK facilitated [1,2]-alkyl shift of 6.9 then afforded 6.37, which serves as 
an intermediate in Higuchi’s total synthesis of (±)-hinckdentine A (6.1).7 This approach shortened the 
previous total synthesis of 6.1 from 20-steps (Liu and McWhorter) and 21-steps (Higuchi et al.) down 




Scheme 6.4 – Formal Synthesis of (–)-Hinckdentine A by Han et al.8 
 
6.1.5 Total Synthesis of (+)-Hinckdentine A by Douki and Co-workers 
Two years later in 2016, the Fukuyama group reported the first asymmetric total synthesis of natural 
(+)-hinckdentine A (6.1) (Scheme 6.5).9 This was achieved using a 3-step literature synthesis of the N-
benzoyl tetrahydrocarbozole (6.38) from 6.39, following work by Liu and co-workers.14 A palladium 
catalyzed intramolecular Heck dearomatization cyclization then afforded 6.5 in 98% (and 86% ee) 
employing the phosphoramidite ligand 6.40 developed by Teichert and co-workers.15 The chiral 
intermediate 6.5 then underwent reaction with nitrosyl chloride to afford the ketoxime 6.41 in 79%. 
All attempts to effect a direct Beckmann rearrangement failed, instead a Beckmann fragmentation 

















































of E:Z isomers. Hydrogenation with catalytic Pd/C then afforded 6.43 in 98%. It was found that rinsing 
the crystals of 6.43 in EtOH at 0 °C gave the enantiomerically pure 6.43. A second hydrogenation, this 
time with Raney Ni, followed by treatment with NaHCO3 afforded the desired lactam 6.44 in 84% over 
2-steps. Reduction and amide cleavage then gave 6.45, which was subsequently TES and TFA 
protected. Oxidation with Jones reagent and conversion to the aldoxime 6.47 was achieved, followed 
by a modified procedure from Kim et al. involving direct conversion of 6.47 into the isothiocyanate 
6.49 after reaction with the pyrimidinethione 6.48.16 Potassium thioacetate then afforded the anilide 
6.50 which was primed for bromination to give 6.51 in 64% over 2-steps. Finally, treatment of 6.51 
with trimethyl orthoformate under acidic conditions afforded (+)-hinckdentine A (6.1), presumably 
through the amidinium intermediate 6.52. This synthesis by Douki and co-workers features a 
palladium catalyzed intramolecular Heck dearomatization cyclization using a phosphoramidite ligand 
as the key step, alongside a NaHCO3 mediated lactamisation and a late stage tribromination. Overall, 
this impressive synthesis of 6.1 is achieved in 16-steps and is the first reported asymmetric total 
synthesis of the natural (+)-hinckdentine A (6.1).  
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Scheme 6.5 – Total Synthesis of (+)-Hinckdentine A by Douki et al. 9 
 
6.1.6 Total Synthesis of (+)-Hinckdentine A by Torres-Ochoa et al. 
In 2018, the Zhu group reported a 14-step asymmetric total synthesis of (+)-hinckdentine A (6.1) 
achieved through a catalytic asymmetric Michael addition (Scheme 6.6).10 This involved treatment of 
the isocyanoacetate 6.55 with vinyl selenone (6.54) and the quinidine derived catalyst 6.53 to afford 
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displacement, isocyanide hydrolysis and a Staudinger cyclization gave 6.57 in 53% over 3-steps. Boc 
protection, subsequent hetro-annulation and an intramolecular cyclization with an in situ generated 
benzyne (from 6.58) then formed the indole 6.59 in 38%. Reduction of the nitro motif of 6.59 afforded 
the corresponding aniline, which was subsequently treated with trimethyl orthoformate to give the 
quinazoline core of 6.10 in 83%. Wittig reaction between 6.59 and methyl 
(triphenylphosphoranylidene)acetate (6.60) followed by a 1,4-reduction gave 6.61 in 52%. Next, Boc 
protection with Boc2O and KHMDS afforded 6.62, which underwent a regioselective debromination 
through reaction with NBS to afford 6.63 in 75%. Unfortunately, all efforts towards the tribrominated 
product failed at this step. Instead, removal of the Boc protecting group and concomitant 
lactamisation gave the desired pentacycle 6.64. It was found that tetrabutylammonium tribromide 
was unique at effecting the desired bromination to give 6.65 in quantitative yield. Finally, TPAP 
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6.1.7 Total Synthesis of (±)-Hinckdentine A by Hou and Co-workers 
To date the shortest and arguably the most elegant synthesis of (±)-hinckdentine A (6.1) was published 
in 2018 by Hou and co-workers (Scheme 6.7).11 This synthesis begins with a 3-step synthesis of the 
urea 6.6 which undergoes a key electrochemical dehydrogenative [3+2] annulation to give 6.68 in 
70%. This impressive transformation forms the core quinazoline (6.2) scaffold in a single step 
highlighting the power of electrochemistry in the construction of complex polycyclic frameworks. TBS 
deprotection and reduction then affords 6.69 in 87% over 2-steps. Subsequent Bn deprotection, Boc 
protection and bromination through treatment with NBS then afforded 6.70. Boc deprotection and 
oxidation then sets up the synthesis of 6.71 which undergoes a Schmidt reaction to give the ring 




Scheme 6.7 – Total Synthesis of (±)-Hinckdentine A by Hou and co-workers11 
 
6.1.8 Total Synthesis of (±)-Hinckdentine A by Jeon and Co-workers 
The most recent total synthesis of (±)-hinckdentine A (6.1) was reported by Jeon et al. in 2021 (Scheme 
6.8).12 This began through a TiCl4 mediated condensation of amino-3,5-cinnamate (6.72) with 5-
bromo-2-nitrobenzaldehyde (6.73), followed by a cyanide catalyzed imino-Stetter reaction to afford 
6.74 in 83% over 2-steps.  Amidation of the ester with p-methoxybenzyl (PMB) amine, followed by 
reduction with BH3 afforded a secondary amine, which was reacted with AcCl to give the tertiary amide 
6.11. Next, oxidation of 6.11 with Oxone gave the 3-hydroxy indolenine. Thermal rearrangement then 
afforded a [1,2]-alkyl shift installing the quaternary centre at C2, and subsequent reduction of the 
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reaction with formaldehyde and Boc protection to afford 6.76. An aldol reaction with LDA at –78 °C 
then afforded 6.77 in 91%. Dehydration of the C3 hydroxyl group through mesylation and elimination 
then provided the 𝛼, 𝛽-unsaturated lactam 6.78 in 73%. Selective reduction of 6.78 with magnesium 
then gave 6.79 in 45%, followed by treatment with BF3 in anisole, enabled the global deprotection of 
6.79 to 6.80 in 63%. Finally, Ley oxidation of 6.80 with TPAP according to the literature procedure by 
Torres-Ochoa et al. then afforded a total synthesis of (±)-hinckdentine A (6.1) in 81%.10 
 
 
Scheme 6.8 – Total Synthesis of (±)-Hinckdentine A by Jeon and co-workers12 
 
6.1.9 Proposal for the Total Synthesis of (±)-Hinckdentine A 
Interestingly, when we looked carefully through these previous syntheses, we observed the common 
intermediate 6.82 (Figure 6.2). This indol-3-one intermediate was found in all approaches to 6.1 with 
the exception of work by Douki et al. and work by Hou and co-workers.9, 11 Clearly, efforts towards the 
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felt that the prospects of an efficient synthesis could be rapidly improved through a more biomimetic 
approach featuring the formamide 6.83.  
 
Figure 6.2 – Our Approach to the Total Synthesis of (±)-Hinckdentine A 
 
Our proposal for the total synthesis of (±)-hinckdentine A (6.1) begins from reduction of commercially 
available E-2-nitro-cinnamic acid (6.77) to afford 6.78 (Scheme 6.9). Dibromination of the resultant 
electron rich aniline would then afford 6.79, followed by amidation with 5-bromo tryptamine (6.80) 
to give 6.81. We then propose that a biomimetic oxidative ring opening of the electron rich indole 
carbon-carbon double bond would give 6.82, unveiling the formamide and ketone functional groups 
which we hope to be the key precursor to (±)-hinckdentine A (6.1). An intramolecular condensation 
reaction between the aniline, the ketone and the formamide would then produce a pyrimidine moiety 
affording the cyclic enamine 6.83. Similar condensation reactions have been reported by Hao et al. in 
the total synthesis of trigonoliimine A.18 Next, we envisage that heating of 6.83 could result in an 
antarafacial [1,6]-H shift to afford the stabilized, and highly conjugated azomethine ylides which would 
exist in resonance (i.e. 6.84, 6.85 and 6.86). We predict that 6.86 could then ring close via a 6𝜋-
electrocyclization reaction to give (±)-hinckdentine A (6.1) in a 5-step total synthesis featuring a 
spectacular cascade of pericyclic reactions. Related pericyclic cascade reactions involving conjugated 





























Scheme 6.9 – Proposed Total Synthesis of (±)-Hinckdentine A 
 
6.2 Results and Discussion 
6.2.1 Initial Efforts Towards the Total Synthesis of (±)-Hinckdentine A  
Synthesis of (±)-hinckdentine A (6.1) began with reduction of E-2-nitro-cinnamic acid (6.77), in an 
attempt to form aniline 6.78. Unfortunately, reaction of 6.77 with catalytic Pd/C and H2 gave the 
lactonized product 6.87 in 89%, presumably due to its high thermodynamic stability (Scheme 6.10). 
All attempts to suppress this cyclization through shorter reaction times failed.  
 
  
































































































To overcome this issue, we decided to change the order of our reactions. Instead, reaction of 6.77 
with tryptamine (6.88), DCC and DMAP afforded the amide 6.89 in 20% (Scheme 6.11). Gratifyingly, 
we found that using the amide coupling reagent EDCI in the place of DCC gave a quantitative yield of 
6.89 when the reaction was left for 48 h. Next, reduction of 6.89 afforded the aniline 6.81 in 96% and 
subsequent oxidation of the indole motif of 6.81 was attempted. Unfortunately, treatment of 6.81 
with methylene blue and O2 in CH2Cl2 gave only decomposition. However, we found that Tsuji’s 
conditions (i.e. CuCl, O2 and pyridine) afforded the key formamide 6.82 in a modest 25% yield.20  
 
 
Scheme 6.11 – Synthesis of the Key Formamide 6.82 
 
With 6.82 in hand, our efforts then turned towards screening conditions for the key condensation, 
[1,6]-H shift, and 6𝜋-electrocyclization cascade to afford the hinckdentine A scaffold 6.90 (Table 6.1). 
It was found that leaving 6.82 in 4Å sieves at room temperature in CH2Cl2 gave starting material (entry 
1), whilst heating 6.82 to reflux in PhMe resulted in formation of the undesired lactam 6.87 (entry 2). 
It became clear to us at this point that the formation of 6.87 was going to be problematic and that 
attempts to suppress this would be challenging. Next, a series of Lewis acids were screened (TMSCN, 
TMSOTf, t-BuMe2OTf, BF3·OEt2 and SnCl4) (entries 3 – 8), however these reactions only resulted in 
decomposition or formation of the lactam 6.87. Attempts to selectively activate the formamide 
functional group through reaction with POCl3 and pyridine only gave decomposition (entry 9), while 













































Table 6.1 – Conditions Screened for the Key Reaction Cascade of 6.82 
 
Entry Reagents Solvent Time Temperature Result 
1 4Å sieves CHCl3 48 h rt NR 
2 4Å sieves 
 




CH2Cl2 8 h rt decomp. 










CH2Cl2 4 h –78 °C → rt decomp. 
6 t-BuMe2OTf 
(1.1 equiv.) 
CH2Cl2 4 h –78 °C → rt decomp. 
7 BF3·OEt2 
(1.0 equiv.) 
CH2Cl2  –78 °C → rt decomp. 
8 SnCl4 
(10 mol%) 







CH2Cl2 1 h –78 °C → rt decomp. 
10 CSA 
(5 mol%) 
CH2Cl2 8 h rt NR 
 
6.2.2 Efforts Towards the Total Synthesis of (±)-Hinckdentine A Through a Bn Formamide 
Aside from the obvious problematic formation of 6.87, another explanation behind our lack of 
promising results could be due to the spatial conformation of 6.82, which could be adopting a linear 
conformation in solution (due to steric repulsion) rather than undergoing condensation with aniline 


























Figure 6.3 – Possible Conformations of the Formamide 6.82 
 
To overcome this issue, it was envisaged that protection of the amide 6.82 with a more sterically 
hindered benzyl group (i.e. 6.91) could result in a more stable formation of the non-linear conformer 
and we hoped that this would help facilitate condensation and assist in the formation of the 
hinckdentine scaffold (Figure 6.4). 
 
 
Figure 6.4 – Possible Conformations of the Formamide 6.91 
 
The benzyl protected formamide 6.91 was synthesized analogous to our previous synthesis of 6.83, 
except this time through the synthesis of the benzyl protected tryptamine 6.92 (Scheme 6.12). This 
was achieved following a literature procedure from Martin and Vanderwal through reductive 
amidation of 6.88 with benzaldehyde and treatment with NaBH4, which afforded 6.92 in 87% yield.21 
Amidation of 6.92 with E-2-nitro-cinnamic acid (6.77), EDCI and DMAP then gave 6.93 in 60%. The 
yield for this amidation was lower than that observed when compared to the synthesis of the 
unprotected amide 6.89, most likely due to a combination of steric and electronic effects.  
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Gratifyingly the obtained 1H NMR spectra of 6.93 showed the presence of rotamers suggesting that 
the benzyl group was indeed serving its desired purpose (Figure 6.5). This can be very clearly seen by 
inspection of the alkyl peaks at C8 and C9. 
 
 
Figure 6.5 – 1H NMR (500 MHz) of the Benzyl Protected Amide 6.93 
 
Chemoselective reduction of 6.93 following a modified procedure from Soom et al. using NaBH4 and 
catalytic Pd/C then gave the reduced aniline 6.94 in 82%.22 Oxidation again using conditions developed 
by Tsuji and co-workers afforded the desired formamide 6.91 (Scheme 6.13).20 
 
 
Scheme 6.13 – Synthesis of the Benzyl Protected Formamide 6.91 
 
With access to the key formamide 6.91 our efforts then turned towards screening conditions for the 
key condensation, [1,6]-H shift, and 6𝜋-electrocyclization cascade to afford the hinckdentine A 
scaffold 6.95 (Table 6.2). Unfortunately, similar to our previous observations we found that treatment 
of 6.91 with 4Å sieves and thermal heating only gave the lactam 6.87 in 27% (entry 1), while reactions 
with Lewis acids (i.e. TMSCN, TMSOTf, BF3·OEt2 and SnCl4) (entries 2 – 6) only resulted in 













































those seen previously in the key step reaction of the unprotected 6.82. Reaction with POCl3 and either 
pyridine or Et3N only gave decomposition (entries 7 – 8), and finally we attempted treatment of 6.91 
with the Brønsted acids CSA and TsOH (entries 9 – 10). Disappointingly, only decomposition was 
observed.  
 


















Entry Reagents Solvent Time Temperature Result 


















CH2Cl2 14 h –78 °C → rt decomp. 
6 SnCl4 
(1.0 equiv.) 














CH2Cl2 6 h rt decomp. 
10 CSA 
(5 mol%) 










6.2.3 A Revised Model Study Towards the Total Synthesis of (±)-Hinckdentine A  
Having made minimal progress towards the total synthesis of (±)-hinckdentine A (6.1) through our 
proposed biomimetic route, efforts turned towards a new yet equally ambitious non-biomimetic 
approach (Scheme 6.16). We envisaged this could be achieved through synthesis of the 𝛼-chloride 
6.96, which could undergo a Witkop cyclization reaction according to a literature procedure by 
Bhandari and co-workers to afford the lactam 6.97.23 We then hoped that treatment of the lactam 
6.97 with a phenyl isocyanide (i.e. 6.98) could afford the N-imination product 6.99. Recent work by 
Kim and Hong highlighted the use of N-heterocyclic carbenes to catalyse similar transformations in 
good to excellent yields.24 We then propose that 6.99 could undergo a protonation event and E/Z-
isomerisation to afford the imine 6.100, which would be primed to undergo a 6-𝜋-electrocyclization 




Scheme 6.14 – Revised Synthetic Proposal for the Hinckdentine A Scaffold 6.90 
 
To begin our investigations into a revised synthesis of (±)-hinckdentine A (6.1) we targeted a short 
model study starting from commercially available 1,2,3,4-tetrahydrocarbazole (6.102). Synthesis of 4-
bromophenyl isocyanide (6.103) was achieved following a two-step modified procedure from 
Hosseini-Sarvari and Sharghi (Scheme 6.15).25 This occurred through synthesis of the formamide 6.104 














































Scheme 6.15 – Synthesis of 4-Bromophenyl isocyanide25 
 
With 6.103 in hand, we then attempted the N-imination to form 6.106 following a literature procedure 
from Kim and Hong (Scheme 6.16).24 Pleasingly we found that reaction of 6.102 with 6.103 in the 
presence of the NHC catalyst 6.107 gave the desired formamidine 6.106 in quantitative yield after 
stirring at room temperature for 24 h. It is proposed that this reaction occurs through a duel NHC 
organocatalytic activation of both the indole and the isocyanide. This involves addition of the NHC 
catalyst (6.107) to 6.103 which gives the imidoyl intermediate 6.107. Next, a proton transfer then 
activates the carbazole (via deprotonation) to afford 6.108 and the imidoyl (via protonation) to afford 
6.109. This results in a dual activation of a nucleophile and an electrophile which couple to give the 






































































Having succeeded in the synthesis of 6.106, conditions for the key protonation, E/Z-isomerisation, 6-
𝜋-electrocyclization and aromatization reaction cascade to form 6.110 was investigated (Table 6.3). 
Frustratingly, treatment of 6.110 under thermal conditions (entries 1 – 3) gave decomposition, while 
treatment in a microwave reactor gave no reaction (entry 4). Next, reaction of with various Brønsted 
acids (i.e p-TsOH·H2O and CSA) were explored. However, these reactions only afforded the hydrolysis 
products 6.105 and 6.111 (entries 5 – 6). The Lewis acids BF3·OEt2, MgBr2 and SiO2 gave no reaction 
(entries 7 – 9), as did photoredox conditions (entries 10 – 11), meanwhile radical initiation using AIBN 





























Entry Reagents Solvent/ 
Conditions 
Time Temperature Result 
6.105 6.111 Comment 
1 -- DMF  5 h 153 °C -- -- decomp. 
2 -- i-PrOH 5 h 85 °C -- -- decomp. 
3 -- THF/ H2O 24 h 66 °C -- -- decomp. 
4 -- benzene 
microwave 
1 h 150 °C -- -- NR 
5 p-TsOH·H2O 
(1.0 equiv.) 
PhMe 3 h rt 18% 50% -- 
6 CSA  
(1.0 equiv.) 
EtOH 3 h rt 40% 40% -- 
7 BF3·OEt2 THF 30 min –78 °C -- -- NR 
8 MgBr2 MeCN 16 h 80 °C -- -- NR 





4 h rt -- -- NR 
11 4-MeO-TPT  DCE 
blue LED 
4 h rt -- -- NR 
12 AIBN benzene 5 h 60 °C  -- -- decomp. 
 611 
Finally, we considered the possibility that this reaction might be better mediated through a light 
induced electrocyclization (Table 6.4). We found that the best way to screen a high throughput for 
these conditions was through monitoring the reaction of 6.106 with light in a variety of deuterated 
solvents over a period of 6 h. We began irradiating 6.106 to visible light in 6 different solvents (d6-
acetone, d6-benzene, CDCl3, d6-DMSO, d4-MeOH, d5-pyridine), however in all cases no reaction was 
observed. Next, we screened UVA light which again gave no reaction, while UVC light either gave no 
reaction, decomposition or afforded the hydrolysis products 6.105 and 6.111. Reaction with sunlight 
also gave no reaction.   
 






















6.2.4 Revised Efforts Towards the Total Synthesis of (±)-Hinckdentine A 
Despite not being able to successfully achieve the key protonation, E/ Z-isomerisation, 6-𝜋-
electrocyclization and aromatization reaction cascade, we were still determined to attempt this 
cascade on the real system. To this end, we began by targeting synthesis of the nitrile 6.112. Pleasingly 
Entry Reagents d-Solvents Time Result 
1 visible light 
 












3 UVC d6-acetone  6 h NR 
d6-benzene NR 
CDCl3 decomp. 
d6-DMSO 6.105 + 6.111 
d4-MeOH 6.105 + 6.111 
d5-pyridine NR 







this could be achieved following a 3-step literature procedure from Nowacki and co-workers (Scheme 
6.17).26 This involved reduction of indole-2-carboxylic acid (6.113) with LiAlH4, followed by benzoyl 
protection of the alcohol to give 6.114 in 60% (over 2-steps). Subsequent reaction with NaCN through 
reflux in MeCN for 48 h then afforded 6.112 in 64%.  Alternatively, direct access to 6.112 could be 
achieved in 1-step from indole (6.115) through an [Ir(dmppy)2(dtbbpy)]PF6 mediated photoredox 
umpolung addition with bromoacetonitrile. This procedure was first reported in 2018 by O’Brien and 
co-workers.27 Although this afforded 6.112 in 63%, we found that this reaction gave inconsistent and 
poor yields upon scale up, presumably this was due to difficulty of the blue LED to irradiate the 
solution well and uniformly on a large scale.  
 
 
Scheme 6.17 – Synthesis of nitrile 6.112 
 
Reduction of the nitrile 6.112 was then attempted, in the hope of synthesizing isotryptamine 6.116. 
Surprisingly this reaction was particularly challenging, all attempted reductions with LiAlH4 in THF at a 
variety of temperatures failed, resulting only in decomposition. Additionally, we found that reductions 
with LiAlH4 in Et2O at room temperature failed. It was only upon heating this solution to reflux that 
formation of 6.116 was observed (Scheme 6.18). Frustratingly, this amine was not stable enough for 
purification by flash column chromatography on SiO2 even with the addition of Et3N or phosphate 
buffered (pH = 7) SiO2. It was found that the best approach to purify this compound was simply 
through a telescopic work up. The crude 6.116 was then treated with chloroacetyl chloride in the 






    0 ºC → rt, 2.5 h
ii). benzoyl chloride
     Et3N, THF































this compound was not stable to flash column chromatography on SiO2 and the product was observed 
to be cleaner without any attempted purification.  
 
 
Scheme 6.18 – Synthesis of the 𝜶-Chloramide 6.96 
 
Following a literature procedure from Bhandari et al. 6.96 was then reacted through a NaHCO3 
mediated Witkop cyclization affording 6.97 in quantitative yield (Scheme 6.19).22 This reaction 
proceeds through a photon induced electron transfer (PET) to afford 6.117. Subsequent 
dechlorination to 6.118, followed by radical cyclization then gives 6.119 which undergoes a 




Scheme 6.19 – Witkop Cyclization of 6.96 to 6.97 
 
Treatment of the witkop product 6.97 with Kim and Hong’s NHC organocatalytic N-imination was then 
attempted (Scheme 6.20). Unfortunately, all reactions of 6.97 with 4-bromo isocyanide (6.103) and 
the catalyst 6.107 only afforded decomposition. It is most likely that this was due to poor functional 





























































Scheme 6.20 – Attempted N-Imination of 6.97 
 
6.3 Conclusion and Future Work 
6.3.1 Conclusion 
In this chapter we have investigated some unique cascade reaction towards the total synthesis of (±)-
hinckdentine A (6.1). Our initial attempt featured a biomimetic approach through the synthesis of a 
formamide (and later the synthesis of a benzyl protected formamide) where we investigated a 
condensation, [1,6]-H shift, and 6𝜋-electrocyclization cascade.  A non-biomimetic approach employing 
a Witkop cyclization, N-imination and a unique protonation, E/ Z-isomerisation, 6-𝜋-electrocyclization 
and aromatization reaction cascade was also explored. Unfortunately, although the synthesis of 6.1 
was eluded in both approaches, we hope that these results offer some insight into the challenges 
associated in the synthesis of (±)-hinckdentine A (6.1). 
 
6.3.2 Future Work 
For future work we would like to revisit our first biomimetic approach. On reflection, it is possible that 
the difficulty we observed in this cascade may be due to the unfavoured formation of a 10 membered 
ring in the condensation reaction. Instead, it is possible that access to (±)-hinckdentine A (6.1) may be 
achieved through a more conservative intermolecular cascade reaction (Scheme 6.21). This would 
involve the reaction between two known compounds 6.120 and 6.121 which could undergo an 


























































































6.4.1 General Methods 
All chemicals used were purchased from commercial suppliers and used as received. All reactions were 
performed under an inert atmosphere of N2 unless otherwise stated. Thin layer chromatography was 
performed using aluminium sheets coated with silica gel. Visualization was aided by viewing under a 
UV lamp and staining with the appropriate stain followed by heating. All Rf values were measured to 
the nearest 0.05. Flash chromatography was performed using 40-63 micron grade silica gel. Melting 
points were recorded on a digital melting point apparatus and are uncorrected. Infrared spectra were 
recorded using an FT-IR spectrometer as the neat compounds. High field NMR was recorded using a 
600 MHz spectrometer (1H at 600 MHz, 13C at 150 MHz) or a 500 MHz spectrometer (1H at 500 MHz, 
13C at 125 MHz). The solvent used for NMR spectra was CDCl3 unless otherwise specified. 1H chemical 
shifts are reported in ppm on the δ-scale relative to TMS (δ 0.0) and 13C{1H} NMR are reported in ppm 
relative to chloroform (δ 77.16). Multiplicities are reported as (br) broad, (s) singlet, (d) doublet, (t) 
triplet, (q) quartet and (m) multiplet. All J-values were rounded to the nearest 0.1 Hz. ESI high 
resolution mass spectra were recorded on a Q-TOF mass spectrometer. Photochemistry with UVA light 
was performed using a generic brand commercial LED UV light globe; wavelength: 365 nm. 
Photochemistry with UVC light was performed using a generic brand commercial LED UV light globe; 
wavelength: 254 nm. Photochemical reactions with visible light were performed with a conventional 
commercial LED desk lamp at 240 V with a 4 W 5000 K 32 mÅ globe. Reactions conducted under 470 

























To a solution of E-2-nitrocinnamic acid (6.77) (4.00 g, 20.0 mmol, 1.0 equiv.) in MeOH (20 mL) at room 
temperature was added portion wise Pd/C (1.37 g, 2.00 mmol, 10 mol %) and the solution was placed 
under an environment of vacuum/ H2 three times, then left to stir under 1 atm of H2. After 16 h the 
solution was filtered through a pad of celiteTM with EtOAc (300 mL) and concentrated in vacuo. The 
residue was purified by flash column chromatography on SiO2 (9:1 hexanes/ EtOAc) to give lactam 
6.87 (2.70 g, 89%) as white crystals. Data for 6.87 matched that previously reported in the literature.28 
 
Data for 6.87: 
Rf: 0.20 (8:1 hexanes/ EtOAc).  
FTIR (neat): 3185, 3089, 1686, 1593, 12491, 1436, 1390, 1340, 1281, 1246, 1198, 1033, 813 cm-1. 
1H NMR (500 MHz, CDCl3): δ 9.60 (s, 1H), 7.18 – 7.13 (m, 2H), 6.98 (t, J = 7.5 Hz, 1H), 6.88 (d, J = 7.8 
Hz, 1H), 2.96 (t, J = 7.6 Hz, 2H), 2.65 (t, J = 7.6 Hz, 2H) ppm.  
13C NMR (125 MHz, CDCl3): δ 172.6, 137.5, 127.9, 127.6, 123.7, 123.1, 115.8, 30.8, 25.4 ppm.  



























To a solution of E-2-nitrocinnamic acid (6.77) (2.50 g, 13.0 mmol, 1.0 equiv.) in DMF (30 mL) at room 
temperature was added tryptamine (6.88) (2.06 g, 13.0 mmol, 1.0 equiv.), DMAP (1.73 g, 14.2 mmol, 
1.1 equiv.) and EDCI·HCl (2.47 g, 13.0 mmol, 1.0 equiv.). After 48 h, the reaction was quenched with 
sat. brine (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic layers were dried with 
MgSO4, filtered and concentrated. The residue was purified by flash column chromatography on SiO2 
(1:1 hexanes/ EtOAc) to give 6.89 (4.33 g, quant.) as a yellow solid.   
 
Data for 6.89: 
Rf: 0.20 (1:1 hexanes/ EtOAc).  
FTIR (neat): 3322, 2980, 1647, 1603, 1534, 1432, 1340, 1223, 968 cm-1. 
1H NMR (500 MHz, CDCl3): δ 8.09 (br s, 1H), 8.00 (dd, J = 8.1, 1.3 Hz, 1H), 7.91 (d, J = 15.6 Hz, 1H), 7.64 
(d, J = 8.3 Hz, 1H), 7.61 – 7.58 (m, 1H), 7.56 – 7.53 (m, 1H), 7.49 (td, J = 7.7, 1.6 Hz, 1H), 7.39 (d, J = 8.2 
Hz, 1H), 7.22 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.17 – 7.12 (m, 1H), 7.10 (d, J = 2.3 Hz, 1H), 6.23 (d, J = 15.6 
Hz, 1H), 5.77 (s, 1H), 3.75 (q, J = 6.4 Hz, 2H), 3.07 (t, J = 6.6 Hz, 2H) ppm. 
13C NMR (125 MHz, CDCl3): δ 165.0, 136.6, 135.9, 133.5, 131.3, 129.9, 129.2, 127.5, 126.6, 125.0, 
122.5, 122.4, 119.8, 118.9, 113.0, 111.5, 40.1, 25.4 ppm. 


































To a solution of 6.89 (877 mg, 2.60 mmol, 1.0 equiv.) in MeOH (10 mL) at room temperature was 
added portion wise Pd/C (300 g, 0.260 mmol, 5% wt./ wt., 10 mol%) and the solution was placed under 
an environment of vacuum/ H2 three times, then left to stir under 1 atm of H2. After 5 h the solution 
was filtered through a pad of celiteTM with EtOAc (200 mL) and concentrated in vacuo. The residue 
was purified by flash column chromatography on SiO2 (neat EtOAc) to give 6.81 (769 mg, 96%) as an 
orange solid.  
 
Data for 6.81: 
Rf: 0.10 (1:1 hexanes/ EtOAc).  
FTIR (neat): 3291, 1649, 1581, 1515, 1451, 1198, 909, 751 cm-1. 
1H NMR (500 MHz, CDCl3): δ 8.38 (br s, 1H), 7.54 (d, J = 7.9 Hz, 1H), 7.33 (d, J = 8.1 Hz, 1H), 7.19 (t, J = 
7.5 Hz, 1H), 7.11 (t, J = 7.5 Hz, 1H), 7.04 (t, J = 7.5 Hz, 1H), 6.97 (dd, J = 7.4, 1.6 Hz, 1H), 6.77 (s, 1H), 
6.71 (t, J = 7.4 Hz, 1H), 6.63 (d, J = 7.9, 1H), 5.66 (br s, 1H), 3.86 (br s, 2H), 3.52 (q, J = 6.4 Hz, 2H), 2.87 
(t, J = 6.7 Hz, 2H), 2.81 (t, J = 7.2 Hz, 2H), 2.37 (t, J = 7.2 Hz, 2H) ppm. 
13C NMR (125 MHz, CDCl3): δ 172.9, 144.7, 136.5, 129.9, 127.5, 127.4, 125.6, 122.4, 122.2, 119.5, 
118.8, 118.7, 116.1, 112.72, 111.4, 39.9, 36.5, 26.8, 25.2 ppm. 






























To a solution of 6.81 (4.21 g, 13.7 mmol, 1.0 equiv.) in CHCl3 (20 mL) at room temperature was added 
pyridine (3.0 mL, 37.2 mmol, 2.7 equiv.) and CuCl (1.08 g, 10.4 mmol, 80 mol%). The solution was 
placed under an environment of vacuum/ O2 three times, then left to stir under 1 atm of O2. After 6 h 
the solution was quenched upon addition of a 10% wt./ wt. citric acid(aq) solution (20 mL) and the 
reaction was left to stir for a further 15 mins. The organic layer was then separated and extracted with 
CHCl3 (2 x 20 mL), dried with MgSO4, filtered and concentrated. The residue was purified by flash 
column chromatography on SiO2 (EtOAc) to give 6.82 (1.17 g, 25%) as an orange oil.  
 
Data for 6.82: 
Rf: 0.20 (EtOAc).  
FTIR (neat): 3344, 2924, 1614, 1547, 1450, 1208, 1160, 1065 cm-1. 
1H NMR (500 MHz, CDCl3): δ 11.47 (br s, 1H), 8.75 (d, J = 8.5 Hz, 1H), 8.48 (br s, 1H), 7.86 (dd, J = 8.0, 
1.6 Hz, 1H), 7.59 (t, J = 7.9 Hz, 1H), 7.18 (t, J = 7.7 Hz, 1H), 6.96 (dd, J = 7.5, 1.5 Hz, 1H), 6.84 (t, J = 7.6 
Hz, 1H), 6.58 (td, J = 7.4, 1.2 Hz, 1H), 6.49 (d, J = 7.9 Hz, 1H), 6.10 – 6.02 (m, 1H), 3.84 (br s, 1H), 3.58 
(q, J = 5.9 Hz, 2H), 3.17 (t, J = 5.7 Hz, 2H), 2.84 (t, J = 7.1 Hz, 2H), 2.48 (t, J = 7.1 Hz, 2H) ppm. 
13C NMR (125 MHz, CDCl3): δ 203.5, 201.3, 172.9, 171.3, 159.9, 144.4, 135.6, 131.0, 129.9, 127.6, 
125.2, 123.3, 121.8, 118.8, 116.0, 39.5, 36.4, 34.4, 27.0 ppm. 






























Following a modified procedure from Martin and Vanderwal et al.,21 a solution of tryptamine (6.88) 
(2.88 g, 18.0 mmol, 1.0 equiv.) was dissolved MeOH (20 mL) at room temperature and benzaldehyde 
(1.83 mL, 18.0 mmol, 1.0 equiv.) and Na2SO4 (1.37 g, 36.0 mmol, 2.0 equiv.) were added. The solution 
was left to stir under N2 for 1 h, then cooled to 0 °C and NaBH4 (680 mg, 18.0 mmol, 1.0 equiv.) added 
portion-wise. After 30 min distilled H2O (20 mL) was added to quench the reaction, and the product 
was extracted with CHCl3 (3 x 20 mL), dried with MgSO4, filtered and concentrated in vacuo to give 
6.92 (3.92 g, 87%) as an orange oil. Data for 6.92 matched that previously reported in the literature.21 
 
Data for 6.92: 
FTIR (neat): 3413, 2842, 1730, 1454, 1247, 1094, 1044, 697 cm-1. 
1H NMR (500 MHz, CDCl3): δ 7.98 (br s, 1H), 7.63 (d, J = 8.0 Hz, 1H), 7.40 – 7.36 (m, 1H), 7.33 – 7.28 
(m, 4H), 7.26 – 7.18 (m, 2H), 7.14 – 7.11 (t, J = 7.5 Hz, 1H), 7.03 (d, J = 2.2 Hz, 1H), 3.84 (s, 2H), 3.05 – 
2.99 (m, 4H), 1.54 (br s, 1H) ppm.  
13C NMR (125 MHz, CDCl3): δ 140.0, 136.4, 128.4, 128.2, 127.4, 127.0, 122.2, 121.8, 119.1, 118.8, 
113.4, 111.3, 53.8, 49.3, 25.6 ppm. 




















rt, 1h, then; 







To a solution of 6.77 (6.06 g, 31.0 mmol, 1.0 equiv.) and 6.92 (7.84 g, 31.0 mol, 1.0 equiv.) in DMF (500 
mL) was added DMAP (4.2 g, 34.0 mmol, 1.1 equiv.) and EDCI·HCl (6.6 g, 34.0 mmol, 1.1 equiv.) and 
the reaction was left to stir at room temperature. After 48 h the reaction was quenched with sat. brine 
(500 mL) and extracted with EtOAc (3 x 500 mL). The combined organic layers were dried with MgSO4, 
filtered and concentrated. The residue was purified by flash column chromatography on SiO2 (7:3 
hexanes/ EtOAc) to give 6.93 (17.7 g, 60%) as a yellow solid.   
 
Data for 6.93: 
Rf: 0.70 (1:1 hexanes/ EtOAc).  
FTIR (neat): 3280, 1619, 1495, 1452, 1230, 1018 cm-1. 
1H NMR (500 MHz, d6-DMSO, 1:0.4 mixture of rotamers): δ 10.78 (br s, 1H), 10.75 (br s, 0.4H), 7.98 
(d, J = 8.1 Hz, 0.4H), 7.93 – 7.89 (m, 1H), 7.86 – 7.82 (m, 0.8H), 7.80 (s, 0.4H), 7.68 (t, J = 7.8 Hz, 0.4H), 
7.57 (t, J = 7.8 Hz, 0.4H), 7.54 – 7.58 (m, 3H), 7.34 – 7.26 (m, 4.6H), 7.25 – 7.15 (m, 3.4H), 7.09 (s, 0.4H), 
7.05 – 7.00 (m, 2.3H), 6.97 – 6.91 (t, 1.4H), 6.81 – 6.77 (m, 1H), 6.52 (d, 1H), 4.79 (s, 0.8H) 4.65(s, 2H), 
3.66 (t, J = 6.8 Hz, 2H), 3.56 (t, J = 6.8 Hz, 2H), 2.85 – 2.86 (m, 2.8H) ppm.  
13C NMR (125 MHz, d6-DMSO, 1:0.4 mixture of rotamers): δ 165.0, 165.0, 148.2, 138.2, 136.3, 136.3, 
136.2, 135.0, 133.6, 133.5, 130.4, 130.0, 129.8, 129.2, 128.7, 128.6, 128.5, 128.0, 127.4, 127.2, 127.0, 
126.9, 124.5, 124.4, 123.9, 123.4, 123.1, 122.7, 121.1, 121.0, 118.6, 118.4, 118.3, 118.0, 111.6, 111.4, 
110.5, 50.8, 48.1, 47.4, 47.2, 24.2, 23.3 ppm. 






























To a solution of amide 6.93 (7.74 g, 18.0 mmol, 1.0 equiv.) in PhMe (500 mL) was added AcOH (3 mL), 
Pd/C (1.24 g, 0.90 mmol, 5% wt./ wt., 5 mol%) and NaBH4 (2.40 g, 60.0 mmol, 3.5 equiv.). The solution 
was then stirred at room temperature for 16 h, then filtered through celiteTM (CH2Cl2) and product 
extracted with CH2Cl2 (3 x 500 mL). The combined organic extracts were then dried with MgSO4, 
filtered and concentrated in vacuo. The residue was purified by flash column chromatography on SiO2 
(7:3 hexanes/ EtOAc) to give 6.94 (5.96 g, 82%) as a yellow solid. 
 
Data for 6.94: 
Rf: 0.60 (1:1 hexanes/ EtOAc).  
FTIR (neat): 3245, 1687, 1630, 1580, 1450, 1296, 1196, 977 cm-1. 
1H NMR (500 MHz, CDCl3, 1:1 mixture of rotamers): δ 8.32 (s, 1H), 8.24 (s, 1H), 7.59 (d, J = 7.9 Hz, 1H), 
7.49 (d, J = 7.9 Hz, 1H), 7.42 – 7.22 (m, 9H), 7.26 – 7.03 (m, 10H), 7.01 (d, J = 7.5 Hz, 1H), 6.91 – 6.86 
(m, 2H), 6.83 (s, 1H), 6.78 – 6.63 (m, 4H), 4.66 (s, 2H), 4.35 (s, 2H), 3.96 – 3.59 (br s, 4H), 3.70 (t, J = 7.6 
Hz, 2H), 3.49 (t, J = 7.2 Hz, 2H), 3.03 (t, J = 7.5 Hz, 2H), 2.94 (dt, J = 13.9, 7.2 Hz, 4H), 2.84 (t, J = 7.2 Hz, 
2H), 2.70 (t, J = 7.2 Hz, 2H), 2.57 (t, J = 7.2 Hz, 2H) ppm. 
13C NMR (125 MHz, CDCl3, 1: 1 mixture of rotamers): δ 173.4, 144.9, 144.8, 137.7, 137.0, 136.3, 136.3, 
130.0, 129.9, 128.9, 128.7, 128.0, 127.6, 127.5, 127.4, 127.4, 127.3, 127.1, 126.4, 125.9, 125.9, 122.5, 
122.3, 122.2, 122.0, 119.6, 119.4, 118.8, 118.7, 118.4, 116.0, 116.0, 113.1, 112.0, 111.6, 111.3, 51.9, 
48.7, 47.9, 47.7, 33.2, 32.7, 26.8, 26.7, 24.5, 23.6 ppm. 



























To a solution of 6.94 (86 mg, 0.20 mmol, 1.0 equiv.) in CHCl3 (5 mL) at room temperature was added 
pyridine (0.20 mL, 2.48 mmol, 12.4 equiv.) and CuCl (20 mg, 0.170 mmol, 80 mol%). The solution was 
placed under an environment of vacuum/ O2 three times, then left to stir under 1 atm of O2. After 4 h 
the solution was quenched upon addition of a 10% wt./ wt. citric acid(aq) solution (20 mL) and reaction 
was left to stir further for 15 mins. The organic layer was then separated and extracted with CHCl3 (2 
x 10 mL), dried with MgSO4, filtered and concentrated. The residue was purified by flash column 
chromatography on SiO2 (neat EtOAc) to give 6.91 (42.0 mg, 47%) as an orange oil.  
 
Partial Data for 6.91: 
Rf: 0.40 (1:1 hexanes/ EtOAc).  
FTIR (neat): 3245, 2913, 1687, 1631, 1580, 1512, 1496, 1450, 1296, 1196, 977 cm-1. 
1H NMR (500 MHz, CDCl3): δ 11.41 (br s, 1H), 11.28 (br s, 0.5H), 8.70 – 8.64 (m, 1H), 8.41 (s, 1H), 7.87 
(d, J = 7.5 Hz, 1H), 7.52 – 7.46 (m, 2H), 7.26 – 6.95 (m, 10 H), 6.90 (d, J = 7.5 Hz, 1H), 6.67 – 6.55 (m, 
3H), 4.57 (s, 1H), 4.50 (s, 2H), 3.98 (br s, 2H), 3.66 (t, J = 6.8 Hz, 2H), 3.60 (t, J = 7.3 Hz, 1H), 3.26 (t, J = 
6.8 Hz, 2H), 2.97 – 2.89 (m, 2H), 2.83 (t, J = 7.2 Hz, 2H), 2.75 (t, J = 6.8 Hz, 1H), 2.63 (t, J = 7.2 Hz) ppm.  
































Following a modified literature procedure from Hosseini-Sarvari and Sharghi et al.,25 4-bromoaniline 
(6.105) (10.0 g, 58.1 mmol) was refluxed in formic acid (30 mL). After 18 h, EtOAc (100 mL) was added 
followed by sat. NaHCO3(aq) (100 mL) and the organic layer separated. The aqueous layers were further 
extracted with EtOAc (2 x 100 mL) then the combined organic layers were washed with sat. brine (2 x 
100 mL), dried with MgSO4, filtered and concentrated to give 6.104 (10.3 g, 89%) as a brown solid 
which was used directly without further purification. Data for 6.104 matched that previously reported 
in the literature.25 
 
Data for 6.104: 
Rf: 0.10 (CH2Cl2).  
FTIR (neat): 3262, 1685, 1489, 1395, 1306, 821 cm-1. 
1H NMR (600 MHz, CDCl3 , 1.5:1 mixture of cis/ trans): δ 8.46 (d, J = 11.3 Hz, 1H), 8.20 (s, 1.5H), 7.43 
(br s, 1H), 7.29 (d, J = 8.8 Hz, 2H), 7.26 – 7.24 (m, 5H), 7.07 – 7.06 (m, 5H), 6.95 (br s, 1.5H), 6.77 (d, J 
= 8.8 Hz, 2H) ppm.  
13C NMR (150 MHz, CDCl3, 1.5:1 mixture of cis/ trans): δ 162.0, 158.8, 135.98, 135.8, 133.0, 132.3, 
121.6, 120.6, 118.5, 117.7 ppm. 




























Following a modified literature procedure from Hosseini-Sarvari and Sharghi et al.,25 Et3N (24 mL, 
0.170 mol, 3.3 equiv.) and POCl3 (5.3 mL, 57.2 mmol, 1.1 equiv.) were added dropwise to a stirred 
solution of 6.104 (10.3 g, 52.0 mmol, 1.0 equiv.) in dry THF (30 mL) at 0 °C. After 2, h the reaction was 
quenched with distilled water (30 mL) and product extracted with EtOAc (2 x 30 mL). The combined 
organic layers were washed with sat. brine (30 mL), dried with MgSO4, filtered and concentrated. 
Trituration (9:1 hexanes/ EtOAc) then gave 6.103 (2.83 g, 30%) as a yellow solid. Data for 6.103 
matched that previously reported in the literature.25 
 
Partial Data for 6.103: 
Rf: 0.40 (9:1 hexanes/ EtOAc).  
FTIR (neat): 3087, 2125, 1670, 1481, 1402, 1070, 822 cm-1. 
1H NMR (600 MHz, CDCl3): δ 7.57 – 7.51 (d, J = 8.5 Hz, 2H), 7.27 – 7.24 (d, J = 8.5 Hz, 2H) ppm. 





























Following a modified literature procedure from Kim and Hong,24 1,2,3,4-tetrahydrocarbazole (6.102) 
(450 mg, 2.62 mmol, 1.0 equiv.), t-BuONa (48 mg, 0.79 mmol, 0.3 equiv.), and the triazolium NHC salt 
6.107 (126 mg, 0.52 mmol, 0.20 equiv.) were dissolved in 1,4-dioxane (5 mL) at room temperature. 
6.103 (642 mg, 5.24 mmol, 2.0 equiv.) was then added after 5 min, and after 24 h the solution was 
concentrated and residue purified by flash column chromatography on SiO2 (9:1 hexanes/ EtOAc +1% 
Et3N) to afford 6.106 (92 mg, quant.) as a yellow solid. Data for 6.106 matched that previously reported 
in the literature.24 
 
Data for 6.106: 
Rf: 0.50 (9:1 hexanes/ Et2O).  
FTIR (neat): 2843, 2122, 1641, 1456, 1208, 1068, 824 cm-1. 
1H NMR (500 MHz, CDCl3): δ 8.53 (d, J = 8.1 Hz, 1H), 8.48 (s, 1H), 7.51 – 7.41 (m, 3H), 7.32 – 7.24 (m, 
2H), 7.04 (d, J = 8.1 Hz, 1H), 2.88 (t, J = 6.1 Hz, 2H), 2.71 (t, J = 6.1, 2H), 2.04 – 1.94 (m, 2H), 1.94 – 1.84 
(m, 2H) ppm. 
13C NMR (125 MHz, CDCl3): δ 149.7, 143.9, 135.4, 134.4, 132.3, 130.2, 123.6, 123.0, 122.9, 117.9, 
117.8, 116.5, 115.3, 23.1, 22.8, 22.6, 21.0 ppm. 

































Following a modified procedure from Nowacki and co-workers,26 a solution of indole-2-carboxylic acid 
(6.113) (4.73 g, 29.3 mmol, 1.0 equiv) was dissolved in dry THF (40 mL) and LiAlH4 (19.0 mL, 38.1 mmol, 
2.0 M in THF, 1.3 equiv.) added at 0 °C. The reaction was left to stir for 2.5 h, then quenched with a 
dropwise addition of distilled water (1.2 mL), 15% NaOH(aq) (1.2 mL) and distilled water (1.2 mL). The 
reaction was left to stir further for 30 min then filtered, and filtrate washed with Et2O (4 x 25 mL). The 
filtrate was then dried with MgSO4, filtered and concentrated in vacuo. Purification via flash column 
chromatography on SiO2 (4:1 → 2:1 hexanes/ EtOAc, gradient elution) then gave 6.129 (3.33g, 77%) 
as a white solid. Data for 6.129 matched that previously reported in the literature.26 
 
Data for 6.129: 
Rf: 0.10 (4:1 hexanes/ EtOAc).  
FTIR (neat): 3375, 1618, 1488, 1453, 1416, 1339, 1289, 1230, 1137, 1058, 928 cm-1. 
1H NMR (500 MHz, CDCl3): δ 8.31 (br s, 1H), 7.55 (d, J = 7.9 Hz, 1H), 7.20 (d, J = 7.9 Hz, 1H), 7.15 (td, J 
= 7.9 1.3 Hz, 1H), 7.09 (td, J = 7.9, 1.3 Hz, 1H), 6.32 (s, 1H), 4.62 (s, 2H), 2.60 (s, 1H) ppm. 
13C NMR (125 MHz, CDCl3): δ 137.6, 136.5, 128.1, 122.3, 120.7, 120.1, 111.2, 100.7, 58.6 ppm. 



























Following a modified procedure from Nowacki et al.,26 6.129 (3.29 g, 22.4 mmol, 1.0 equiv.) was 
dissolved in THF (80 mL), Et3N (3.73 mL, 26.8 mmol, 1.2 equiv.) and benzoyl chloride (3.11 mL, 26.8 
mmol, 1.2 equiv.) added at 0 °C. The solution was then left to warm to room temperature and the 
reaction was stirred for 3 h. A sat. NaHCO3(aq) (80 mL) solution was then used to quench the reaction 
and product extracted with EtOAc (5 x 50 mL). The combined organic layers were then washed with 
sat. brine (200 mL) and the organic layer dried with MgSO4, filtered and concentrated in vacuo to give 
6.114 (4.37 g, 78%) as a white solid which was used without further purification. Data for 6.114 
matched that previously reported in the literature.26 
 
Data for 6.114: 
Rf: 0.45 (4:1 hexanes/ EtOAc).  
FTIR (neat): 3350, 1704, 1453, 1273, 1097, 1097, 924 cm-1. 
1H NMR (500 MHz, CDCl3): δ 8.72 (br s, 1H), 8.07 (dd, J = 8.4, 1.4 Hz, 2H), 7.64 – 7.53 (m, 2H), 7.46 – 
7.42 (m, 2H), 7.37 (dd, J = 8.2, 0.9 Hz, 1H), 7.20 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.13 – 7.07 (m, 1H), 6.62 
(s, 1H), 5.49 (s, 2H) ppm. 
13C NMR (125 MHz, CDCl3): δ 168.0, 136.8, 133.5, 133.2, 130.0, 129.8, 128.6, 127.7, 123.0, 121.1, 
120.2, 111.3, 104.3, 60.4 ppm. 



























Following a modified procedure from Nowacki et al.,26 6.114 (2.04 g, 8.11 mmol, 1.0 equiv.) was 
dissolved in MeCN (100 mL) and NaCN (790 mg, 16.2 mmol, 2.0 equiv.) was added at room 
temperature.26 The suspension was then heated to 80 °C, left to stir for 48 h, cooled to room 
temperature, then quenched with sat. NaHCO3(aq) (100 mL). The product was extracted with EtOAc (3 
x 100 mL), dried with MgSO4, filtered and concentrated. Purification via flash column chromatography 
on SiO2 (4:1 hexanes/ EtOAc) then gave 6.112 (812 mg, 64%) as a white solid. Data for 6.112 matched 
that previously reported in the literature.26 
 
Data for 6.112: 
Rf: 0.20 (4:1 hexanes/ EtOAc).  
FTIR (neat): 3392, 3052, 2255, 1453, 1299, 1007, 910 cm-1. 
1H NMR (500 MHz, CDCl3): δ 8.21 (br s, 1H), 7.59 (d, J = 8.1 Hz, 1H), 7.35 (d, J = 8.1 Hz, 1H), 7.23 (t, J = 
7.1 Hz, 1H), 7.15 (t, J = 7.1 Hz, 1H), 6.48 (s, 1H), 3.88 (s, 2H) ppm. 
13C NMR (125 MHz, CDCl3): δ 136.6, 128.1, 126.0, 122.8, 120.6, 120.5, 116.7, 111.1, 102.7, 17.5 ppm. 




























Following a modified procedure from O’Brien et al.,27 indole (6.115) (1.95 g, 16.6 mmol, 2.0 equiv.), 
NaHCO3 (1.40 g, 16.6 mmol, 2.0 equiv.), and [Ir(dmppy)2(dtbbpy)]PF6 (160 mg, 0.332 mmol, 0.02 mol%) 
was dissolved in DCE (4.2 mL). Bromoacetonitrile (0.58 mL, 8.3 mmol, 1.0 equiv.) was added at room 
temperature. N2 was then bubbled through the solution for 5 min and the reaction was placed at a 5 
cm distance while exposed to a 470 nm blue LED lamp at 0 °C. After 48 h, the reaction was 
concentrated and purified by flash column chromatography on SiO2 (4:1 hexanes/ EtOAc) to afford 
6.112 (821 mg, 63%) as a white solid. Data for 6.112 matched that previously obtained and previously 





































To a solution of 6.112 (106 mg, 0.68 mmol, 1.0 equiv.) in dry Et2O (5 mL) was added dropwise LiAlH4 
(3.2 mL, 1.0 M in Et2O, 3.2 mmol, 4.7 equiv.) at 0 °C. The solution was left to stir for 30 min, then 
warmed to room temperature and heated at reflux. After 2 h, the reaction was cooled to 0 °C and 
quenched upon a dropwise addition of distilled water (10 mL). The organic layer was extracted with 
Et2O (3 x 10 mL), dried with MgSO4, filtered and concentrated in vacuo to afford 6.116 (100 mg, 91%) 
which was used directly without further purification. Data for 6.116 matched that previously reported 
in the literature.29 
 
Data for 6.116: 
Rf: 0.05 (20:1 CH2Cl2/ MeOH).  
FTIR (neat): 3394, 2868, 1583, 1456, 1288, 908, 744 cm-1. 
1H NMR (600 MHz, CDCl3): δ 9.05 (br s, 1H), 7.54 (d, J = 7.7 Hz, 1H), 7.30 (d, J = 8.0 Hz, 1H), 7.12 (t, J = 
7.1 Hz, 1H), 7.08 (t, J = 7.1 Hz, 1H),6.23 (s, 1H), 3.03 (t, J = 6.2 Hz, 2H), 2.84 (t, J = 6.2 Hz, 2H), 2.24 (br 
s, 2H) ppm.  
13C NMR (150 MHz, CDCl3): δ 138.2, 136.1, 128.7, 121.1, 119.9, 119.6, 110.7, 99.9, 41.6, 31.1 ppm. 



























At 0 °C chloroacetyl chloride (0.38 mL, 4.60 mmol, 1.0 equiv.) was added dropwise to a stirring solution 
of 6.116 (735 mg, 4.80 mmol, 1.1 equiv.) and Et3N (0.67 mL, 4.80 mmol, 1.1 equiv.) in CH2Cl2 (10 mL). 
The reaction was left to slowly warm to room temperature over 45 min, then quenched upon addition 
of distilled water (10 mL) and product extracted with CH2Cl2 (3 x 10 mL), dried with MgSO4, filtered 
and concentrated to afford 6.96 (490 mg, 45%) as an orange oil which was used directly without 
further purification.  
 
Data for 6.96: 
Rf: 0.20 (1:1 cyclohexane/ EtOAc).  
FTIR (neat): 3393, 3299, 1655, 1533, 1412, 1288, 907 cm-1. 
1H NMR (500 MHz, CDCl3): δ 8.23 (br s, 1H), 7.55 (d, J = 8.0 Hz, 1H), 7.33 (d, J = 8.0 Hz, 1H), 7.15 (t, J = 
8.0 Hz, 1H), 7.09 (t, J = 8.0 Hz, 1H), 6.79 (br s, 1H), 6.32 (s, 1H), 4.04 (s, 2H), 3.68 (q, J = 6.6 Hz, 2H), 
3.03 (t, J = 6.8 Hz, 2H) ppm. 
13C NMR (125 MHz, CDCl3): δ 166.6, 136.3, 135.8, 128.6, 121.5, 120.0, 119.8, 110.8, 100.5, 42.7, 39.4, 
28.3 ppm. 






























Following a modified procedure from Bhandari et al.,22 6.96 (42 mg, 0.177 mmol, 1.0 equiv.) was 
dissolved in EtOH (10 mL) and added to a solution of NaHCO3 (24 mg, 0.230 mmol, 1.3 equiv.) in 
distilled water (10 mL). N2 was then bubbled through the solution and the reaction was irradiated with 
a 254 nm UV LED lamp in a quartz vessel. After 16 h, the rection was concentrated and the crude 
residue purified via flash column chromatography on SiO2 (20:1 MeOH/ CHCl3) to afford 6.97 (35 mg, 
quant.) as a yellow solid. Data for 6.97 matched that previously reported in the literature.22 
 
Data for 6.96: 
Rf: 0.10 (10:1 hexanes/ EtOAc).  
FTIR (neat): 3364, 1648, 1461, 1355, 749 cm-1. 
1H NMR (600 MHz, d4-MeOH): δ 7.43 (d, J = 8.0 Hz, 1H), 7.25 (d, J = 8.0 Hz, 1H), 7.04 (t, J = 8.0Hz, 1H), 
7.00 (t, J = 8.0Hz, 1H), 3.71 – 3.65 (m, 2H), 3.32 – 3.30 (m, 2H), 2.98 – 2.96 (m, 2H) ppm. 
13C NMR (150 MHz, d4-MeOH): δ 179.2, 137.1, 134.3, 129.1, 122.1, 119.8, 116.0, 111.4, 102.9, 40.2, 
31.8, 28.9 ppm. 






























6.4.3 NMR Spectra 
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